11 Annual Meeting Program - American Society for Dermatologic

Transcription

2011
It ’s a Monumental Experience!
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
Washington Marriott Wardman Park
Final Program
& Abstracts
Featuring...
Hands-on Training with
High-fidelity Cutaneous Models:
• Tumor Excision/Wound Repair
and Injectables
• Fillers & Injectables
Exhibit Hall Highlights:
• 128 exhibiting companies
• Complimentary breakfast, lunch
& beverage breaks
• Wine and Cheese Reception
• RESIDENT KNOWLEDGE BOWL
A Capital Welcome
Reception and Silent Auction
A Star-Spangled Soirée:
ASDS Sixth Annual Gala
Final Program & Abstracts publication supported by a grant from
Together, we’ve
changed the face of
aesthetic medicine
One woman at a time
Your expertise. Our products and support.
Together we redefined rejuvenation.
And we’ve only just begun.
©2011 Allergan, Inc., Irvine, CA 92612
™ mark owned by Allergan, Inc. www.allergan.com APC54VD11 112438
AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY (ASDS)
2010-2011 ASDS OFFICERS AND BOARD OF DIRECTORS
President Richard G. Bennett, MD
President-Elect Susan H. Weinkle, MD
Vice President Timothy C. Flynn, MD
Secretary Thomas E. Rohrer, MD
Treasurer Seth L. Matarasso, MD
Immediate Past President Jeffrey S. Dover, MD, FRCPC
Historian/Parliamentarian Stephen H. Mandy, MD
Board of Directors
Murad Alam, MD
Jeffrey A. Klein, MD, MPH
Suzanne L. Kilmer, MD
Arielle N.B. Kauvar, MD
Mary P. Lupo, MD
E. Victor Ross, MD
Mark G. Rubin, MD
Roberta D. Sengelmann, MD
Abel Torres, MD
William P. Coleman, III, MD, Ex-Officio
Aerlyn Dawn, MD, Resident Representative
Oliver A. Perez, MD, Resident Representative
Katherine J. Duerdoth, CAE, Executive Director
ANNUAL MEETING WORK GROUP
Dee Anna Glaser, MD, Chair
Ken Lee, MD, Co-Chair
Kenneth R. Beer, MD
Richard G. Bennett, MD
Sandra Y. Han, MD
George J. Hruza, MD
Kavita Mariwalla, MD
Keyvan Nouri, MD
ASDS STAFF
Tara Azzano, Director of Development and Industry Relations
Bill Brady, Director of Finance
Dana Brown, Trade Show and Ad Sales Specialist
Nicholas Carson, Public Policy Specialist
Lisa Doty, Director of Marketing and Communications
Katherine J. Duerdoth, CAE, Executive Director
Debra Kennedy, Associate Executive Director
Merrille Martinez, Staff Accountant
Alethea McQuitter, Database Administrator
Jeannette Panzke, Member Services Assistant
April Samuelson, Marketing and Communications Specialist
Kim Santaniello, Director of Education, Meetings and Research
Shonnie Shelton, Meetings and Program Assistant
Lisle Soukup, Director of Advocacy and Public Policy
Cindy Sommerfeld, Marketing Manager
Vanessa Spinnato, Education Programs Manager
Tamika Walton, Executive Assistant
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
© 2011 American Society for Dermatologic Surgery
No part of this publication may be reproduced without the prior
written permission of the ASDS.
Photos courtesy of the Washington Marriott Wardman Park and
the Washington, DC Convention and Visitors Bureau.
American Society for Dermatologic Surgery
5550 Meadowbrook Drive, Suite 120
Rolling Meadows, IL 60008
Phone: 847-956-0900
Fax: 847-956-0999
Email: [email protected]
Website: www.asds.net
1
TABLE OF CONTENTS
ASDS Annual Meeting Commercial Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3
Welcome Message from the Program Co-chairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4
Annual Meeting Recordings - Live Learning Center. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
ASDS Continuing Medical Education Mission Statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8-9
State of the Art Cosmetic and Reconstructive Anatomy Course and Cadaver Laboratory Educational DVD . . . . . . . . . . . . . . . . . . . .9
Program-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10-11
ASDS Commercial Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12
Independent Hot Topic Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13
A Star-Spangled Soirée: Sixth Annual Gala Reception and Dinner. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14, 55
Residents/Post-residency Trainee/Young Dermatologic Surgeons Focus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16
ASDS 2012 Annual Meeting, Atlanta, GA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18
ASDS Dermasurgery Advancement Fund. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20-21
A Capital Welcome Reception and Silent Auction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22-23, 43
Special Keynote Lectures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24
CME Disclosures of Interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26-31
ASDS Art and Science of Fillers and Injectables: Best of the Best DVD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32
Resident Knowledge Bowl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
Hotel Room Locator and Floor Plan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .34
Pre-conference: MANAGING CHANGE: Practice Management in a Changing Healthcare Environment. . . . . . . . . . . . . . . . . . . . . .35
Residents/Post-residency Trainee Pre-conference: STARTING YOUR PRACTICE: Advance Knowledge is Power. . . . . . . . . . . . . . . . .36
Young Dermatologic Surgeons Hands-on Workshop: Tumor Excision/Wound Repair and Injectables . . . . . . . . . . . . . . . . . . . . . . .37
PRE-CONFERENCE SESSIONS: Wednesday, November 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38
SCIENTIFIC SESSIONS: Thursday, November 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39-43
SCIENTIFIC SESSIONS: Friday, November 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44-49
Wine and Cheese Reception in the Exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .47
SCIENTIFIC SESSIONS: Saturday, November 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50-55
SCIENTIFIC SESSIONS: Sunday, November 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56
ASDS Practice Management Book: Building Your Dermatologic Surgery Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57
ASDS Primer in Dermatologic Surgery: A Study Companion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57
ASDS Lab Coats . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58
POSTER PRESENTATIONS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59
Faculty Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60-61
Exhibiting Companies - Product Category Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62-63
Exhibiting Companies - Alphabetical Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64-73
Exhibit Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .74
Pre-Registrants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75-84
Friday Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85-101
Saturday Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101-107
Abstracts/Poster Presentations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108-120
ADVERTISEMENTS
Allergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . inside front cover
Galderma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Jan Marini Skin Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Revitalash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Liquid Ice CosMedicals AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Geisinger Health System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Young Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .inside back cover
Clarisonic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .back cover
2
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
THANK YOU
Annual Meeting Commercial Supporters
Allergan, Inc.
Allergan Foundation
DEKA Medical Inc.
Delasco
Dermik, a business of sanofi-aventis
ETHICON
Fibrocell Science Inc.
Galderma Laboratories
Kythera Biopharmaceuticals
Medicis Aesthetics
Merz Aesthetics
Merz Pharmaceuticals
NeoStrata Company
Procter & Gamble
Revance Therapeutics
Syneron/Candela
Ulthera
ZELTIQ
Please extend a special thank you for their support while visiting the technical exhibits.
WELCOME FROM THE CO-CHAIRS
We cordially welcome you to our capital city for the 2011 ASDS
Annual Meeting. A stellar event filled with unsurpassed medical
content, global presenters, state-of-the-art tradeshow and a
full schedule of networking and social events awaits you. The
2011 meeting claims an increase in international registration,
an unprecedented 200 residents and many new faces on the
educational program.
Before the main meeting even begins, we have three
pre-conference sessions covering health care reform, practice
start-up for residents, and hands-on experience in tumor excision/wound repair and injectables. Thursday starts
four days of fast-paced learning and networking.
An inspirational and thought-provoking keynote lecture begins each day, with RADM Boris D. Lushniak, MD,
MPH, US Deputy Surgeon General discussing prevention strategies on Thursday, Michael McMillan teaching
us how to reframe problems into solutions on Friday, and Mohit Bhandari, MD, PhD, FRCSC making evidencebased medicine easier to understand on Saturday.
The 2011 “You Asked for It Session” will cover the latest in sun-screen regulations, the economic future
of dermatologic surgery, and the next step in light based technology. The Reconstructive Challenge track
covers repairs of key anatomical regions such as lip, eyes, nose and more. The Core Curriculum in Cosmetic
Dermatologic Surgery track ensures participants will obtain the basics of fillers, lasers, peels, etc. to ensure
maintenance of critical base-line knowledge. And, for the fourth year, we present the ever popular Iron Surgeon.
The hands-on workshops featuring high-fidelity cutaneous surgical training models will offer the most realistic
hands-on experience possible without cadavers or live patients. Also debuting during the workshops and in the
exhibit hall will be the just invented Diaphanous translucent model for filler injections. These models will change
the paradigm in hands-on experience for dermatologists.
The exhibit hall will feature 122 companies offering products and services to keep your practice state-of-the-art.
Do not forget about the 8am open on Friday and Saturday offering light breakfast fare so that attendees have
ample time to view all the available booths. Don’t miss the high energy jeopardy-style Resident Knowledge Bowl.
Face-to-face meetings are NOT the thing of the past with ASDS. Much is learned from colleagues and industry
and we have ensured ample networking and social opportunities. From the Wednesday YDS and Residents
receptions to the Welcome Reception, Silent Auction, Resident Hospitality Suite, Wine and Cheese Reception,
Wine Tasting and finally the Star Spangled Soirée Gala on Saturday ASDS offers inclusivity, camaraderie and
community.
We would like to thank all the members of the Annual Meeting, Tradeshow, Development and other related Work
Groups for their participation. All this would not be possible without the tireless effort from the ASDS staff. We
would like to especially thank Kim Santaniello, Shonnie Shelton, Dana Brown, Tara Azzano and all the ASDS
staff for their extraordinary skills.
We are pleased you have chosen to join us in Washington and look forward to your feedback.
Dee Anna Glaser, MD
Ken K. Lee, MD
ASDS Annual Meeting Co-Chairs
4
*DOGHUPDZHNQRZVNLQRXWVLGHDQGLQ
Important Safety Information
Oracea® (doxycycline, USP) is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. In clinical trials, the most common
adverse events reported were gastrointestinal upsets, nasopharyngitis/pain, and nasal congestion/sinusitis. Oracea® should not be used to treat microbial infections, and should
be used only as indicated. This drug is contraindicated in people who have shown hypersensitivity to any of the tetracyclines, and, like other tetracycline drugs, may cause fetal
harm when administered to a pregnant woman. Oracea® should not be used during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years).
Although photosensitivity was not observed in clinical trials, Oracea® patients should minimize or avoid exposure to natural or artificial sunlight. All contraindications, warnings,
and precautions associated with tetracyclines must be considered before prescribing Oracea®. The safety of Oracea® treatment beyond 9 months has not been established.
Galderma is a registered trademark.
©2011 Galderma Laboratories, L.P.
Galderma Laboratories, L.P., 14501 N. Freeway, Fort Worth, TX 76177
GEN-316 Printed in USA. 08/11
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
Explore more educational sessions with the
LIVE LEARNING CENTER
Can’t take notes fast enough?
Wish you could attend more sessions?
Order the ASDS Live Learning Center!
"$$&440/-*/&
03%08/-0"%
"$$&44
to Annual Meeting
sessions, including
Q&As
50:063*10%.11-":&3
Bookmark sections
Highlight key information
Search key areas of interest
Visit
Vi
i the
h ASDS L
Learning
i Library
Lib
Sales
S l Desk
D
(across from registration)
Save $50 when you order onsite!
"4%4NFNCFSt/PONFNCFS
(Content subject to faculty agreement.)
ASDS CME MISSION STATMENT
The American Society for Dermatologic Surgery is an organization
whose primary purpose is to promote optimal quality care for
patients as well as support and develop investigative knowledge
in the field of dermatologic surgery. The Society carries out this
mission in order to further the interests and needs of the specialty,
with the underlying purpose of contributing to the delivery of
quality care in the ambulatory setting.
Purpose
The purpose of the Society’s overall CME program includes the
following:
• To provide physicians performing dermatologic surgery with
a forum for the exchange of ideas and methodologies in
dermatologic surgery and related medical and basic sciences
• To increase the body of knowledge existing in the field of
dermatologic surgery
• To provide educational opportunities to members in all aspects
of dermatologic surgery and its practices
• To promote the highest possible standards in clinical
dermatologic surgery practice that foster increased physician
competence, optimal procedural performance, and/or patient
outcomes.
Content Areas
The scope of the Society’s educational program includes
consideration of both the medical/surgical aspects of the specialty
as well as basic science principles related to dermatologic surgery.
The Society also includes selected socio-economic, legal, and
ethical content within the overall scope of the program.
Audience
The primary target audience of the ASDS CME program includes
the more than 5,200 members of the Society. Secondary audiences
include members of the American Academy of Dermatology and
other membership organizations who are dermatologists, but not
ASDS members. The ASDS does not educate non-physicians with
the exception of subject matter such as general dermatologic
surgery or practice management.
Activities and Services
The following live learning activities are sponsored by the Society
for CME credit:
• The Annual Scientific and Clinical Meeting;
• Periodic regional educational programs and courses conducted
by the Society;
Other collateral learning resources not designated for CME include:
• Video, DVD and CD-ROM educational tools;
• A special core curriculum for dermatologic surgery appropriate
as a reference for physicians in training as well as practicing
dermatologic surgeons;
• The Dermatologic Surgery journal published by the Society;
Expected Results
The expected results of the American Society for Dermatologic
Surgery’s (ASDS) CME program are:
1. Enhance the ability for dermatologic surgeons to demonstrate
a. increased competence - measured through increased ability
to identify and define the latest dermatologic surgery
developments from pre-activity to post-activity;
b. improved performance of dermatologic procedures –
measured by comparison of immediate post-activity
commitment to change responses to 6-month post-activity
change responses;
and/or
c. improved health outcomes - measured by learner surveyed
responses in areas including but not limited to lower
complication/recurrence rates, faster acting or longer acting
results, higher patient satisfaction.
2. Foster broader base-line competence in the cosmetic and
surgical aspects of the Core Curriculum in Dermatology
measured by a continuous 5 percent year-over-year participation
of post-residency training in core-curriculum courses and
improvements in post versus pre-survey results regarding the
ability to properly identify and define the accepted standard of
care for a particular procedure.
3. Achieve at least a mean score of 4.0 from aggregate learner
population of entire CME program regarding learners’ assessed
educational value and impact on practice.
RESOLUTION OF CONFLICTS OF INTEREST
The ASDS is committed to providing an open forum for the
exchange of ideas and methodology for dermatologic surgery and
related basic sciences. The ASDS must ensure that the content of
its educational activities are scientifically based, accurate, current,
and objectively presented. The ASDS has developed policies that
will resolve all conflicts of interest prior to the educational activity
being delivered to participants.
EDUCATIONAL ACTIVITY DISCLAIMER
The views expressed and the techniques presented by the speakers
at ASDS sponsored educational meetings are not necessarily shared
or endorsed by the organization. Speakers are required to disclose
all relevant conflicts of interest and any unapproved or “off-label”
uses of medical devices or pharmaceutical agents that they discuss,
describe or demonstrate during their presentations. Registrants
must use their independent judgment in applying the information
discussed in these educational sessions in the treatment of
patients. It is the responsibility of any presenter to obtain all
necessary consent forms for use of patient or other images in
their presentations. Any and all handout materials are prepared
and submitted for distribution by the presenters who are solely
responsible for their content. Attendees are required to use their
best judgment when participating in any panel discussions.
• Funding research to promote the goals of the Society and the
interests of the specialty; and
• Preceptorships.
7
GENERAL INFORMATION
2011 ASDS ANNUAL MEETING TARGET AUDIENCE:
The primary target audience for the ASDS Annual Meeting is its
members; board-certified dermatologists practicing dermatologic
surgery. Secondary audiences for the ASDS Annual Meeting include
dermatologists who have an interest in dermatologic surgery and
allied health personnel who are employed by a dermatologic surgeon.
2011 ASDS ANNUAL MEETING MISSION/LEARNING
OBJECTIVES:
The ASDS Annual Meeting’s mission is to provide dermatologic
surgeons with an educational forum that fosters increased
competence to perform current medical procedures and
techniques, expands the ability to apply today’s issues to practice
management, and enhances physicians’ interpersonal and
communication skills for the betterment of surgical and cosmetic
outcomes and patient care. We ask that all accepting faculty
members incorporate the ASDS Annual Meeting’s objective within
their content development process.
Upon completion of the ASDS Annual Meeting, participants will:
• Understand and identify new techniques and advances in
general, cosmetic and reconstructive dermatologic surgery;
• Identify areas of improvement in clinical practice resulting in
improved patient care and health outcomes;
• Comprehend the results of current and evolving research and
their applicability to patient care;
• Identify areas of improvement in practice management which
can be immediately applied.
HIGHLIGHTS OF THE ASDS ANNUAL MEETING:
• Hands-on workshops for residents and young dermatologic
surgeons covering reconstructive and cosmetic procedures
• Mohs surgery, cancer treatment, dermatopathology, tumor
oncology and research
• Reconstructive dermatologic surgery including flaps, scar and
vein treatment patient demonstrations in fillers/injectables and
vein therapy and reconstructive diamonds
• Lasers and light-based technology
• General dermatologic surgery
• Fillers and injectables; facial and body rejuvenation/sculpting; hair
transplantation
• Coding, social networking, documentation, and other practice
management and socio-economic issues
FACULTY AND ATTENDEE DISCLOSURE OF FINANCIAL
RELATIONSHIPS:
All faculty members are required to complete a faculty disclosure
form of their financial relationships. All faculty members are
required to disclose their relevant financial relationships both
verbally and through a PowerPoint first-slide at the beginning
of their presentation. Faculty disclosures are also printed in
this Final Program Book. Attendees are required to disclose
any commercial interests before asking a question or making any
statements within a session
ACCREDITATION STATEMENT AND CME CREDIT
DESIGNATION:
The American Society for Dermatologic Surgery is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
The American Society for Dermatologic Surgery designates this live
activity for a maximum of 24.75 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the
extent of their participation in the activity.
8
Credit is designated separately for ASDS Annual Meeting
Pre-conferences and Workshops. Please see pages 35 and 37
for credit designation for those activities.
Post-graduate Credit for Other Medical Societies: Appropriate
credit for attendance should be ascertained and reported by the
individual physicians to the particular state or medical society to
which he or she belongs.
Verification of Attendance: Certificates of attendance will be
available adjacent to the registration desk. Certificates will reflect
the maximum amount of credit designated for the annual meeting,
and physicians are on their honor to report credit according to their
actual participation in sessions.
CORE CURRICULUM IN COSMETIC DERMATOLOGIC
SURGERY TRACK:
The ASDS is committed to providing education on the breadth
of dermatologic surgery. A particular focus is providing learning
opportunities to fill the gap in cosmetic dermatology. Attendees
can select a special track of courses under the heading of Core
Curriculum in Cosmetic Dermatologic Surgery, identified with the
mark. Please reference full details of these courses within
the program description pages. Each of the designated courses
is comprised of the basic, need to know content in their specific
topic area. These courses will provide additional learning, as well as
an up-to-date refresher, for the younger and veteran dermatologic
surgeon respectively.
ACGME/ABMS DESIRABLE PHYSICIAN ATTRIBUTES/
COMPETENCIES:
Demonstration of the ACGME/ABMS published list of core
competencies is critical to a well-rounded physician. Based on
Criterion #6 of the Accreditation Council for Continuing Medical
Education’s Provider Requirements for CME, the ASDS has
developed the 2011 Annual Meeting educational program to
address the 6 core competencies as outlined below. Each session
within the program pages is marked with the core competency(ies)
addressed in the content of that session.
Patient Care that is compassionate, appropriate and effective
for the treatment of health problems and the promotion of health
Medical Knowledge about established and evolving
biomedical, clinical and cognate (e.g. epidemiological and social
behavior) sciences and the application of this knowledge to patient
care
Practice-based Learning and Improvement that involves
investigation and evaluation of their own patient care, appraisal
and assimilation of scientific evidence, and improvement in patient
care
Interpersonal & Communication Skills that result in effective
information exchange and teaming with patients, their families,
and other health professionals
Professionalism as manifested through a commitment
to carry out professional responsibilities, adherence to ethical
principles, and sensitivity to a diverse patient population
Systems-based Practice as manifested by actions that
demonstrate an awareness of and responsiveness to the larger
context and system for health care and the ability to effectively call
on system resources to provide care that is of optimal value
GENERAL INFORMATION
ANNUAL MEETING SESSION RECORDINGS:
All sessions at the 2011 ASDS Annual Meeting will be captured
via synchronized slide and audio (based on presenter permission),
including question and answer sessions, and made available
for internet download for a fee. Attendees may purchase the
recordings at the on-site price of $129 member/$179 non-member.
Please see the Promotion on page 6 for more information.
REGISTRANT CODE OF CONDUCT:
Camera/Video Recording Policy: Use of cameras/photography,
camera phones and video equipment is strictly prohibited in all of the
educational sessions. Violations of this policy will result in immediate
removal from the session and confiscation of the equipment.
Session Content and Patient Confidentiality: Patient images
are an essential element of continuing medical education to
demonstrate conditions, treatments, and outcomes in dermatologic
surgery. It is the responsibility of all presenters to obtain the
necessary consent forms for use of patient or other images in
their presentations at ASDS, and presenters take full responsibility
for the content of their presentations. It is the responsibility of all
educational session faculty AND participants to maintain a patient’s
right to privacy and keep confidential all discernable patient
information disseminated during the meeting and in any collateral
materials. Photographing, copying, downloading or any other
capture or transfer of presentation images is against ASDS policy
and strictly prohibited.
Cell Phone Policy: Cell phone usage and/or disruption are
prohibited in all of the educational sessions. Please remember to
turn off your cell phone or place it on vibrate. Violations of this
policy will result in immediate removal from the session.
Misuse of Name Badges: Under no circumstance is an attendee
with an individual name badge permitted to give the badge to
another individual who is or is not a paid attendee at the meeting.
Fraudulently allowing an individual to gain access to educational
sessions, social events and/or exhibits by using another’s credentials
is grounds for immediate removal of all parties from the meeting.
Disclosure of Commercial Interest: All participants in
presentations AND discussion sessions are required to disclose any
commercial interests prior to speaking. This includes attendees who
participate in question and answer sessions as well.
Code of Conduct: The American Society for Dermatologic
Surgery expects all Annual Meeting attendees to maintain high
standards of professional conduct and uphold the policies and
procedures set forth for the annual meeting. To the degree that an
attendee, individually or collectively, purposefully and fraudulently
circumvents the Society’s rules, regulations and ethical standards,
the Society views such conduct as a serious violation that will
jeopardize attendance at the meeting and could jeopardize
attendance at future Society meetings.
AMERICANS WITH DISABILITIES ACT:
The ASDS wishes to take steps to ensure that no individual with
a disability is excluded, denied services, segregated, or otherwise
treated differently than other individuals because of the absence of
auxiliary aids and services. If you require any of the auxiliary aids or
services identified in the Americans with Disabilities Act in order to
attend any ASDS program, please contact the ASDS office prior to
arrival.
State of the Art Cosmetic and Reconstructive
Anatomy Course and Cadaver Laboratory
Optimize your cosmetic and reconstructive
onstructive outcomes with a thorough
understanding of facial anatomyy and this review of advanced techniques.
You will become more aware of the underlying anatomy and how it
affects procedures, master surgical
cal techniques with tips from the
experts, and develop a sense andd appreciation for facial aesthetics.
DVD is PowerPoint synced to audio,
dio, with one video presentation.
Introduction to Reconstructive
ve and Aesthetic Anatomy
Stephen H. Mandy, MD
PanFacial Volume Restoration
n
Facelifting Techniques
Ronald L. Moy, MD
Lax Lids: Cosmetic Blepharoplasty
Ronald L. Moy, MD
Anatomy of Facial Aging and Facial Aesthetics
Tiffani K. Hamilton, MD
Anatomical Structures of the Face
(video presentation with cadaveric specimen)
Thomas H. Champney, PhD
New
DVD!
State of the Art Cosmetic and
Reconstructive Anatomy Course
and Cadaver Laboratory
EDUCATIONAL DVD-ROM
See it at the ASDS Booth #108
Or order today at www.asds.net or call 847-956-0900.
$149.95 ASDS members
$209.95 Non-member dermatologists
U.S. shipping and handling included. Sales tax for
Illinois residents and international shipping will be
added to applicable orders.
9
PROGRAM-AT-A-GLANCE
Don’t miss our KEYNOTE SPEAKERS IN SALON 2 & 3): RADM Boris D. Lushniak, MD, MPH – Thursday, 9:40 am;
Michael McMillan – Friday, 9:10 am and Mohit Bhandari, MD, PhD, FRCSC – Saturday, 9:00 am
WEDNESDAY, NOVEMBER 2, 2011
8:30 am – 4:15 pm
1:00 – 5:15 pm
1:00 – 5:30 pm
PRE-CONFERENCE: Managing Change: Practice Management
in a Changing Healthcare Environment (Maryland C)
Pre-conference Director: Derek Jones, MD
(Additional fee and registration required)
RESIDENTS/POST-RESIDENCY TRAINEES
PRE-CONFERENCE: Starting Your Practice:
Advance Knowledge is Power (Maryland A)
Symposium Directors: Kavita Mariwalla, MD; George Hruza, MD
Supported by a grant from Medicis Aesthetics
2:00 - 3:15 pm
SCIENTIFIC SESSIONS
RX114
2:00 – 3:15 pm
AFTERNOON TEAS
WITH THE MASTERS
ASDS INDUSTRY ADVISORY COUNCIL RECEPTION
FOR RESIDENTS/POST-RESIDENCY TRAINEES (Madison)
5:30 - 7:00 pm
YOUNG DERMATOLOGIC SURGEON RECEPTION
(Harding)
Graciously supported by NeoStrata Company, Inc.
Elizabeth Tanzi, MD; Jeffrey S. Dover, MD
MC123
TALKS
7:15 – 9:00 am
AB101
Evaluating the Cosmetic Patient (Maryland C)
Richard G. Glogau, MD; Heidi A. Waldorf, MD
AB102
Techniques for Flap Success (Maryland B)
Joel Cook, MD; Christopher J. Miller, MD
AB103
Dipping Your Toes into the Liposuction Lake
(Maryland A)
Kyle Coleman, MD; Norma H. Kassardjian, MD
AB104
Managing Unusual Tumors (Virginia A)
Kishwer S. Nehal, MD; Vicki J. Levine, MD;
Erica Lee, MD
AB105
Core Curriculum in Cosmetic Dermatologic
Surgery Track: Lasers (Virginia B)
Arielle N.B. Kauvar, MD; Suzanne L. Kilmer, MD
AB107
Hair Restoration (Hoover)
Marc R. Avram, MD; Dow B. Stough, IV, MD
NETWORKING BREAK IN EXHIBIT HALL
(Complimentary beverages served)
4:00 - 5:30 pm
SCIENTIFIC SESSION
GD130
5:30 – 7:00 pm
A CAPITAL WELCOME: RECEPTION AND SILENT AUCTION
(Marriott Foyer) (Open to all attendees.)
Graciously supported by Dermik, a business of sanofi-aventis
7:00 – 9:00 pm
INDEPENDENT INDUSTRY ORGANIZED HOT TOPIC SESSIONS
New Wave of Radiofrequency: Breakthrough Technologies
for Evidence Based Face and Body Rejuvenation (Virginia C)
Mastering Fractional Co2 Treatments with the SmartXide
Dot (Virginia A)
Laviv: The First and Only FDA Approved Cell Therapy for
Personalized Aesthetics (Maryland A & B)
7:15 – 8:45 am
MORNING COFFEE
TALKS
FRIDAY, NOVEMBER 4, 2011
AB201
8:45 – 9:00 am
TRANSITION BREAK FROM COFFEE TALKS
AB203
9:00 – 9:40 am
OPENING
9:00 am
9:08 am
9:17 am
AB204
SESSION (Salon 2 & 3)
President and Program Co-chairs Remarks
Session Teasers
Future Leaders Network Presentations
10:30 – 10:45 am
TRANSITION BREAK
10:45 – 11:30 am
SCIENTIFIC SESSIONS
CS110
Surgical and Non-surgical Body Sculpting
(Salon 2)
PM129
Patient Images and Consents: Protecting Your
Practice and Your Patients
(Salon 1)
Abel Torres, MD; Jeanine B. Downie, MD
Medical Treatment of Skin Cancer
(Salon 3)
Whitney D. Tope, MD; Scott W. Fosko, MD
Mathew M. Avram, MD, JD; Gary Lask, MD
RX112
11:30 am – 12:30 pm
SCIENTIFIC SESSIONS
CS113
Advanced Fillers (Salon 2)
GD114
You Asked for It Session (Salon 1)
Ken K. Lee, MD; Dee Anna Glaser, MD
If You Could Only Buy Two Types of Lasers
Which Would You Buy? (Salon 3)
E. Victor Ross, MD
12:30 - 2:00 pm
AB205
AB206
AB207
EXHIBIT HALL OPENING (Complimentary light lunch)
RESIDENTS LUNCHEON (Maryland A & B)
Graciously supported by Allergan, Inc.
GD120
RESEARCH LUNCHEON SESSION:
Dermatologic Surgery Procedures: What
is Known About Evidence-based Medicine
Demonstrated Through Select Topics
(Virginia C)
Murad Alam, MD; Suzanne Olbricht, MD
Non-invasive Fat Reduction (Maryland B)
Mathew M. Avram, MD, JD; Adam M. Rotunda, MD
Fillers and Toxins: Maximizing Injections and
Minimizing Tools (Maryland C)
Dee Anna Glaser, MD; Michael S. Kaminer, MD
Managing Skin Cancers in Organ Transplant
Recipients (Virginia A)
Fiona O’Reilly Zwald, MD; Chrysalyne Schmults, MD
Non-surgical Eye Rejuvenation (Virginia B)
Rebecca Fitzgerald, MD; Doris J. Day, MD
Comprehensive Coding (Virginia C)
George J. Hruza, MD; Brett M. Coldiron, MD
Science of Skin Care (Hoover)
Patricia Farris, MD; Zoe D. Draelos, MD
7:15 – 8:45 am
RESIDENTS/POST-RESIDENCY TRAINEES/YOUNG
DERMATOLOGIC SURGEONS HOSPITALITY SUITE (Harding)
8:00 – 9:00 am
NETWORKING IN EXHIBIT HALL
(Complimentary light breakfast fare served)
8:45 – 9:00 am
9:00 – 10:15 am
GENERAL SESSION
9:00 am
9:10 am
10:15 – 11:00 am
11:00 am – 12:15 pm
SCIENTIFIC SESSIONS
CS211
Lisa M. Donofrio, MD; Seth L. Matarasso, MD
CS114
Reconstructive Challenge - Lip and Ear
(Maryland A)
Rachel Moore, MD; Isaac M. Neuhaus, MD;
Andrea Willey, MD
AB202
KEYNOTE SPEAKER: RADM BORIS D. LUSHNIAK, MD, MPH,
U.S. DEPUTY SURGEON GENERAL
Graciously supported by Merz Aesthetics (Salon 2 & 3)
Iron Surgeon:
Reconstructive and Cosmetic (Salon 2 & 3)
Andrew J. Kaufman, MD; Thomas E. Rohrer, MD
9:40 – 10:30 am
Reconstructive Challenge: Eyes and Nose
(Virginia B)
Jeremy S. Bordeaux, MD, MPH; Ken K. Lee, MD
Surgery Track: Fillers (Hoover)
Stephen H. Mandy, MD; Melanie Palm, MD, MBA;
Cheryl M. Burgess, MD
3:15 – 4:00 pm
THURSDAY, NOVEMBER 3, 2011
7:15 – 8:45 am
MORNING COFFEE
Lasers: The Pulsating Truth on the Latest
and Greatest (Salon 2)
Tina S. Alster, MD; Roy G. Geronemus, MD
Pathology Babble: What Does My
Dermatopathologist Mean? (Salon 3)
Valencia D. Thomas, MD
MC121
Complications in Light-based Technologies
(Virginia A)
MC122
HANDS-ON WORKSHOP (Young Dermatologic Surgeons
Only) (Maryland B)
Workshop Director: Naomi Lawrence, MD; Patrick K. Lee, MD
Supported by ETHICON, Inc. and a grant from Merz Aesthetics
5:30 – 6:15 pm
CS128
RS213
Session Teasers (Salon 2 & 3)
KEYNOTE SPEAKER: Michael McMillan, BestSelling Author, Speaker, and Innovation and
Creativity Consultant (Salon 2-3)
Graciously supported by Merz Aesthetics
Controversies in Dermatologic Surgery (Salon 3)
Murad Alam, MD; Roberta D. Sengelmann, MD
Resident Oral Abstracts (Salon 1)
Monica Halen, MD; Allison Hanlon, MD
12:15 – 12:30 pm
TRANSITION BREAK TO MEMBERS BUSINESS MEETING/
EXHIBITS
12:30 – 1:30 pm
ANNUAL MEMBERS BUSINESS MEETING LUNCH
(Members ONLY) (Salon 3)
12:30 – 1:30 pm
NETWORKING BREAK IN EXHIBIT HALL (Light lunch available
for purchase – non-members/non-business meeting attendees)
Posters, including a special resident section, are available for viewing in the exhibit hall during hall hours.
10
PROGRAM-AT-A-GLANCE
1:30 - 3:00 pm
SCIENTIFIC SESSIONS
CS228
GD231
1:30 - 3:00 pm
AFTERNOON TEAS
WITH THE MASTERS
Dermatologic Surgery Around the World
(Salon 3)
CS312
MC224
MC225
MC226
Surgery of the Nail: Hammering Down Your
Technique (Maryland B)
Phoebe Rich, MD
Surgery: Veins (Maryland C)
Girish S. Munavalli, MD; Jeffrey T.S. Hsu, MD
The State-of-the-Art in Botulinum Toxin
Treatments (Virginia A)
Joel L. Cohen, MD; Sue Ellen Cox, MD;
Alastair Carruthers, FRCPC
Aesthetics and Ethnic Skin (Virginia B)
Pearl E. Grimes, MD; Jeanine B. Downie, MD;
Jonith Y. Breadon, MD
What to Do When a Chart Audit Happens
to You (Virginia C)
Mark S. Nestor, MD, PhD; Allan S. Wirtzer, MD
3:00 – 3:45 pm
3:45 – 5:15 pm
SCIENTIFIC SESSIONS
PD240
(Complimentary light lunch; Hall closes at 2:00 pm)
YOUNG DERMATOLOGIC SURGEONS LUNCHEON (Hoover )
WOMEN’S DERMATOLOGIC SURGEONS LUNCHEON
(Advance registration through WDS required) (Wilson A-C)
INDUSTRY ADVISORY COUNCIL LUNCH
(Open to IAC members only) (Madison)
2:00 – 3:30 pm
SCIENTIFIC SESSIONS
CS309
CS310
2:00 - 3:30 pm
AFTERNOON TEAS
WITH THE MASTERS
CS233
5:30 – 7:00 pm
WINE AND CHEESE RECEPTION IN EXHIBIT HALL
Graciously supported by Revance Therapeutics
MC321
Getting Started in Facelifts and Browlifts
(Virginia A)
MC322
Surgery: Neurotoxins (Virginia B)
Vince Bertucci, MD; Vivian W. Bucay, MD;
Mary P. Lupo, MD
PDT: Blue Light, Red Light, No Light?
A Comprehensive Review (Virginia C)
Macrene Alexiades-Armenakas, MD;
Mitchel P. Goldman, MD; Peter K. Lee, MD, PhD
Protecting Your Practice: Employee Management,
Theft and More (Maryland C)
David A. Laub, MD; Allan Wirtzer MD;
Steven Leninger CPA
MC323
MC324
3:30 – 3:45 pm
TRANSITION BREAK
3:45 - 5:15 pm
SCIENTIFIC SESSIONS
CS314
Repair of Repairs (Salon 2)
PM332
Entering the Electronic Age (Salon 3)
Saadia Raza, MD; Ashish Bhatia, MD
SATURDAY, NOVEMBER 5, 2011
7:15 – 8:45 am
MORNING COFFEE
TALKS
AB301
Facial Shaping (Maryland A)
3:45 – 5:15 pm
WORKSHOP
Derek H. Jones, MD; Nowell J. Solish, MD
AB302
AB303
AB304
AB305
AB306
AB307
Patient Safety (Maryland B)
Conway C. Huang, MD; Carl F. Schanbacher, MD
Managing Surgical Complications (Maryland C)
Tatyana R. Humphreys, MD;
Hugh M. Gloster, Jr., MD; Marc D. Brown, MD
Reconstructive Challenge: Legs, Arms and Scalp
(Virginia A)
Scott Isenhath, MD; Juan-Carlos Martinez, MD;
Joseph Sobanko, MD
How to Build and Manage a Cosmetic Practice
(Virginia B)
Paul M. Friedman, MD; Vic A. Narurkar, MD
Blepharoplasty Basics: How to Get Started
(Virginia C)
Sorin Eremia, MD; Steven C. Dresner, MD
The International Dermatologic Surgery
Mentorship Exchange Program – An Endowed
Teaching Program (Hoover)
Lawrence M. Field, MD
7:15 – 8:45 am
8:00 – 9:00 am
NETWORKING IN EXHIBIT HALL
(Complimentary light breakfast fare served)
8:45 – 9:00 am
9:00 – 9:50 am
SPECIAL KEYNOTE SPEAKER : Mohit Bhandari, MD, PhD,
FRCSC (Salon 2 & 3)
9:50 - 10:00 am
ITMP PRESENTATION: Lawrence M. Field, MD
10:00 – 10:45 am
10:45 – 11:30 am
SCIENTIFIC SESSIONS
CS327
What’s New in Fat Transfer (Salon 2)
PM310
Practice Management Pointers for the
Perfectionist (Salon 3)
Mary E. Maloney, MD; Elizabeth I. McBurney, MD
General Dermatologic Surgery Abstracts (Salon 1)
Deborah MacFarlane, MD; Kee Yang Chung, MD
3:45 – 5:15 pm
PATIENT
David G. Brodland, MD; Jonathan L. Cook, MD
WS330
Hands-on Workshop: Fillers and
Injectables (Maryland B )
Dee Anna Glaser, MD; Rhoda S. Narins, MD
PD340
DEMONSTRATIONS
3:45 – 5:15 pm
AFTERNOON TEAS
WITH THE MASTERS
Patient Demonstrations: Advanced
Sclerotheraphy and Other Vein Treatments
(Maryland A)
Girish S. Munavalli, MD; Robert A. Weiss, MD
MC330
MC331
MC332
Surgery: Peels (Virginia A)
Harold J. Brody, MD; Gary D. Monheit, MD;
Seaver Soon, MD
Scar Wars (Virginia B)
Suzanne L. Kilmer, MD; Peter R. Shumaker, MD;
Kenneth A. Arndt, MD
How to Develop Your Own Skin Line
(Virginia C)
Patricia S. Wexler, MD; Katie Rodan, MD
6:00 – 7:30 pm
SECOND ANNUAL FLIGHT WITH THE MASTERS: TASTING
WINE WITH YOUR BRAIN (Coolidge)
(Tickets required for attendance)
Stephen H. Mandy, MD and Robin Kelley O’Connor, Christie’s
Head of Wine, Americas
7:00 pm – Midnight
A STAR-SPANGLED SOIRÉE
SIXTH ANNUAL GALA RECEPTION AND DINNER
(Tickets required for attendance) (Thurgood Marshall Ballroom)
SUNDAY, NOVEMBER 6, 2011
8:30 – 10:00 am
SCIENTIFIC SESSION
GD400
8:30 – 11:30 am
WORKSHOP
10:00 – 11:30 am
SCIENTIFIC SESSION
CS401
11:30 am
MEETING ADJOURNS
Naomi Lawrence, MD; William P. Coleman, III, MD
RX311
Cosmetic Chaos - How to Stay Coherent
Following Complications (Salon 2)
Vic A. Narurkar, MD; Douglas G. Hamilton, MD
Managing Common Medical Mishaps
(Salon 3)
Abel Torres, MD; Jenny Kim, MD, PhD
Steven M. Rotter, MD; Greg S. Morganroth, MD
Patient Demonstration - Fillers and Neurotoxins
(Salon 2)
Better Than Pearls: Reconstructive Diamonds
(Salon 3)
Christopher J. Arpey, MD; Hayes B. Gladstone, MD
Cosmetic Oral Abstracts (Salon 1)
Rebecca Kazin, MD; Rebecca C. Tung, MD
Commonly Seen Defects: How Would You
Reconstructive It? (Salon 2)
Glenn D. Goldman, MD; George J. Hruza, MD
Late-breaking Oral Abstracts (Salon 1)
Quenby Erickson, DO; Joely Kaufman, MD
12:30 – 2:00 pm
Jean Carruthers, MD; Miriam P. Cummings, MD;
HemaSundaram, MD
RX229
How to Enter the Social Media Age (Salon 3)
Darrell S. Rigel, MD; Alysa R. Herman, MD
Cutting Edge Research Grant Award and
Research Abstracts (Salon 1)
Sigried Yu, MD; Eva A. Hurst, MD
Gregory J. Goodman, MD;
Christopher B. Harmon, MD; Douglas Fife, MD
MC223
PM313
RX314
MC221
Acne Scarring (Maryland A)
MC222
11:30 am - 12:30 pm
SCIENTIFIC SESSIONS
Susan H. Weinkle, MD
Global Cancer Treatments (Salon 1)
(Includes Buffet Breakfast)
John A. Carucci, MD, PhD; Carl V. Washington, MD
WS410
Hands-on Workshop: Tumor Excision/
Wound Repair and Injectables (Maryland A)
(Residents/Post-residency Trainees ONLY)
Kavita Mariwalla, MD; Murad Alam, MD
Cosmetic Quick Tips (Salon 3)
Kimberly J. Butterwick, MD; Timothy Flynn, MD
Program participants and timing subject to change. Social functions are subject to change based on participation levels.
11
2011 COMMERCIAL SUPPORT
It is through the participation and generous contributions of our commercial supporters
that we are able to offer you quality educational programming.
The ASDS would like to express sincere appreciation and thanks
to the following companies for their support.
PLATINUM LEVEL SUPPORT
$250,000 and above
Allergan, Inc.
and the Allergan Foundation
GOLD LEVEL SUPPORT
$175,000-$249,000
Medicis Aesthetics, Inc.
SILVER LEVEL SUPPORT
$100,000 - $174,999
Merz Aesthetics
BRONZE LEVEL SUPPORT
$50,000-$99,999
ETHICON
Galderma Laboratories
COPPER LEVEL SUPPORT
$25,000-$49,999
Fibrocell Science
KYTHERA Biopharmaceuticals
Lumenis, Inc.
Merz Pharmaceuticals
Obagi Medical Products, Inc.
Procter & Gamble
Syneron/Candela, Inc.
BRASS
$15,000 - $24,999
DEKA Medical, Inc.
Neutrogena
Palomar Medical Technologies, Inc.
PEWTER
Up to $14,999
Delasco
NeoStrata Company
Onset Dermatologics
SkinCeuticals
Tiemann Surgical
Ulthera, Inc.
ZELTIQ
Please extend a special thanks to these generous supporters while visiting the technical exhibits.
ASDS is extremely grateful for the support of industry partners. The provision of support does not in
Supported by
The first-ever Resident Knowledge Bowl will be held in the exhibit hall. Residents
any
way
imply
commercial
input
into
the
educational
content
of
this
meeting.
All
content
has
abeen
grant from
will go head to head in a Jeopardy-style competition to compete for cash prizes and
developed
to
be
fair
and
balanced
and
the
result
of
content
oversight
that
is
free
of
bias.
test their knowledge in surgical and procedural dermatology, as well as current events.
The competition will take place during lunches and receptions in the hall. Don’t miss it!
*As of October 18, 2011
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
HOT TOPIC SESSIONS
Thursday, November 3 s 7:00 – 9:00 pm
Everyone is welcome to attend the following Hot Topic Sessions hosted
by members of Industry to learn new developments and technologies.
Laviv: The First and Only FDA
Approved Cell Therapy for
Personalized Aesthetics
Hosted by Fibrocell
Maryland A & B
Mastering Fractional Co2 Treatments
with the SmartXide Dot
Hosted by DEKA Medical, Inc.
Virginia A
New Wave of Radiofrequency:
Breakthrough Technologies for
Evidence Based Face and Body
Rejuvenation
Hosted by Syneron/Candela
Virginia C
The above sessions are independent of the 2011 ASDS Annual Meeting
with regard to topic, planning, and available CME credits.
Don’t Miss the Biggest Celebration
of the Year at the ASDS Annual Meeting!
Saturday, November 5, 2011 • 7:00 pm - Midnight
Washington Marriott Wardman Park • Thurgood Marshall Ballroom
Dinner, dancing and entertainment
by the Right On Band – the World’s Greatest
70’s Show Band
This promises to be the talk of the meeting!
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
$125 per person — a limited number of tickets
are available at the Onsite Registration Desk.
GENERAL INFORMATION
Providing the fastest fractional resurfacing
options in the industry – full face coverage
in as little as 5 minutes.
Unmatched Speed
Superior Safety
Proven Efficacy
Application Versatility with In-Motion,
Stationary Delivery and Surgical Options
Laser
Beam
Final Laser
Pixel Beams
Epidermis
Dermis
Visit Booth #1514 during exhibit hours
Call now for an onsite demonstration.
almalasers.com | 866.414.2562 x2010
Connect with Alma Lasers on
almalasers.com/connect
©2011 Alma Lasers, Inc. All rights reserved. ProgASDS112011
Scan this with your
smartphone to learn more.
ASDS
A
SDS CME
CME MISSION
MISSION STATEMENT
STATEMENT
2011
ATTENTION:
• Residents
• Post-residency Trainees
• Young Dermatologic Surgeons
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
Welcome to the Premier Educational Forum for Dermatologists who specialize
in Cosmetic, Mohs Micrographic and General Dermatologic Surgery!
2011 Annual Meeting features:
•
Diverse scientific sessions
•
Intimate instructional morning Coffee Talks and afternoon
Teas with the Masters
•
Live patient demonstrations
•
Dynamic keynote lectures
•
Reconstructive Challenge track
•
The now popular “You Asked for It” session and the
unopposed Iron Surgeon Competition
•
Networking via luncheon and social events including the
Sixth Annual Fundraising Gala Reception and Dinner: A
Star-Spangled Soirée
•
Expansive exhibits featuring over 110 companies
•
And more!
Special resident/Post-residency trainee
focused offerings:
•
Resident/Post-residency Trainee Practice
Management Pre-conference
•
Wednesday Industry Advisory Council reception
to network and learn the latest information
•
Hands-on Workshops: Tumor Excision/Wound Repair and
Injectables, and Fillers and Injectables
Supported by ETHICON, Inc. and a grant from Merz
Aesthetics
NEW! Attend the Resident Knowledge
Bowl and cheer on your favorite resident
The first-ever Resident Knowledge Bowl will be held in the exhibit
hall at the 2011 ASDS Annual Meeting. Resident teams from
across the country will meet fierce competitors as they battle in
a Jeopardy-style competition to win cash prizes and test their
knowledge in surgical and procedural dermatology, as well as
current events. There will be several rounds of competition during
lunches and the Wine & Cheese Reception in the exhibit hall. The
grand prize winners will walk away with $1,000 cash, a trophy,
and bragging rights as the first ever ASDS Resident Knowledge
Bowl Grand Champions!
COMPETITION SCHEDULE IN BOOTH #100 IN THE EXHIBIT HALL:
Thursday, Nov. 3 1:00 pm - 1:30 pm
Friday, Nov. 4
6:00 pm - 6:30 pm
Saturday, Nov. 5
1:00 pm - 1:30 pm
Special young dermatologic surgeonfocused offerings:
•
Hands-on Workshops: Tumor Excision/Wound Repair and
Injectables, and Fillers and Injectables
Supported by ETHICON, Inc. and a grant from Merz
Aesthetics
•
Wednesday reception to network and learn the latest
information
Graciously supported by
NeoStrata Company,Inc.
•
Morning Hospitality Suite
•
Morning Hospitality Suite
•
Resident Luncheon
•
Young Dermatologic Surgeon Luncheon
•
ASDS Resource Center – information on offerings with
reduced rates for Residents
•
Core-curriculum in Cosmetic Dermatologic Surgery track
•
Core-curriculum in Cosmetic Dermatologic Surgery Track
Visit the ASDS Resource Center, Booth # 108 in the Exhibit Hall
for a complete overview of offerings!
For more information, contact the ASDS Headquarters office via
the web at www.asds.net or by phone at (847) 956-0900.
From the myriad continuing medical education sessions,
to exhibits to social events, you’ll find the perfect balance
of content and networking for professional growth and
information you can apply to your practice and patient
care. Sessions are coded based on the ACGME/ABMS Core
Competencies to which they are relevant.
B
UTY
CHO
IC
PRODUCT
E
EA
NE WBEAUT Y
WINNER
AW
ARD
INTRODUCING A PORTFOLIO OF PRODUCTS
EXCLUSIVELY DEVELOPED FOR PHYSICIAN OFFICES
Jan Marini Skin Research is a leading manufacturer of clinically validated skin care and aesthetic products for the professional
marketplace. Jan Marini Skin Research is known for creating breakthrough product solutions and dramatic technological
HK]HUJLTLU[Z 6]LY [OL `LHYZ [OL JVTWHU` OHZ LZ[HISPZOLK H WVY[MVSPV VM WYVWYPL[HY` MVYT\SHZ [OH[ YLÅLJ[ P[Z VUNVPUN
commitment to be the preeminent developer of skin care products that produce measurable clinical results. Continuing the
tradition of innovation, Jan Marini Skin Research introduces four new products exclusively for the physician market...
The Skin Care Management System MD™ is formulated
Age Intervention® Enlighten MD is specifically
for all skin types and is designed for prolonged use with little
to no irritation or acclimation. It utilizes synergistic layered
technology to measurably improve the appearance of common
skin conditions such as:
designed to combat the appearance of sun damage, fine
lines, wrinkles and hyperpigmentation. The advanced
non-hydroquinone formulation delivers rapid improvement
with long-term control to achieve maximum results. Facial
skin will appear noticeably more even toned, smooth
and rejuvenated.
Acne
Fine Lines & Wrinkles
Hyperpigmentation
Rosacea
Age Intervention® Retinol Plus MD is a unique
Age Intervention® Duality MD™ is a breakthrough
WHFKQRORJ\ WKDW PD[LPL]HV WKH DIIHFW RI UHWLQRO WR VLJQLÀFDQWO\
LPSURYHWKHDSSHDUDQFHRIÀQHOLQHVDQGZULQNOHVZLWKPLQLPDO
irritation and little to no acclimation period. Especially
formulated to utilize the maximum amount of all-transretinol PLUS anti-aging and collagen boosting peptides,
antioxidants, hydrators and skin soothing ingredients.
anti-aging acne solution. The unique dual chamber
dispensing solution combines the maximum allowed
percentage of benzoyl peroxide and a concentrated retinol.
The gentle formulation also includes powerful anti-aging
technologies, including multiple peptides, anti-inflammatory
agents and antioxidants.
JANMARINI.COM
© 2011 Jan Marini Skin Research, Inc - MDASDS09/11
2012 CALL FOR ABSTRACTS
January 16 - February 27
www.asds.net
Save the Date!
Add CURL, SHINE and BEAUTY
to your Natural Eyelashes!
• Dermatologist and
Ophthalmologist Tested
• Non-allergenic
• Over 97% Saw an Improved
Appearance of Eyelashes in
Only 3 Weeks!
Booth 624
877-909-5274
revitalash.com
The Future of
Dermatologic Surgery
is in your Hands…
…and the American Society for Dermatologic
Surgery (ASDS) Dermasurgery Advancement Fund
is helping to ensure that future is a very bright one.
How? The Dermasurgery Advancement Fund (DSAF) supports
three areas of great importance to the specialty:
Research
Public Awareness
about the scope
of our practice
Patient
Education
You can help shape the future of dermatologic surgery. Give to the
Dermasurgery Advancement Fund today…
because our future depends on it.
To make a donation, call ASDS at 847-956-0900,
or contribute online at www.asds.net.
The ASDS Board of Directors is pleased to recognize the
2011 contributors to The Dermasurgery Advancement Fund.
SUSTAINING STEGMAN CIRCLE MEMBERS
$30,000 - $49,999
$26,000 - $29,999
Gifts of more than
original $25,000 pledge
Gifts of more than
original $25,000 pledge
Murad Alam, MD
Jean Carruthers, MD
Tina Alster, MD
Hal Brody, MD
Kim. Butterwick, MD
STEGMAN CIRCLE
MEMBERS
Amy Derick, MD
Lisa M. Donofrio, MD*
Jeffrey S. Dover, MD, FRCPC*
Patricia Farris, MD
Rebecca Fitzgerald, MD
Timothy Flynn, MD
Paul J. Frank, MD
Paul M. Friedman, MD
Louis R. Frisin
Henry Gasiorowski, MD &
Michele Gasiorowski, MD
Roy G. Geronemus, MD*
Hayes B. Gladstone, MD*
Dee Anna Glaser, MD*
David J. Goldberg, MD, JD*
Leonard Goldberg, MD
Mitchel P. Goldman, MD*
Pearl E. Grimes, MD*
Karyn L. Grossman, MD*
Douglas G. Hamilton, MD*
Tiffani K. Hamilton, MD
Gifts of $25,000 over 5 years
Murad Alam, MD*
Tina S. Alster, MD*
Rex A. Amonette, MD*
David E. Bank, MD
Steve Basta
Leslie Baumann, MD*
Leonard J. Bernstein, MD*
Jeffrey H. Binstock, MD
Harold J. Brody, MD*
Forrest C. Brown, MD*
Kimberly J. Butterwick, MD*
Alastair Carruthers, FRCPC*
Jean Carruthers, MD*
Suneel Chilukuri, MD*
Brett M. Coldiron, MD*
Sue Ellen Cox, MD*
Doris J. Day, MD*
Carrie Jacob, MD
Sue Ellen Cox, MD
Jeffrey Dover, MD
Roy Geronemus, MD
Naomi Lawrence, MD
Gary Monheit, MD
Liz Tanzi, MD
Susan Weinkle, MD
Pat Wexler, MD
Robert A. Weiss, MD*
Kathleen M. Welsh, MD
Patricia S. Wexler, MD*
John A. Zitelli, MD
C. William Hanke, MD*
Christopher B. Harmon, MD*
William L. Heimer, II, MD
Ranella Hirsch, MD
George J. Hruza, MD*
Hiroshi Ikeno, MD
Carolyn I. Jacob, MD*
Derek H. Jones, MD
David A. Laub, MD*
Naomi Lawrence, MD*
Mary P. Lupo, MD
Stephen H. Mandy, MD*
Joseph M. Masessa, MD
Seth L. Matarasso, MD*
Elizabeth I. McBurney, MD*
Gary D. Monheit, MD*
Rhoda S. Narins, MD*
Vic A. Narurkar, MD
Mark S. Nestor, MD, PhD*
Thomas G. Olsen, MD
Melanie Palm, MD, MBA
William T. Parsons, MD*
Laurie J. Polis, MD
Darrell S. Rigel, MD*
Thomas E. Rohrer, MD
Neil S. Sadick, MD*
Howard D. Sobel, MD
Neil A. Swanson, MD
Elizabeth Tanzi, MD*
Jennifer T. Trent, MD
Susan H. Weinkle, MD*
Margaret A. Weiss, MD
BENEFACTOR
SPONSOR
ADVOCATE
FRIEND
Gifts of $1,000 - $5,000
Gifts of $500 - $999
Gifts of $250 - $499
Gifts up to$250
Murad Alam, MD
Hiroshi Ikeno, MD
Elvira Chiritescu, MD
Tim Ioannides, MD
Glynis R. Ablon, MD
Christopher J. Arpey, MD
Kay Bishop, MD
Paul S. Cabiran, MD
Zoe D. Draelos, MD
Stephen Noah Horwitz, MD
Byron L. Limmer, MD
John C. Long, Jr. MD
Octant Marketing
Stephanie Smith-Phillips, MD
Amy F. Taub, MD
Whitney D. Tope, MD
Patricia S. Wexler, MD
Sylvia W. Wright, MD
Jay Applebaum, MD
Garin D. Barth, MD
Beatrice J. Berkes, MD
Kelly M. Bickle, MD
Chris N. Buatti, DO
Robert A. DeStefano, MD
Jean-Pierre D. Donahue, MD
David B. Flach, MD
Bert C. Frichot, MD
Jeffrey J. Heller, DO
Howard Hines, MD
Steven E. Hodgkin, MD
George J. Hruza, MD
Farouk Iqbal, MD
D. Scott Karempelis, MD
Tae-Heung Kim, MD
Francis C. Lee, MD
Christiane Machado, MD
Daria Maldonado-Knapp, MD
Jason D. Marquart, MD
D
T he
D e r m a s u r g e ry
F
Advancement
Fund
STEGMAN CIRCLE
CORPORATE
Gifts of $125,000 over 5 years
Allergan*
Dermik Aesthetics*
Galderma Laboratories*
Lumenis, Inc.
Medicis Aesthetics*
Mentor Corporation
Merz Aesthetics*
Merz Pharmaceuticals, LLC
Obagi Medical Products
Ortho Dermatologics
Aesthetic*
Stiefel, a GSK Company
Laura N. Marquart, MD
Maria I. Martinez-Colon, MD
David H. McDaniel, MD
Suzan Obagi, MD
Scott M. Ravis, MD
Jennifer M. Ridge, MD
Sarah K. Sarbacker, MD
Richard H. Shereff, MD, PA
Peter G. Singer, MD
Cindy Firkins Smith, MD
Michel A. Snyder, MD
Cylburn E. Soden, Jr. MD, MA
Cylburn E. Soden, Sr. MD
Adrienne E. Stewart, MD
Sabra Sullivan, MD, PhD
Viseslav Tonkovic-Capin, MD
Dwight R. Tribelhorn, MD
Ingrid Warmuth, MD
Michael R. Warner, MD
John R. West, MD
The American Society for Dermatologic Surgery gratefully acknowledges
the following corporate partners and ASDS members for providing support to the
11th Annual ASDS Silent Auction
ASDS Member Supporters*
Tina S. Alster, MD
Michael H. Gold, MD
Vic A. Narurkar, MD
Christopher B. Harmon, MD
Neil S. Sadick, MD
Jean Carruthers, MD
Bruce E. Katz, MD
Elizabeth Tanzi, MD
Sue Ellen Cox, MD
David M. Duffy, MD
Jennifer MacGregor, MD
Corporate Supporters*
Allergan, Inc.
Lasering, USA
NeoStrata® Company, Inc.
Allergan Medical
Liposuction.com, Inc.
Palmor Medical Technologies, Inc.
Biopelle, Inc.
Medco Data, LLC
Revision Skincare
Canfield Imaging Systems
NIA 24
Photocure
CONMED
Neocutis, Inc.
Procter & Gamble
Envy Medical
The Theraplex Company, LLC
Fallene, Ltd.
Tiemann Surgical
Galderma Labs
Ulthera®
HK Surgical
Viora
Jan Marini Skin Research, Inc.
Young Pharmaceuticals, Inc.
Kennedy Care, LLC
Be sure
to visit
the exhibit
booths with
balloons
to see their
donated silent auction
items and to place your bids.
ZELTIQ
Join us Thursday, November 3 from 5:30 pm -7:00 pm for the
ASDS Welcome Reception and Silent Auction
Marriott Foyer, Mezzanine Level
*As of October 18, 2011
A Capital Welcome
RECEPTION & SILENT AUCTION
All registered attendees are invited to enjoy
cocktails, hors d’oeuvres, entertainment and fun at the
11th Annual ASDS Silent Auction & Welcome Reception.
Recep
ption.
4HURSDAY.OVEMBERsPMPM
Marriott Foyer, Mezzanine Level
Bid
Bid on
on exciting
exciting items
items such
such as
as restaurant,
restaurant, hotel
hotel and
and
department store gift certificates, concert & sporting
event tickets,, “dayy with a doctor,”
doctor,,” electronics,, artwork,,
gift baskets, fine wines, collectibles, surgical instruments
and educational offerings, to name a few!
Proceeds from the
tth
h Silentt Auction
benefit ASDS programs and
an educational initiatives.
an
SlimVest
TM
Made in Switzerland
Body Contouring Suit
Reduce uS to
2 Sizes Ser Month
Non Invasive
QRWDPDFKLQH
0LQLPXP,QYHVWPHQW
Maximum Return
+LJKSDWLHQWVDWLVIDFWLRQ
6DIHIRUDOOVNLQW\SHV
&RPSDWLEOHZLWKDOORWKHU
ERG\FRQWRXULQJSURFHGXUHV
SRVWWUHDWPHQWDIWHUOLSRVXFWLRQ
ERG\VFXOSWLQJDQGRWKHUV
Institute and Home Programs
3HUVRQDOFKRLFHRIWRSGRFWRUVZRUOGZLGH
Patent registered system stimulates metabolism
while active ingredients combine to free and use
excess fat energy
See us at the ASDS 2011
Booth 501
Your Size Solution
made by Liquid Ice CosMedicals AG 6ZLW]HUODQG
www.SlimVest.com
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
KEYNOTE SPEAKERS
THURSDAY, NOVEMBER 3 9:40 – 10:30 am s Salon 2 & 3
Opening Keynote E
RADM Boris D. Lushniak, MD, MPH, U.S. Deputy Surgeon General
RADM Boris D. Lushniak, MD, MPH is the Deputy Surgeon General, assisting the Surgeon General in articulating the best available
scientific information to the public regarding ways to improve personal health and the health of the Nation. He also oversees the
operations of the U.S. Public Health Service Commissioned Corps comprising approximately 6,600 uniformed health officers who
serve in locations around the world to promote, protect, and advance the health and safety of the American People.
Dr. Lushniak’s career includes a position with the CDC during which he was part of the CDC/NIOSH team at Ground Zero (World
Trade Center) and part of the team investigating the anthrax attacks in Washington, DC. He later served as Chief Medical Officer
of the Office of Counterterrorism and then Assistant Commissioner with the FDA. While at the FDA, he was deployed to serve as
the DHHS representative in San Antonio during Hurricane Katrina. Dr. Lushniak was promoted in 2006 to Rear Admiral, Lower Half
and in 2010 to Rear Admiral, Upper Half. Dr. Lushniak recently completed his tour with the FDA as the Assistant Commissioner,
Counterterrorism Policy and Director of the Office of Counterterrorism and Emerging Threats within the Office of the
Commissioner.
FRIDAY, NOVEMBER 4 9:10 – 10:15 am s Salon 2 & 3
Special Keynote E
Michael McMillan, Best-Selling Author, Speaker, and Innovation
and Creativity Consultant
Michael McMillan has a reputation for creative thinking and delivering innovative results. Early in his career, his visual
communications firm counted among its client roster Fortune 100™ corporations, sports and music legends, non-profit
organizations and more. His creative direction on Michael Jordan’s New York Times best-selling pictorial autobiography Rare Air
established a new niche in retail publishing. Award-winning books Mario Andretti, The NBA at 50, and John Deer’s Genuine Value
followed. Michael’s work has been recognized by every major design, advertising and communication organization around the
world.
After 20 consecutive years of growth, Michel sold his firm to share his unique insight on creative thinking, innovation and making
a positive change. He is a perception catalyst and truth seeker, inspiring others to question, think differently, and take action. As an
accomplished author, some of his books include Pink Bat: Turning Problems into Solutions; Paper Airplane: A Lesson for Flying
Outside the Box, and; Jonny the Bagger: The Simple Truths of Service.
Michael McMillan’s breadth of knowledge and experience, combined with his story-telling ability, allow his messages to resonate
with audiences. Hear Michael’s keynote and leave highly motivated and committed to embracing a future of endless possibilities.
SATURDAY, NOVEMBER 5 9:00 – 9:50 am s Salon 2 & 3
Special Keynote E
Mohit Bhandari, MD, PhD, FRCSC, Academic Professor and Chair,
Department of Orthopaedic Surgery, McMasters University, Toronto
Mohit Bhandari MD, PhD, FRCSC, Professor and Academic Chair, Orthopaedic Surgery, McMaster University extensive research
broadly focuses upon clinical trials, meta-analyses, methodological aspects of surgery trials and the translation of evidence into
surgical practice. Specific areas of interest include identifying optimal management strategies to improve patient-important
outcomes in patients with multiple injuries, lower extremity fractures and severe soft tissue injuries.
Dr. Bhandari has been a leader in the area of fostering understanding of evidence-based medicine so that clinicians wishing to use
today’s medical literature will have a solid understanding of the validity and rigor upon which the information is based. He is a
sought after speaker, as well as a prolific author of many articles including “Challenges to the Practice of Evidence-Based Medicine
during Residents’ Surgical Training: A Qualitative Study Using Grounded Theory.” He has edited several textbooks in surgical
research and is senior editor of the textbook Evidence-based Orthopaedics. Join us as Mohit Bhandari, MD, makes evidence-based
medicine understandable and even exhilarating.
Keynote Lectures graciously supported by
CME DISCLOSURES OF INTEREST
11AMPM: Jeffrey S. Dover, MD, George J. Hruza, MD and Ella
L. Toombs, MD have no commercial interest to disclose. Eric F.
Bernstein, MD has a consulting relationship with Syneron and
Tria Beauty; ownership interest with Tria Beauty; has equity
with American Medical Media; received discounted or free
equipment from Cynosure, Deka and Syneron and has received
research funding from Cutera, Cynosure and Syneron. Brett M.
Coldiron, MD has received research funding from the ASDS.
Jeanine B. Downie, MD has a consulting relationship with
Allergan, Galderma, GSK/Stiefel, Intendis, Johnson & Johnson,
Medicis, Merz, Novantis, Photocure, Sanofi-aventis, SkinMedica,
Theraplex; received honoraria from Allergan, Galderma, GSK/
Stiefel, Intendis, Johnson & Johnson, Medicis, Merz, Novantis,
Photocure, Sanofi-aventis, SkinMedica and has received funding
from Allergan, GSK/Stiefel, Johnson & Johnson and Photocure.
Derek Jones, MD has a consulting relationship with and received
honoraria from Allergan, Galderma, Kythera and Merz; received
research funding with Allergan, Galderma and Merz. Gary
D. Monheit, MD has a consulting relationship with Allergan,
Dermik, Contura, Electro-Optical Sciences, Genzyme, Revance,
Kythera, Galderma, Mentor and Merz; received honoraria from
Galderma, Ipsen and Merz and research funding from Allergan,
Dermik, Contura, Electro-Optical Sciences, Galderma, Genzyme,
Ipsen/Medicis, Kythera, Mentor, Merz and Revance. Page S.
Piland has received writing honoraria from Allergan and Steifel.
Kristal Polder, MD has received honoraria and discounted or
free equipment from Solta Medical. Michael Sacopulos, JD has a
consulting relationship with Medical Justice. Hema A. Sundaram,
MD has a consulting relationship with ColorScience, Johnson &
Johnson Consumer Products, Medicis, Mentor, Merz, SkinMedica,
Suneva, Syneron/Candela, Ulthera and has received research
funding from Medicis, Merz, SkinMedica, Syneron/Candela,
Ulthera and has received discounted or Free Equipment from
Syneron/Candela.
11WS330: John M. Soderberg, MD has no commercial interest
to disclose. Alastair Carruthers, FRCPC has a Consulting
relationship and has received funding from Allergan and Merz.
Lisa M. Donofrio, MD is an Investigator with Allergan, Cynosure,
Galderma, Medicis, Merz; Clinical Grading Canfield, FotoFinder;
Ad Board Medicis; Clinical Trials Allergan, Medicis, Mentor,
Medicis; has consulted for Medicis, Merz, Niadyne, Unilever,
Vichy and has received honoraria from Canfield, FotoFinder,
Ipsen, L'Oreal, Medicis, Mentor, Niadyne. Dee Anna Glaser,
MD has a consulting relationship with Allergan, BioForm
Medical, Connetics, Johnson & Johnson, Proctor and Gamble,
Stiefel Laboratories and Unilever; has received honoraria from
Allergan, received research funding from Allergan, Altana, Anika
Therapeutics, Novartis and Valeo Pharma, ongoing relationship
with SkinMed: On Going Journal Relationship. Seth L. Matarasso,
MD has a consulting relationship with Allergan and Medicis.
Rhoda S. Narins, MD has a consulting relationship with Contura,
Merz/BioForm and Revance and has been an investigator for
Allergan, Contura, Galderma, Merz/BioForm, Revance and
Suneva. Melanie Palm, MD, MBA has received honoraria from
Lumenis, Medicis and Sanofi-aventis.
26
11WS410: Murad Alam, MD, Allison Hanlon, MD and Daniel
I. Wasserman, MD have not commercial interest to disclose.
Jeremy S. Bordeaux, MD, MPH has received research funding
from Dermatology Foundation. Kimberly J. Butterwick, MD – has
a consulting relationship and received honoraria from Allergan
and Sanofi-aventis, has ownership interest in SkinMedica and
has received funding from Allergan and SkinMedica. Rebecca C.
Tung, MD – has received honoraria from Medicis and Merz.
11WSYDS: Ryan W. Ahern, MD, Jonathan L. Bingham, MD,
Naomi Lawrence, MD, Patrick K. Lee, MD, Juan-Carlos Martinez,
MD, Chad L. Prather, MD and Teresa Soriano, MD have no
commercial interest to disclose. Joseph F. Greco, MD has received
honoraria from Sciton.
KeyNote: Boris Lushniak, MD has no commercial interest to
disclose.
Keynote: Michael McMillan has no commercial interest to
disclose
Keynote: Mohit Bhandari, MD, PhD, FRCSC has no commercial
interest to disclose.
AB101: Richard G. Glogau, MD has a consulting relationship
with Allergan, Liposonix, Lumenis, Medicis, Myoscience, Revance,
Skin Map, Tautona and ownership interest in Skin Map. Heidi A.
Waldorf, MD has received honoraria from Merz Aesthetics, has a
relationship as consultant to Medicis, Allergan, Biopelle, Unilever,
Proctor & Gamble, Valeant, Athena and Solta, Board of Directors
for WDS as well as co-chair of fundraising and a member
Volunteers Council with AAD.
AB102: Joel Cook, MD and Christopher J. Miller, MD have no
commercial interest to disclose.
AB103: Kyle Coleman, MD and Norma H. Kassardjian, MD have
no commercial interest to disclose.
AB104: Erica M. Lee, MD, Vicki J. Levine, MD and Kishwer S.
Nehal. MD have no commercial interest to disclose.
AB105: Arielle N.B. Kauvar, MD has received research funding
from Candela and Palomar. Suzanne L. Kilmer, MD has a
consulting relationship and received honoraria from Candela,
Cutera, Cooltouch, Cynosure, Iriderm, Lumenis, Miramar,
Palomar, Sciton, Solta, Ulthera and Zeltiq.
AB107: Marc R. Avram, MD has a consulting relationship and
ownership interest with Biolux. Dow B. Stough, IV, MD is a
Non-Paid consultant for Transderm Cap Inc, a Laser Hair Growth
Device Company.
AB201: Rachael Moore, MD, Isaac M. Neuhaus, MD and Andrea
Willey, MD have no commercial interest to disclose.
AB202: Mathew M. Avram, MD, JD has a consulting relationship
with Merz and Zeltiq and stock options with Biolux and Zeltiq.
Adam M. Rotunda, MD has a consulting relationship with
Kythera Biophram and Lithera, ownership interest with Kythera
Biophram and honoraria with Lithera.
AB203: Dee Anna Glaser, MD has a consulting relationship
with Allergan, BioForm Medical, Connetics, Johnson & Johnson,
Proctor and Gamble, Stiefel Laboratories and Unilever; has
received honoraria from Allergan; has received research funding
from Allergan, Altana, Anika Therapeutics, Novartis and
Valeo Pharma and has relationships with American Academy
of Cosmetic Surgery: Board Member, American Academy of
Dermatology: Committee Member, American Board of Cosmetic
Surgery: Board Member, Archives of Dermatology: Ongoing
Journal Relationship, Cosmetic Surgery Foundation: Board
Member, International Hyperhidrosis Society: Board Member,
Missouri Dermatology Society: Board Member, Practical
Dermatology: Ongoing Journal Relationship, SkinMed: On Going
Journal Relationship. Michael S. Kaminer, MD has a consulting
relationship with Cabodian, Miramar, Solta and Zeltiq, has
ownership interest with Cabodian, Miramar and Zeltiq, has
received honoraria from Zeltiq and research funding from
Cabodian, Miramar, Solta and Zeltiq.
AB204: Chrysalyne Schmults, MD has no commercial interest
to disclose. Fiona O'Reilly Zwald, MD has received funding from
Derm Foundation.
AB205: Doris J. Day, MD has a consulting relationship and has
received honoraria from Allergan, Medicis and Merz. Rebecca
Fitzgerald, MD – has a consulting relationship with Sanofi-aventis
and has received honoraria from Allergan, Medicis and Merz.
AB206: George J. Hruza, MD has no commercial interest to
disclose. Brett M. Coldiron, MD has received research funding
from the ASDS.
AB207: Zoe D. Draelos, MD has no commercial interest to
disclose. Patricia Farris, MD has a consulting relationship and
received honoraria from Beiersdorf, Guthy-Renker, Medicis,
Neostrata, Neutrogena and receives Royalties from Guthy-Tenker.
AB301: Derek Jones, MD – has a consulting relationship with
and received honoraria from Allergan, Galderma, Kythera and
Merz; has received research funding with Allergan, Galderma
and Merz; serves on the Editorial Board of JDS and JCLT. Nowell
J. Solish, MD has a consulting relationship and has received
research funding from Allergan, Medicis, Allergan and has
honoraria with Allergan and Medicis.
AB302: Andrew A. Nelson, MD and William Stebbins, MD have
no commercial interest to disclose. Carl F. Schanbacher, MD
has a consulting relationship and has received honoraria from
Ethicon.
AB303: Hugh M. Gloster, Jr., MD and Tatyana R. Humphreys,
MD have no commercial interest to disclose. Marc D. Brown, MD
has a consulting relationship and has received honoraria from
Graceway and Novartis.
AB304: Scott Isenhath, MD, Juan-Carlos Martinez, MD and
Joseph Sobanko, MD have no commercial interest to disclose.
AB305: Paul M. Friedman, MD has received honoraria from
Solta Medical. Vic A. Narurkar, MD has a consulting relationship
with Allergan, has ownership interest in Cobochon Aesthetics,
Cosmetic Boot Camp, Myoscience and Revance, has received
honoraria from Allergan, Cosmetic Boot Camp, Palomar Medical
and Solta Medical, received funding from Allergan, Myoscience,
Palomar Medical, Solta Medical and Zeltiq and has received
discounted or free equipment from Palomar Medical.
AB306: Steven C. Dresner, MD and Sorin Eremia, MD have no
AB307: Lawrence M. Field, MD has no commercial interest to
disclose.
CS110: Mathew M. Avram, MD, JD has a consulting relationship
with Merz and Zeltiq and stock options with Biolux and Zeltiq.
Jeffrey A. Klein, MD. MPH has ownership interest in HK Surgical
and Liposuction.Com, has received free or discounted equipment
from Cynasure, HK Surgical and Sciton and has received research
funding from AM Asc Cosmetic Surgery. Adam M. Rotunda,
MD has a consulting relationship with Kythera Biophram and
Lithera, ownership interest with Kythera Biophram and honoraria
with Lithera. Robert A. Weiss, MD has received honorarium,
grant funding, equipment, was an investigator and speaker
for Palomar. Christopher B. Zachary, FRCP has a consulting
relationship with Alma, Medicis, Solta and Suneva, has received
honoraria from Allergan, Alma, Medicis, Merz, Solta and Suneva,
has received discounted or free equipment from Iridex and Solta
and has received research funding from Alma and Suneva.
CS113: Sue Ellen Cox, MD has a consulting relationship
with Allergan, Johnson & Johnson, Medicis and Revance; has
ownership Interest in Allergan; and has received funding from
Allergan, Coapt, Johnson & Johnson, Medicis and Revance. Lisa
M. Donofrio, MD is Assistant EditorJournal of Dermatologic
Surgery; Advisory Board Health Magazine, Investigator Allergan,
Cynosure, Galderma, Medicis, Merz; Clinical Grading Canfield,
FotoFinder; Ad Board Medicis; Clinical Trials Allergan, Medicis,
Mentor, Medicis; has consulted for Medicis, Merz, Niadyne,
Unilever, Vichy and has received honoraria from Canfield,
FotoFinder, Ipsen, L'Oreal, Medicis, Mentor, Niadyne. Derek
Jones, MD – has a consulting relationship with and received
honoraria from Allergan, Galderma, Kythera and Merz; has
received research funding with Allergan, Galderma and Merz;
serves on the Editorial Board of JDS and JCLT. Seth L. Matarasso,
MD has a consulting relationship with Allergan and Medicis.
Mark G. Rubin, MD has a consulting relationship with Medicis,
The Dermatology Company, has received honoraria from AGI,
Kythera Biopharmecuticals, Revance, SkinMedica and has
relationships with Cosmetic Dermatology: Editorial Board, Crown
Laboratory: Medical Advisory Board, LipoSonix: Medical Advisory
Board, Lutronic: Medical Advisory Board. Nowell J. Solish, MD
has a consulting relationship and has received research funding
from Allergan, Medicis, Allergan and has honoraria with Allergan
and Medicis.
27
CS114: Melanie Palm, MD, MBA – has received honoraria from
Lumenis, Medicis and Sanofi-aventis. E. Victor Ross, MD – has
a consulting relationship and received honoraria from Cutera,
Lumenis, Palomar and Syneron, has received discounted or free
equipment from Cutera, Lumenis, Palomar and Sciton and has
received funding from Cutera, Palomar, Sciton and Syneron.
Elizabeth Tanzi, MD has a consulting relationship with Medicis,
Uthera and Zeltiq; has received research funding from Lumenis,
Palomar, Solta and Syneron.
CS128: Tina S. Alster, MD, Jeffrey S. Dover, MD, FRCPC and Lori
A. Brightman, MD have no commercial interest to disclose. Roy
G. Geronemus, MD is a stockholder of Solta Medical; has served
as Medical Advisor for Candela, Cynosure, Lumenis, Photomedex,
Syneron and Zeltiq; has been Investigator for Cutera, Cynosure,
Palomar, Solta Medical and Syneron. Thomas E. Rohrer, MD has a
consulting relationship with Allergan, Candela, Julia Therapeutics,
Radiancy, has received honoraria from Candela, Radiancy, has
received funding from Allergan, Candela, Julia Therapeutics,
Merz, Radiancy and has received discounted or free equipment
from Candela and Radiancy.
CS211: Murad Alam, MD has no commercial interest to
disclose. Hayes B. Gladstone, MD has received discounted or
free equipment from Sciton. Leonard H. Goldberg, MD, FRCP
has received research funding from Rochel Genentech. Derek
Jones, MD – has a consulting relationship with and received
honoraria from Allergan, Galderma, Kythera and Merz; has
received research funding with Allergan, Galderma and Merz;
serves on the Editorial Board of JDS and JCLT. Ellen S. Marmur,
MD has a consulting relationship with DUSA and Medicis and has
received honoraria from Allergan. Thomas E. Rohrer, MD has a
consulting relationship with Allergan, Candela, Julia Therapeutics,
Radiancy, has received honoraria from Candela, Radiancy, has
received funding from Allergan, Candela, Julia Therapeutics,
Merz, Radiancy and has received discounted or free equipment
from Candela and Radiancy. Roberta D. Sengelmann, MD has a
consulting relationship with Allergan, Genentech and Merz. Ava
T. Shamban, MD has a consulting relationship with Allergan,
Galderma, Medicis and Merz, ownership interest in Allergan
and Merz, has received honoraria from Allergan, Galderma,
Medicis and Merz and has received research funding from
Allergan, Galderma, Kythera and Medicis. Elizabeth Tanzi, MD
has a consulting relationship with Medicis, Uthera and Zeltiq;
has received research funding from Lumenis, Palomar, Solta and
Syneron and is on the board of directors for ASLMS. John A.
Zitelli, MD has a consulting relationship with Genentech.
CS228: Davi de Lacerda, MD has received honoraria from
Galderma and Springer, has received free or discounted
equipment from Allergan and has received research funding from
Colbar. Hassan Galadari, MD has received honoraria from Merz
and discounted or free equipment from Allergan and Teoxane.
Gregory J. Goodman, MD has a consulting relationship with
Allergan, C3, Dermatech, Galderma, Neutrogena and Peplin,
has received honoraria from Allergan and has received research
funding from Allergan, Kythera, Galderma and Peplin. Doris
Hexsel, MD has a consulting relationship with Galderma, Ipsen,
Medicis and Revance, has received honoraria from Galderma
and Ipsen and research funding from Allergan, Galderma, Ipsen,
28
Medicis and Revance. Marina Landau, MD has a consulting
relationship with Croma, L'Oreal and Viora, has received
honoraria form Allergan, Alma Lasers, Croma, L'Oreal, Qmed
and Syneron, has received free or discounted equipment from
Viora and has received research funding form Croma. Susan
H. Weinkle, MD has a consulting relationship with Allergan,
BioForm Medical, Johnson & Johnson, Kythera Biopharmecuticals,
Medicis, The Dermatology Company, Procter & Gamble, Stiefel
Laboratories, has received research funding from Allergan and
has relationships with American Academy of Dermatology: Board
of Directors. Nowell J. Solish, MD has a consulting relationship
and has received research funding from Allergan, Medicis,
Allergan and has honoraria with Allergan and Medicis. Sabine
Zenker, MD has a consulting relationship with L'Oreal and Merz,
has received honoraria and research funding with Artes and
Merz.
CS233: Rebecca A. Kazin, MD has consulting relationships and
has received honoraria from Medicis and Merz.
CS309: Steve C. Dresner, MD has no commercial interest to
disclose. Jean Carruthers, MD has a consulting relationship,
received honoraria and research funding from Allergan, Lumenis
and Merz. Roy G. Geronemus, MD is a stockholder of Solta
Medical; has served as Medical Advisor for Candela, Cynosure,
Lumenis, Photomedex, Syneron and Zeltiq; has been Investigator
for Cutera, Cynosure, Palomar, Solta Medical and Syneron.
Pearl E. Grimes, MD has a consulting relationship with Allergan,
Combe, Galderma, Inamed, Steifel, has received honoraria from
Allergan, Galderma and Steifel and has funding from Allergan,
Galderma, Skin Medica, Steifel and Young Pharma. Douglas
G. Hamilton, MD has a consulting relationship with 302 Skin
Care, Deep Skincare, Merz, Suneva, has received honoraria from
Allergan, Suneva and has received funding from 302 Skin Care,
Galderma, Merz, Suneva. Vic A. Narurkar, MD has a consulting
relationship with Allergan, has ownership interest in Cobochon
Aesthetics, Cosmetic Boot Camp, Myoscience and Revance, has
received honoraria from Allergan, Cosmetic Boot Camp, Palomar
Medical and Solta Medical, received funding from Allergan,
Myoscience, Palomar Medical, Solta Medical and Zeltiq and has
received discounted or free equipment from Palomar Medical.
CS310: Patrick K. Lee, MD, Sandra Read, MD and Andrew A.
Nelson, MD have no commercial interest to disclose. Jenny Kim,
MD, PhD has consulting relationships with Allergan, Galderma,
Herbalife, Medicis and Stifel/GSK and has received funding from
Dong Sung Pharm. Abel Torres, MD has a consulting relationship
with 3M, Collagenex, Graceway, Pharmaderm, Stiefel, has
received honoraria from 3M, Collagenex, Galderma, Graceway,
Pharmaderm, Stiefel, has received funding from Graceway and
Lucid, Inc and has been a speaker for Galderma, Graceway,
Pharmaderm and Stiefel.
CS312: Quenby Erickson, MD has no commercial interest to
disclose. Joely Kaufman, MD has a consulting relationship with
Cutera, Elizabeth Arden and Mentor and has received research
funding from Medicis, Revance and Teoxane.
CS314: David G. Brodland, MD, Galen H. Fisher, MD, Glenn D.
Goldman, MD, Ali Hendi, MD, Juan-Carlos Martinez, MD and
Steven M. Rotter, MD have no commercial interest to disclose.
Jonathan L. Cook, MD – has a consulting relationship and has
received honoraria from Ethicon. Hayes B. Gladstone, MD has
received discounted or free equipment from Sciton.
CS327: Aerlyn G. Dawn, MD and Naomi Lawrence, MD have
no commercial interest to disclose. William P. Coleman, III, MD
has received research funding from Allergan, Merz, Miramar,
Ultrashape. Sydney R. Coleman, MD has a consulting relationship
with Armed Forces Institute of Regenerative Medicine, Intellicell
Biosciences and Mentor Worldwide, ownership interest in
Intellicel.
CS401: Tina S. Alster, MD and Naomi Lawrence, MD have
no commercial interest to disclose. Fredric S. Brandt, MD has
received funding from Allergan, Anika Therapeutics, Contura,
Fibrocell, Galderma, Medicis, Mentor, Merz, Revance, Sanofiaventis, Suneva and Teoxane. Kimberly J. Butterwick, MD – has
a consulting relationship and received honoraria from Allergan
and Sanofi-aventis, has ownership interest in SkinMedica and
has received funding from Allergan and SkinMedica. Jean
Carruthers, MD has a consulting relationship, received honoraria
and research funding from Allergan, Lumenis and Merz. Timothy
Flynn, MD has ownership interest in Allergan and has received
funding from Merz. Stephen H. Mandy, MD has a consulting
relationship and has received honoraria from BioForm Medical,
Inc (Merz Pharmaceuticals), Dermik a business unit of Sanofiaventis -Aventis and Proctor & Gamble for and has received
honoraria from Dermik, Proctor and Gamble, and BioForm (Merz),
has a relationship with the American Academy of Dermatology:
DAN Committee, Co-Chair Candidate for Board of Directors.
Robert A. Weiss, MD has received honorarium, grant funding,
equipment, was an investigator and speaker for Palomar. Patricia
S. Wexler, MD has ownership in Bath and Body Works.
GD114: Brett M. Coldiron, MD has received research funding
from the ASDS. Dee Anna Glaser, MD has a consulting
relationship with Allergan, BioForm Medical, Connetics, Johnson
& Johnson, Proctor and Gamble, Stiefel Laboratories and
Unilever; has received honoraria from Allergan; has received
research funding from Allergan, Altana, Anika Therapeutics,
Novartis and Valeo Pharma and has relationships with American
Academy of Cosmetic Surgery: Board Member, American
Academy of Dermatology: Committee Member, American Board
of Cosmetic Surgery: Board Member, Archives of Dermatology:
Ongoing Journal Relationship, Cosmetic Surgery Foundation:
Board Member, International Hyperhidrosis Society: Board
Member, Missouri Dermatology Society: Board Member, Practical
Dermatology: Ongoing Journal Relationship, SkinMed: On Going
Journal Relationship. Ken K. Lee, MD has received research
funding from Allergan, Medicis, The Dermatology Company,
Graceway Pharmaceuticals and NIH; Darrell S. Rigel, MD has
a consulting relationship with Beiersdorf, Graceway, Mela
Sciences, Neutrogena, Procter & Gamble; has received honoraria
from Beiersdorf, Graceway, Johnson & Johnson, Mela Sciences,
Neutrogena, Procter & Gamble and has received funding from
Beiersdorf. Christopher B. Zachary, FRCP has a consulting
relationship with Alma, Medicis, Solta and Suneva, has received
honoraria from Allergan, Alma, Medicis, Merz, Solta and Suneva,
has received discounted or free equipment from Iridex and Solta
and has received research funding from Alma and Suneva.
GD120: Murad Alam, MD, Diana Bolotin, MD, Douglas Fife,
MD, Sherrif Ibrahim, MD and Suzanne Olbricht, MD have no
commercial interest to disclose. Mathew M. Avram, MD, JD has
a consulting relationship with Merz and Zeltiq and stock options
with Biolux and Zeltiq. Jeffrey A. Klein, MD. MPH has ownership
interest in HK Surgical and Liposuction.Com, has received free
or discounted equipment from Cynasure, HK Surgical and Sciton
and has received research funding from AM Asc Cosmetic
Surgery. Michael E. Ming, MD has received research funding
form NIH. Jeffrey S. Orringer, MD is editorial board for Journal of
the American Academy of Dermatology.
GD130: Tatyana R. Humphreys, MD, Christopher B. Harmon,
MD and Andrew J. Kaufman, MD have no commercial interest
to disclose. Fredric S. Brandt, MD has received funding from
Allergan, Anika Therapeutics, Contura, Fibrocell, Galderma,
Medicis, Mentor, Merz, Revance, Sanofi-aventis, Suneva and
Teoxane. Marc D. Brown, MD has a consulting relationship and
has received honoraria from Graceway and Novartis. Brett M.
Coldiron, MD has received research funding from the ASDS.
Lisa M. Donofrio, MD is Assistant EditorJournal of Dermatologic
Surgery; Advisory Board Health Magazine, Investigator Allergan,
Cynosure, Galderma, Medicis, Merz; Clinical Grading Canfield,
FotoFinder; Ad Board Medicis; Clinical Trials Allergan, Medicis,
Mentor, Medicis; has consulted for Medicis, Merz, Niadyne,
Unilever, Vichy and has received honoraria from Canfield,
FotoFinder, Ipsen, L'Oreal, Medicis, Mentor, Niadyne. Thomas E.
Rohrer, MD has a consulting relationship with Allergan, Candela,
Julia Therapeutics, Radiesse, has received Honoraria from
Candela, Radiancy, has received funding from Allergan, Candela,
Julia Therapeutics, Merz, Radiancy and has received discounted
or free equipment from Candela and Radiancy.
GD231: Eva A. Hurst, MD has a consulting relationship with
Cutera and Genentech, received honoraria from Genentech and
discounted or free equipment from Cutera. Siegrid Sisin Yu, MD
has a consulting relationship with Hoffman, Horst, Wagner LCP,
has received honoraria from Dermatology Nurses Association and
Guidepoint and has received research funding from ASDS, NIH,
Derm Foundation and UCSF.
GD400: Chrysalyne Schmults, MD, John Carrucci, MD and Carl
V. Washington, MD- have no commercial interest to disclose.
Fiona O'Reilly Zwald, MD has received funding from Derm
Foundation.
MC121: Jeffrey S. Dover, MD, FRCPC has no commercial interest
to disclose. Elizabeth Tanzi, MD has a consulting relationship
with Medicis, Uthera and Zeltiq; has received research funding
from Lumenis, Palomar, Solta and Syneron.
MC122: Jeremy S. Bordeaux, MD, MPH has received research
funding from Dermatology Foundation. Ken K. Lee, MD
has received research funding from Allergan, Medicis, The
Dermatology Company, Graceway Pharmaceuticals and NIH;
has relationships with American College of Mohs Surgery
(ACMS):Program Committee, Chair, Association of Academic
Dermatologic Surgeons: Board of Directors.
29
MC123: Cheryl M. Burgess, MD has honoraria with Allergan,
Merz Aesthetics and Sanofi-aventis and has received research
funding from Allergan. Stephen H. Mandy, MD has a consulting
relationship and has received honoraria from BioForm Medical,
Inc (Merz Pharmaceuticals), Dermik a business unit of Sanofiaventis -Aventis and Proctor & Gamble for and has received
honoraria from Dermik, Proctor and Gamble, and BioForm (Merz),
has a relationship with the American Academy of Dermatology:
DAN Committee, Co-Chair Candidate for Board of Directors.
Melanie Palm, MD, MBA – has received honoraria from Lumenis,
Medicis and Sanofi-aventis.
MC221: Douglas Fife, MD and Christopher B. Harmon, MD
have no commercial interest to disclose. Gregory J. Goodman,
MD has a consulting relationship with Allergan, C3, Dermatech,
Galderma, Neutrogena and Peplin, has received honoraria from
Allergan and has received research funding from Allergan,
Kythera, Galderma and Peplin.
MC222: Phoebe Rich, MD has no commercial interest to
disclose.
MC223: Jeffrey T.S. Hsu, MD – has a consulting relationship
and has received honoraria with Allergan, BioForm, Merz and
Suneva and has received research funding with Allergan and
Suneva. Girish S. Munavalli, MD has a consulting relationship and
received honoraria from Merz and is a Medical Director Merz
Product Adverse Events Reporting.
MC224: Alastair Carruthers, FRCPC has a consulting relationship
and has received funding from Allergan and Merz. Joel L. Cohen,
MD has a consulting relationship with Allergan, Biopelle, DUSA,
Graceway, Medicis, Merz and SkinMedica; has received honoraria
from Allergan, Biopelle, DUSA, Graceway, Guthy-Renker,
Medicis, Merz and SkinMedica and has received funding from
Allergan, Biopelle, Graceway, Medicis, Merz and SkinMedica.
Sue Ellen Cox, MD has a consulting relationship with Allergan,
Johnson & Johnson, Medicis and Revance; has ownership Interest
in Allergan; and has received funding from Allergan, Coapt,
Johnson & Johnson, Medicis and Revance.
MC225: Jonith Y. Breadon has a consulting relationship with
Dermik/Sanofi-aventis, Medicis and Suneva; has ownership
Interest with Suneva and has honoraria with Dermik/Sanofiaventis and Medicis. Jeanine B. Downie, MD has a consulting
relationship with Allergan, Galderma, GSK/Stiefel, Intendis,
Johnson & Johnson, Medicis, Merz, Novantis, Photocure, Sanofiaventis, SkinMedica, Theraplex; has received honoraria from
Medicis, Merz, Novantis, Photocure, Sanofi-aventis, SkinMedica
and has received funding from Allergan, GSK/Stiefel, Johnson &
Johnson and Photocure. Pearl E. Grimes, MD has a consulting
relationship with Allergan, Combe, Galderma, Inamed, Steifel,
has received honoraria from Allergan, Galderma and Steifel and
has funding from Allergan, Galderma, Skin Medica, Steifel and
Young Pharma.
30
MC226: Allan S. Wirtzer, MD has no commercial interest to
disclose. Mark S. Nestor, MD, PhD has a consulting relationship
with Erchonia, Galderma, GSK Stiefel Labs, HumanMed and
Transdermal, has received honoraria and research funding from
Erchonia, Galderma, GSK Stiefel Labs, HumanMed, Medicis
and Transdermal and has ownership interest in Advanced
Dermatology Management and Skin & Cancer Associates.
MC321: Greg S. Morganroth, MD and Steven M. Rotter, MD
have no commercial interest to disclose.
MC322: Vivian W. Bucay, MD has no commercial interest
to disclose. Vince Bertucci, MD, FRCPC – has a consulting
relationship with Allergan, Medicis and Proctor & Gamble and
has received honoraria from Allergan, Medicis, Merz and Proctor
& Gamble. Mary P. Lupo, MD has a consulting relationship with
Philosophy, ownership interest in Cosmetic Boot Camp, has
received honoraria from Allergan, Botox National Educational
Faculty, Dermik a business unit of Sanofi-aventis, Lumenis, Merz,
Theraplex and has relationships with BioForm Medical.
MC323: Peter K. Lee, MD, PhD has no commercial interest to
disclose. Mitchel P. Goldman, MD has a consulting relationship
and has received research funding from Lumenis and Photocure,
has ownership interest with Lumenis, has discounted or free
equipment from Cynosure, DUSA and Lumenis. Steven E.
Leininger, CPA has no commercial interest to disclose. Amy
F. Taub, MD has a consulting relationship and has received
honoraria from DUSA; has received research funding from DUSA
and Medicis and is a consultant for DUSA.
MC324: David A. Laub, MD and Allan S. Wirtzer, MD have no
MC330: Harold J. Brody, MD and Seaver Soon, MD have no
commercial interest to disclose. Gary D. Monheit, MD has a
consulting relationship with Allergan, Dermik, Contura, ElectroOptical Sciences, Genzyme, Revance, Kythera, Galderma, Mentor
and Merz, has received honoraria from Galderma, Ipsen and
Merz and research funding from Allergan, Dermik, Contura,
Electro-Optical Sciences, Galderma, Genzyme, Ipsen/Medicis,
Kythera, Mentor, Merz and Revance.
MC331: Peter R. Shumaker, MD has no commercial interest to
disclose. Kenneth A. Arndt, MD has received honoraria from
Allergan and Medicis. Suzanne L. Kilmer, MD has a consulting
relationship and received honoraria from Candela, Cutera,
Cooltouch, Cynosure, Iriderm, Lumenis, Miramar, Palomar,
Sciton, Solta, Ulthera and Zeltiq.
MC332: Katie Rodan, MD has no commercial interest to disclose.
Patricia S. Wexler, MD has ownership interest in Bath and Body
Works.
PD240: Cheryl M. Burgess, MD has honoraria with Allergan,
funding from Allergan. Jean Carruthers, MD has a consulting
relationship, received honoraria and research funding from
Allergan, Lumenis and Merz. Miriam P. Cummings, MD has no
commercial interest to disclose. Hema A. Sundaram, MD has a
consulting relationship with ColorScience, Johnson & Johnson
Consumer Products, Medicis, Mentor, Merz, SkinMedica, Suneva,
Syneron/Candela, Ulthera and has received research funding
from Medicis, Merz, SkinMedica, Syneron/Candela, Ulthera
and has received discounted or Free Equipment from Syneron/
Candela. Robert A. Weiss, MD has received honorarium, grant
funding, equipment, was an investigator and speaker for
Palomar. Girish S. Munavalli, MD has a consulting relationship
and received honoraria from Merz and is a Medical Director
Merz Product Adverse Events Reporting. Margaret A. Weiss,
MD has a consulting relationship with Bioniche, Cooltouch,
Cynosure, Medicis, Merz and VNUS, has received honoraria
from Allergan, Bioniche, Cooltouch, Cynosure, Exllis, Fivrocell,
Neutrogena/Johnson and Johnson, Lumenis, Medicis, Merz,
Palomar, Solta, VNUS and Zeltiq, has received research funding
from Cynosure, Galderma, Fibrocell, Lumenis, Polarmar, Revance,
Solta, Ultrashape and Zeltiq, has received free or used equipment
from Cooltouch, Cynosure, Lumenis, Palomar and Solta, has
stockholding interest with Cooltouch, has been a speaker or
investigator for Allergan, Cooltouch, Cynosure, Exllis, Galderma,
Fibrocell, Neutrogena/Johnson and Johnson, Medicis, Palomar,
Revance, Solta, Ultrashape and Zeltiq.
PM313: Alysa Herman, MD has no commercial interest to
disclose. Darrell S. Rigel, MD has a consulting relationship with
Beiersdorf, Graceway, Mela Sciences, Neutrogena, Procter &
Gamble; has received honoraria from Beiersdorf, Graceway,
Johnson & Johnson, Mela Sciences, Neutrogena, Procter &
Gamble and has received funding from Beiersdorf. Tom Seery has
ownership interest in RealSelf, Inc which is partnered with other
medical organizations including ASAPS, ISAPS and CSAPS and
has received honoraria from ASPS. Daniel M. Siegel, MD has a
consulting relationship with DUSA, Encite, EOS, Leerink Swann,
LES Logical Images, MD Solar Sciences, MedaCorp and Telederm
Solutions, has stock options with DermFirst, Logical Images,
Photomedex, Quinnova, Remote Derm and Telederm Solutions,
has received honoraria from Dermik, DUSA, EOS Leerink Swann
and MedaCorp, has received research funding from Derm
Tech, Estee Lauder and Galderma and has other relationships
with Elsevier, Michelson and Vivacare. Robert A. Weiss, MD
has received honorarium, grant funding, equipment, was an
investigator and speaker for Palomar.
PD340: Girish S. Munavalli, MD has received research funding
from Fibrocell Technologies. Margaret A. Weiss, MD has a
consulting relationship with Bioniche, Cooltouch, Cynosure,
Medicis, Merz and VNUS, has received honoraria from Allergan,
Bioniche, Cooltouch, Cynosure, Exllis, Fivrocell, Neutrogena/
Johnson and Johnson, Lumenis, Medicis, Merz, Palomar, Solta,
VNUS and Zeltiq, has received research funding from Cynosure,
Galderma, Fibrocell, Lumenis, Polarmar, Revance, Solta,
Ultrashape and Zeltiq, has received free or used equipment
from Cooltouch, Cynosure, Lumenis, Palomar and Solta, has
stockholding interest with Cooltouch, has been a speaker or
investigator for Allergan, Cooltouch, Cynosure, Exllis, Galderma,
Fibrocell, Neutrogena/Johnson and Johnson, Medicis, Palomar,
Revance, Solta, Ultrashape and Zeltiq. Robert A. Weiss, MD
has received honorarium, grant funding, equipment, was an
investigator and speaker for Palomar.
PM332: Barry Leshin, MD, Saadia Raza, MD and Marta J.
VanBeek, MD, MPH have no commercial interest to disclose.
Ashish Bhatia, MD has a consulting relationship with Mentor,
OrthoDermatologics and Suneva, has received honoraria from
OrthoDermatologics.
PM129: Cheryl M. Burgess, MD has honoraria with Allergan,
funding from Allergan. Jeanine B. Downie, MD has a consulting
relationship with Allergan, Galderma, GSK/Stiefel, Intendis,
Johnson & Johnson, Medicis, Merz, Novantis, Photocure, Sanofiaventis, SkinMedica, Theraplex; has received honoraria from
Medicis, Merz, Novantis, Photocure, Sanofi-aventis, SkinMedica
and has received funding from Allergan, GSK/Stiefel, Johnson
& Johnson and Photocure. Abel Torres, MD has a consulting
relationship with 3M, Collagenex, Graceway, Pharmaderm,
Stiefel, has received Honoraria from 3M, Collagenex, Galderma,
Graceway, Pharmaderm, Stiefel, has received funding from
Graceway and Lucid, Inc and has been a speaker for Galderma,
Graceway, Pharmaderm and Stiefel.
PM310: Kyle Coleman, MD. Naomi Lawrence, MD, Mary E.
Maloney, MD and Elizabeth I. McBurney, MD have no commercial
interest to disclose. Cheryl M. Burgess, MD has honoraria with
Allergan, Merz Aesthetics and Sanofi-aventis and has received
research funding from Allergan. Elizabeth Tanzi, MD has a
consulting relationship with Medicis, Uthera and Zeltiq; has
received research funding from Lumenis, Palomar, Solta and
Syneron.
RS213: Monica Halem, MD and Allison Hanlon, MD have no
RX112: Christopher J. Arpey, MD and Patricia Missall, MD, PhD
have no commercial interest to disclose. Scott W. Fosko, MD
has received funding from Saint Louis University Cancer Center.
Jeffrey E. Petersen, MD has a consulting and received honoraria
from DUSA. Whitney D. Tope, MD has received honoraria and
funding from Cutera.
RX114: Zeina Tannous, MD and Valencia D. Thomas, MD have
no commercial interest to disclose. Kenneth Y. Tsai, MD, PhD has
received research funding from DX Biosciences and is Associate
Editor for Journal World Dermatology.
RX229: Christopher J. Arpey, MD, John Carrucci, MD, Christian
Baum, MD, Daniel B. Eisen, MD, Larisa Ravitskiy, MD and Marta
VanBeek, MD, MPH have no commercial interest to disclose.
Jeremy S. Bordeaux, MD, MPH has received research funding
from Dermatology Foundation. Jerry D. Brewer, MD has received
research funding from Dermatology Foundation; Board Member
of International Transplant Skin Cancer Collaborative and an
AAD Committee member. Hayes B. Gladstone, MD has received
discounted or free equipment from Sciton.
RX311: Kee-Yang Chung, MD has no commercial interest to
disclose.
RX314: Glenn D. Goldman, MD, Todd E. Holmes, MD, George
J. Hruza, MD and Stephen N. Snow, MD have no commercial
interest to disclose. Leonard H. Goldberg, MD, FRCP has received
research funding from Rochel Genentech.
31
COSMETIC DERMATOLOGIST OPPORTUNITY
Geisinger Medical Center (GMC) is seeking
a BE/BC Dermatologist with an interest in
Cosmetics to join our growing practice in
Ambulatory Care Center, Danville, PA
About this opportunity:
• Join a system wide Dermatology practice
with 13 Dermatologists; 5 MOHS Surgeons;
1 Podiatrist and 1 Wound Care Specialist
• Opportunity to help develop a Cosmetic
Center with Dermatology; Plastic Surgery
and Otolaryngology
• Enjoy a well-established practice with a vast
referral base
•Teach 12 Dermatology residents annually
•Opportunity to perform research opportunities
in your area of interest at the Henry Hood
Center for Health Research and the Sigfried
and Janet Weis Center for Research
Geisinger fosters an atmosphere of clinical
excellence while offering the best of life in smalltown America: good schools, safe neighborhoods
with affordable housing and a wealth of cultural
and recreational activities. The surrounding natural
beauty provides opportunities for fishing, skiing,
canoeing, hiking and mountain biking. Urban life is
easily accessible, with New York City, Philadelphia
or Washington DC just an afternoon’s drive away.
Geisinger Health System is a physician-led,
academic multi-specialty group practice that
serves nearly 3 million people in Central and
Northeastern Pennsylvania. Geisinger Health
System utilizes a mature, fully integrated electronic
health record (EHR) connecting a comprehensive
network of 2 hospitals, 38 community practice
sites, and more than 800 Geisinger primary and
specialty care physicians.
Discover for yourself why Geisinger has earned
national attention as a visionary model of
integrated healthcare. To learn more about this
position contact: Elaine Tomaschik, Professional
Staffing, [email protected] 570.271.7003
or 800.845.7112
The Art and Science of Fillers
and Injectables
BEST OF THE BEST LIVE
PATIENT DEMONSTRATIONS
Featuring:
My Technique for Treating the Glabellar Region
Ronald L. Moy, MD
My Technique for Treating the Periorbital Area
Ellen S. Marmur, MD
My Technique for Treating Nasolabial Folds
Neil S. Sadick, MD
My Technique for Treating Nasolabial Folds
Ronald L. Moy, MD
My Technique: Oral Nerve Blocks
Derek H. Jones, MD
My Technique for Lips
Ellen C. Gendler, MD
My Technique for Lips
Derek H. Jones, MD
My Technique for Treating Cheeks and Zygomatic Arch
Derek H. Jones, MD
My Technique for Treating the Periorbital Area
Derek H. Jones, MD
My Technique for Treating Marionette Lines and
Pre-Jowl Sulcus
Elizabeth K. Hale, MD
My Technique: Botulinum Toxins
Member price: $149.95
Non-Member price: $209.95
U.S. shipping and handling included. Sales tax for Illinois residents and
international shipping will be added to applicable orders.
H E A LT H S Y S T E M
See it at the ASDS Booth #108
REDEFINING THE BOUNDARIES OF MEDICINE
Join the health system whose innovations are influencing the
future of healthcare. Learn more at geisinger.org/national.
Or order today at
www.asds.net
or call 847-956-0900.
RESIDENT KNOWLEDGE BOWL
Attend and cheer on
your favorite resident!
Come to the exhibit hall to cheer on your favorite residents in the
first-ever Resident Knowledge Bowl! Resident teams from across the
country will meet fierce competitors as they battle in a Jeopardystyle competition to win cash prizes and test their knowledge in
surgical and procedural dermatology, as well as current events.
There will be several rounds of competition during lunches and the
Wine & Cheese Reception in the exhibit hall.
The grand prize winners will walk away with $1,000 cash,
a trophy, and bragging rights as the first-ever
ASDS Resident Knowledge Bowl Grand Champions!
Competition Schedule
in Booth #100 in the Exhibit Hall:
Thursday, Nov. 3 1:00 pm - 1:30 pm
Friday, Nov. 4
6:00 pm - 6:30 pm
Saturday, Nov. 5
1:00 pm - 1:30 pm
Supported by a grant from
HOTEL FLOOR PLAN
MEZZANINE LEVEL
LOBBY LEVEL
34
WEDNESDAY, NOVEMBER 2
2011
MANAGING CHANGE: Practice Management
in a Changing Health Care Environment
ASDS
ANNUAL
MEETING
Wednesday, November 2 • 9:00 am – 4:15 pm
Washington , DC
Fee: $400 Members; $200 Residents; $750 Non-member.
See registration desk to register.
N O V E M B E R 3 - 6 , 2 0 11
Pre-conference Director: Derek H. Jones, MD, Education Work Group Chair
The ASDS is committed to providing dermatologic surgeon learners with fair and balanced continuing medical education.
Course Learning Objectives: Upon completion of this symposium, participants should be able to:
•
•
•
•
Evaluate the impact of changes in health care on dermatologic surgery practice
Explore the future practice of dermatologic surgery and the forces driving its evolution
Identify new techniques, tools and strategies for managing change
Incorporate these new tools into practice in the changing environment
Core Competencies: The ASDS acknowledges the need for CME content to be designed within the context of desirable physician
attributes as expressed by the ACGME/ABMS Core Competencies and the Dermatology Residency Committee. This course content
addresses ACGME/ABMS Core Competencies as indicated below:
Medical Knowledge
Professionalism
Interpersonal & Communication Skills
Systems-based Practice
8:30 – 9:00 am
Continental Breakfast and Networking
9:00 – 9:10 am
Welcome and Course Introduction
9:10 – 9:30 am
What is the Future of Dermatologic
Surgery?
Derek H. Jones, MD
1:40 – 2:00 pm
Eric F. Bernstein, MD
2:00 – 2:20 pm
Common Issues in Coding
From Ordinary to Extraordinary: Rewarding
Employees to Promote Productivity, Build
Cohesion and Build Your Practice
Kristel Polder, MD
Derek H. Jones, MD
9:30 – 9:50 am
The Future of Medical Practice Marketing
2:20 – 2:30 pm
Discussion
2:30 – 2:50 pm
Financial Management for your Practice in
an Uncertain Economy
Sharon Andrews, RN, CCS-P
9:50 – 10:10 am
Cost Control Tips and Tricks
Jeffrey S. Dover, MD
10:10 – 10:30 am
Dermatologic Surgery Financial Benchmarks
Page S. Piland
10:30 – 10:40 am
Discussion
10:40 – 10:50 am
Networking Break
10:50 – 11:10 am
H.R. 3962, The Affordable Health Care Act:
What it is and Isn’t
Ella L. Toombs, MD
11:10 – 11:30 am
Health Care Reford and what it Means to
the Dermatologic Surgery Specialty
George J. Hruza, MD
11:30 – 11:50 am
Delivering High Quality Customer Service
Page S. Piland
2:50 – 3:10 pm
Delivering High Quality Customer Service
Page S. Piland
3:30 – 3:50 pm
The Present and Future of Imaging for
Practice and Practice Management
3:30 - 3:50 pm
The Present and Future of Aesthetic
Medicine
Hema Sundaram, MD
Gary D. Monheit, MD
3:50 – 4:15 pm
Wrap-up Discussion
4:15 pm
Pre-Conference Course Adjournment
Page S. Piland
11:50 am – 12:00 Noon
Discussion
12:00 Noon – 1:00 pm
Networking Lunch with Residents/Postresidency Trainees
1:00 – 1:20 pm
Stress Reduction and Physician Wellness
1:20 – 1:40pm
The Cyber Professional: Addressing Legal
Issues of Physician Website Content and
Use Rating Sites, and Social Media Policies
for Your Practice
Michael J. Sacopoulos, JD
ACCREDITATION STATEMENT AND CREDIT DESIGNATION: The American
Society for Dermatologic Surgery is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education for
physicians.
The American Society for Dermatologic Surgery designates this live activity for a
maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the
credit commensurate with the extent of their participation in this activity.
As a sponsor accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the ASDS must adhere to the ACCME Guidelines throughout
its overall CME program. The ASDS must ensure balance, independence, objectivity,
and scientific rigor in all its educational activities. The ASDS is committed to
providing dermatologic surgeon learners with fair and balanced continuing medical
education, and requires that all faculty members complete the Disclosure of Interest
and Faculty Attestation forms. Our accreditation is important to us. We look
forward to working together to provide CME of the highest standard.
35
2011
RESIDENTS/POST-RESIDENCY TRAINEES PRE-CONFERENCE:
STARTING YOUR PRACTICE:
Advance Knowledge is Power
Wednesday, November 2, 2011 • 12:00 pm – 5:15 pm
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
Fee: $75 – lunch included. See registration desk to register.
Pre-conference Directors: Kavita Mariwalla, MD and George J. Hruza, MD, Members, Annual Meeting Work Group
The ASDS is committed to providing dermatologic surgeon learners with fair and balanced continuing medical education.
Course Learning Objectives: Upon completion of this activity, participants should be able to:
•
•
•
•
•
Differentiate between the benefits of academic and private practices
Identify details that require focus to ensure efficient practice start-up
Select from the myriad examples given those which will be best suited for implementation in a new practice
Describe the various aspects of office automation, both required (such as EMR) and suggested that will foster higher levels
of practice efficiency
Implement tactics to ensure smooth practice start-up
12:00 Noon
Networking Lunch with Practice Management Pre-conference Attendees and YDS Committee Members
1:00 – 1:15 pm
Opening Remarks: The Table of Contents for Today’s Book of Knowledge
Kavita Mariwalla, MD and George J. Hruza, MD
1:15 – 1:30 pm
Self-respect and Respect Received from Others is Hard-earned: How You Can Evolve Toward Being a “Guiding
Light” from Today Onward
1:30 – 1:45 pm
Why Do We Have to Discuss Electronic Medical Records Again?
1:45 – 2:00 pm
Discussion
2:00 – 2:15 pm
Practice Efficiency Using Digital and Office Automation
2:15 – 2:30 pm
The Cyber Professional: Addressing Legal Issues of Physician Website Content and Use, Rating Sites, and Social
Media Practices for your Practice
Daniel M. Siegel, MD
Ashish Bhatia, MD
Michael J. Sacopulos, JD
2:30 – 2:45 pm
10 Minute Discussion and Break
2:45 – 3:00 pm
ICD-10 & Dermatological Surgical Procedures
3:00 – 3:15 pm
Different Types of Practice Settings for the Dermatologic Surgeon
George J. Hurza, MD
3:15 – 3:30 pm
Starting a Dermatologic Surgery Practice: Pearls and Pitfalls
Tina S. Alster, MD
3:30 – 3:45 pm
Tips and Tales for an Optimal Practice in an Academic Center
Jeremy S. Bordeaux, MD, MPH
3:45 – 4:00 pm
The Common Cents of Starting a Practice
4:00 – 4:15 pm
Creating an Extraordinary Practice
4:15 – 4:30 pm
What You “Really” Need to Do to Secure a Fellowship
4:30 – 4:45 pm
Fellowship: What It’s Really Like
Page S. Piland
Adam J. Rotunda, MD
Daniel T. Wasserman, MD
4:45 – 5:00 pm
Where’s the Education? What You Need to Learn to Augment Your
Residency Education
5:00 – 5:15 pm
Wrap-up Discussion
5:30 – 6:15 pm
Industry Advisory Council Reception for Residents and
Post-residency Trainees
36
This pre-conference is made possible
in part by a generous educational
grant from Medicis Aesthetics.
HANDS-ON WORKSHOP:
Tumor Excision/Wound Repair and Injectables
2011
ASDS
ANNUAL
MEETING
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
Wednesday, November 2, 2011 • 1:00 pm – 5:30 pm
Registration for this course has reached capacity
Moderators: Naomi Lawrence, MD; Patrick K. Lee, MD
Faculty / Monitors: Theresa Soriano, MD; Ryan W. Ahern, MD; Johnathan Bingham, MD;
Chad Prather, MD; Joseph Grecco, MD; Juan Carlos Martinez, MD
Hands-on Workshop Using High-fidelity
Cutaneous Surgical Training Models**
Learning Objectives: Specifically targeted for young dermatologic surgeons, this live CME
activity offers hands-on experience featuring new high-fidelity cutaneous surgical models.
These models accurately simulate anatomy, including sub-mucosa structure, allowing for
realistic hands-on practice. In order to maximize hands-on experience with models,
all didactic materials will be available electronically in the anatomy lab for self-directed learning. In addition, all attendees will
receive a pre-course survey prior to the meeting. Based on survey results, attendees will be grouped based on their specific
educational interests and focus. At the conclusion of this course, attendees should be able to: increase their competence in patient
positioning and instrument handling for all procedures; properly excise tumors using both standard and Mohs techniques; execute complex
linear closures, Z-plasty repairs, rotation and advancement flaps; finesse closure techniques they already know with pearls from experts
in the field, and; gain an understanding of facial anatomy in order to correctly perform injection techniques for hyaluronic acid fillers and
neurotoxins.
Core Competencies: The ASDS acknowledges the need for CME content to be designed within the context of desirable physician
attributes as expressed by the ACGME/ABMS Core Competencies and the Dermatology Residency Committee. This course content
addresses ACGME/ABMS Core Competencies as indicated below:
Patient Care
Medical Knowledge
Practice-based Learning and Improvement
Accreditation Statement and Credit Designation:
The American Society for Dermatologic Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
The American Society for Dermatologic Surgery designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their participation in the activity.
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), the ASDS must adhere to the ACCME Guidelines
throughout its overall CME program. ASDS must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. ASDS
is committed to providing dermatologic surgeon learners with fair and balanced continuing medical education, and requires that all faculty members
complete the Disclosure of Interest and Faculty Attestation forms. Our accreditation is important to us. We look forward to working together to
provide CME of the highest standard.
*84 percent of residencies still using pig’s feet which represent low fidelity experience and do not
accurately simulate skin. Only 9 percent of residencies utilize actual cadavers as access and cost
is a challenge. Currently, the majority of dermatology residencies are only required to read about
cosmetic procedures rather than observe or demonstrate competence. Hands-on practice decreases
discrepancies across training methodologies.
This workshop is made possible in part
by generous support from ETHICON,
Inc. and a grant from Merz Aesthetics
**Invented by Keoni Nguyen, DO of DermSurg Scientific).
37
 8:30 AM – 4:15 PM PRE-CONFERENCE
Managing Change: Practice Management in a Changing
Healthcare Environment (see page 36
Pre-conference Director: Derek H. Jones, MD, Chair, ASDS Education Work Group
 1:00 – 5:15 PM
RESIDENTS/POST-RESIDENCY TRAINEES SYMPOSIUM
Starting Your Practice: Advance Knowledge is Power (see page 35)
Pre-conference Director: Kavita Mariwalla, MD; George Hruza, MD
 1:00 - 5:30 PM
HANDS-ON WORKSHOP
Tumor Excision/Wound Repair and Injectables
(see page 37)
Workshop Directors: Naomi Lawrence, MD; Patrick K. Lee, MD
 5:30 – 6:15 PM
INDUSTRY ADVISORY COUNCIL RECEPTION FOR RESIDENTS/POST-RESIDENCY TRAINEES
 5:30 - 7:00 PM
RECEPTION FOR YOUNG DERMATOLOGIC SURGEONS
Graciously supported by NeoStrata
Find us on Facebook!
Become a fan of the American Society for Dermatologic
Surgery and the American Society for Dermatologic Surgery
Association to get the latest updates right to your news feed.
38
THURSDAY, NOVEMBER 3
ALL annual meeting sessions are open ONLY TO DERMATOLOGISTS unless marked with the E symbol.
 7:15 – 8:45 AM MORNING COFFEE TALKS
AB105
Advance registration is strongly encouraged in order to obtain the
Coffee Talk of your choice. Sessions have a cost of $60, are limited
by the seating available, and may be closed. See registration desk
to register for courses not marked CLOSED.
AB101
(Virginia B)
Learning Objectives: At the conclusion of this course,
attendees should be able to: understand the latest advances
in fractional resurfacing; explore the latest in fat removal
and skin tightening devices; explore new approaches with
vascular and pigmented lesion lasers, and; identify new
devices and their therapeutic advancement to the field.
Core topics addressed may include optics of light-skin
interactions, selective and fractional photothermolysis,
clinical endpoints, vascular and pigmented laser interactions,
tattoos, and hair.
Evaluating the Cosmetic Patient
(Maryland C)
attendees should be able to: understand anatomic
changes of the aging face; develop a therapeutic plan for
rejuvenation and manage patient expectations.
Richard G. Glogau, MD; Heidi A. Waldorf, MD
AB102
Techniques for Flap Success E
(Maryland B) Closed
attendees should be able to: learn to critically analyze
a surgical defect to design the repair most likely to yield
reproducible aesthetic results; understand the limitations of
single staged repairs for more complex wounds, and; begin
to develop a regional approach to wound closure options –
which flaps work best where and why.
Joel Cook, MD; Christopher J. Miller, MD
AB103
Dipping Your Toes into the Liposuction Lake
(Maryland A)
Surgery Track: Lasers
Arielle N.B. Kauvar, MD; Suzanne L. Kilmer, MD
AB107
Hair Restoration
(Hoover)
attendees should be able to: identify appropriate male and
female candidates for the procedure; distinguish that hair
restoration surgery can be successfully applied to eyebrows,
eyelashes, beard and body hair; describe the differences
in strip removal and follicular unit extraction techniques;
understand the role of medical therapy with hair
transplantation; identify value and data associated with laser
hair growth devices; recognize and apply new techniques in
hair transplant and restoration surgery, and; better integrate
hair transplant surgery into a dermatologic surgery practice.
Marc R. Avram, MD; Dow B. Stough, IV, MD
attendees should be able to: plan for the addition of
liposuction to their patient care offerings, including but
not limited to: required office space, equipment, cost and
marketing; describe the techniques including tumescent;
identify appropriate patients and select technique for
optimal outcome; select and effectively utilize the proper
local anesthesia for selected technique; discuss pros and
cons, possible risks, and management of complications,
properly perform selected liposuction technique, and;
evaluate and incorporate new technology as it becomes
available.
Kyle Coleman, MD; Norma H. Kassardjian, MD
AB104
 7:15 – 9:00 AM RESIDENTS/FELLOWS-IN-TRAINING/
YOUNG DERMATOLOGIC
SURGEONS HOSPITALITY SUITE
(Harding)
 8:45 – 9:00 AM TRANSITION BREAK
Managing Unusual Tumors E
(Virginia A)
attendees should be able to: recognize less commonly
encountered non-melanoma skin cancers; describe the key
clinical features of these unusual tumors; identify challenges
in surgical management, and; discuss the diagnostic and
treatment pitfalls of these tumors.
CORE CURRICULUM IN COSMETIC DERMATOLOGIC SURGERY
Kishwer S. Nehal, MD; Vicki J. Levine, MD; Erica Lee, MD
ABMS Competencies:
Patient care
Medical knowledge
Practice-based learning and improvement
Interpersonal and communication skills
Professionalism
Systems-based practice
39
 9:00 – 9:40 AM OPENING SESSION (Salon 2 & 3)
9:00 am
9:05 am
9:08 am
9:11 am
9:14 am
9:17 am
ASDS President Remarks
Annual Meeting Program Co-chairs Remarks
Dee Anna Glaser, MD; Ken K. Lee, MD
Teaser for RX114 – You Really Can Understand the
Babble: Come Learn Dermatopathology in Clear Terms
Teaser for PM129 – Necessary Red Tape: The Ins and
Outs of Patient Consents
Abel Torres, MD; Jeanine B. Downie, MD
Teaser for CS228 – We Seek it Here, We Seek it There –
Dermatologic Surgery Everywhere!
Future Leaders Network Project Presentations
Alastair Carruthers, FRCPC – Chair, Leadership Development
Work Group; Melanie Palm, MD; Ian Maher, MD;
Kyle Coleman, MD; Jeremy Kampp, MD; Burt Steffes, MD;
 9:40 – 10:30 AM OPENING KEYNOTE (Salon 2 & 3)
RADM Boris D. Lushniak, MD, MPH
U.S. Deputy Surgeon General
 10:45 - 11:30 AM CONCURRENT SCIENTIFIC
SESSIONS
CS110
(Salon 2)
Learning Objectives: At the conclusion of this session,
attendees should be able to: describe invasive and noninvasive body sculpting technologies; assess their efficacy
and optimize appropriate patient selection for these devices
and techniques.
Moderator(s): Mathew M. Avram, MD, JD;
Gary Lask, MD
0:45 am
10:50 am
10:58 am
11:06 am
11:14 am
Welcome: Richard G. Bennett, MD, ASDS President
Introduction: Dennis Condon, President and CEO,
Merz Aesthetics
Boris Lushniak is the Deputy Surgeon General, assisting the Surgeon
General in articulating the best available scientific information to the
public regarding ways to improve personal health and the health of the
Nation. He also oversees the operations of the U.S. Public Health Service
Commissioned Corps comprising approximately 6,600 uniformed health
officers who serve in locations around the world to promote, protect,
and advance the health and safety of the American People.
11:22 am
PM129
attendees should be able to: be familiar with the MedicoLegal implications of clinical photography; know how
to review HIPAA regulations concerning clinical images,
and recognize examples of consents for obtaining clinical
images.
Moderator(s): Abel Torres, MD;
Jeanine B. Downie, MD
10:45 am
10:55 am
11:05 am
11:15 am
11:25 am
Patient care
Medical knowledge
Professionalism
40
Patient Images and Consents: Protecting
Your Practice and Your Patients E
ABMS Competencies:
Introductions
Mathew M. Avram, MD, JD; Gary Lask, MD
Non-Invasive Treatment of Fat & Cellulite, What’s the
Truth?
Mathew M. Avram, MD, JD
Radiofrequency for Non-Invasive Fat Removal, Does It
Work?
Christopher B. Zachary, FRCP
Traditional Tumescent Liposuction: Still the Gold
Standard?
Laser Lipolysis, What Does This Add to Traditional
Liposuction?
Robert A. Weiss, MD
Injectables for Fat Removal: Where Do We Stand?
Adam M. Rotunda, MD
(Salon 1)
The ASDS is honored to have RADM Boris D. Lushniak, U.S. Deputy
Surgeon General, deliver his keynote speech entitled “Prevention
Strategy” during the opening session of the Annual Meeting.
 10:30 – 10:45 AM TRANSITION BREAK
Surgical and Non-surgical Body Sculpting
Informed Consent and Patient Scenarios
Civil Liability Related to Images: Consents for Obtaining
Clinical Images
Hugh F. Hill III, MD, JD
Medical-Legal Implications of Photography
HIPAA Regulation
Questions and Answers
RX112
Medical Treatment of Skin Cancer E
CS114
(Salon 3)
10:45 am
11:00 am
11:15 am
If You Could only Buy Two Types of Lasers
Which Would You Buy?
(Salon 1)
Learning Objectives: At the conclusion of the course,
attendees should be able to: understand the mechanism of
action, treatment methods, and adverse events of candidate
medical therapies for skin cancer management; evaluate
and select patients for non-surgical treatment of cutaneous
malignancies and implement medical treatment of skin
cancer in appropriate clinical settings.
Moderator(s): Whitney D. Tope, MD;
Scott W. Fosko, MD
attendees should be able to: understand laser tissue
interactions; make decisions on best practices regarding
optimal laser purchases and understand which lasers are
most likely to work for which indications.
Moderator(s): E. Victor Ross, MD;
Melanie Palm, MD, MBA;
Elizabeth Tanzi, MD
Imiquimod for the Treatment of Lentigo Maligna and
Non-melanoma Skin Cancer
Tricia Missall, MD, PhD
5 FU (Including Chemo-Wraps) and Capecitabine for
Non-melanoma Skin Cancer
Jeffrey E. Petersen, MD
Intralesional Therapy for Non-melanoma Skin Cancer
 12:30 - 2:00 PM EXHIBIT HALL OPENING
(COMPLIMENTARY LIGHT LUNCH)
 12:30 – 2:00 PM RESIDENTS LUNCHEON (Maryland A & B)
(Advance sign up necessary - luncheon closed)
 11:30 AM - 12:30 PM CONCURRENT SCIENTIFIC
SESSIONS
 12:30 – 2:00 PM RESEARCH LUNCHEON
CS113
GD120
Advanced Fillers Beyond the Nasolabial Fold
(Salon 2)
Learning Objectives: At the conclusion of this session, attendees
should be able to: become familiar with all commercially
available dermal fillers and select the correct product for the
underlying anatomic defect; identify new indications and
learn the techniques for soft tissue augmentation other than
the nasolabial fold; recognize adverse reactions and select
an appropriate treatment paradigm, and; learn advanced
treatment pearls that can enhance your existing technique
Moderator(s): Lisa M. Donofrio, MD; Seth L. Matarasso, MD
11:30 am
11:35 am
11:45 am
11:55 am
12:05 pm
12:15pm
12:25pm
GD114
Course Introduction
Lisa M. Donofrio, MD; Seth L. Matarasso, MD
The Future of Autologous Fat in the World of Hyaluronic
Acids
Filler Selection: What to Put Where
Mark Rubin, MD
Off-label Indications for Fillers
Sue Ellen Cox, MD
Non-facial Augmentation
Derek H. Jones, MD
Complications that I Have Seen and How I Have
Managed Them
Nowell J. Solish, MD
You Asked for It Session E
(Salon 1)
attendees will have a better understanding of some of the
most critical issues affecting the specialty of dermatologic
surgery and their own practice. Within this session, course
faculty will present topics submitted by the membership or
as relevant due to current events.
Moderator(s): Ken K. Lee, MD; Dee Anna Glaser, MD
11:30 am
11:50 am
12:10 pm
Research Luncheon Session: Dermatologic
Surgery Procedures: What is Known About
Evidence Based Medicine Demonstrated
Through Select Topics E
(Virginia C )
attendees should be able to: understand current indications,
techniques, and adverse events associated with some
common and complex dermatologic surgery procedures,
including oncologic and elective surgeries; review highlevel evidence pertaining to safety and efficacy of these
dermatologic surgery procedures, and; highlight areas
where evidence regarding dermatologic surgery procedures
is limited and further research is required.
Moderator(s): Murad Alam, MD; Suzanne Olbricht, MD
12:30 pm
12:40 pm
12:50 pm
1:00 pm
1:10 pm
1:20 pm
1:40 pm
1:50 pm
Introduction
Suzanne Olbricht, MD; Murad Alam, MD
Treatment of Complex and Resistant Non-melanoma
Skin Cancer
Diana Bolotin, MD
Treatment of Advanced Melanoma
Michael E. Ming, MD
Treatment of Dermatofibrosarcoma Protuberans
Sherrif Ibrahim, MD
Skin Resurfacing
Jeffrey S. Orringer, MD
Body Contouring
Marc R. Avram, MD; Jeffry A. Klein, MD, MPH
Acne Scarring
Douglas Fife, MD
Suzanne Olbricht, MD
Sunscreen Regulations in the Spotlight
Darrel S. Rigel, MD
The Next Frontier in Light-based Technology
Christopher Zachary, MD
The Economic Future of Dermatologic Surgery
Brett M. Coldiron, MD
41
 2:00 - 3:15 PM CONCURRENT SCIENTIFIC SESSIONS
 2:00 – 3:15 PM
CS128
Tea of your choice. Sessions have a cost of $35, are limited by the
seating available, and may be closed.
See registration desk to register for courses not marked CLOSED.
Lasers: The Pulsating Truth on the Latest and
Greatest
(Salon 2)
attendees should be able to: describe the advantages and
disadvantages of non-invasive devices for body contouring;
identify the latest skin resurfacing lasers and devices
and their relative clinical efficacy and side effect profiles;
determine the best laser techniques for scar revision; be
familiar with the at-home market and identify strategies
applicable to laser and device treatment in dark skin tones.
Moderator(s): Tina S. Alster, MD;
Roy G. Geronemus, MD
2:00 pm
2:05 pm
2:15 pm
2:25 pm
2:35 pm
2:45 pm
2:55 pm
RX114
Introduction
Tina S. Alster, MD; Roy G. Geronemus, MD
Body Contouring
Lori A. Brightman, MD
Fractional Laser and RF Skin Resurfacing
Laser Scar Revision
Tina S. Alster, MD
Home Laser and Light Devices
Laser Treatment of Difficult Cases
Jeffrey S. Dover, MD, FRCPC
All Panel Discussion
Tina S. Alster, MD
attendees should be able to: identify pathology terms and
understand significance in dermatologic surgery; describe
difficult melanocytic terminology and describe basal cell
carcinoma variants.
Moderator(s): Valencia D. Thomas, MD
2:20 pm
2:40 pm
3:00 pm
Deciphering the Language of the Dermatopathologist
Valencia Thomas, MD
Tumors and their Mimickers,
Kenneth Y. Tsai, MD, PhD
Post-Laser Dermatopathology
Zeina Tannous, MD
Complications in Light-based Technologies
(Virginia A) Closed
attendees should be able to: recognize the most common
side effects and complications of cutaneous laser and
light-based treatments including ablative and non-ablative
fractionated resurfacing, non-invasive skin tightening, hair
removal, pigment- and vascular- specific laser treatments;
identify methods to reduce the risk of complications after
cutaneous laser surgery and understand and implement
appropriate therapy for the most common side effects and
complications of laser and light-based treatments.
Elizabeth Tanzi, MD; Jeffrey S. Dover, MD
MC122
Reconstructive Challenge: Eyes and Nose E
(Virginia B) Closed
attendees should be able to: describe the anatomy of
periorbital and nasal region as it applies to reconstruction;
develop a logical approach to repair periorbital and nasal
defects and select and demonstrate appropriate surgical
techniques for performance of safe and effective periorbital
and nasal reconstruction.
Pathology Babble: What Does My
Dermatopathologist Mean? E
(Salon 3)
2:00 pm
MC121
AFTERNOON TEAS WITH THE
MASTERS
Jeremy S. Bordeaux, MD, MPH; Ken K. Lee, MD
MC123
Surgery Track: Fillers
(Hoover)
Closed
attendees should be able to: understand facial aesthetics
and changes associated with aging; learn the basics of facial
shaping; understand critical facial anatomy and learn which
filler, in which patient, for which purpose. Core topics
addressed may include molecular structure, mechanisms
and properties of different HA’s, CaHA’s, silicone and
others; regional uses of soft-tissue fillers; FDA indications,
and; complications.
Cheryl M. Burgess, MD; Stephen H. Mandy, MD;
 3:15 – 4:00 PM
NETWORKING BREAK IN EXHIBIT
HALL (COMPLIMENTARY BEVERAGES SERVED)
ABMS Competencies:
Patient care
Medical knowledge
Professionalism
42
Want more from your Annual Meeting?
Complete our Annual Meeting Evaluation
and be heard!
 4:00 - 5:30 PM
GD130
SCIENTIFIC SESSION
 5:30 – 7:00 PM
Iron Surgeon: Reconstructive and Cosmetic
(Marriott Foyer) Lobby Mezzanine.
(Salon 2 & 3)
Open to all attendees.
The 11th Annual Silent Auction will kick off
on Thursday evening from 5:30-7:00 p.m.
in conjunction with the Welcome Reception.
All attendees are invited to enjoy the
entertainment, hors d’oeuvres and cocktails,
and to bid on great auction items. The Silent
Auction raises money for ASDS program
initiatives.
attendees should be able to: identify new techniques in
reconstructive surgery; describe anatomy and reconstructive
principles related to repair of surgical defects; select
appropriate repairs of surgical defects and demonstrate
different approaches to rejuvenation of the face.
Graciously supported by Dermik, a business of sanofi-aventis
Moderator(s): Andrew J. Kaufman, MD;
4:00 pm
4:30 pm
5:00 pm
Match # 1
Tatyana R. Humphreys, MD; Marc D. Brown, MD
Match # 2
Christopher B. Harmon, MD; Brett M. Coldiron, MD
Match # 3
Lisa M. Donofrio, MD; Fredric S. Brandt, MD
“A CAPITAL WELCOME”
RECEPTION AND SILENT AUCTION
Graciously supported by Dermik, a business of
sanofi-aventis
 7:00 – 9:00 PM
INDEPENDENT INDUSTRY
ORGANIZED HOT TOPIC SESSIONS
See page 11 for details.
A Capital Welcome
RECEPTION & SILENT AUCTION
All registered attendees are invited to enjoy
cocktails, hors d’oeuvres, entertainment and fun at the
11th Annual ASDS Silent Auction & Welcome Reception.
Thursday, November 3, 2011 • 5:30 pm - 7:00 pm • Lobby Mezzanine
Bid on exciting items such as restaurant, hotel and department store gift certificates,
concert & sporting event tickets, “day with a doctor,” electronics, artwork, gift baskets,
fine wines, collectibles, surgical instruments and educational offerings, to name a few!
Proceeds from the Silent Auction benefit ASDS programs and educational initiatives.
43
FRIDAY, NOVEMBER 4
AB205
AB201
attendees should be able to: review aging of the area/
anatomy; have treatment options - topical; have treatment
options - devices, and have treatment options - soft filler
fillers.
Reconstructive Challenge - Lip and Ear E
Rebecca Fitzgerald, MD; Doris J. Day, MD
(Maryland A)
attendees should be able to: understand surgical defects of
the lip and ears in terms of relevant anatomy; design closure
options for the lip and ear; analyze complex reconstructive
cases and manage and predict complications of the lip and
ear.
AB206
Non-invasive Fat Reduction
Mathew M. Avram, MD, JD; Adam M. Rotunda, MD
AB203
Fillers and Toxins: Maximizing Injections and
Minimizing Tools
(Maryland C) Closed
attendees should be able to: discuss and implement
efficient techniques; recognize potential complications and
understand relevant anatomy.
(Virginia C)
attendees should be able to: identify correct codes and
apply more accurately for proper patient encounter
documentation; properly apply codes for more complex
repairs and new soft-tissue excisions; ensure that coding
correctly reflects service/treatment performed; recognize
potential audit targets and ensure coding to avoid RAC
audits and billing for more than 24 hours of service in a
day; describe how CPT codes are valued, and; discern why
you must E-prescribe at least 10 times a year – or not.
(Maryland B)
attendees should be able to: identify and understand the
mechanism of action and clinical applications of novel laser
and energy based technologies that selectively remove
fat; identify and understand the mechanism of action and
clinical applications of novel injectable compounds currently
in development that remove fat and understand the
available data describing the potential uses, limitations and
adverse effects of each of these non-surgical methods and
technologies.
Comprehensive Coding E
Isaac M. Neuhaus, MD; Andrea Willey, MD;
Rachel Moore, MD
AB202
Non-surgical Eye Rejuvenation
(Virginia B) Closed
by the seating available, and may be closed. See registration desk
for to register for courses not marked CLOSED.
George J. Hruza, MD; Brett M. Coldiron, MD
AB207
Science of Skin Care
(Hoover)
attendees should be able to: identify new trends in skin
care; summarize the current science driving skin care
product development and select appropriate skin care
products.
Patricia Farris, MD; Zoe D. Draelos, MD
 7:15 – 9:00 AM RESIDENTS/FELLOWS-IN-TRAINING/
YOUNG DERMATOLOGIC
(Harding)
Dee Anna Glaser, MD; Michael S. Kaminer, MD
AB204
Managing Skin Cancers in Organ Transplant
Recipients E
(Virginia A)
 8:00 – 9:00 AM NETWORKING BREAK IN EXHIBIT
HALL (COMPLIMENTARY LIGHT BREAKFAST
FARE SERVED)
attendees should be able to: identify high risk skin cancer
as it pertains to the solid organ transplant population; to
manage high risk skin cancer appropriately with the use of
adjuvant therapies and field therapy in addition to surgical
therapy in order to reduce the risk of recurrence and
metastatic; institute a multidisciplinary form of patient care
and thoroughly understand the role of the dermatologist
in reduction of immunosuppression for organ transplant
recipients at high risk for aggressive skin cancer.
Fiona O’Reilly Zwald, MD; Chrysalyne Schmults, MD
 8:45 – 9:00 AM TRANSITION BREAK FROM
COFFEE TALKS
ABMS Competencies:
Patient care
Medical knowledge
Check out the new educational DVDs
in ASDS Booth #108.
Professionalism
44
FRIDAY, NOVEMBER 4
 9:00 – 10:15 AM GENERAL SESSION (Salon 2-3)
9:00 am
9:03 am
9:06 am
9:10 am
Teaser for CS310 – Nightmares Come True: Medical
Mishaps Can Happen to You
Jenny Kim, MD, PhD; Abel Torres, MD
Teaser for PM313 – To be Seen or Not to be Seen on the
Social Media Scene
Darrel S. Rigel, MD; Alysa R. Herman, MD
Teaser for RX314 – The Usual Suspects: Taking Charge of
Common Defects
George J. Hruza, MD; Glenn D. Goldman, MD
KEYNOTE LECTURE: Michael McMillan
Best-Selling Author, Speaker, and Innovation and
Creativity Consultant
Michael McMillan has a reputation for creative thinking
and delivering innovative results. Early in his career,
his visual communications firm counted among its
client roster Fortune 100™ corporations, sports and
music legends, non-profit organizations and more. His
creative direction on Michael Jordan’s New York Times
best-selling pictorial autobiography Rare Air established
a new niche in retail publishing. Award-winning
books Mario Andretti, The NBA at 50, and John Deer’s Genuine Value
followed. Michael’s work has been recognized by every major design,
advertising and communication organization around the world.
After 20 consecutive years of growth, Michel sold his firm to share his
unique insight on creative thinking, innovation and making a positive
change. He is a perception catalyst and truth seeker, inspiring others to
question, think differently, and take action. As an accomplished author,
some of his books include:
Pink Bat: Turning Problems into Solutions. This book will turn your
thinking upside down and have you seeing problems as solutions.
Moderator(s):
11:00 am
11:20 am
11:40 am
12:00 pm
Resident Oral Abstracts
11:00 am
Sentinel Lymph Node Biopsy in Cutaneous and
Non-cutaneous Cancer
Moderator(s): Monica Hale, MD; Allison Hanlon, MD
Clinical Application of FISH in the Management and
Diagnosis of Melanoma
Rajiv Nijhawan, MD
1064 Nd:YAG Q-switched Laser for the Treatment
of Toenail Onychomycosis
Jason D. Boyd MD
Consensus Recommendations and Current Practices
for the Reconstitution and Storage of Botulinum Toxin
Type A
Austin Liu, MD
Safety of Storing and Reusing Hyaluronic Acid Fillers:
A Retrospective Chart Review
Patrick Safo, MD, PhD
How Accurate is Botulinum Toxin A? Can We Correct for
Eyebrow Height Asymmetry?
Jason Sneath, MD
Inflammation and Fibrosis on Moh’s Levels, What Does It
Mean?
Jason Sneath, MD
Is Cryosurgery or Curettage More Effective at Treating
Seborrheic Keratoses?
Lance D. Wood, MD
Sunscreen Use, Behaviors and Attitudes among NCAA
Collegiate Athletes
Ashley Wysong, MD
Discussion
Clinical Efficacy and Safety Evaluation of the New
Monopolar Radiofrequency (mRF) Device with Comfort
Pulsed Technology for the Treatment of Facial Skin
Laxity: A 10 Month Experience with 64 Patients
Arden Fredeking, MD
Establishing the Safety and Efficacy of Simultaneous
Facelift and Intro-operative Full Face and Neck Fractional
CO2 Resurfacing
Tyler Hollmig, MD
A Novel Approach to the Treatment of Medial Canthal
Webs Using an Ablative Fracitional Laser-based Protocol
Tara Dever, MD
Discussion
11:05 am
11:10 am
11:15 am
Jonny the Bagger: The Simple Truths of Service. Working with Ken
Blanchard and Barbara Glanz, Michael created this book to illustrate the
importance of customer service that comes from the heart.
11:20 am
Michael McMillan’s breadth of knowledge and experience, combined
with his story-telling ability, allow his messages to resonate with
audiences. Hear Michael’s keynote at 9:10 am on Friday, November
4 and leave highly motivated and committed to embracing a future of
endless possibilities.
11:30 am
11:35 am
11:40 am
(COMPLIMENTARY BEVERAGES SERVED)
SESSIONS
CS211
11:45 am
11:50 am
11:55 am
Controversies in Dermatologic Surgery
(Salon 3)
12:00 pm
Learning Objectives: Following this session, participants
will be able to: select whether and for which procedures
physician extendors may be appropriate; discern when to
provide topical chemophrophylaxis of skin cancers and
pre-cancers; recite the indications and contradindications
for performing more advanced cosmetic procedures, and;
decide when visual examination alone for detection of
melanoma is no longer optional.
Are physician assistants and nurse practitioners essential
and appropriate for dermatologic surgery practices, and
can they can provide almost any type of care that is
delivered in such practices?
Ava T. Shamban, MD; Derek H. Jones, MD
Should topical chemoprophylaxis of skin cancers and
precancers be provided to all patients with a history of
actinic keratoses or skin cancer?
Leonard H. Goldberg, MD; Ellen Marmur, MD
To evolve or not to evolve: Perform more advanced
cosmetic procedures such as liposuction, endovenous
ablations, and face-lifts, or risk becoming glorified
aestheticians.
Hayes B. Gladstone, MD; Elizabeth Tanzi, MD
When does visual examination alone for detection
of melanoma become a quaint tradition of dubious
scientific value?
John A. Zitelli, MD, Thomas E. Rohrer, MD
RS213
Paper Airplane: A Lesson for Flying Outside the Box. This entertaining story
provides a profound and lasting impact on the power of creative thinking.
 10:15 – 11:00 AM NETWORKING BREAK
IN EXHIBIT HALL
Murad Alam, MD;
12:05 pm
12:10 pm
(Salon 1)
45
FRIDAY, NOVEMBER 4
 12:15 – 12:30 PM TRANSITION BREAK TO MEMBERS
BUSINESS MEETING/EXHIBITS
GD231
 12:30 – 1:30 PM ANNUAL MEMBERS BUSINESS
MEETING LUNCH (MEMBERS ONLY) (Salon 3)
1:30 pm
Cutting Edge Research Grant Award and
Research Abstracts (Salon 1)
Moderator(s): Eva Hurst, MD; Sigfried Yu, MD
 12:30 – 1:30 PM NETWORKING LUNCH BREAK IN
EXHIBIT HALL FOR NON-MEMBERS
1:36 pm
(LIGHT LUNCH AVAILABLE FOR PURCHASE)
(Exhibit Hall A-B (all))
1:42 pm
CS228
Dermatologic Surgery Around the World
1:48 pm
(Salon 3)
will be able to: identify various cosmetic techniques
utilized around the globe; compare effectiveness of these
techniques to those currently utilized in their own practices,
and; recognize areas where patient care can be improved
by broadening knowledge of advances made in various
countries.
Moderator(s): Susan H. Weinkle, MD
1:30 pm
1:35 pm
1:45 pm
1:55 pm
2:05 pm
2:15 pm
2:25 pm
2:35 pm
2:45 pm
Introduction
Neurotoxin Update
Doris Hexsel, MD
Combination Resurfacing
Gregory J. Goodman, MD
The Beauty of Chemical Peels
Marina Landau, MD
Soft Tissue Augmentation with Cannulas
Hassan Galadari, MD
Advanced Dermal Filler Injection Techniques: European
Experience
Sabine Zenker, MD
Hyaluronic Acid Full Face-lift
Davi de Lacerda, MD
Innovations from North of the Border
Discussion
ABMS Competencies:
Patient care
Medical knowledge
Professionalism
46
1:54 pm
2:00 pm
2:12 pm
2:18 pm
2:24 PM
2:30
Cost Comparison of Non-melanoma Skin Cancer (NMSC)
Treatment Options: The Actual Global Costs Incurred By
One Managed Care Organization
2009 CERG Winner Vanessa A. London, MD
Voriconazole as a Risk Factor for Squamous Cell
Carcinoma in Lung Transplant
2010 CERG Winner Andreas Boker, MD
An Investigation of Coagulation Cascade Activation
and Induction of Fibrinolysis by Foam Sclerotherapy of
Reticular Veins
2010 CERG Winner Sabrina Guillen Fabi, MD
Collagenase-Digested Autologous Fat Transfer
2010 CERG Winner Naomi Lawrence, MD;
Catastrophic Cutaneous Carcinomatosis in the Non-organ
Transplant Population
2010 CERG Winner Ellen S. Marmur, MD
Rate of Change in Diagnosis after Excision of Biopsyproven Atypical Nevi and Examination of risk of
Malignant Potential
2010 CERG Winner Kavitha K. Reddy, MD
Combining Field Therapies with Sequential Topical
5-Fluorouracil Followed by 5-Aminolevulinic Acid
Photodymanic Therapy for Actinic Keratosis
Edidong Ntuen Kaminska, MD
Efficacy and Safety of the Hedgehog Pathway Inhibitor
Vismodegib in Patients with Advanced Basal Cell
Carcinoma: A Pivotal Multicenter Trial
Michael R. Migden, MD
Propective, Double-blind, Randomized Pilot Study
Comparing Ibuprofen to a Narcotic for Pain Management
During Micro-focused Ultrasound Treatment
Hema Sundaram, MD
Discussion
FRIDAY, NOVEMBER 4
 1:30 - 3:00 PM
MASTERS
MC224
Tea of your choice. Sessions are limited by seating available, with a
cost of $35, and may be closed.
MC221
Acne Scarring
attendees should be able to: understand structure and
mechanism of action for botulinum toxin; review the
regions of treatment for upper face and discuss potential
complications; review the regions of treatment for the
lower face and discuss potential complications and explain
some of the identifying features of currently available
formulations.
(Maryland A) Closed
attendees should be able to: understand how the facial
rejuvenation paradigm of cohesive treatment of volume,
surface and movement relates to scarring; evaluate and
classify acne scars of different morphologies, and develop
individualized treatment plans; identify patients who
will need combined methods of treatment; prepare the
acne scar patient for expected outcomes and possible
complications and properly perform the necessary
procedures to treat the most difficult forms of scarring.
Joel L. Cohen, MD; Sue Ellen Cox, MD;
MC225
attendees should be able to: identify unique aesthetic
considerations with respect to the aging patient with skin
of color; expand on specific treatments and considerations
when treating skin of color patients; identify common skin
aging concerns in patients with skin of color and discuss
unique and specific cosmeceutical and procedural cosmetic
procedures geared toward the skin of color patient.
Surgery of the Nail: Hammering Down Your
Technique NO E
(Maryland B)
Pearl E. Grimes, MD; Jeanine B. Downie, MD;
attendees should be able to: be familiar with the
surgical anatomy of the nail unit; select the appropriate
surgical approach to various nail lesions, and; demonstrate
improved competence regarding the nuances of nail surgery
procedures. Case presentations, short video clips and
possible cadaver digits demonstration/ dissection may be
employed.
Phoebe Rich, MD
MC223
Surgery: Veins
(Maryland C)
Closed
attendees should be able to: discuss relevant venous
anatomy and pathophysiology of venous disease; the basics
of sclerotherapy and complications of sclerotherapy.
Aesthetics and Ethnic Skin
(Virginia B)
Gregory J. Goodman, MD; Christopher B. Harmon, MD;
Douglas Fife, MD
MC222
The State-of-the-Art in Botulinum Toxin
Treatments
(Virginia A) Closed
MC226
“What to Do When a Chart Audit Happens to
You” E
(Harding)
participants will be able to: describe the required
components for a complete patient chart; understand
the ramifications of chart audit issues, and; demonstrate
methods for ensuring preparedness in the event of an audit.
Mark S. Nestor, MD, PhD; Allan S. Wirtzer, MD
 3:00 – 3:45 PM
NETWORKING BREAK IN EXHIBIT
HALL (COMPLIMENTARY BEVERAGES SERVED)
Girish S. Munavalli, MD; Jeffrey T.S. Hsu, MD
All registered attendees
are invited to the
Wine & Cheese
Reception
in the Exhibit Hall
Friday, November 4, 2011
5:30 - 7:00 PM
47
FRIDAY, NOVEMBER 4
PD240
CS233
Patient Demonstration
onstration – Fillers and
Neurotoxins
(Salon 2)
3:45 pm
3:50 pm
attendees should be able to: identify the structural and
functional anatomy considerations that enable clinicians to
achieve safe and efficacious injection of fillers and toxins;
discuss how individualized patient assessment can optimize
pan-facial rejuvenation with fillers and toxins; describe
an evidence-based approach to treatment with fillers and
toxins, including selection of the appropriate products
and injection strategies and discuss the avoidance and
management of potential complications from filler and toxin
injections.
Moderator(s): Jean Carruthers, MD;
Miriam P. Cummings, MD;
Hema Sundaram, MD
Introduction
Jean Carruthers, MD
4:00 pm
Combining HA and PMMA Fillers
Cheryl M. Burgess, MD - Injecting
Hema Sundaram, MD - Facilitating
4:25 pm
Combining HA Fillers
Robert A. Weiss, MD - Injecting
Jean Carruthers, MD - Facilitating
4:50 pm
Combining HA, CaHA and PLLA Fillers
Hema Sundaram, MD - Injecting
Miriam P. Cummings, MD - Facilitating
Questions from the Audience Throughout the Demonstrations;
Aisle Microphones will be Available.
3:55 pm
4:00 pm
4:05 pm
3:45 pm
RX229
Better Than Pearls: Reconstructive Diamonds
E
(Salon 3)
4:15 pm
4:20 pm
4:25 pm
4:30 pm
4:35 pm
attendees should be able to: improve approaches to postcancer surgical reconstruction techniques via primary
repair, flap, graft, and granulation; gain confidence in
employing a logical and step-wise method for managing
facial wounds and wounds in critical locations and improve
patient education skills to improve psychological and longterm outcomes regardless of repair method selected, and
establish a mindset that considers wound and host factors
in each repair, rather than a preconceived repair choice.
Moderator(s): Christopher J. Arpey, MD;
Hayes B. Gladstone, MD
3:45 pm
3:50 pm
4:00 pm
4:10 pm
4:20 pm
4:30 pm
4:40 pm
4:50 pm
5:00 pm
5:10 pm
48
Introduction
Christopher J. Arpey, MD; Hayes B. Gladstone, MD
Executing Ear Repairs
Christian Baum, MD
Rotations, Risks and Rarities
Marta Van Beek, MD
Adding Zip to Your Z-plasties
Nasal Nuances
Jerry D. Brewer, MD
Creative Contouring of Staged Flaps
John A. Carucci, MD, PhD
Cartilage Grafting for the Nasal Ala
Daniel B. Eisen, MD
How to Close a Large Scalp Defect
Simplifying Skin Grafts
Larisa Ravitskiy, MD
4:45 pm
4:50 pm
4:55 pm
5:00 pm
5:05 pm
5:10 pm
Cosmetic Oral Abstracts
(Salon 1)
Moderator(s): Rebecca Kazin, MD; Rebecca Tung, MD
Topical Botulinum Toxin
Gary D. Monheit, MD
Onset and Durability of Response to Abobotulinumtoxin
A for Glabellar Lines in Patients With Skin of Color and
White Patients
Valerie D. Callender, MD
Multicenter Phase II and Phase III Studies of Single and
Repeat Doses of Incobotulinum toxinA in Treatment of
Glabellar Frown Lines for Up to Two Years
Poly-L-Lactic Acid for Chest Rejuvenation:
A Retrospective Study of 28 Cases Using a 5-point Chest
Sabrina Guillen Fabi, MD
Efficacy of a Novel Bi-directional Sidelight Optical Fiber
& 1440 nm Nd:YAG Laser in the Treatment of Cellulite
as Measured by 3-dimensional Surface Imaging
Bruce E. Katz, MD
Review of a Novel Compound
(1% 4-Ethoxybenzaldehyde) in Reducing Facial Erythema
Leon H. Kircik, MD
Assessment of Safety and Efficacy of a Bipolar
Fractionated Radiofrequency Device in the Rejuvenation
of Aged and Photodamaged Skin
Jeremy R. Man, MD
Full Face Soft Restoration with Hyaluronic Acid Gel
Fillers and Microcannulas
Giovanni Salti, MD
Autologous Fibroblast Therapy for Treatment of Facial
Rhytids
Stacy R. Smith, MD
ATX-101 Treatment Offers Long-term Durability of
Submental Fat Reduction: Preliminary Follow-up Study,
Results of Subjects from Phase 2 Studies
Kevin C. Smith, MD
Evaluation of Safety, Efficacy and Patient Satisfaction
After Multi-Plane Nonsurgical Lifting of the Face,
Submental Region and Neck with a Novel Micro-Focused
Ultrasound Device with Simultaneous Ultrasound
Visualization
Hema Sundaram, MD; Oge Onwudiwe, MD; Ashley Lodha
The Transplanted Hairline. A Leg Room for Improvement
Sanusi H. Umar, MD
Safety of Fractional CO2 Laser of the Neck and Chest:
A Review of 122 Cases
Susan Brunner Van Dyke, MD
Laser Assisted Delivery of Allogeneic Porcine
Mesenchymal Stem Cells
Jill S. Waibel, MD
Long-Term Follow-Up For 1927nm Fractional Resurfacing
of Actinic Keratoses on the Face
Elliot T. Weiss, MD
Enhancement of the Brow using Botulinum Toxin A in
Combination with Hyaluronic Acid Filler as Evaluated by
Patient Satisfaction
Derek H. Jones, MD
 5:30 – 7:00 PM
WINE AND CHEESE RECEPTION
IN EXHIBIT HALL (Exhibit Hall A-B)
Graciously supported by Revance Theraputics
SATURDAY, NOVEMBER 5
AB305
by the seating available, and may be closed.
AB301
Facial Shaping
attendees should be able to: successfully integrate cosmetic
procedures into their existing practice; formulate a plan to
acquire new equipment and office personnel rationally and
implement effective marketing strategies for maintaining a
successful and patient-centered cosmetic practice.
(Maryland A) Closed
attendees should be able to: identify appropriate fillers for
facial fillers; select appropriate patients for facial shaping
procedures; thoroughly understand relevant anatomical
structures to avoid adverse events and demonstrate proper
best practice injection techniques.
Paul M. Friedman, MD; Vic A. Narurkar, MD
AB306
Patient Safety E
(Virginia C)
attendees should be able to: understand the planning and
execution of upper and lower lid blepharoplasty; understand
how to recognize lower eyelid laxity and commonly used
techniques for lower lid tightening; understand the effects
of brow ptosis and lateral hooding and various treatment
options; have a comprehensive approach to “dark lower
eyelid circles” with focus on tear troughs and lateral
orbital hollowing, the anatomic basis, proper photographic
documentation, and the use of fillers for aesthetic
contouring and select additional complementary methods
for periorbital rejuvenation.
(Maryland B)
attendees should be able to: identify high risk areas in
dermatologic procedures; learn to formulate protocols,
create check lists for entire staff and develop team approach
to indentifying issues and problems subverting patient and
staff safety.
Carl F. Schanbacher, MD, Andrew A. Nelson, MD;
William Stebbins, MD
AB303
Managing Surgical Complications
(Maryland C)
attendees should be able to: recognize the causes
and prevention of bleeding; understand proper use of
anticoagulants; identify risks for infections, proper use
of antibiotics pre and post operatively; understand the
inter-related cause of tissue necrosis and dehiscence
and recognize potential adverse outcomes of simple and
complex cutaneous surgical procedures.
Tatyana R. Humphreys, MD; Hugh M. Gloster, Jr., MD;
Marc D. Brown, MD
AB304
Reconstructive Challenge: Legs, Arms and
Scalp E
(Virginia A)
attendees should be able to: develop an approach to
reconstruction of challenging surgical defects on the
legs, arms and scalp; understand pitfalls and potential
complications of flaps on the legs, arms and scalp and
identify the utility of wound care assisted skin grafts and the
keystone flap for challenging defects on the legs.
Scott Isenhath, MD; Juan-Carlos Martinez, MD;
Joseph Sobanko, MD
Blepharoplasty Basics: How to Get Started
Derek H. Jones, MD; Nowell J. Solish, MD
AB302
How to Build and Manage a Cosmetic
Practice
(Virginia B)
Sorin Eremia, MD; Steven C. Dresner, MD
AB307
The ASDS-based International Dermatologic
Surgery Mentorship Exchange Program –
An Endowed Teaching Program (Hoover)
Learning Objectives: A special gathering for already-
approved Mentors or for those contemplating participating
in the program, and for those representing entities
interested in submitting an application for approval. Those
interested in future participation must be board certified
(or accepted equivalent) dermatologists who wish to
share their expertise internationally or as hosts who will
accept committee-approved dermatologists for in-office
or in-hospital training in areas of deficiency in the host
dermatologist’s respective training program or country. All
attendees will share their own experiences and ideas for
expanding the program and for increasing its international
exposure and influence. Note: Advance registration is
necessary, space is limited, however no fee is required
Moderator(s): Lawrence M. Field, MD
 7:15– 9:00 AM
RESIDENTS/FELLOWS-IN-TRAINING/
YOUNG DERMATOLOGIC
(Harding)
ABMS Competencies:
Patient care
Medical knowledge
 8:00 – 9:00 AM NETWORKING BREAK
IN EXHIBIT HALL
(COMPLIMENTARY LIGHT BREAKFAST FARE SERVED)
Professionalism
 8:45 – 9:00 AM TRANSITION BREAK FROM COFFEE
TALKS
49
 9:00 – 10:00 AM SPECIAL KEYNOTES (Salon 2 & 3)
9:00 am
PM310
Mohit Bhandari, MD, PhD, FRCSC
Professor and Academic Chair, Department of
Orthopeadic Surgery, McMasters University, Toronto
Dr. Bhandari’s extensive research broadly focuses upon
clinical trials, meta-analyses, methodological aspects
of surgery trials and the translation of evidence into
surgical practice. Specific areas of interest include
identifying optimal management strategies to improve
patient-important outcomes in patients with multiple
injuries, lower extremity fractures and severe soft
tissue injuries. He is a leader in the area of fostering
understanding of evidence-based medicine so that
clinicians wishing to use today’s medical literature will
have a solid understanding of the validity and rigor
upon which the information is based.
Practice Management Pointers for the
Perfectionist E
(Salon 3)
attendees should be able to: recognize and implement
successful management strategies; obtain and employ new
practice management ideas and procedures to enhance
patient care and run a successful office; effectively manage
office staff to minimize clerical and administrative errors;
recognize signs of and/or utilize technique to avoid
embezzlement, and learn of and introduce technological
media changes as they pertain to the practice of
dermatologic surgery.
Moderator(s): Mary E. Maloney, MD;
Elizabeth I. McBurney, MD
We are honored to have such an esteemed colleague
address the ASDS Annual Meeting attendees.
11:25 am
The Importance of a Unified Message
Elizabeth Tanzi, MD
Checks and Balances to Minimize Embezzlement in
Private Practice
Survival Tips for New Media
Kyle Coleman, MD
Building an Office Team Through Better Performance
Reviews
Naomi Lawrence, MD
RX311
General Dermatologic Surgery Oral Abstracts
Dr. Bhandari is a sought after speaker, as well as a
prolific author of many articles including “Challenges
to the Practice of Evidence-Based Medicine during
Residents’ Surgical Training: A Qualitative Study Using
Grounded Theory.” He has edited several textbooks in
surgical research and is senior editor of the textbook
Evidence-Based Orthopaedics.
10:45 am
10:55 am
11:05 am
11:15 am
(Salon 1)
Moderator(s):
9:50 am
A Success in the Works: Expansion of the International
Traveling Mentorship Program
 10:00 – 10:45 AM
NETWORKING BREAK IN
EXHIBIT HALL
10:45 am
10:50 am
(COMPLIMENTARY BEVERAGES SERVED)
 10:45 - 11:30 AM CONCURRENT SCIENTIFIC SESSIONS
CS327
What’s New in Fat Transfer
(Salon 2)
10:55 am
11:00 am
attendees should be able to: review the new techniques
in fat/stem cell augmentation; select fat transfer as a
reconstructive alternative to lifting/skin procedures and
understand the benefits and risks of adipose grafting.
Moderator(s): Naomi Lawrence, MD;
William P. Coleman, III, MD
10:45 am
11:00 am
Emqyme Processing to Enhance Fat Graft Survival
Aerlyn G. Dawn, MD
Applying Scientific Data to Maximize the Effect of
Transplanted Fat
Sydney R. Coleman, MD
11:05 am
11:10 am
11:15 am
Deborah MacFarlane, MD;
Kee-Yang Chung, MD
Cutler-Beard Flap: A Useful Technique for Repairing
Large Full-Thickness Upper Eyelid Defects
Cyanoacrylate Lamination Technique in Miniature Punch
Grafting in stable Vitiligo at Difficult Sites
Niteen V. Dhepe, MD
Dermatologic Surgery Consultation and Follow-up:
A Patient-based Research Survey
Omar Ibrahimi MD, PhD
The Use of Novel Bipolar Wound Sealer (Radiofrequency
with Conductive Saline) to Achieve Hemostasis in
Andrew A. Nelson, MD
Embryonic-like Secreted Proteins Enhance Follicular Unit
Viability and Improve Donor Site Healing
Neil S. Sadick, MD
The Expanded Utility of the Burrow’s Advancement Flap
Oliver J. Wisco, DO
Treatment of Post Burn Hypertrophic Scars with
Fractional CO2 Laser in Indian Skin
Niteen V. Dhepe, MD
ABMS Competencies:
Patient care
Medical knowledge
Order a new lab coat or plaque at the
ASDS Booth #108 in the Exhibit Hall.
50
Professionalism
SESSIONS
RX314
Commonly Seen Defects: How Would You
Reconstructive It?
(Salon 2)
12:00 pm
12:05 pm
attendees should be able to: take a logical approach to the
reconstructive options for repair of moderate-sized defects
on the face and scalp; find the optimal reconstructive option
for a given head and neck defect and be more familiar
with the reconstructive details or steps needed to optimally
execute the chosen reconstructive option.
Moderator(s): Glenn D. Goldman, MD;
George J. Hruza, MD
11:30 am
11:50 am
12:10 am
PM313
Reconstructive Options for Common Perioral Defects
Leonard H. Goldberg, MD, FRCP
Reconstructive Options for Common Proximal Nose
Stephen N. Snow, MD
Reconstructive Options for Common Distal Nose Defects
Todd E. Holmes, MD
How to Enter the Social Media Age E
(Salon 3)
11:30 am
11:35 am
11:50 am
12:05 pm
CS312
12:10 pm
A Split-Face Comparison Between Combined Fractional
Ablative with Non-Ablative Lasers and Fractional
Ablative Lasers
Joel L. Cohen, MD
Evaluation of Orbicularis Oculi Muscle Striping on the
Cosmetic Outcome of Upper Lid Blepharoplasty: A
Randomized, Controlled Study
Matteo C. LoPiccolo, MD
Effect of Anxiety on Patient Satisfaction With the Postoperative Outcomes in Mohs Micrographic Surgery
Iren Kossintseva, MD
 12:30 – 2:00 PM NETWORKING BREAK IN EXHIBIT
HALL (COMPLIMENTARY LIGHT LUNCH;
HALL CLOSES AT 2:00 PM)
 12:30 – 2:00 PM YOUNG DERMATOLOGIC
SURGEONS LUNCHEON(ADVANCE
SIGN-UP REQUIRED)
(Hoover) Closed
 12:30 – 2:00 PM WOMEN’S DERMATOLOGIC
SURGEONS LUNCHEON
(ADVANCE REGISTRATION THROUGH WDS REQUIRED)
will be better able to: describe the various types of social
media available; recite the benefits of using social media
to enhance their practice, and; recognize areas of concern
regarding social media content, overuse and misuse.
Moderator(s): Darrell S. Rigel, MD;
Alysa R. Herman, MD
(Wilson A- C)
 12:30 – 2:00 PM INDUSTRY ADVISORY COUNCIL
LUNCH (OPEN TO IAC MEMBERS ONLY) (Madison)
Introductions
Alyssa Herman, MD; Darrell S. Rigel, MD
Social Media in the Dermatologic Surgery Practice
Robert A. Weiss, MD
Making Social Media Work For Your Practice
Tom Seery
Evil Tidings: The Dark Side of Connectivity
Late Breaking Oral Abstracts
(Salon 1)
Moderator(s): Quenby Erickson, DO; Joely Kaufman, MD
11:30 am
11:35 am
11:40 am
11:45 am
11:50 am
11:55 am
Two-Center, Open-Label, Randomized, Split-Face Study
to Assess the Efficacy of One Versus Three Intradermal
Injection Sites of Abobotulinum toxin A in the
Treatment of Lateral Periocular Rhytides
Mitchel P. Goldman, MD
Repeat Cryotreatment on Motor Nerves to Reduce
Muscle Movement in a Rodent Model
Vic A. Narurkar, MD
A Prospective, Long-Term Observational Study of the
Efficacy & Safety of an Hyaluronic Acid (HA) Filler in the
Correction of Mild to Severe Mid-Face Volume Deficits:
18 Month Interim Analysis
A Novel Triple Combination Injection for Resolution of
Keloids and Hypertrophic Scars
Nilesh Narendra Goyal, MD
Fractional Photothermolysis in the Treatment of Acne
Scars: A Comparison of the CO2, Fraxel and Er:Yag
Lasers
Timothy Cragun, DO
Discussion
51
 2:00 – 3:30 PM CONCURRENT SCIENTIFIC SESSIONS
 2:00 - 3:30 PM AFTERNOON TEAS WITH THE
MASTERS
CS309
Tea of your choice. Sessions are limited by seating available, with a
cost of $35, and may be closed.
Cosmetic Chaos - How to Stay Coherent
Following Complications
(Salon 2)
attendees should be able to: recognize long term and short
term complications from injectables, devices and cosmetic
dermatologic procedures; create a treatment plan to
address complications; identify areas of high risk in cosmetic
dermatologic procedures and create an algorithm for
optimizing safety, efficacy and reducing complications.
Moderator(s): Vic A. Narurkar, MD;
Douglas G. Hamilton, MD
2:00 pm
2:20 pm
2:40 pm
3:00 pm
Injectable Complications and Management
Jean Carruthers, MD
Energy Based Devices: Complications and Management
Roy Geronemus, MD
Aesthetic Complications and Management in Skin of
Color
Pearl Grimes, MD
Blepharoplasty and Periorbital Laser Resurfacing
Complications
MC321
Getting Started in Facelifts and Browlifts
(Virginia A)
attendees should be able to: understand the indications,
contraindications, and proper patient selection for face
and browlifts; describe the key anatomy and technical
pearls of face and browlifts to effective deliver a consistent
rejuvenation result; effectively prevent, detect, and treat
potential complications of face and brow lifting and
describe the rationale behind the vertical vector face lift
including the distinguishing characteristics from traditional
lifting techniques.
Steven M. Rotter, MD; Greg S. Morganroth, MD
MC322
Steve Dresner, MD
Surgery: Neurotoxins
(Virginia B)
Closed
CS310
attendees should be able to: understand currently available
neurotoxins and those on the immediate horizon and
how to best use each to achieve optimal patient results;
better utilize neurotoxins for both common and novel
“off-label” uses; identify situations that may predispose to
complications and better manage complications and identify
situations where neurotoxin benefits are limited and in
which neurotoxins are best combined with other cosmetic
procedures. Core topics addressed may include relevant
facial anatomy, mechanisms of action, innvervation, danger
zones and complications.
Managing Common Medical Mishaps
(Salon 3)
attendees should be able to: recognize areas of their
practice prone to medical mishaps, (mislabeling, etc.);
understand the medico-legal implications of medical
mishaps and learn how to improve their communication
with their patients regarding those mishaps.
Moderator(s): Jenny Kim, MD, PhD; Abel Torres, MD
2:00 pm
2:05 pm
2:25 pm
2:45 pm
3:00 pm
3:15 pm
Introduction
Jenny Kim, MD, PhD and Abel Torres, MD
Areas of Practice Prone to Mishap
Sandra Read, MD
Medico-legal Implications of Mishaps
Abel Torres, MD
Communicating With Your Patient
Patrick K. Lee, MD
First Year in Practice: Exponential Learning Curve
Moderators and Faculty
Vince Bertucci, MD; Vivian W. Bucay, MD; Mary P. Lupo, MD
MC323
PDT: Blue Light, Red Light, No Light?
A Comprehensive Review
(Virginia C) Closed
attendees should be able to: understand mechanism of
action and therapeutic efficiency for PDT treatment; learn
presenter techniques for PDT treatment of AK, BCCs, SCCs,
Acne, Photo damage and seb-hyperplusia, and; learn ways
to maximize PDT efficiency and learn ways to minimize
adverse outcomes.
Amy Taub, MD
Mitchel P. Goldman, MD; Peter K. Lee, MD, PhD
MC324
Protecting Your Practice: Employee
Management, Theft and More E
(Maryland C)
Learning Objectives: Following the presentation,
participants will be able to: recognize the different forms of
embezzlement; discuss safeguards against embezzlement in
the medical practice office, and; recite tips on how to best
work with an accountant.
David A. Laub, MD; Allan S. Wirtzer, MD;
Steven E. Leininger, CPA
52
 3:30 – 3:45 PM
TRANSITION BREAK
 3:45 – 5:15 PM
 3:45 - 5:15 PM
CONCURRENT SCIENTIFIC SESSIONS
Advance registration is strongly encouraged. Sessions are limited by
seating available and may be closed at on-site registration.
See registration form for pricing and registration.
CS314
Repair of Repairs
(Salon 2)
WORKSHOPS/PATIENT
DEMONSTRATIONS
attendees should be able to: identify areas at risk for
distortion when performing closures; thoroughly relate the
different techniques to prevent these complications and
describe and demonstrate different techniques to repair
these complication if they are to occur.
Moderator(s): David G. Brodland, MD;
Jonathan L. Cook, MD
3:45 pm
3:55 pm
4:05 pm
4:15 pm
4:45 pm
5:00 pm
5:15 pm
PM332
Revision of Depressed and Hypo-pigmented Surgical
Scars
Glenn D. Goldman, MD
Revision of an Ala and Revision of a Pincushioned
Bilobed Transposition Flap
Juan-Carlos Martinez, MD
Repair of Trapdoor Deformity of the Chin and
Commissuroplasty for Repair of Microstomia
Ali Hendi, MD
Laser Revision of Mohs Surgical Scars
Galen H. Fisher, MD
Ecotropian Repair after a Mustarde Flap and Repair of
the Elevated Alar Rim
Revision of a Dead Forehead Flap
Steven M. Rotter, MD
Conundrum Cases and Commentary
Panel and Moderators
Electronic Health Records and Your Office E
(Salon 3)
participants will be able to: have a better understanding of
how to choose an EHR system for your office; maximize use
of the system you have or purchase; communicate the legal
implications of EHR; understand the recent government
incentive programs and regulations, and; introduce other
devices that would enhance the digital world in your office
Moderator(s): Saadia Raza, MD; Ashish Bhatia, MD
3:45 pm
4:00 pm
4:15 pm
4:30 pm
4:45 pm
4:55 pm
5:05 pm
What I Like/Dislike About My EHR
Ashish Bhatia, MD
What I Like/Dislike About My EHR
Barry Leshin, MD
Medical-legal Implications of EHR
Marta J. Van Beek, MD, PhD (invited)
EHR Incentive Program Updates
Saadia Raza, MD
PQRS and E-prescribing
Saadia Raza, MD
Other Tips on Digitizing Your Office
Suneel Chilukuri, MD
Questions
WS330
Hands-on Workshop on Fillers and Injectables
(Maryland B)
(Residents/Post-residency Trainees/Young
Dermatologic Surgeons ONLY- Limited to 30)
Learning Objectives: Specifically targeted to residents,
post-residency trainees and young dermatologic surgeons,
this workshop offers hands-on experience practicing
basic and complex suturing and tumor excision and
repair including flaps and basic and complex suturing.
This course features new high-fidelity cutaneous surgical
models which accurately simulate anatomy, including submucosa structure, allowing for realistic hands-on practice
not standard in training programs. Upon completion of
this workshop, participants will be able to: recite their
understanding of facial anatomy in order to enhance a
patient’s cosmetic appearance; increase their competence in
patient positioning for all procedures; utilize the appropriate
grasp for handling injection syringes; Deploy the appropriate
push pressure for injection of material based on consistency
(with and without lidocaine, etc.); accurately select injection
site and inject filler/injectable material, and; perform
ancillary procedures including but not limited to massage to
obtain the best cosmetic outcome.
Moderator(s): Dee Anna Glaser, MD;
Rhoda S. Narins, MD
Faculty:
Alastair Carruthers, MD, FRCP; Seth Matarasso, MD;
Lisa Donofrio, MD; John Soderberg, MD; Melanie Palm, MD
Supported by ETHICON, Inc. and a Grant from
Merz Aesthetics
53
PD340
including appropriate timeframe to treat patients, laser
parameters and the use of other modalities in treating scars,
selection of appropriate lasers and understanding laser scar
revision with different laser devices.
Patient Demonstrations: Advanced
Sclerotherapy and Other Vein Treatments
(Maryland A)
Learning Objectives: At the conclusion of this session
and viewing of live demonstrations of patient evaluations
and vein correction procedures, participants will be able
to: demonstrate knowledge about patterns and common
distribution of spider veins/telangiectasis on the lower
extremities, with a regard for the zones of influence of the
axial and truncal branches of the superficial venous system;
recite commonly used sclerosants, including indications for
usage, pros/cons of each class of sclerosant, and potential
complications, and; identify the indications for using liquid
versus foam.
Moderator(s): Girish S. Munavalli, MD; Robert A. Weiss, MD
3:45 pm
4:00 pm
4:15 pm
4:30 pm
4:45 pm
Introduction
Simplified Venous Anatomy of the Lower Extremities
Advances in Sclerosing Agents 2011
Complications of Sclerotherapy
Patient Demonstrations: Liquid Sclerotherapy, Foam
Sclerotherapy, Treatment of Reticular and Spider Veins
and hand sclerotherapy
Girish S. Munavalli, MD; Robert A. Weiss, MD - Injectors;
Margaret A. Weiss, MD - Commentator
 3:45 – 5:15 PM
MASTERS
Tea of your choice. Sessions have a cost of $35, are limited by the
seating available, and may be closed.
Suzanne L. Kilmer, MD; Peter R. Shumaker, MD;
MC332
How to Develop Your Own Skin Line
(Virginia C) Closed
attendees should be able to: use your passion to find
your niche in the marketplace;develop your own product
line either on your own or as a consultant for a skin care/
cosmetics company and be able to select the best means of
distribution for your product among the myriad of choices
available in the marketplace.
Patricia S. Wexler, MD; Katie Rodan, MD
 6:00 – 7:30 PM
SECOND ANNUAL FLIGHT WITH
THE MASTERS: TASTING WINE WITH
YOUR BRAIN (Coolidge)
(Limited to 40 attendees, additional fee and registration required)
Back by popular demand!! During this exclusive event, participants will
experience a comparative tasting led by ASDS’ own Stephen H. Mandy,
MD. Participants will taste and learn about eight specially chosen and
unique wines, experience specially paired accompaniments for each wine
and enjoy a festive, first-of-its kind social gathering with fellow members
prior to the Sixth Annual Gala. Whether you are a wine aficionado or are
just interested in learning, don’t miss this event that is fast-becoming an
Annual Meeting favorite.
Presented by Stephen H. Mandy, MD; Guest Speaker: Robin Kelly
O’Connor, Christie’s Head of Wine, Americas
 7:00 – 11:00 PM SIXTH ANNUAL GALA
RECEPTION AND DINNER E
(Thurgood Marshall Ballroom)
MC330
Surgery: Peels
(Virginia A) Closed
attendees should be able to: describe the science of various
peeling agents and their physiologic response to skin;
compare and contrast levels of chemical peeling including
superficial, medium and deep depth, as well as methods of
peel applications; assess photo-aging, wrinkles and scarring
indications for correct selection of chemical peeling depth(s)
and methods; utilize appropriate techniques for superficial,
medium and deep chemical peeling in combination face
peels, and recognize and manage basic complications
associated with operative and post-operative peeling
procedures. Core topics addressed may include chemical
differences peels, mechanisms of action and formulations
of various peels, indications, comparison of peels to other
resurfacing techniques, and safety concerns.
Harold J. Brody, MD; Gary D. Monheit, MD;
Seaver Soon, MD
MC331
Scar Wars
(Virginia B) Closed
attendees should be able to: discuss different types of burn
scars and healing of burn wounds; evaluate effectiveness of
different lasers and other modalities in treatment of a wide
variety of burns and scars caused by improperly performed
laser and cosmetic procedures; develop treatment protocols
54
(Tickets required for attendance)
“A Star-Spangled Soirée”
Don’t miss the Sixth Annual Gala. This year’s must-attend event will
be held on Saturday, November 5 at the Marriott Wardman Park. The
gala promises to be an evening filled with high energy, dancing and
celebration. The event will start with cocktails, hors d’oeuvres and
entertainment. An elegant dinner follows at 7:30 as we honor our stars,
including Stegman Circle donors and the 2011 Samuel J. Stegman, MD
Award for Distinguished Service. The Gala dinner celebration honors
advances in dermatologic surgery through the years, those who made
them possible and the vast possibilities that lie ahead. The event also
supports the Dermasurgery Advancement Fund (DSAF) and Stegman
Circle. The DSAF supports new research and satisfies a long-standing
need to increase public awareness about the scope of practice of
dermatologic surgeons and to educate consumers about patient safety.
Gala tickets may be purchased by checking the appropriate box on the
Annual Meeting Registration Form, by completing the form available
on the ASDS website at www.asds.net, or by contacting the ASDS
office at 847-956-0900. Please join us for an evening of camaraderie,
entertainment, celebration, and to benefit a great cause.
Graciously supported in part by a grant from
The Allergan Foundation
Don’t Miss the Biggest Celebration
of the Year at the ASDS Annual Meeting!
Saturday, November 5, 2011 • 7:00 pm - Midnight
Washington Marriott Wardman Park • Thurgood Marshall Ballroom
Dinner, dancing and entertainment
by the Right On Band – the World’s Greatest
70’s Show Band
This promises to be the talk of the meeting!
2011
ASDS
ANNUAL
MEETING
Graciously supported in part by a grant from
The Allergan Foundation
Washington , DC
N O V E M B E R 3 - 6 , 2 0 11
$125 per person — a limited number of tickets
are available at the Onsite Registration Desk.
SUNDAY, NOVEMBER 6
 8:30 - 10:00 AM SCIENTIFIC SESSION
GD400
Breakfast Session: Global Cancer Treatments
(Includes complimentary breakfast buffet)
(Salon 1)
 8:30 – 11:30 AM
WS410 Hands-on Workshop: Tumor Excision/
Wound Repair and Injectables
(Maryland A)
(Residents/Post-residency Trainees ONLY; Limited to 30.
Registration for this session has reached capacity.
attendees should be able to: develop a therapeutic strategy
for managing patients with multiple and or complex
cancers that includes surgery and post operative adjunctive
treatments as part of a coordinated multidisciplinary
approach; understand when to obtain and how to interpret
pre-operative imaging studies and understand how their
interpretation might change management; appreciate
the latest available field treatments in order to be able
to coordinate a state of the art approach for your most
complex patients; understand the current data in the
management and outcomes of complex skin cancers and
utilize newly acquired understanding/information to plan
an accurate and clinically relevant/cost effective plan for
treating challenging patients.
Moderator(s): John A. Carucci, MD, PhD;
Carl V. Washington, MD
8:30 am
8:45 am
9:05 am
9:25 am
9:45 am
HANDS-ON WORKSHOP
Learning Objectives: Specifically targeted for young
dermatologic surgeons, this live CME activity offers
hands-on experience featuring new high-fidelity cutaneous
surgical models. These models accurately simulate anatomy,
including sub-mucosal structure, allowing for realistic handson practice. At the conclusion of this course, attendees
should be able to: increase their competence in patient
positioning and instrument handling for all procedures;
properly excise tumors using both standard and Moh’s
techniques; execute complex linear closures, z-plasty repairs,
rotation and advancement flaps; finesse closure techniques
they already know with pearls from experts in the field,
and; gain an understanding of facial anatomy in order to
correctly perform injection techniques for hyaluronic acid
fillers and neurotoxins.
Moderator(s): Kavita Mariwalla, MD; Murad Alam, MD
Faculty:
Jeremy S. Bordeaux, MD, MPH;
Allison Hanlon, MD; Sheethal Mehta, MD;
Rebecca C. Tung, MD;
Kimberly J. Butterwick, MD;
Melissa Pugliano-Maura, MD;
Daniel Wasserman, MD
Introduction
John A. Carucci, MD, PhD; Carl V. Washington, MD
Chemoprevention of High Risk Skin Cancer
Fiona O’Reilly Zwald, MD
High Risk SCC: Risk Stratification and Implications
for Management
Chrysalyne Schmults, MD
Translational Approaches to the Management
of Skin Cancer
Supported by ETHICON, Inc. and a grant from
Merz Aesthetics
 10:00 - 11:30 AM
SCIENTIFIC SESSION
CS401 Cosmetic Quick Tips
(Salon 3)
Objectives: At the conclusion of this session, attendees
should be able to: identify simple valuable clinical pearls for
use in the clinic; advance patient care through improved
practice and summarize the best of the many nuggets of
wisdom we use
Moderator(s): Kimberly J. Butterwick, MD;
Timothy Flynn, MD
10:00 am
10:20 am
ABMS Competencies:
10:30 am
Patient care
10:40 am
Medical knowledge
10:50 am
11:00 am
Professionalism
11:10 am
11:20 am
Program participants and timing subject to change.
Social events are subject to change based on participation levels.
56
Cosmetic Pearls
Kimberly J. Butterwick, MD
Cosmetic Pearls
Cosmetic Pearls
Cosmetic Pearls
Tina S. Alster, MD
Cosmetic Pearls
Robert A. Weiss, MD
Cosmetic Pearls
Naomi Lawrence, MD
Cosmetic Pearls
Fredric S. Brandt, MD
 11:30 AM MEETING ADJOURNS
Must-read chapters include:
An all-new primer from ASDS offering
dermatologic surgeons practical knowledge
in procedural and surgical dermatology – an
ideal study companion for the ABD Certifying
Examination or the MOC-D Examination!
s Cutaneous Anatomy
s Electrosurgery
s Neurotoxins
s Local Anesthetics
s Cryosurgery
s Soft Tissue Fillers
s Surgical Instruments
s Elliptical Excision
s Suture Materials
s Grafts
s Laser and
Light-based Devices
s Skin Cancer - Basal Cell,
Squamous Cell
Carcinoma, Melanoma
s Flaps
s Mohs Micrographic
Surgery
s Notes section on each page allows you to
add supplemental information for later
reference
s Liposuction
s Nail Anatomy and
Surgery
s Hair Transplant
s Chemical Peels and
Dermabrasion
Softbound,
8 ½ x11, 142 pages,
Member price: $69.95*
Non-Member price: $79.95*
s Bibliographies in each chapter give you
additional study options
s Open-ended questions to test your
knowledge
s Sclerotherapy
* sales tax for Illinois residents
added to all orders
l
Specia
t
n
u
o
c
dis
ely
iv
s
lu
c
x
e
S
for ASD
s!
r
e
b
m
me
Order your copy today at ASDS Booth # 108,
online at www.asds.net/primerbook.aspx
or call 847-956-0900.
ASDS Practice Management Book:
Building Your Dermatologic Surgery Practice
Offered exclusively by ASDS, Building Your Dermatologic Surgery Practice is a
comprehensive guide designed to help dermatologic surgeons master the
development of a successful practice, respond to the challenges that medical
practices face and find ways to create a thriving practice with loyal patients.
Building Your Dermatologic Surgery Practice provides templates to help you establish
and manage a flourishing dermatologic practice including:
s Fundamental business principles, tailored to the practice of dermatologic surgery
s Methods for establishing your brand and image
s Answers to the who, what, where, when, why, and how of running a practice
s Strategies for marketing your services to today’s informed patients
Building Your
Dermatologic Surgery Practice
Softbound, 359 pages
Member price: $79.99*
Non-Member price: $89.99*
*U.S. shipping included. Illinois residents,
please note that sales tax will be added
to your order.
s Tactics for building traffic and referrals and for converting and retaining patients
Whether you are starting your dermatologic surgery practice or expanding or refreshing
your existing practice model, you will find Building Your Dermatologic Surgery Practice
to be an indispensable resource that you refer to time and again.
Preview it in ASDS Booth #108 or order
your copy today! Log on to www.asds.net
or call 847-956-0900.
ASDS & Doc’s Duds
offer the best in lab coats
ASDS is now partnering with Doc’s Duds to bring you a high quality, high fashion line of lab coats in men’s and women’s
styles. The coats feature state-of-the-art technology that enables them to resist most stains and spills, including blood
and Betadine®. Available exclusively to ASDS members, the coats will be custom embroidered with the ASDS logo and
your name. (All prices include the embroidery).
THE MEN’S LINE FEATURES:
Wayne The understated elegance of the singlebreasted design reflects your stature as an
eminently successful healthcare provider. This
full-length coat features two large pleated patch
pockets with side openings that offer access to
trouser pockets. This outstanding member of our
designer portfolio is finished with a single breast
pocket, epaulets, and back belt detail. $150.
Alex A sense of fashion and style in a lab coat…
without sacrificing tradition. This classic three
Alex
Wayne
Chris
quarter length, single-breasted unisex lab coat
buttons down the front. The coat has a breast
pocket and two lower patch pockets with tailored side openings. Top-stitching runs from shoulder to hem and adds an
eye-appealing detail to the look and feel of this garment. $125.
Chris This traditional waist-length lab coat is a single-breasted lab coat that buttons down the front. The coat has a breast
pocket and two lower patch pockets. Topstitching runs from shoulder to hem and adds an eye-appealing detail to the look
and feel of this garment. $80.
Betty
Diana
Barbara
Jennifer
THE WOMEN’S LINE FEATURES:
Betty The high-fashion, three-quarter length lab coat has a Mandarin collar. full-length sleeves, breast darts and princess
lines. Patch pockets, top-stitching, and a full-front two-way zipper running from collar to hem, contribute to the overall style
and sophistication. Side vents allow for comfort and movement. $140.
Diana The height of sophistication, style, elegance—all in a simple, full-length lab coat. Let your mood dictate how you wear
the the stylish collar, up or down. And the chic garment’s vented sleeves can be worn down or rolled up into a French cuff.
A full-length, two-way zipper and side and back vents add to your comfort whether you’re sitting or standing. The lab coat’s
elegant silhouette is complemented by diagonal envelope pockets and a belt that conceals an elasticized waist in the back.
$150.
Barbara The vintage look and classic tailoring make this stunning garment an essential addition to any professional
wardrobe. With the three quarter length lab coat, you’ll find design elements like a Mandarin collar, bust darts, and a twoway front zipper that zips three quarters of the way for added comfort. The design also boasts full sleeves, two hidden side
pockets, and a single breast pocket. $140.
Jennifer This high fashion, slightly flared lab coat in a full-length A-line design and easy fit flatters a wide range of figures.
With princess seams and a belted treatment in the back, the full button front lab coat comes with breast pocket, two side
seam pockets, and front flaps. $150.
See them in the Exhibit Hall, ASDS booth # 108
POSTER PRESENTATIONS
This represents the Poster Listing as of October 10, 2011. Program participants and timing subject to change.
Posters are available for viewing in the Exhibit Hall from Thursday, November 2 at 12:30 pm through Saturday,
November 5 at 2:00 pm. Poster presenters will be available to discuss their posters during the Wine and Cheese
Reception on Friday, November 3 from 5:30 to 7:00 pm.
Poster #1: A Multicenter, Randomised, Double-Blind Study to
Evaluate the Efficacy of 20 units of OnabotulinumtoxinA in the
Treatment of Glabellar Lines, When Compared to 30 Units of
IncoboulinumtoxinA
Marion Moers-Carpi, MD
Poster #2: A Novel Use of Dermal Fillers for Linear Morphea
Associated “En Coup de Sabre” and Hemifacial Atrophy
Antonio Cruz, MD
Poster #3: A Randomized, Evaluator-Blinded, Controlled Study of
the Effectiveness and Safety of a Small Gel Particle Hyaluronic Acid
for Lip Augmentation
Richard G. Glogau, MD
Poster #4: Acne Keloidalis Nuchae: Surgical Management with
Electrosection and Second-intention Healing
Jordan Carqueville, MD
Poster #5: An Inter- and Intra-Rater Reliability Study of 3 Photographic Scales for Classifying Aesthetic Features of the Perioral Area
Joel L. Cohen, MD
Poster #20: Opioid Prescribing Patterns of Dermatologic Surgeons in
the United States: An Email-based Survey
Payam Tristani-Firouzi, MD
Poster #21: Persistence of the Reduction of Abdominal
Subcutaneous Fat by LIPO-102 (Salmeterol Xinafoate (SX) +
Fluticasone Propionate (FP) for Injection)
Poster #22: Post-traumatic and Postoperative Keratoacanthomas
Yekaterina Kleydman, DO
Poster #23: Prevention of Surgical Site Infection Using
2- Octylcyanoacrylate Following Mohs Micrographic Surgery on
MRSA Positive Patients
Poster #24: Reduction of Submental Fat with ATX-101: Results
from a Phase IIB Study Using Investigator, Subject, and Magnetic
Resonance Imaging Assessments
Poster #6: An Aid in the Selection of Repairs: Tensile Strength
Quantification of Purse String versus Buried Vertical Mattress Closures
Ern Loh, MD
Poster #25: Successful Treatment of Acne Scars with Autologous
Cultured Fibroblasts: A Prospective, Double Blind, Placebocontrolled, Multi-center Clinical Trial
Girish S. Munavalli, MD
Poster #7: An Inter-Rater and Intra-Rater Reliability Study of a
Photographic Scale for Lip Fullness
Wm. Philip Werschler, MD
Poster #26: Successful Treatment of Exogenous Ochronosis With
Fractionated CO2 Technology
Gary Mendese, MD
Poster #8: Assessment of Safety and Efficacy of a New Bipolar
Radiofrequency Vacuum Assisted Device in the Temporary
Improvement in the Appearance of Cellulite
Jeremy R. Man, MD
Poster #27: The Long Term Utility of Bimatoprost Ophthalmic
Solution (0.03%) for Eyelash Augmentation in Asian Subjects: A
40-week Comparative Assessment of the Safety and Efficacy of
Ongoing Bimatoprost Treatment Versus Treatment Discontinuation
After 20 Weeks
Oh Sang Kwon
Poster #9: Case Studies Using a Novel Surgical Stapling Device
in Private Practice Dermatologic Surgery
Todd E. Schlesinger, MD
Poster #10: Controlled Release of Fibrous Septae for the Treatment
of Cellulite
Michael Kaminer, MD
Poster #11: Evaluating the Efficacy of Cold Air Cooling in Improving
Patient Comfort During Photodynamic Therapy as Well as Its Effect
on Therapeutic Outcomes
Poster #28: The Positive Impact of Providing Information From a
Computer-Aided Multispectral Digital Skin Lesion Analysis System
on Melanoma Biopsy Sensitivity
Jane Yoo, MD
Poster #29: The Study of Lipoma: Relation Between Development
Site and Location Depth
Bark-Lynn Lew, MD
Poster #12: Excimer Laser in the Treatment of Mycosis Fungoides
Ashley Cauthen, MD
Poster #30: The Utility of the Purse-string Closure for the Repair of
Facial Defects Following Mohs Micrographic Surgery
Francis Hsiao, MD
Poster #13: Full-face Treatment of Argyria Using the 1064nm
Q- switched Nd:Yag Laser
Whitney W. Hovenic, MD
Poster #31: Treatment of a Large Intramammary Defect with
Bilateral 180° Rotated Island Pedicle Flaps
Lori Sanford, MD
Poster #14: Improvement in Abdominal Edema After Tumescent
Liposuction Using Manual Lymphatic Drainage Massage
Daniel Levy, MD
Poster #32: Treatment of Mild to Moderate Acne Vulgaris Using a
Combined Light and Heat Energy Device: Home-Use Clinical Study
Neil S. Sadick, MD
Poster #15: Improvement in Skin Appearance with Blue Light Using
Hexyl Aminolevulinate HCl: A Split Face Study of the Differential
Effect of Microdermabrasion
Poster #33: Beauty and the Skin Cancer Beast: Assessment of
the Relative Perceived Newsworthiness of Cosmetic and Surgical
Dermatology Using Content Analysis of Print Media
Kristina Collins, MD
Poster #16: Infection of the Face and Neck with the Emerging
Pathogen M. Massiliense Following CO2 Fractional Laser
Bishr Al Dabagh, MD
Poster #34: Eruptive Squamous Cell Carcinomas Associated with
BRAF Inhibitor Therapy in a Patient with Metastatic Melanoma
Navid Ezra, MD
Poster #17: Laser Assisted Bone Marrow Transplantation
Jill S. Waibel, MD
Poster #35: Skin Characteristics After Fractional Photothermolysis
Byung Ho Oh, MD
Poster #18: Nasal Contour Reconstruction with Full-Thickness Skin
Grafting: A Novel Approach to a Classic Method
Jessica Weiser, MD
Poster #36: Successful Single Session Treatment of Facial Acne Scars
with Combination Tumescent Anesthesia, Extensive Subcision, and
Fractional Ablative CO2 Laser Ablation.
Mark Taylor, MD
Poster #19: Non-Invasive Ultrasound Treatment for Circumferential
Reduction of the Abdomen
Michael Kaminer, MD
59
FACULTY
Ryan W. Ahern, MD
Houston, TX 37
Bishr Al Dabagh, MD
Durham, NC 59
Murad Alam, MD
Chicago, IL 41, 45, 46
Tina S. Alster, MD
Washington, DC 36, 42, 56
Pensacola, FL 36
Chestnut Hill, MA 54
Rochester, MN 41, 48
Marc R. Avram, MD
New York, NY 39, 41
Mathew M. Avram, MD, JD
Boston, MA 40, 44
Christian Baum, MD
Rochester, MN 48
Santa Monica, CA 40
Eric Bernstein, MD
Ardmore, PA 35
Vince Bertucci, MD
Woodbridge, ON CANADA 52
Mohit Bhandari, MD, PhD, FRCSC
Toronto, ONT, CANADA 24, 50
Ashish Bhatia, MD
Naperville, IL 36, 53
Johnathan Bingham, MD
Silver Springs, MD 37
Andreas Boker, MD
San Francisco, CA 46
Diana Bolotin, MD
Chicago, IL 41
Cleveland, OH 36, 42, 48, 50, 56
Jason D. Boyd MD
San Antonio, TX 45
Coral Gables, FL 43, 56
Chicago, IL 47
Jerry D. Brewer, MD
Rochester, MN 48
New York, NY 42
David G. Brodland, MD
Pittsburgh, PA 53
Harold J. Brody, MD
Atlanta, GA 54
Marc D. Brown, MD
Rochester, NY 43, 49
Vivian W. Bucay, MD
San Antonio, TX 52
Washington, DC 24, 40, 42, 48, 50
San Diego, CA 56
Glenn Dale, MD 48
Chicago, IL 59
60
Vancouver, BC CANADA 47, 48, 53
Jean Carruthers, MD
Vancouver, BC CANADA 48, 52
New York, NY 48, 56
Ashley Cauthen, MD
Tampa, FL 59
Suneel Chilukuri, MD
Bellaire, TX 53
Kee-Yang Chung, MD
Seoul, SOUTH KOREA 50
Joel L. Cohen, MD
Englewood, CO 47, 51, 59
Brett M. Coldiron, MD
Cincinnati, OH 35, 41, 43, 44
Kyle Coleman, MD
Marble Falls, TX 39, 50
Sydney R. Coleman, MD
New York, NY 50
William P. Coleman, III MD
Metairie, LA 50
Kristina Collins, MD
Boston, MA 59
Joel Cook, MD
Charleston, SC 39
Durham, NC 30
Sue Ellen Cox, MD
Chapel Hill, NC 41, 47
Timothy Cragun, DO
San Antonio, TX 51
Antonio Cruz, MD
Providence, RI 59
Miriam P. Cummings, MD
Phoenix, AZ 48
Aerlyn G. Dawn, MD
Bryn Mawr, PA 50
Doris J. Day, MD
New York, NY 44
Davi de Lacerda, MD
Sao Paulo, BRAZIL 46
Tara Dever, MD
San Diego, CA 45
Niteen Dhepe, MD
Pune Maharashtra, INDIA 50
Matthew R. Donaldson, MD
Cincinnati, OH
Lisa M. Donofrio, MD
New Haven, CT 41, 53
Jeffrey S. Dover, MD, FRCPC
Chestnut Hill, MA 35, 42, 59
Montclair, NJ 40, 47
Zoe D. Draelos, MD
High Point, NC 44
Steven C. Dresner, MD
Santa Monica, CA 49, 52
Daniel B. Eisen, MD
Sacramento, CA 48
Sorin Eremia, MD
Riverside, CA 49
Quenby Erickson, DO
St. Louis, MO 51
Navid Ezra, MD
Santa Monical, CA 59
San Diego, CA 46, 48, 59
Patricia Farris, MD
Metairie, LA 44
Foster City, CA 36, 49, 50
Douglas Fife, MD
Las Vegas, NV 41, 47
Galen H. Fisher, MD
Richmond, VA 53
Los Angeles, CA 44
Timothy Flynn, MD
Cary, NC 56
Scott W. Fosko, MD
Saint Louis, MO 41
Arden Fredeking, MD
Washington, DC 45
Houston, TX 49
Hassan Galadari, MD
Dubai, UNITED ARAB EMIRATES 46
New York, NY 42, 52
Los Altos Hills, CA 45, 48, 53
Dee Anna Glaser, MD
Saint Louis, MO 40, 41, 44, 53
San Francisco, CA 39, 59
Hugh M. Gloster, Jr. MD
Cincinnati, OH 49
Leonard H. Goldberg, MD, FRCP
Houston, TX 45, 51
Burlington, VT 45, 51, 53
San Diego, CA 51, 52, 59
South Yarra VIC, AUSTRALIA 46,
47, 51
Mumbal Maharashtra, INDIA 51
Joseph Grecco, MD
Tustin, CA 37
Pearl E. Grimes, MD
Los Angeles, CA 47, 52
Monica Hale
New York, NY 45
Douglas G. Hamilton, MD
Woodland Hills, CA 52
Allison Hanlon, MD
New Haven, CT 45, 56
Birmingham, AL 43, 47
C. Lenny Henderson, MD
Oklahoma City, OK
Ali Hendi, MD
Bethesda, MD 53
Alysa R. Herman, MD
Miami, FL 45, 51
Doris Hexsel, MD
Porto Alegre RS, BRAZIL 46
Baltimore, MD 40
Tyler Hollmig, MD
Redwood City, CA 45
Todd E. Holmes, MD
Burlington, VT 51
Whitney W. Hovenic, MD
Columbia, MO 59
George J. Hruza, MD
Chesterfield, MO 35, 36, 38, 44,
45, 51
Francis Hsiao, MD
Sacramento, CA 59
Jeffrey T.S. Hsu, MD
Naperville, IL 47
Tatyana R. Humphreys, MD
Philadelphia, PA 43, 49
Eva Hurst, MD
Saint Louis, MO 46
Sherrif Ibrahim, MD
Rochester, NY 41
Omar Ibrahimi MD, PhD
Sacramento, CA 50
Scott Isenhath, MD
Seattle, WA 49
Derek H. Jones, MD
Los Angeles, CA 35, 38, 41, 45, 48,
49
Michael S. Kaminer, MD
Chestnut Hill, MA 49, 59
Edidong Ntuen Kaminska, MD
Chicago, IL 46
Norma H. Kassardjian, MD
San Juan Capistrano, CA 39
Bruce E. Katz, MD
New York, NY 48
Andrew J. Kaufman, MD
Thousand Oaks, CA 43
Joely Kaufman, MD
Coral Gables, FL 51
New York, NY 39
Rebecca Kazin, MD
Lutherville, MD 48
Sacramento, CA 39, 54
Jenny Kim, MD, PhD
Los Angeles, CA 45, 52
Leon H. Kircik, MD
Louisville, KY 48
San Juan Capistrano, CA 40, 41
Yekaterina Kleydman, DO
Brooklyn, NY 59
Vancouver, BC, CANADA 51
Maria Landau, MD
Herzlia, ISRAEL 46
Matteo C. LoPiccola, MD
Detroit, MI 51
Gary Lask, MD
Los Angeles, CA 40
FACULTY
David A. Laub, MD
Mill Valley, CA 52
Naomi Lawrence, MD
Marlton, NJ 37, 38, 46, 50, 56
Erica Lee, MD
New York, NY 39
Ken K. Lee, MD
Portland, OR 40, 41, 42
Patrick K. Lee, MD
Tustin, CA 37, 38, 52
Peter K. Lee, MD, PhD
Edina, MN 52
Steven E. Leininger, CPA
Mill Valley, CA 52
Barry Leshin, MD
Winston-Salem, NC 53
Vicki J. Levine, MD
New York, NY 39
Daniel Levy, MD
Bellevue, WA 59
Austin Liu, MD
Detroit, MI 45
Ern Loh, MD
Sacramento, CA 59
Vanessa A. London, MD
Philadelphia, PA 46
Mary P. Lupo, MD
New Orleans, LA 52
RADM Boris D. Lushniak, MD, MPH
Washington, DC 24, 40
Bark Lyn Lew, MD
Seoul, KOREA 59
Deborah MacFarlane, MD
Houston, TX 50
Mary E. Maloney, MD
Worcester, MA 50
Jeremy R. Man, MD
New York, NY 48, 59
Miami Beach, FL 42, 54, 56
New York, NY 36, 38, 56
Ellen S. Marmur, MD
New York, NY 45, 46
Jacksonville, FL 37, 49, 53
Seth L. Matarasso, MD
San Francisco, CA 41, 53
Slidell, LA 50
Michael McMillan
Chicago, IL 24, 45
Sheethal Mehta, MD
Chicago, IL 56
Gary Mendese
Salem, MA 59
Houston, TX 46
Christopher J. Miller, MD
Philadelphia, PA 39
Michael E. Ming, MD
Philadelphia, PA 41
Tricia Missall, MD, PhD
Saint Louis, MO 41
Munich, Bavaria GERMANY 59
Gary D. Monheit, MD
Birmingham, AL 35, 48, 54
Rachael Moore, MD
Venice, CA 44
Greg S. Morganroth, MD
Mountain View, CA 52
Charlotte, NC 47, 54, 59
Rhoda Narins, MD
White Plains, NY 53
Vic A. Narurkar, MD
San Francisco, CA 49, 51, 52
Kishwer S. Nehal, MD
New York, NY 39
Marlboro, MA 49, 50, 52, 59
Mark S. Nestor, MD, PhD
Aventura, FL 47
Isaac M. Neuhaus, MD
Rajiv Nijhawan, MD
New York, NY 45
Robin Kelly O’Connor
New York, NY 54
Byung Ho Oh, MD
Seoul, SOUTH KOREA 59
Burlington, MA 41
Atlanta, GA 44, 56
Jeffrey S. Orringer, MD
Ann Arbor, MI 41
Encinitas, CA 41, 42, 53
Jeffrey E. Petersen, MD
Columbus, IN 41
Page S. Piland, MD
Windemere, FL 35, 36
Kristel Polder, MD
Dallas, TX 35
Chad Prather, MD
Baton Rouge, LA 37
Melissa Pugliano-Maura, MD
Pittsburgh, PA 56
Larisa Ravitskiy, MD
Gahanna, OH 48
Saadia Raza, MD
O’Fallon, MO 53
Sandra Read, MD
Washington, DC 52
Kavitha K. Reddy, MD
Boston, MA 46
Phoebe Rich, MD
Portland, OR 47
Darrell S. Rigel, MD
New York, NY 41, 45, 51
Katie Rodan, MD
Oakland, CA 54
Chestnut Hill, MA 42, 43, 45
E. Victor Ross, MD
San Diego, CA 41
Vienna, VA 52, 53
Adam M. Rotunda, MD
Irvine, CA 36, 40, 44
Mark Rubin
Beverly Hills, CA 41
Michael J. Sacopulos, JD
Terre Haute, IN 35, 36
Neil S. Sadick, MD
New York, NY 50, 59
Patrick Safo, MD, PhD
Wexford, PA 45
Giovanni Salti, MD
Florence, ITALY 48
Lori Sanford, MD
Indianapolis, IN 59
Oh Sang Kwon, MD
Seoul, KOREA 59
Carl F. Schanbacher, MD
Millford, MA 49
Charleston, SC 59
Jamaica Plain, MA 44, 56
Tom Seery, MD
Seattle, WA 51
Santa Barbara, CA 45
Ava T. Shamban, MD
Santa Monica, CA 45
Peter R. Shumaker, MD
San Diego, CA 54
Smithtown, NY 36, 51
Kevin C. Smith, MD
Niagara Falls, NY 48
Stacy R. Smith, MD
Cardiff, CA 48
Jason Sneath, MD
Vancouver, BC CANADA 45
Stephen N. Snow, MD
Madison, WI 51
Joseph Sobanko, MD
Philadelphia, PA 49
John M. Soderberg, MD
Chapel Hill, CA 53
Toronto, ON CANADA 41, 46, 49
Seaver Soon, MD
San Diego, CA 54
Theresa Soriano, MD
Los Angeles, CA 37
Nashville, TN 49
Dow B. Stough, IV, MD
Hot Springs, AR 39
Hema Sundaram, MD
Rockville, MD 35, 46, 48
Zeina S. Tannous, MD
Boston, MA 42
Elizabeth Tanzi, MD
Washington, DC 41, 42
Mark Taylor, MD
Salt Lake City, UT 59
Houston, TX 40, 42
Whitney D. Tope, MD
Edina, MN 41
Abel Torres, MD
Loma Linda, CA 40, 45, 52
Payam Tristani-Firozi, MD
Kenneth Y. Tsai, PhD
Houston, TX 42
Rebecca C. Tung, MD
Chicago, IL 48, 56
Sanusi H. Umar, MD
Redondo Beach, CA 48
Susan Brunner Van Dyke, MD
Paradise Valley, AZ 48
Marta J. VanBeek, MD, MPH
Iowa City, IA 48, 53
Jill S. Waibel, MD
Miami, FL 48, 59
Heidi A. Waldorf, MD
Nanuet, NY 39
Atlanta, GA 56
Daniel Wasserman, MD
Naples, FL 36, 56
Bradenton, FL 40, 46
Jessica Weiser, MD
New York, NY 59
Hunt Valley, MD 54
Robert A. Weiss, MD
Hunt Valley, MD 40, 48, 51, 53, 46
Elliot T. Weiss, MD
Southampton, NY 48
Spokane, WA 59
New York, NY 54, 56
Andrea Willey, MD
Sacramento, CA 44
Allan S. Wirtzer, MD
Sherman Oaks, CA 47, 52
Oliver J. Wisco, DO
Arlington, MA 50
Lance D. Wood, MD
Hershey, PA 45
Ashley Wysong, MD
Redwood City, CA 45
Jane Yoo, MD
Boston, MA 59
Sigfried Yu, MD
Christopher B. Zachary, FRCP
Irvine, CA 40, 47
Sabine Zenker, MD
Munchen, GERMANY 46
John A Zitelli, MD
Pittsburgh, PA 45
61
TECHNICAL EXHIBITS
EXHIBITING COMPANIES BY PRODUCT CATEGORY
Associations, Foundations, Medical
Societies
Accreditation Association for Ambulatory
Health Care (AAAHC) . . . . . . . . . . . . . . . . 1002
American Academy of Dermatology . . . . . . 511
American Society for Dermatologic
Surgery (ASDS) . . . . . . . . . . . . . . . . . . . . . . 108
The Dermatologic & Aesthetic Surgery
International League (DASIL) . . . . . . . . . . . . 203
Dermatology Foundation . . . . . . . . . . . . . . . 709
Theraplex. . . . . . . . . . . . . . . . . . . . . . . . . . 1614
Young Pharmaceuticals, Inc. . . . . . . . . . . . . 700
ZO® Skin Health by Zein Obagi, MD. . . . . . . 500
MJD Patient Communications . . . . . . . . . . 1515
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
RGP, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 408
Dermal Fillers
Pharmaceutical
Allergan. . . . . . . . . . . . . . . . . . . . . . . . . . . 1707
Dermik, a business of sanofi-aventis . . . . . 1401
Medicis Aesthetics, Inc. . . . . . . . . . . . . . . . 1600
Mentor Worldwide, LLC. . . . . . . . . . . . . . . . 717
Merz Aesthetics . . . . . . . . . . . . . . . . . . . . . . 909
Allergan. . . . . . . . . . . . . . . . . . . . . . . . . . . 1707
Allergan Medical Affairs. . . . . . . . . . . . . . . 1007
Axia Medical Solutions. . . . . . . . . . . . . . . . 1610
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
DermAvance Pharmaceuticals Inc. . . . . . . . . 411
Dermik, a business of sanofi-aventis . . . . . 1401
DUSA Pharmaceuticals. . . . . . . . . . . . . . . . . 513
Galderma Laboratories, LP . . . . . . . . . . . . . . 810
Genentech. . . . . . . . . . . . . . . . . . . . . . . . . 1407
Graceway Pharmaceuticals, LLC . . . . . . . . . 1201
Hopewell Pharmacy . . . . . . . . . . . . . . . . . . . 506
Medicis Aesthetics, Inc. . . . . . . . . . . . . . . . 1600
Medicis Medical Information . . . . . . . . . . . 1612
Merz Aesthetics . . . . . . . . . . . . . . . . . . . . . . 909
Merz Medical Affairs . . . . . . . . . . . . . . . . . . 601
Obagi Medical Products . . . . . . . . . . . . . . . 1303
Onset Dermatologics . . . . . . . . . . . . . . . . . 1208
Ortho Dermatologics . . . . . . . . . . . . . . . . . . 712
Computer Software & Hardware
Digital Photographing/Imaging
3Gen, LLC / DermLite . . . . . . . . . . . . . . . . 1607
ClientTell . . . . . . . . . . . . . . . . . . . . . . . . . . 1001
Digital Assent, LLC. . . . . . . . . . . . . . . . . . . 1615
Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . 1004
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . 1209
Modernizing Medicine . . . . . . . . . . . . . . . . . 311
NexTech. . . . . . . . . . . . . . . . . . . . . . . . . . . 1101
Smile Reminder . . . . . . . . . . . . . . . . . . . . . 1308
3Gen, LLC / DermLite . . . . . . . . . . . . . . . . 1607
Canfield Imaging Systems . . . . . . . . . . . . . 1406
Enhanced Image Technologies . . . . . . . . . . . 716
MELA Sciences. . . . . . . . . . . . . . . . . . . . . . . 507
Laboratory Services
Dermpath Diagnostics . . . . . . . . . . . . . . . . 1508
Doctors Pathology Services . . . . . . . . . . . . . 101
Laser & Laser Supplies
Cosmetics/Skin Care Products
Advanced Bio-Technologies, Inc. . . . . . . . . 1106
Axia Medical Solutions. . . . . . . . . . . . . . . . 1610
Beiersdorf, Inc.. . . . . . . . . . . . . . . . . . . . . . . 202
Biopelle, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 705
CaerVision Corp. . . . . . . . . . . . . . . . . . . . . . 210
Clarisonic. . . . . . . . . . . . . . . . . . . . . . . . . . . 911
Colorescience Pro . . . . . . . . . . . . . . . . . . . 1412
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
DermAvance Pharmaceuticals, Inc.. . . . . . . . 411
Envy Medical . . . . . . . . . . . . . . . . . . . . . . . . 800
Fallene, Ltd. . . . . . . . . . . . . . . . . . . . . . . . . 1512
Hill Dermaceuticals, Inc. . . . . . . . . . . . . . . . . 208
Iredale Mineral Cosmetics . . . . . . . . . . . . . . 611
Jan Marini Skin Research, Inc. . . . . . . . . . . . 305
La Roche-Posay . . . . . . . . . . . . . . . . . . . . . . 117
Liquid Ice CosMedicals AG. . . . . . . . . . . . . . 501
Neocutis, Inc.. . . . . . . . . . . . . . . . . . . . . . . . 405
NeoStrata Company, Inc. . . . . . . . . . . . . . . 1207
Neutrogena . . . . . . . . . . . . . . . . . . . . . . . . . 710
NIA24 / Niadyne, Inc.. . . . . . . . . . . . . . . . . . 505
PCA SKIN. . . . . . . . . . . . . . . . . . . . . . . . . . . 605
PhotoCure . . . . . . . . . . . . . . . . . . . . . . . . . . 115
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . 1100
Pierre Fabre Dermo-Cosmetique USA. . . . . 1003
Procter & Gamble . . . . . . . . . . . . . . . . . . . 1300
Revision Skincare . . . . . . . . . . . . . . . . . . . . 1309
Revitalash . . . . . . . . . . . . . . . . . . . . . . . . . . 604
Sensus Healthcare . . . . . . . . . . . . . . . . . . . 1513
SkinCeuticals . . . . . . . . . . . . . . . . . . . . . . . 1713
SkinMedica, Inc. . . . . . . . . . . . . . . . . . . . . . 901
Stiefel, a GSK Company. . . . . . . . . . . . . . . 1702
62
Alma Lasers . . . . . . . . . . . . . . . . . . . . . . . . 1514
BTL Industries, Inc. . . . . . . . . . . . . . . . . . . . . 205
Cutera . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1606
Cynosure, Inc. . . . . . . . . . . . . . . . . . . . . . . . 510
DEKA Medical, Inc. . . . . . . . . . . . . . . . . . . . 711
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
Eclipse Aesthetics, LLC . . . . . . . . . . . . . . . . . 607
IRIDEX Corporation . . . . . . . . . . . . . . . . . . 1609
LASERING USA . . . . . . . . . . . . . . . . . . . . . . 404
Light Age, Inc. . . . . . . . . . . . . . . . . . . . . . . 1802
Lumenis . . . . . . . . . . . . . . . . . . . . . . . . . . . 1400
Lutronic, Inc. . . . . . . . . . . . . . . . . . . . . . . . . 111
Palomar Medical Technologies, Inc. . . . . . . . 610
PhotoMedex . . . . . . . . . . . . . . . . . . . . . . . 1100
Ra Medical Systems, Inc. . . . . . . . . . . . . . . . 410
Sandstone Medical Technologies . . . . . . . . . 704
Sciton . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
Solta Medical. . . . . . . . . . . . . . . . . . . . . . . . 504
Surgimedics . . . . . . . . . . . . . . . . . . . . . . . . 1413
Syneron and Candela. . . . . . . . . . . . . . . . . . 804
ThermoTek, Inc.. . . . . . . . . . . . . . . . . . . . . 1613
Tiemann Surgical . . . . . . . . . . . . . . . . . . . . 1601
Ulthera, Inc.. . . . . . . . . . . . . . . . . . . . . . . . 1706
UltraShape NA, Inc. . . . . . . . . . . . . . . . . . . 1203
Viora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
ZELTIQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1507
Office Equipment & Supplies
3Gen, LLC / DermLite . . . . . . . . . . . . . . . . 1607
CONMED. . . . . . . . . . . . . . . . . . . . . . . . . . . 413
Medelita Scrubs & Lab Coats . . . . . . . . . . . 1107
Midmark Corporation . . . . . . . . . . . . . . . . 1501
Practice Management
Advanced Dermatology Management,
Inc./South Beach Symposium . . . . . . . . . . . 1313
DermResources,LLC . . . . . . . . . . . . . . . . . . . 201
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . 1209
MyCustomerData.com . . . . . . . . . . . . . . . . 1109
NexTech. . . . . . . . . . . . . . . . . . . . . . . . . . . 1101
Smile Reminder . . . . . . . . . . . . . . . . . . . . . 1308
Publishing & Education Materials
THE Aesthetic Guide . . . . . . . . . . . . . . . . . . 200
CaerVision Corp. . . . . . . . . . . . . . . . . . . . . . 210
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
Dermatology Times . . . . . . . . . . . . . . . . . . 1408
DermResources, LLC . . . . . . . . . . . . . . . . . . 201
Elsevier . . . . . . . . . . . . . . . . . . . . . . . . . . . 1004
Journal of Clinical and Aesthetic
Dermatology (JCAD) . . . . . . . . . . . . . . . . . . 203
Journal of Drugs in Dermatology (JDD) . . . 1306
MedEsthetics Magazine . . . . . . . . . . . . . . . 1511
Skin & Aging . . . . . . . . . . . . . . . . . . . . . . . 1206
Wiley-Blackwell . . . . . . . . . . . . . . . . . . . . . . 707
TECHNICAL EXHIBITS
Surgical Instruments/Supplies
Acuderm, Inc. . . . . . . . . . . . . . . . . . . . . . . 1703
Advanced Bio-Technologies, Inc. . . . . . . . . 1106
CONMED. . . . . . . . . . . . . . . . . . . . . . . . . . . 413
Delasco . . . . . . . . . . . . . . . . . . . . . . . . . . . . 615
Ellis Instruments, Inc. . . . . . . . . . . . . . . . . . . 212
Ellman International. . . . . . . . . . . . . . . . . . 1712
ETHICON, Inc. . . . . . . . . . . . . . . . . . . . . . . 1506
HK Surgical, Inc. . . . . . . . . . . . . . . . . . . . . . 220
Medelita Scrubs & Lab Coats . . . . . . . . . . . 1107
Mercedes Medical . . . . . . . . . . . . . . . . . . . . 406
Microsurgery Instruments, Inc. . . . . . . . . . . . 801
Palomar Medical Technologies, Inc. . . . . . . . 610
Restoration Robotics, Inc.. . . . . . . . . . . . . . 1411
Surgimedics . . . . . . . . . . . . . . . . . . . . . . . . 1413
Tiemann Surgical . . . . . . . . . . . . . . . . . . . . 1601
Viscot Medical, LLC . . . . . . . . . . . . . . . . . . . 701
Ground-Breaking Products to be Exhibited
More than 20 first-time exhibitors will showcase brand
new products and services never before seen at an ASDS
meeting! In all, 128 companies will exhibit the most
innovative products and services on the market to help
you become a full-service resource for your patients.
The exhibit hall is located just down the escalators from
the general meeting area so be sure to stop by often.
Complimentary lunches and beverage breaks will be
served in the hall. Plus, NEW in 2011, complimentary
breakfast will be served in the hall on Friday and
Saturday mornings, giving you extra time to speak
with industry personnel and ask questions about new
equipment you may be considering for your office.
Website Design/Services
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . 1209
MedNet Technologies . . . . . . . . . . . . . . . . . 608
MyCustomerData.com . . . . . . . . . . . . . . . . 1109
Yodle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307
NEW Extended Exhibit Hours
Other
Friday, November 4 . . . . . . . . . . . . . . . 8:00 am – 1:30 pm &
3:00 pm – 7:00 pm
Acuderm, Inc. . . . . . . . . . . . . . . . . . . . . . . 1703
CareCredit . . . . . . . . . . . . . . . . . . . . . . . . . 1302
Celleration . . . . . . . . . . . . . . . . . . . . . . . . . . 113
CONMED. . . . . . . . . . . . . . . . . . . . . . . . . . . 413
DermResources, LLC . . . . . . . . . . . . . . . . . . 201
Doctors Pathology Services . . . . . . . . . . . . . 101
Fibrocell Technologies, Inc. . . . . . . . . . . . . 1710
Hill Dermaceuticals, Inc. . . . . . . . . . . . . . . . . 208
human med, inc. . . . . . . . . . . . . . . . . . . . . . 216
International Master Course on Aging Skin
(IMCAS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Liposuction.com. . . . . . . . . . . . . . . . . . . . . . 508
MedCo Data, LLC . . . . . . . . . . . . . . . . . . . 1209
Microsurgery Instruments, Inc. . . . . . . . . . . . 801
Miramar Labs. . . . . . . . . . . . . . . . . . . . . . . 1200
Modernizing Medicine . . . . . . . . . . . . . . . . . 311
NeoGraft . . . . . . . . . . . . . . . . . . . . . . . . . . . 407
Real Aesthetics . . . . . . . . . . . . . . . . . . . . . . 301
RGP, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 408
Sensus Healthcare . . . . . . . . . . . . . . . . . . . 1513
Solveras Payment Solutions . . . . . . . . . . . . . 109
Sound Surgical Technologies . . . . . . . . . . . . 609
ThermoTek, Inc.. . . . . . . . . . . . . . . . . . . . . 1613
Ulthera Inc. . . . . . . . . . . . . . . . . . . . . . . . . 1706
Viora . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Viscot Medical, LLC . . . . . . . . . . . . . . . . . . . 701
Yodle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 307
Thursday, November 3 . . . . . . . . . . . . . 12:30 pm – 5:00 pm
Complimentary Lunch. . . . . . . . . . . . . . . . . . . . 12:30 pm – 2:00 pm
Complimentary Beverage Break . . . . . . . . . . . 3:15 pm – 4:00 pm
Complimentary Breakfast. . . . . . . . . . . . . . . . .
Complimentary Beverage Break . . . . . . . . . . .
Lunch for Purchase . . . . . . . . . . . . . . . . . . . . . .
Exhibit Hall Closed . . . . . . . . . . . . . . . . . . . . . .
Complimentary Beverage Break . . . . . . . . . . .
Wine & Cheese Reception . . . . . . . . . . . . . . . .
8:00 am – 9:00 am
10:15 am – 11:00 am
12:30 pm – 1:30 pm
1:30 pm – 3:00 pm
3:00 pm – 3:45 pm
5:30 pm – 7:00 pm
Saturday, November 5 . . . . . . . . . . . . . 8:00 am – 2:00 pm
Complimentary Breakfast. . . . . . . . . . . . . . . . . 8:00 am – 9:00 am
Complimentary Beverage Break . . . . . . . . . . . 10:00 am – 10:45 am
Complimentary Lunch. . . . . . . . . . . . . . . . . . . . 12:30 pm – 2:00 pm
View the posters during all exhibit hours
63
TECHNICAL EXHIBITS
3Gen, LLC / DermLite . . . . . . . . . . . . . 1607
31521 Rancho Viejo Road, #104
Phone: 949-481-6384
www.dermlite.com
3Gen manufactures the DermLite brand of skin
imaging devices.
A
Accreditation Association for
Ambulatory Health Care (AAAHC) . . 1002
5250 Old Orchard Road, Suite 200
Skokie, IL 60077
Phone: 847-853-6060
www.aaahc.org
The Accreditation Association for Ambulatory
Health Care (AAAHC/Accreditation Association),
founded in 1979, has become the leader in
ambulatory health care accreditation with
more than 5,000 organizations accredited. The
AAAHC offers organizations including officebased surgery centers, ambulatory surgery
centers, and large medical group practices
a cost-effective, flexible and collaborative
approach to accreditation.
Acuderm, Inc . . . . . . . . . . . . . . . . . . . . 1703
5370 NW 35th Terrace, Suite 106
Fort Lauderdale, FL 33309
Phone: 954-733-6935
www.acuderm.com
Founded in 1983, Acuderm is a leading
manufacturer of Dermatology products. With
8 patents across its product lines, Acuderm is
always at the leading edge of what’s new &
innovative for today’s Dermatologist. Products
include Biopsy Punches, Biopsy Punch Kits,
Curettes, Smoke Evacuators, Sutures, Needles,
Reusable Instruments and more.
Advanced Bio-Technologies, Inc . . . . 1106
1100 Satellite Blvd.
Suwanee, GA 30024
Phone: 678-684-1426
www.kelocote.com
Advanced Bio-Technologies, Inc. is a world
leader in the global scar treatment market.
ABT’s innovative products include Kelo-cote®
Advanced Formula Scar Gel, a proprietary
silicone technology used to treat and
prevent abnormal scarring such as keloids
and hypertrophic scars, and physician only
bioCorneum®+, the only 100% silicone scar
product with SPF 30 UV protection ingredients.
Advanced Dermatology
Management, Inc./South Beach
Symposium . . . . . . . . . . . . . . . . . . . . . 1313
1111 Park Centre Boulevard, Suite 300
Miami Gardens, FL 33169
Phone: 305-623-5595
www.scacce.com
Advanced Dermatology Management, Inc.
“ADM” is a Physician Practice Management
Company specializing in dermatology. ADM
has an exclusive arrangement with Skin &
Cancer Associates providing comprehensive
management, including information systems,
billing, human resources, accounting, and
quality assurance. Skin & Cancer Associates
currently stands at 41 physicians in 26 locations
throughout Florida.
The Aesthetic Guide . . . . . . . . . . . . . . . 200
120 Vantis, Suite 470
Aliso, Viejo, CA 92656
Phone: 949-830-5409
www.miinews.com
930 East Woodfield Road
Schaumburg, IL 60173
Phone: 847-240-1269
www.aad.org
The AAD’s mission is to promote leadership
in dermatology and excellence in patient care
through education, research and advocacy.
Additionally, the Academy is committed to the
highest quality standards in continuing medical
education. Visit our booth to view new products
and services and to ask your Maintenance of
Certification-Dermatology questions!
American Society for Dermatologic
Surgery (ASDS) . . . . . . . . . . . . . . . . . . . 108
5550 Meadowbrook Drive, Suite 120
Rolling Meadows, IL 60008
Phone: 847-956-0900
www.asds.net
THE Aesthetic Guide, which has a readership of
20,000 medical aesthetic practices, is published
by Medical Insight, Inc. We also publish THE
European Aesthetic Guide. Free subscriptions are
available to qualified medical aesthetic practices.
Medical Insight, Inc. also conducts market
research and publishes market studies. Visit
www.miinews.com for a complete list of services.
Discover your newest ASDS member benefits!
Learn about 2012 hands-on educational
opportunities, innovative mentoring and
leadership programs, and Cutting Edge Research
Grants. Get a grip on legislation affecting
your practice and take charge with the ASDSA
legislative action center. And don’t forget to
check out the latest products and services to
help make your practice successful. Ask about
special meeting promotions!
Allergan . . . . . . . . . . . . . . . . . . . . . . 1707
Axia Medical Solutions, LLC. . . . . . . . 1610
PLATINUM LEVEL PARTNER
2105 Camino Vida Roble, Suite L
Carlsbad, CA 92011
Phone: 866-494-4466
www.dermesse.com
2525 Dupont Drive
Irvine, CA 92612
Phone: 714-246-4500
www.allergan.com
Allergan Medical offers the most comprehensive,
science-based, aesthetic product offerings,
including BOTOX® Cosmetic; hyaluronic acid
and collagen-based dermal fillers and LATISSE®
(bimatoprost ophthalmic solution) 0.03%.
Allergan Medical also offers the industry’s widest
range of silicone gel-filled and saline-filled breast
implant options for reconstructive and aesthetic
breast surgery.
The Manufacturer and Distributor of the popular
Dermesse™ prescription strength hydroquinone
and tretinoin regimen. also offers Salicylic Acid
acne products, un-buffered Glycolic Acid peels,
Tretinoin (0.025%, 0.05%, 0.10%), and back
bar sizes. A Private Label program is available for
all products.
B
Allergan Medical Affairs . . . . . . . . . . 1007
Beiersdorf, Inc. . . . . . . . . . . . . . . . . . . . 202
2525 Dupont Drive
Irvine, CA 92612
Phone: 714-246-4500
www.allergan.com
187 Danbury Road
Wilton, CT 06897
Phone: 203-563-5800
www.eucerinus.com
We are a team of dedicated professionals
committed to supporting scientific education,
research and clinical practice related to Allergan
products. Medical Affairs provides the highest
quality information in the most respectful,
ethical and unbiased fashion.
Beiersdorf is a global leader in therapeutic skin
care products. Visit our booth to learn about our
newest additions to the Eucerin® line along with
our existing Eucerin® Skin Care products and
Aquaphor® Healing Ointment.
Alma Lasers . . . . . . . . . . . . . . . . . . . . 1514
780 West 8 Mile Road
Ferndale, MI 48220
Phone: 866-424-6735
www.biopelle.com
485 Half Day Road, Suite 100
Buffalo Grove, IL 60089
Phone: 224-377-2178
www.almalasers.com
Alma Lasers develops and manufacturers laser,
light-based, radiofrequency and ultrasound
devices for aesthetic applications. Alma Lasers
have been at the forefront of innovative multitechnology/multi-application systems for today’s
practitioners. Alma’s mission is to provide
modular, cost-effective and high-performance
systems that enable practitioners to confidently
offer safe, effective and profitable aesthetic
treatments to their patients.
64
American Academy of
Dermatology (AAD) . . . . . . . . . . . . . . . 511
Biopelle, Inc . . . . . . . . . . . . . . . . . . . . . . 705
Biopelle’s global spectrum of skin care includes:
AFA®, exfoliator; Auriderm®, Vitamin K Oxide,
clearing hemosidrin; L.M.X.®, topical anesthetic;
OC Eight®, addressing facial shine and acne;
Ascorderm, Vitamin C; Retriderm®, topical
Vitamin A; Tensage®, SCA growth factor,
PRESCRIBEDsolutions®, CUSTOMIZED SKINCARE,
Heliocare® oral sun protection and SYNERGIES
KITS, addressing specific skincare concerns.
TECHNICAL EXHIBITS
BTL Industries, Inc. . . . . . . . . . . . . . . . . 205
Celleration . . . . . . . . . . . . . . . . . . . . . . . 113
Cutera . . . . . . . . . . . . . . . . . . . . . . . . . 1606
47 Loring Drive
Framingham, MA 01702
Phone: 866-285-1656
www.exilis.com
6321 Bury Drive, Suite 15
Eden Prairie, MN 55346
Phone: 866-307-6478
www.celleration.com
3240 Bayshore Boulevard
Brisbane, CA 94005
Phone: 415-657-5500
www.cutera.com
BTL Aesthetics introduces RF RedeFined with
Exilis. A significant technological advance in
Focused Radio Frequency aesthetic treatments.
The exclusive Energy Flow Control system
with variable surface cooling delivers precise
volumetric heating of tissue for wrinkles, laxity
and body contouring. Exilis patented applicators
deliver maximum thermal effect to desired
depths, without costly consumables, while
ensuring total safety, comfort and control.
Celleration is the manufacturer of MIST® Deep
Healing Energy. MIST® is unlike other healing
therapys because it penetrates deep below the
surface to accelerate the body’s normal healing
process by reducing inflammation and bacteria,
and increasing collagen deposition. MIST® has
shown to reduce pain, swelling, redness, and
recovery following post-laser resurfacing.
Cutera is a leading provider of laser and other
energy-based aesthetic systems for practitioners
worldwide. Cutera is excited to launch its
breakthrough Excel V vascular laser workstation
in 2011. In addition, Cutera’s multi-application
Xeo platform combines the most versatile laser
and light technologies in a single, upgradeable
system. Since 1998, Cutera has been developing
innovative, easy-to-use products that enable
physicians and other qualified practitioners to
offer safe and effective aesthetic treatments
to their patients. For more information, call
1-888-4CUTERA or visit www.cutera.com.
C
CaerVision Corp. . . . . . . . . . . . . . . . . . . 210
4539 Metropolitan Court, Suite 289
Frederick, MD 21704
Phone: 888-841-2237
www.caervision.com
The CaerVision Cosmetic Network delivers
customized patient education programming
and digital media marketing loops presented on
a flat screen television in your reception area.
Change the face of your reception area and
profitability of your practice with HD customized
programming on the products and procedures
that generate potential revenue opportunities
for your practice during patient waiting
times. Get in the Loop with the CaerVision
Cosmetic Network! Call 888.841.2237 for more
information, or visit us at
www.caervision.com/cosmetic.html.
Canfield Imaging Systems . . . . . . . . . 1406
253 Passaic Avenue
Fairfield, NJ 07004
Phone: 973-276-0336
www.canfieldsci.com
Canfield Imaging Systems is the leading
worldwide developer of imaging software and
photographic systems for the medical and skin
care industries. Product lines include Mirror®
imaging software, VISIA® Complexion Analysis,
VECTRA® 3D Systems, Reveal® facial imagers,
customized photographic studio solutions and
numerous specialized imaging devices and
lighting systems for clinical photography.
CareCredit . . . . . . . . . . . . . . . . . . . . . . 1302
2995 Red Hill Avenue, Suite 100
Costa Mesa, CA 92626
Phone: 866-247-3049
www.carecredit.com
CareCredit®, a part of GE Capital, is a revolving
line of credit that offers patient financing
programs. Exclusively endorsed by the ASDS,
CareCredit offers convenient monthly payment
plans to help you attract and schedule more
patients. There is no cost to get started today.
Call 866-247-3049 ext. 2 or visit
www.carecredit.com.
Clarisonic . . . . . . . . . . . . . . . . . . . . . . . . 911
13222 SE 30th Street, Suite A1
Bellevue, WA 98005
Phone: 888-525-2747
www.clarisonic.com
At Clarisonic, we have a passion for bringing
great new ideas to life. Our mission is to develop
and market technically advanced and clinically
proven products that make a clear difference,
and revolutionize skin care.
ClientTell . . . . . . . . . . . . . . . . . . . . . . . 1001
119 N. Patterson Street
Valdosta, GA 31601
Phone: 877-244-9178
www.clienttell.net
ClientTell provides outbound notifications
through phone, email, text and smartphone
applications. ClientTell delivered messages have
proven to be an effective, economical means
to notify patients of scheduled appointments,
annual exams, lab results, delinquent balances
and more. Benefits include reduced no-shows
and improved office efficiency. Visit
www.clienttell.net or call (877) 244-9178.
Colorescience Pro . . . . . . . . . . . . . . . . 1412
24921 Dana Point Harbor Drive, Suite 210
Dana Point, CA 92629
Phone: 866-426-5673
www.colorescience.net
Cynosure, Inc. . . . . . . . . . . . . . . . . . . . . 510
5 Carlisle Road
Westford, MA 01886
Phone: 978-256-4200
www.cynosure.com
Cynosure, Inc. develops and markets premier
cosmetic laser systems that are used by
physicians and other practitioners to perform
non-invasive and minimally invasive procedures
to remove hair, treat vascular and pigmented
lesions, rejuvenate the skin, liquefy and remove
unwanted fat through laser lipolysis and
temporarily reduce the appearance of cellulite.
D
DEKA Medical, Inc. . . . . . . . . . . . . . . . . 711
BRASS LEVEL PARTNER
665 Third Street, #20
Phone: 650-96SMART (76278)
www.dekamedinc.com
Experience makeup that does more.
Colorescience Pro’s high-performance cosmetics
were created to remedy and camouflage
specific skin concerns and protect skin from the
damaging effects of the sun and environment.
Our dermatologist recommended formulations
blend and layer together to achieve an instant
and easy flawless face.
DEKA Medical, based in San Francisco, CA,
is the medical division of the El En Group,
the world’s largest manufacturer of lasers
and pulsed light equipment for aesthetic and
medical applications. DEKA offers a range of
premium devices, including the highly acclaimed
SmartXide DOT, Synchro FT, Excilite-µ, Duolite,
PhotoSilk and MiniSilk to the North American
market. DEKA Medical is focused on providing
advanced devices capable of delivering the
highest standards of safety, performance, and
reliability.
CONMED . . . . . . . . . . . . . . . . . . . . . . . . 413
Delasco. . . . . . . . . . . . . . . . . . . . . . . . . . 615
525 French Road
Utica, NY 13502
Phone: 800-448-6506
www.conmed.com
PEWTER LEVEL PARTNER
CONMED® Hyfrecator series of electrosurgical
devices are designed for outpatient surgical
procedures. The Hyfrecator® 2000 is used by
physicians to achieve two main outcomes: the
destruction of all types of cutaneous lesions and
to control bleeding. The NEW HyfreSurg OP™
is for surgical procedures requiring cut/blend,
bi-polar and coag currents.
608 13th Avenue
Council Bluffs, IA 51501
Phone: 800-831-6273
www.delasco.com
Delasco carries a full-line of quality products
for the dermatologic surgeon: electrosurgical
units (Electricator®, Hyfrecator 2000®, Aaron®),
cryosurgical units (CRY-AC®, FrigiSpray®,
Nitrospray), German-made instruments, surgical
and cosmetic supplies and much more! We
offer electrosurgery repair and instrument
engraving/repair as well as personal customer
service. Stop by to say hello!
65
TECHNICAL EXHIBITS
The Dermatologic & Aesthetic Surgery
International League (DASIL). . . . . . . . 203
333 N. Michigan Avenue
Chicago, IL 60601
Phone: 312-263-1147
www.thedasil.org
The Dermatologic & Aesthetic International
League (DASIL) is the most open and
transparent international Dermatologic and
Aesthetic Surgical organization ever created.
We are dedicated physicians and teachers from
all over the world, and invite all interested
dermatologists to be part of this exciting new
League.
Dermatology Foundation. . . . . . . . . . . 709
1560 Sherman Avenue, Suite 870
Evanston, IL 60201
Phone: 847-328-2256
www.dermatologyfoundation.org
The DF provides research funding that helps
develop and retain tomorrow’s leaders
in all areas of dermatology, and enables
advancements in patient care. Each year the
Foundation sets aside a half-million dollars in
research funding for dermatologic surgery. Stop
by the DF exhibit and learn more about the DF’s
role in advancing dermatologic surgery.
Dermatology Times . . . . . . . . . . . . . . 1408
485F US Highway 1 South, Suite 100
Iselin, NJ 08830
Phone: 732-346-3089
www.dermatologytimes.com
Dermatology Times is a leading source for
dermatologists, offering credible, relevant and
timely reporting on the latest trends. Our
print, digital editions, web site and weekly
e-newsletter provide more than just factual
coverage of cutting-edge research and current
trends. They provide the context for practical
application in day-to-day practice.
DermAvance Pharmaceuticals, Inc. . . . 411
274 West Lancaster Avenue, Suite 200
Malvern, PA 19355
Phone: 484-568-0306
www.dermavance.com
DermAvance’s unique physician-dispensed
products include: HYDRO-Q 4% Gel, a
Rx water-based hydroquinone gel that will
not oxidize. ARNIKA FORTE, a combination
bromelain /arnica in one capsule, recommended
at filler injection sessions to stop bruising fast.
HYALOGY, a topical nano-hyaluronic acid that is
delivered to the dermis.
Dermik, a business of
sanofi-aventis . . . . . . . . . . . . . . . . . . . 1401
COPPER LEVEL PARTNER
Dermpath Diagnostics . . . . . . . . . . . . 1508
7111 Fairway Drive, Suite 400
Palm Beach Gardens, FL 33418
Phone: 866-467-SKIN (7546)
www.dermpathdiagnostics.com
Dermpath Diagnostics is exclusively focused
on providing exceptional dermatopathology
services. Our commitment to dermatopathology
is backed by an unrivaled team of over 90
board-certified dermatopathologists, advanced
diagnostic technologies and unparalleled
clinician/patient support. Our goal is to assist in
providing the best health care for every patient.
DermResources, LLC . . . . . . . . . . . . . . . 201
3483 River Gardens Circle
Pensacola, FL 32514
Phone: 877-692-0171
www.dermresources.com
DermResources is a Dermatology-specific
consulting company specializing in On Site
Practice Management Consultations, Accounts
Receivable Solutions, New Practice Start Ups,
Dermatology Coding Presentations, Record
Audits, Medicare and HIPAA Compliance, and
Practice Management Books and Publications.
Digital Assent, LLC . . . . . . . . . . . . . . . 1615
75 Fifth Street, Suite 210
Atlanta, GA 30308
Phone: 404-382-7589
www.patient-pad.com
Digital Assent is a fast-growing healthcare
technology company based in Atlanta, Ga. The
company’s wireless touch-screen PatientPad
solution streamlines the patient check-in process
and delivers targeted health information to
patients while they sit in a provider’s waiting
room or exam room. By automating patient
intake, the PatientPad enables healthcare
providers to collect patient information in a
standard electronic format, transition from
paper to electronic health records, and improve
the overall patient experience.
Doctors Pathology Services . . . . . . . . . 101
1253 College Park Drive
Dover, DE 19904
Phone: 302-677-0000
www.dpspa.com
Doctors Pathology Services introduces MICS
(Mobile Intra-Operative Consultation Service),
the only licensed and patented mobile pathology
service in the country. Designed to be highly
sophisticated and cost efficient, MICS is a self
contained and powered histology lab on wheels,
with automation and amenities, now available
for sale or lease.
DUSA Pharmaceuticals . . . . . . . . . . . . . 513
55 Corporate Drive
Bridgewater, NJ 08807
Phone: 908-981-5000
www.sanofi-aventis.com
25 Upton Drive
Wilmington, MA 01887
Phone: 978-657-7500
www.dusapharma.com
Dermik is the dermatology business of sanofi
and has developed, marketed and distributed
innovative prescription pharmaceutical products
for nearly 60 years.
DUSA Pharmaceuticals is an integrated,
dermatology pharmaceutical company focused
primarily on the development and marketing
of its Levulan® Photodynamic Therapy (PDT)
technology platform. Levulan Kerastick® plus
blue light illumination using the BLU-U® blue
light photodynamic therapy illuminator is
currently approved for the treatment of Grade I
or II AKs of the face or scalp.
66
E
Eclipse Aesthetics, LLC.. . . . . . . . . . . . . 607
13988 Diplomat Drive, Suite 160
Dallas, TX 75234
Phone: 972-380-2911
www.eclipsemed.com
Eclipse is a proven innovator and
leading manufacturer and distributor of
ground-breaking aesthetic products and
devices. Eclipse product portfolio includes:
Equinox™, a highly respected fractional CO2
laser system, EndyMed Pro™, with 3DEEP®
ablative and non-ablative RadioFrequency
technology, VeinViewer Vision™ for optimal leg
vein visualization, Asclepion MedioStar NeXT™
diode laser, SmoothCool™ and iPulse™ IPL
systems, and the new BioEssence™ Therapy
treatment innovation that combines deep heat
with RegenPlasma™ PRP.
Ellis Instruments, Inc. . . . . . . . . . . . . . . 212
21 Cook Avenue
Madison, NJ 07940
Phone: 800-218-9082
www.ellisinstruments.com
Complete line of Dermatologic Surgey
Instruments. Ellis representatives have attended
every ASDS Annual Meeting since its inception
and every Annual AAD meeting since 1976.
Ellman International . . . . . . . . . . . . . . 1712
3333 Royal Avenue
Oceanside, NY 11572
Phone: 516-594-3333
www.ellman.com
www.pelleve.com
Ellman International is a privately held
manufacturer of medical devices used to
perform a variety of aesthetic and surgical
procedures. The Pellevé™ Wrinkle Reduction
System is a key product used by physicians for
skin tightening and to stimulate new collagen
as a part of the skin rejuvenation process.
Elsevier. . . . . . . . . . . . . . . . . . . . . . . . . 1004
15807 Quince Orchard Road
N. Potomac, MD 20878
Phone: 240-477-8564
www.elsevier.com
Several new ELSEVIER editions and new books
have recently published. NEW EDITION OF
BOLOGNIA- DERMATOLOGY(COMING SOON),
Surgery of the Skin 2ed, Andrews’ Diseases
of the Skin, Treatments for Skin of Color,
Procedures -Chemical Peels, Facial Rejuvenation
with Fillers with DVD, Flaps and Grafts in
Dermatologic Surgery and more.
Enhanced Image Technologies . . . . . . 716
15720 John J. Delaney Drive, Suite 300
Charlotte, NC 28277
Phone: 866-233-3412
www.enhancedimagetech.com
Enhanced Image Technologies (EIT) offers
innovative skin and body imaging systems. The
Image Pro II features 3D spectral analysis for skin
and pores, is easy to use and reasonably priced.
The Body Pro, whole body imaging system
features 3D breast simulations and is show
priced under $10,000.
TECHNICAL EXHIBITS
Envy Medical . . . . . . . . . . . . . . . . . . . . . 800
31340 Via Colinas, Suite 101
Westlake Village, CA 91362
Phone: 818-874-2700
www.envymedical.com
Envy Medical’s mission is to offer highly effective
non-invasive skin rejuvenation therapies for
patients suffering from dermatologic or aesthetic
conditions. Our products include SilkPeel®,
the only true dermalifusion system combining
precision exfoliation with condition-specific
serum infusions for better patient outcomes
and Lumixyl®, the first real topical alternative to
hydroquinone.
ETHICON, Inc. . . . . . . . . . . . . . . . . . . . 1506
BRONZE LEVEL PARTNER
Route 22 West
Somerville, NJ 08876
Phone: 877-ETHICON
www.ethicon360.com
ETHICON, Inc., has been a leader in surgical
sutures for more than 100 years. With
innovative technologies such as DERMABOND®
Topical Skin Adhesive, Plus Antibacterial Sutures
and FlexHD® Acellular Hydrated Dermis,
ETHICON is focused on the specific needs of
the surgeon, nurse, patient and hospital. Our
mission, Restoration of body, and of life.
F
Fallene Ltd. . . . . . . . . . . . . . . . . . . . . . 1512
2555 Industry Lane
West Norriton, PA 19403
Phone: 610-630-6800
www.solarprotectionformula.com
Fallene, Ltd. manufactures the most complete
sun protection products available. Fallene, Ltd.
offers a comprehensive multi-product line of
full spectrum sun protection. Each product is
specifically designed for the unique needs of
individuals concerned with blocking the full light
spectrum. Fallene sun protection products utilize
titanium, zinc, and iron to create a complete
reflective barrier that protects against harmful
UVB/UVA radiation.
Fibrocell Science, Inc. . . . . . . . . . . . . . 1710
G
Galderma Laboratories, LP . . . . . . . . . . 810
BRONZE LEVEL PARTNER
14501 North Freeway
Fort Worth, TX 76177
Phone: 817-961-5000
www.galdermausa.com
Fibrocell Science, Inc., is a biotechnology
company that focuses on developing
personalized autologous cell therapies for
aesthetic, medical, and scientific applications.
LAVIV® (azficel-T), our lead product, is now
FDA approved. LAVIV is the first and only
personalized aesthetic cell therapy indicated for
improvement of the appearance of moderate to
severe nasolabial fold wrinkles in adults.
1271 Puerta Del Sol
San Clemente, CA 92673
Phone: 949-369-0101
www.hksurgical.com
Galderma products include Epiduo® (adapalene
and benzoyl peroxide) Gel 0.1%/2.5%, Differin®
(adapalene) Gel 0.3%, Vectical® (calcitriol)
Ointment 3 mcg/g, Clobex® (clobetasol
propionate) Spray 0.05%, Oracea® (doxycycline,
USP) Capsules, Metrogel® (metronidazole gel)
1%, Cetaphil® Cleansers and Moisturizers,
including new Cetaphil® Restoraderm® Body
Wash and Moisturizer. For more information,
visit www.galdermaUSA.com
HK Surgical is the recognized leader in the
development of highly specialized products in
the medical device industry. We are the original
designers of the NEW HK KleinTouch Infiltration
pump and Klein Aspiration pump. We carry a
full line of disposable tubing, garments, filters
and Super Absorbent Pads. HK Surgical is
proudly the exclusive source of the patented
Capistrano Cannulas, Midine Positioning Pillow,
and the HK Super Absorbent Pads. When you
choose to do business with HK Surgical, you
become more than just a client to us; you
become an important partner in our business.
Genentech . . . . . . . . . . . . . . . . . . . . . . 1407
Hopewell Pharmacy . . . . . . . . . . . . . . . 506
1 DNA Way
South San Francisco, CA 94080
Phone: 650-225-1000
www.gene.com
1 West Broad Street
Hopewell, NJ 08525
Phone: 609-466-1960
www.hopewellrx.com
Considered the founder of the biotechnology
industry, Genentech has been delivering on
the promise of biotechnology for more than
35 years, using human genetic information
to discover, develop, manufacture and
commercialize medicines to treat patients with
serious or life-threatening medical conditions.
Today, Genentech is among the world’s leading
biotech companies, with multiple products
on the market and a promising development
pipeline.
We are a full service compounding pharmacy
in NJ formulating prescriptions for you and
your patients. Specializing in dermatologic and
cosmetic formulas from topical anesthetics and
sclerotherapy solutions or whatever your needs
may be. Looking for Cantharadin or Triluma?
Stop by booth #506 for more info. and to take
advantage of 10% off at the show!
Graceway Pharmaceuticals, LLC. . . . . 1201
222 Valley Creek Boulevard, Suite 300
Exton, PA 19341
Phone: 267-948-0400
www.gracewaypharma.com
Graceway Pharmaceuticals, LLC is dedicated
to bringing the medical community advanced
products with unique benefits, enabling
healthcare professionals to better help patients
live healthier lives. Our products include Zyclara®
(imiquimod) Cream, 3.75%, a topical cream for
the treatment of actinic keratosis and external
genital warts.
405 Eagleview Boulevard
Exton, PA 19341
Phone: 484-713-6000
www.fibrocellscience.com
HK Surgical, Inc. . . . . . . . . . . . . . . . . . . 220
H
Hill Dermaceuticals, Inc. . . . . . . . . . . . . 208
2650 South Mellonville Avenue
Sanford, FL 32773
Phone: 407-323-1887
www.hillderm.com
Hill Dermaceuticals is a pharmaceutical company
that specializes in developing dermatology
products for adults and children with difficult
to treat skin diseases such as scalp psoriasis,
atopic dermatitis/eczema and chronic
eczematous external otitis. Hill Dermaceuticals,
Inc. manufactures, markets and distributes
its products in the U.S.A. To order call
1.800.344.5707.
human med inc. . . . . . . . . . . . . . . . . . . 216
1860 Crown Drive, Suite 1408
Dallas, TX 75234
Phone: 972-556-9593
www.humanmed.com
An innovator and leader in water-jet
surgery, human med® is the world’s first and
foremost manufacturer of water-jet assisted
aesthetic devices. Human med’s innovative
products, including the body-jet®, harvestjet®, FillerCollector™ and LipoCollector™ 3,
have helped to usher in a fundamentally
new approach to lipoplasty and natural fat
harvesting. By continuing to explore and develop
cutting-edge technologies, human med® is
dedicated to playing an integral role in the
ongoing evolution of aesthetic medicine.
I
International Master Course on
Aging Skin (IMCAS) . . . . . . . . . . . . . . . 118
8, rue Foucault
75116 Paris, France
Phone: +33 (0)1 40 73 82 82
www.imcas.com
IMCAS is a congress featuring a rich teaching
program for plastic surgeons, dermatologists
and any expert interested in the field of
aesthetic surgery or cosmetic dermatology.
IMCAS has indeed built itself as an interface for
all practitioners, a platform for exchange and
innovation, and its Parisian edition held annually
in January is now a reference in Europe. The
coming IMCAS 2012, to be held in Paris, on
next January 26 to 29, will be our 14th edition.
67
TECHNICAL EXHIBITS
Iredale Mineral Cosmetics . . . . . . . . . . 611
51 Church Street
Great Barrington, MA 01230
Phone: 800-762-1132
www.janeiredale.com
Multipurpose, multicultural, and mindful of
Mother Earth, our products celebrate skin of
every tone and state; from young, to notso-young, from healthy to help! If you’re
interested in providing sustainable, performancedriven beauty solutions to your clients, visit with
us to learn why we’re the #1 choice of skin care
professionals.
IRIDEX Corporation. . . . . . . . . . . . . . . 1609
1212 Terra Bella Avenue
Phone: 800-388-4747
www.iridex.com
IRIDEX is a leading provider of therapeutic
based laser systems. The VariLite™ system is the
complete skin lesion laser solution for treating
vascular, pigmented, and cutaneous lesions and
acne vulgaris. Gemini® gives you both a KTP
laser and an Nd:YAG laser to treat a vast array
of conditions including acne, wrinkles, redness
diffusion, age spots and unwanted hair.
J
Jan Marini Skin Research, Inc. . . . . . . . 305
6951 Via Del Oro
San Jose, CA 95119
Phone: 800-347-2223
www.janmarini.com
Jan Marini Skin Research markets therapeutic
topical skincare products through physician
offices, which include resurfacing agents,
growth factors, topical lipid soluble Vitamin
C, TGF beta -1, Thymosin beta - 4 and recent
eyelash and hair enhancement breakthroughs.
Jan Marini Skin Research products achieve
outstanding results that have not been possible
prior to these advancements.
Journal of Clinical and Aesthetic
Dermatology (JCAD) . . . . . . . . . . . . . . . 203
1595 Paoli Pike, Suite 103
West Chester, PA 19380
Phone: 866-325-9907
www.jcadonline.com
The Journal of Clinical and Aesthetic
Dermatology (JCAD) is a peer reviewed,
Indexed, monthly publication that has
become an important addition to the field of
Dermatology. JCAD provides Dermatologists
with evidence based information in a practical,
easy to read format that can be applied to
their daily practice. JCAD offers readers
original research,comprehenesive reviews, case
reports, all written by key opinion leaders in
Dermatology.
Journal of Drugs in
Dermatology (JDD) . . . . . . . . . . . . . . . 1306
377 Park Avenue South, 6th Floor
New York, NY 10016
Phone: 212-213-5436
www.jddonline.com
The Journal of Drugs in Dermatology (JDD)
is a full-color, peer-reviewed publication
indexed with MEDLINE®/PubMed®. Written for
68
physicians by physicians, JDD is the fastest to
publish dermatology journal. Its International
Editorial Board of over 150 renowned experts
reviews all original articles, case reports, and
timely departments pertaining to new methods,
techniques, and drug therapy. JDD is published
monthly by an award-winning editorial team,
and is recognized as an entrusted resource to
the dermatology community.
L
La Roche-Posay . . . . . . . . . . . . . . . . . . . 117
575 Fifth Avenue, 20th Floor
New York, NY 10017
Phone: 212-973-5342
www.laroche-posay.us
La Roche-Posay is recommended by 25,000
dermatologists worldwide offering daily skincare
products formulated with highly concentrated
ingredients targeting every skin’s needs.
Tested on sensitive skin, daily use products are
formulated with thermal spring water rich in
selenium, a powerful antioxidant. Formulations
are clinically proven for safety and efficacy.
Lasering USA . . . . . . . . . . . . . . . . . . . . . 404
2246 Camino Ramon
San Ramon, CA 94583
Phone: 866-471-0469
www.mixtoskinresurfacing.com
The MiXto SX® Micro Fractional CO2 Laser
for skin resurfacing features a patent pending
scanning method that delivers a continuous
wave beam in a predetermined / repeatable
pattern. The benefits include - greater patient
comfort - no bleeding - no oozing – reduced
post treatment complications – safe for all skin
types.
Light Age, Inc. . . . . . . . . . . . . . . . . . . . 1802
500 Apgar Drive
Somerset, NJ 08873
Phone: 732-563-0600
www.lightage.com
Light Age, Inc. develops, manufactures and
markets solid-state laser systems for aesthetic
procedures and medical device research and
development. Standard laser products, FDA
approved, include our new ultra compact
Q-Clear™ for treatment of age spots, pigmented
lesions and tattoos, the EpiCare™ for hair
removal, and the Ta2Eraser™ for tattoo
removal.
Liposuction.com, Inc. . . . . . . . . . . . . . . 508
30280 Rancho Viejo Road
Phone: 949-369-7555
www.liposuction.com
Liposuction.com is the #1 surgeon directory on
Google, Yahoo, AOL and all other major search
engines. Over 100,000 patients come to our site
monthly to find a surgeon near them. Capture
these real-time leads. For the best return
on your investment, sign up today and start
scheduling liposuction patients NOW. From our
web site to your waiting room. 1-800-378-9789
or www.liposuction.com.
Liquid Ice CosMedicals AG . . . . . . . . . . 501
Zugerbergstrasse 86
6314 Unterageri Switzerland
Phone: +41 41 750 8989
US Phone: 941-387-6686
www.icemask.com
Liquid Ice CosMedicals AG of Switzerland
produces unique self cooling treatments for post
surgery and aesthetic dermatology care. The
new Ice Mask™ protocols have been created to
reduce patients’ downtime after facial surgery
as well as aesthetic procedures. Liquid Ice
CosMedicals AG is introducing SlimVest™, the
first patented non invasive body contouring
treatment for institute as well as home use.
Lumenis . . . . . . . . . . . . . . . . . . . . . . . . 1400
5302 Betsy Ross Drive
Santa Clara, CA 95054
Phone: 408-764-3000
www.aesthetic.lumenis.com
Lumenis is the leading developer, manufacturer
and marketer of proprietary laser and intense
pulsed light (IPL) systems. Lumenis aesthetic
systems are reknown worldwide for advanced
applications including scar reduction, fractional
resurfacing, photorejuvenation, hair removal,
improvement of vascular and pigmented lesions,
and wrinkle reduction. Leading products include
DeepFX and ActiveFX with UltraPulse, AcuPulse,
LightSheer Duet, LumenisOne and M22.
Lutronic, Inc... . . . . . . . . . . . . . . . . . . . . 111
3003 North 1st Street, Suite 235
San Jose, CA 95134
Phone: 888-588-7644
www.lutronic.com
Lutronic, Inc., is a publicly traded manufacturer
of quality medical laser systems. Products
include systems for non fractional laser
resurfacing, tattoo and pigmented lesion
removal, non-ablative rejuvenation, facial and
body contouring, as well as laser surgery. The
company invests heavily in R & D to continuously
remain at the forefront of new and innovative
technology. Our laser systems have received
worldwide acclaim and are currently serving
physicians in 60 countries.
M
MedCo Data, LLC. . . . . . . . . . . . . . . . . 1209
1410 North Westshore Boulevard
Tampa, FL 33607
Phone: 813-321-1557
www.medcodata.com
MedCo Data’s patent pending Workflow
Centric Evaluation System is a tenured, proven
methodology for matching an individual practice
to the proper electronic record solution and
then implementing with adoption standards
exceeding “Meaningful Use” criteria. MedCo
Data’s process is the most complete solution
in the industry; covering budgeting, selection,
negotiation, implementation, infrastructure and
even long term support. We’ve helped over 350
practices transition to electronic health records
and we support the infrastructure for thousands
of physicians. Drop by our booth to learn how
we can help you.
TECHNICAL EXHIBITS
Medelita Scrubs & Lab Coats . . . . . . . 1107
Mentor Worldwide, LLC. . . . . . . . . . . . 717
Midmark Corporation. . . . . . . . . . . . . 1501
1046 Calle Recodo, Suite D
San Clemente, CA 92673
Phone: 877-987-7979
www.medelita.com
201 Mentor Drive
Phone: 805-879-6000
www.mentorwwllc.com
60 Vista Drive
Versailles, OH 45380
Phone: 800-643-6275
www.midmark.com
Experience sophistication, functionality and
quality at the Medelita boutique- booth #1107.
Try on one of our many styles of professionally
tailored, 100% cotton lab coats or a pair of the
most flattering and comfortable scrubs available.
Receive complimentary shipping and custom
embroidery on 2 or more items.
Mentor Worldwide LLC is a trusted global leader
in aesthetic medicine among both consumers
and clinicians by providing a broad range of
innovative, science and clinical-based solutions
to maintain, enhance, and restore self-esteem
and quality of life.
MedEsthetics Magazine . . . . . . . . . . . 1511
7590 Commerce Court
Sarasota, FL 34243
Phone: 800-331-2716
www.mercedesmedical.com
Midmark Corporation is a leading manufacturer
of the most user-and patient-friendly
examination and procedure equipment available.
Headquartered in Versailles, Ohio, Midmark
provides a full line of power and manual
examination tables, sterilizers, casework, seating,
lighting, ECG’s and accessories for use in
healthcare systems and facilities worldwide.
7628 Densmore Avenue
Van Nuys, CA 91406
Phone: 818-782-7328
www.medestheticsmagazine.com
Medesthetics magazine provides up-to-date
product information and covers service trends
and business management issues for medical
spa owners and physicians offering medical
aesthetic procedures in specialized facilities. Each
issue includes a business profile, an equipment
update, marketing suggestions, management
solutions and information on legal issues and
training options.
Medicis Aesthetics, Inc. . . . . . . . . . . . 1600
GOLD LEVEL PARTNER
7720 North Dobson Road
Scottsdale, AZ 85256
Phone: 602-808-8800
www.medicis.com
Medicis Aesthetics is dedicated to helping
patients attain a healthy and youthful
appearance and self-image, and to help you
redefine beauty in your patients. It’s at the heart
of everything we do for you. And it’s why we
offer a comprehensive collection of products for
your facial aesthetics practice.
Medicis Medical Information . . . . . . . 1612
7720 North Dobson Road
Phone: 602-808-8800
www.medicis.com
Mercedes Medical . . . . . . . . . . . . . . . . . 406
Mercedes Medical, Inc. is a privately held,
woman-owned national medical distribution
company located in Sarasota, Florida and is
a two time winner of the Inc. 500 as one of
America’s fastest growing companies. Mercedes
for 20 years has prided itself on being the low
cost leader in the medical supply market. With
a keen interest on efficiency and customer
service as the basis of their distribution model,
Mercedes has found success in providing
physician and laboratory customers the absolute
lowest price while refusing to sacrifice on
service. Their unique direct marketing approach
and refusal to conform to old model distribution
ideas have helped Mercedes outshine the
competition.
Merz Aesthetics, Inc.. . . . . . . . . . . . . . . 909
SILVER LEVEL PARTNER
1875 South Grant Street, Suite 200
San Mateo, CA 94402
Phone: 866-862-1211
www.merzaesthetics.com
Merz Aesthetics, Inc. is a global medical
aesthetics company which provides minimally
invasive products to enhance a patient’s
appearance. Its product line includes RADIESSE®
filler, for long lasting wrinkle correction, and
Asclera™ (polidocanol) Injection, an FDAapproved sclerosing agent.
MedNet Technologies. . . . . . . . . . . . . . 608
Merz Medical Affairs . . . . . . . . . . . . . . 601
1975 Linden Boulevard, Suite 407
Elmont, NY 11003
Phone: 516-285-2200
www.mednet-tech.com
1875 South Grant Street, Suite 200
San Mateo, CA 94402
Phone: 866-862-1211
www.merzaesthetics.com
MedNet Technologies designs, hosts and
manages websites for medical practices,
hospitals and other healthcare organizations.
Clients range in size from small medical offices
to teaching hospitals to medical societies.
Developing and optimizing your web presence
on the Internet is our goal.
MELA Sciences. . . . . . . . . . . . . . . . . . . . 507
50 South Buckhout Street, Suite 1
Irvington, NY 10533
Phone: 914-373-6935
www.melasciences.com
MELA Sciences is a medical technology
company focused on developing MelaFind®, a
breakthrough tool to assist in the detection of
early melanoma by providing independent and
objective, point-of-care evaluation of clinically
atypical/irregular pigmented skin lesions to aid
clinicians in their lesion management decisions.
Microsurgery Instruments, Inc . . . . . . . 801
PO Box 1378
Bellaire, TX 77402-1378
Phone: 713-664-4707
www.microsurgeryusa.com
Microsurgery Instruments is one of the leading
suppliers of surgical instruments and loupes.
Our new instruments include: titanium scissors,
needle holders, and debakey forceps. Our SuperCut scissors are the sharpest in the market,
and our newly designed surgical loupes offer
up to 130mm field of view, and up to 11x
magnification.
Miramar Labs . . . . . . . . . . . . . . . . . . . 1200
445 Indio Way
Sunnyvale, CA 94085
Phone: 408-940-8700
www.miradry.com
Miramar Labs is a medical device company
dedicated to bringing the next generation
energy modality to treat dermatologic medical
conditions. The company’s miraDry System
utilizes microwave energy technology to treat
primary axillary hyperhidrosis, providing a
lasting and dramatic reduction of excessive
underarm sweat using a non-invasive, outpatient
procedure.
MJD Patient Communications . . . . . . 1515
4915 St. Elmo Avenue, #306
Bethesda, MD 20814
Phone: 301-657-8010
www.mjdpc.com
MJD’s top rated Websites, Looping DVDs,
Procedure Brochures, Messages-On-Hold and
the new TopDocs.com give plastic, cosmetic,
and laser practices a boost. Interested in the
benefits of a TopDocs.com listing and exclusive
buying group? Visit the New TopDocs.com
Portal.
Modernizing Medicine . . . . . . . . . . . . . 311
3330 South Federal Highway, Suite 300
Boynton Beach, FL 33435
Phone: 866-799-2146
www.modernizingmedicine.com
Modernizing Medicine’s, EMA-Dermatology, is
the easiest EMR to install, learn and use. It has
gained rapid acceptance in the derm community
because it really saves the doctor time and
money. EMA couples the latest technologies
with imbedded medical knowledge, and no
special hardware or software is required at the
medical practice.
MTI . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
3655 West Ninigret Drive
Phone: 801-887-5114
www.mti.net
MTI will exhibit samples of surgery and exam
chairs/tables powered by the industry leading
low voltage DC motor technology. We will have
quad, tri, dual and single power surgery tables
and exam chairs, lighting and stools will also be
on display with a large number of integrated
and complementary accessories.
69
TECHNICAL EXHIBITS
MyCustomerData.com . . . . . . . . . . . . 1109
Neutrogena . . . . . . . . . . . . . . . . . . . . . . 710
Onset Dermatologics . . . . . . . . . . . . . 1208
26880 Aliso Viejo Parkway, Suite 250
Aliso Viejo, CA 92656
Phone: 949-297-8496
www.mycustomerdata.com
BRASS LEVEL PARTNER
5760 West 96th Street
Los Angeles, CA 90045
Phone: 310-337-6815
www.neutrogena.com
900 Highland Corporate Drive, Suite 203
Cumberland, RI 02864
Phone: 888-713-8154
www.onsetdermatologics.com
Neutrogena advances skin and hair care science
through continuous support of the medical
community and through the development of
clinically proven products that fulfill the skincare
needs of physicians, nurses and patients. Please
visit our exhibit and website: www.neutrogena.
com for information about the recent addition
to the Neutrogena product line.
Onset Dermatologics, a PreCision Dermatology
company, offers innovative and effective
dermatological products to address the needs
of dermatologists and their patients. Many of
our products feature the proprietary Delevo®
foam technology, a drug delivery platform
that provides enhanced penetration of proven
active ingredients to the skin with optimized
tolerability.
RETAIN, RECAPTURE, and ACQUIRE more
patients with a credit-card quality VIP Savings
Card, automatically delivered to patients unlikely
to return and new patients that have never
visited. Customized offers for each patient
category and monthly email reminders help
the VIP Savings Card generate fantastic results
complete with 100% measureable online
reporting.
N
Neocutis, Inc . . . . . . . . . . . . . . . . . . . . . 405
3053 Fillmore Street, Suite 140
Phone: 866-636-2884
www.neocutis.com
NEOCUTIS, a leader in innovative, effective skin
care brings the precision of Swiss technology
and cellular therapy research together for
scientifically advanced breakthroughs in
anti-aging and post-procedural recovery.
PSP® (Processed Skin Cell Proteins),
NEOCUTIS› proprietary skin care ingredient
is derived from a biotechnology process that
extracts rich proteins such as anti-oxidants,
cytokines and fibroblasts known to optimize
wound healing and skin rejuvenation.
NeoGraft . . . . . . . . . . . . . . . . . . . . . . . . 407
419 Southfork, Suite 103
Lewisville, TX 75057
Phone: 972-219-5600
www.neograft.com
The Follicular Unit Extraction (FUE) technique
of The NeoGraft is the most advanced and
minimally invasive hair transplant method to
date. The NeoGraft system delivers automation
of the FUE technique, the most advanced
technique in the hair transplant industry. With
the NeoGraft system procedure times are cut
in half, with reduced patient discomfort and
the most natural results of any hair transplant
technology.
NeoStrata Company, Inc. . . . . . . . . . . 1207
307 College Road East
Princeton, NJ 08540
Phone: 800-628-9904
www.neostrata.com
NeoStrata® is scientifically advanced, clinically
proven skincare recommended by doctors to
visibly resurface, restore and refine skin so users
experience dramatic, noticeable improvements
in their skin. NeoStrata® products are proven
effective across a wide variety of skin types
and conditions including photoaging, rosacea,
hyperpigmentation, severe dryness and acne.
70
NexTech . . . . . . . . . . . . . . . . . . . . . . . . 1101
5550 West Executive Drive, Suite 350
Tampa, FL 33609
Phone: 813-425-9200
www.nextech.com
NexTech Practice 2011 is fully integrated
Practice Management, Marketing, and EMR/EHR
software designed specifically for Dermatologists
and Dermatologic Surgeons, Cosmetic Medical
Practices, and Medical Spas. With a client base
of over 3500 physician clients and 30,000 in
staff worldwide, Practice 2011 is comprehensive,
completely modular, and CCHIT 2011 certified.
NIA24 / Niadyne, Inc. . . . . . . . . . . . . . . 505
4208 Six Forks Road, 9th Floor
Raleigh, NC 27609
Phone: 919-838-7800
www.nia24.com
NIA 24® Niacin-Powered Skin Therapy delivers a
patented Pro-Niacin® molecule deep within the
skin›s layers to build a stronger, healthier skin
barrier from the inside-out. Nia 24 activates the
skin›s repair processes to promote healthier skin
and reduces the appearance of fine lines, brown
spots and hyperpigmentation.
O
Obagi Medical Products . . . . . . . . . . 1303
3760 Kilroy Airport Way, Suite 500
Long Beach, CA 90806
Phone: 562-256-3009
www.obagi.com
Obagi Medical Products is a specialty
pharmaceutical company that develops and
markets, and is a leading provider of, proprietary
topical aesthetic and therapeutic prescriptionstrength skin care systems in the physiciandispensed market. Obagi Medical’s products are
designed to prevent, correct and improve the
most common skin disorders in adult skin.
Ortho Dermatologics . . . . . . . . . . . . . . 712
5760 West 96th Street
Phone: 310-410-5813
www.orthodermatologics.com
Ortho Dermatologics®, division of Ortho-McNeilJanssen Pharmaceuticals, Inc., is a leader in
delivering novel therapies that address the
multiple needs of dermatologists and Aethetics
physicians for their patients in treatment areas
that span from acne, fungal infections and
wound healing, with dermatological products
including RETIN-A MICRO®, ERTACZOTM,
BIAFINE® and RENOVA®.
P
Palomar Medical Technologies, Inc. . . 610
BRASS LEVEL PARTNER
15 Network Drive
Burlington, MA 01803
Phone: 781-993-2300
www.palomarmedical.com
Palomar Medical Technologies, Inc. develops the
most advanced laser and pulsed-light systems
for aesthetic applications including true laser
body sculpting, fractional skin resurfacing, skin
rejuvenation, and permanent hair reduction.
Palomar’s StarLux®500, SlimLipo™, and
Artisan™ systems empower doctors to offer
remarkable results with exceptional versatility,
ease of use, and comfort. Discover “From Light
Comes Beauty” at palomarmedical.com.
PCA SKIN . . . . . . . . . . . . . . . . . . . . . . . . 605
6710 East Camelback Road, Suite 230
Phone: 480-946-7221
www.pcaskin.com
PCA SKIN® is a healthcare company providing
daily care products and chemical peels for
physicians and clinicians worldwide to address
their patients’ acne, aging skin, sensitive skin
and hyperpigmentation. PCA SKIN is a trusted
educational resource with over a 20-year history
of helping to improve skin health and people’s
lives.
TECHNICAL EXHIBITS
Photocure . . . . . . . . . . . . . . . . . . . . . . . 115
100 Overlook Center, 2nd Floor
Princeton, NJ 08540
Phone: 609-375-2263
www.photocure.com
Photocure, the world leader in photodynamic
technology, specializes in developing and
commercializing highly selective and effective
solutions for cancer and dermatology.
Photocure is pleased to introduce their latest
product, Allumera™, a light-activated cosmetic
treatment, specially formulated to visibly reduce
skin’s outward signs of aging while producing a
more radiant and glowing complexion.
PhotoMedex . . . . . . . . . . . . . . . . . . . . 1100
147 Keystone Drive
Montgomeryville, PA 18936
Phone: 215-619-3600
www.photomedex.com
PhotoMedex offers innovative products including
XTRAC® Excimer Laser for dermatological
applications, such as psoriasis and vitiligo, fiberoptic laser systems for surgical procedures, the
Neova® line of products with patented Copper
Peptide technology for skin, hair and wound
care, and Omnilux™ LED products for acne, fine
lines and wrinkles.
Pierre Fabre Dermo-Cosmétique
USA . . . . . . . . . . . . . . . . . . . . . . . . . . . 1003
9 Campus Drive, 2nd Floor
Parsippany, NJ 07054
Phone: 800-459-8663
www.glytone-usa.com
www.aveneusa.com
Pierre Fabre Dermo-Cosmétique is a global
leader in dermatological skincare. Brands
include: Eau Thermale Avène®, a dermocosmetic brand based on hydrotherapy,
dedicated to sensitive skin; Glytone®, a skin
rejuvenation system offering high effective
skincare regimens, through in-office procedures
(glycolic acid and salicylic acid peels), as well as
at-home treatments.
Procter & Gamble . . . . . . . . . . . . . . . . 1300
1 Procter & Gamble Plaza
Cincinnati, OH 45202
Phone: 513-983-1100
www.pgdermatology.com
P&G Beauty & Grooming delivers innovative
science and consumer insights which help
ensure patient compliance so they can look,
feel and be their best everyday. Our trusted
brands meet the full complement of beauty and
grooming needs in shaving (Gillette®), skincare
(Olay®) and haircare (Head & Shoulders®).
R
Ra Medical Systems . . . . . . . . . . . . . . . 410
2270-L Camino Vida Roble
Carlsbad, CA 92011
Phone: 760-804-1648
www.ramed.com
Ra Medical Systems, Inc. markets the PHAROS
EX-308, an advanced 308-nm super narrowband
UVB excimer laser for psoriasis, vitiligo, atopic
dermatitis, and leukoderma. It is ideal for
localized, recalcitrant, and difficult-to-treat
psoriasis including scalp, palms and soles, and
intertriginous lesions and for localized vitiligo,
including facial and peri-orbital areas.
Visit us at www.ramed.com.
Real Aesthetics . . . . . . . . . . . . . . . . . . . 301
575 Lexington Avenue, Suite 4017
New York, NY 10022
Phone: 877-382-7325
www.realaesthetics.com/usa
Bella Contour by Real Aesthetics is a
revolutionary device for non-invasive body
contouring. FDA cleared for temporary
cellulite reduction with clinical studies showing
significant circumference reduction. Bella
Contour combines 3 technologies - Therapeutic
Ultrasound, Electric Current Therapy, and
Vacuum Therapy. Immediate results can
normally be seen after a single treatment!
Restoration Robotics, Inc.. . . . . . . . . . 1411
1383 Shorebird Way
Phone: 650-965-3612
www.restorationrobotics.com
Restoration Robotics manufactures the
ARTAS System which is a physician
controlled, interactive, computer assisted system
utilizing image-guided technology to enhance
the quality and productivity of follicular unit
harvesting in hair restoration procedures.
Revision Skincare . . . . . . . . . . . . . . . . 1309
9019 Premier Row
Dallas, TX 75247
Phone: 800-385-6652
www.revisionskincare.com
Revision Skincare makes the highest quality
products with one overriding purpose: to solve
a patient’s skincare problems. Based on the
principal that cosmeceuticals must provide a
targeted solution, our formulas are designed to
correct each skincare condition through multiple
pathways. We use only the purest, premium
quality ingredients in our products, highly
effective products like Teamine®, Nectifirm®,
Intellishade® SPF 45 and our Advanced Skincare
Line.
Revitalash . . . . . . . . . . . . . . . . . . . . . . . 604
RGP, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . 408
1 Shannon Court, Suite 103
Bristol, RI 02809
Phone: 800-522-9695
www.rgpergo.com
The Swedish Seating System is an ergonomically
designed operatory stool. Our 400-D combines
unparalleled support with an elegant design
and the hydraulic mechanism allows the stool’s
back and seat to ‘float,’ independently following
one’s movement.
S
Sandstone Medical Technologies . . . . 704
105 Citation Court
Homewood, AL 35209
Phone: 205-290-8251
www.sandstonemedicaltechnologies.com
Sandstone Medical provides aesthetic lasers at
AFFORDABLE prices. Our Product line includes:
The Matrix Co2 for fractional skin resurfacing,
The Whisper-3G for “Lunch time” LaserPeels,
The UltraLight-Q for the removal of Tattoos and
the Cheveux for the removal of unwanted body
hair. We also provide Pre-Owned lasers from
Candela, Lumenis and Iridex for the removal
vascular and pigmented lesions.
Sciton . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
925 Commercial Street
Palo Alto, CA 94303
Phone: 650-493-9155
www.sciton.com
Sciton’s JOULE laser platform can support
ten distinct modules which address fractional
and full-field skin resurfacing, phototherapy,
skin firming, hair reduction, vascular therapy,
onychomycosis* and laser-assisted lipolysis
applications.
*CE mark, FDA 510(k) clearance pending.
Sensus Healthcare. . . . . . . . . . . . . . . . 1513
851 Broken Sound Parkway NW, #215
Boca Raton, FL 33487
Phone: 561-922-5808
www.sensushealthcare.com
Sensus Healthcare is focused on making proven
non-melanoma skin cancer solutions more
accessible to patients. Our dedicated superficial
radiation therapy (SRT) systems are designed
specifically to provide an alternative to surgical
procedures for basal cell and squamous cell
carcinomas. Our mobile, compact SRT-100™
systems are used widely by oncologists and
dermatologists to bring non-melanoma skin
cancer treatment to more patients in more
settings. We also offer a professional skin
care line, Sensus Skin Solutions™, through our
physician SRT-100™ users for their patients.
1500 Palma Drive, Suite 215
Ventura, CA 93003
Phone: 805-256-6131
www.revitalash.com
RevitaLash®-ADVANCED is the next generation
in cosmetic eyelash conditioners, featuring a
unique blend of functional cosmetic ingredients
along with powerful peptides and botanicals.
Developed by an ophthalmologist and clinically
trialed for safety and efficacy. RevitaLash®ADVANCED will add curl, shine, and beauty to
your natural eyelashes!
71
TECHNICAL EXHIBITS
Skin & Aging . . . . . . . . . . . . . . . . . . . . 1206
Solveras Payment Solutions. . . . . . . . . 109
Syneron and Candela . . . . . . . . . . . . . . 804
83 General Warren Blvd., Suite 100
Malvern, PA 19355
Phone: 610-560-0500
www.skinandaging.com
800 Crescent Centre Drive, Suite 400
Franklin, TN 37067
Phone: 800-613-0148
www.solveras.com
Skin & Aging is an award-winning journal that
provides practical advice to help dermatologists
treat common conditions such as skin cancer,
acne and psoriasis, as well as how to incorporate
cosmetic procedures into practice. The journal
also offers practice management topics to help
dermatologists run more efficient and successful
practices.
Solveras provides comprehensive electronic
payment solutions to thousands of medical
practices nationwide. More than just credit card
processing, our solutions also include easy-tounderstand merchant statements, ACH/eCheck,
E-mailable receipts and invoices, and the ability
to collect recurring payments and online Webpayments — anywhere, anytime through our
all-in-one proprietary payment portal, Solveras
SmartPayTM.
SkinCeuticals . . . . . . . . . . . . . . . . . . . . 1713
575 Fifth Avenue
New York, NY 10017
Phone: 800-811-1660
www.skinceuticals.com
Our mission at SkinCeuticals is to improve
skin health. Dedicated to this purpose, we
make one simple promise — provide advanced
skincare backed by science. Born from decades
of research, our products are formulated
with pharmaceutical-grade actives. We offer
a comprehensive line of integrated homecare
products, clinical procedures, and professional
treatments.
SkinMedica, Inc. . . . . . . . . . . . . . . . . . . 901
5909 Sea Lion Place, Suite H
Carlsbad, CA 92010
Phone: 760-448-3600
www.skinmedica.com
Sound Surgical Technologies . . . . . . . . 609
357 McCaslin Boulevard, #100
Louisville, CO 80027
Phone: 888-471-4777
www.vaser.com
Sound Surgical Technologies is a leading
manufacturer and distributor of minimally
invasive and non-invasive ultrasonic body
shaping technologies, including the VASER
Lipo® and VASER® Shape MC1™ Systems.
Origins™ suction-assisted lipoplasty supplies and
accessories is an order-on-demand product line
that allows customized quantities, tips, orifice
patterns, diameters, lengths and handles/hubs
Stiefel, a GSK Company . . . . . . . . . . . 1702
20 T.W. Alexander Drive
Research Triangle Park, NC 27709
Phone: 919-990-6000
www.stiefel.com
530 Boston Post Road
Wayland, MA 01778
Phone: 508-358-7400
www.syneron.com
www.candelalaser.com
Syneron Medical Ltd. – a company devoted to
real technology, real science and real results – is
the leading global aesthetic device company
with a comprehensive product portfolio
combined with world-class service and support.
The Company’s technology enables physicians
to provide advanced solutions for a broad range
of medical aesthetic applications including body
contouring, hair removal, wrinkle reduction,
rejuvenation of the skin’s appearance through
the treatment of superficial benign vascular and
pigmented lesions, and the treatment of acne,
leg veins and cellulite. The Company sells its
products under two distinct brands, Syneron
and Candela. With its innovative approach to
aesthetic treatments, Syneron has now entered
into one of the largest in-demand applications,
skin lightening.
T
Theraplex. . . . . . . . . . . . . . . . . . . . . . . 1614
6410 Poplar Avenue, Suite 110
Memphis, TN 38119
Phone: 888-437-2753
www.theraplex.com
Stiefel, a GSK company, is committed to
advancing dermatology and skin science around
the world in order to help people better achieve
healthier skin. Stiefel’s dedication to innovation,
along with its sole focus on dermatology, has
established Stiefel as a world leader in the skin
health industry. To learn more about Stiefel, visit
www.stiefel.com.
Theraplex SA salicylic acid facial peel kits,
available in 20%, 25% and 30% formulations,
are a convenient, in-office procedure
designed to improve the appearance of
acne, photodamage, post-inflammatory
hyperpigmentation, and melasma with minimal
down-time. Theraplex also offers a line of
moisturizers specially formulated to moisturize
and protect skin post treatment with lasers or
chemical peels.
Smile Reminder . . . . . . . . . . . . . . . . . . 1308
Surgimedics . . . . . . . . . . . . . . . . . . . . . 1413
ThermoTek, Inc . . . . . . . . . . . . . . . . . . 1613
3098 Executive Parkway, Suite 300
Lehi, UT 84043
Phone: 866-605-6867
www.smilereminder.com
2950 Mechanic Street
Lake City, PA 16423
Phone: 800-840-9906
www.surgimedics.com
1200 Lakeside Parkway, #200
Flower Mound, TX 75028
Phone:972-874-4949
www.thermotekusa.com
Smile Reminder is an award winning practice-topatient engagement service designed to increase
productivity and grow your practice -delivering
text/email automated appointment reminders,
recare/recall reminders, birthday messages,
e-newsletters, e-surveys, and custom promotions
to your patient’s mobile devices. Includes an
unlimited, flat fee service, with a 60-day trial.
Smoke Evacuators are primarily used during
ESU and Laser procedures to remove smoke
plume, reduce potential mutagens and reduce
odors near the site. Surgimedics’ unique low
cost removable prefilter protects and extends
the life of primary 4-stage ULPA filter which
is the leading cost of consumables in smoke
evacuations systems. Get yours today!
ThermoTek, Inc. has been a leader in the
medical device industry for more than 17
years with innovative designs for precision
thermal management solutions. Our newest
introductions for the aesthetic and therapeutic
market are the ArTek Spot™ and the ArTek Air™
which are effective dermal cooling devices for
laser/light based treatments and injectables.
An innovator in the area of skin health,
SkinMedica develops and markets prescription
and non-prescription products to physicians
to treat dermatologic conditions and improve
the appearance of skin. Our line of aesthetic
skin care products enhance skin appearance
and reduce signs of aging and include the
revolutionary TNS Essential Serum™ and
hallmark TNS Recovery Complex®.
Solta Medical. . . . . . . . . . . . . . . . . . . . . 504
Tiemann Surgical . . . . . . . . . . . . . . . . 1601
25881 Industrial Boulevard
Hayward, CA 94545
Phone: 877-782-2286
www.solta.com
Solta Medical is a global leader in the aesthetics
market providing innovative, safe and effective
anti-aging solutions for patients that enhance
and expand the practice of aesthetics for
physicians. The company’s products address skin
issues under the industry’s three premier brands:
Thermage®, Fraxel® and Isolaz™.
72
25 Plant Avenue
Hauppauge, NY 11788
Phone: 800-843-6266
www.georgetiemann.com
Manufacturers of Quality Surgical Instruments
since 1826. Specializing in Instruments and
Accessories for Dermatology, Mohs, Liposuction,
Dermabrasion and Hair Transplant Surgery.
Stop by our booth for ASDS and New Practice
Specials.
TECHNICAL EXHIBITS
U
W
Z
Ulthera, Inc. . . . . . . . . . . . . . . . . . . . . . 1706
Wiley-Blackwell. . . . . . . . . . . . . . . . . . . 707
ZELTIQ . . . . . . . . . . . . . . . . . . . . . . . . . 1507
111 River Street
Hoboken, NJ 07030
Phone: 201-748-8893
www.wiley.com
2150 South Country Club Drive, Suite 21
Mesa, AZ 85210
Phone: 480-619-4069
www.ulthera.com
Combining ultrasound imaging with the ability
to deposit ultrasound thermal energy precisely
below the surface of the skin, Ulthera has
created a unique platform technology for the
aesthetics marketplace. Ultherapy™ is the
first energy-based aesthetics procedure to
receive FDA clearance for “LIFTING” facial skin
tissue. Ulthera’s short, non-invasive procedure
is characterized by reliable results and no
downtime.
UltraShape NA, Inc.. . . . . . . . . . . . . . . 1203
Wiley-Blackwell is the international scientific,
technical, medical and scholarly publishing
business of John Wiley & Sons, with strengths in
every major academic and professional field and
partnerships with many of the world’s leading
societies. For more information, please visit
www.wileyblackwell.com or
http://onlinelibrary.wiley.com/.
Y
Yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . 307
2603 Camino Ramon, 2nd Floor
San Ramon, CA 94583
Phone: 925-242-2585
www.ultrashape.com
50 West 23rd Street, Suite 401
New York, NY 10010
Phone: 877-276-5104
www.yodle.com
UltraShape® has redefined focused ultrasound
with the all new UltraShape Contour I Ver3
multi-application platform. The new multiapplication platform is designed to include
propriety Vertical Dynamic Focus™ (VDF)
ultrasound technology and RFVac™ VacuumAssisted Radio Frequency all in an upright
mobile device. The Contour I Ver3 is not
currently FDA cleared for sale in the US.
Yodle, a leader in local online advertising,
connects thousands of local businesses with
consumers in a process so simple and costeffective that business owners can’t imagine any
other way to advertise. Yodle has developed an
integrated approach to signing up and serving
local businesses that are transitioning their
marketing budgets online.
V
Viora. . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
30 Montgomery Street, Suite 660
Jersey City, NJ 07302
Phone: 201-332-4100
www.vioramed.com
Innovation without compromise, Viora is the
future of medical grade aesthetic devices.
Spawned from an infusion of avant-garde
engineering and laser crafted componentry,
Viora’s aesthetic devices define performance
and sustainability. Strategic support, education
and ongoing training optimize the relationship
between the user and device. Clinically tested,
FDA and CE cleared.
4698 Willow Road
Pleasanton, CA 94588
Phone: 925-474-2500
www.coolsculpting.com
CoolSculpting by ZELTIQ™ is a new, noninvasive procedure that uses advanced cooling
technology to gently and effectively target and
eliminate fat in specific areas of a patient’s body
through Cryolipolysis™.
ZO® Skin Health by Zein Obagi, MD . . 500
3790 Via de la Valle, Suite 311
Del Mar, CA 92014
Phone: 858-794-9601
www.zoskinhealth.com
ZO® Skin Health by Zein Obagi, MD is
redefining skincare technology and delivery
systems to bridge the gap between therapeutic
treatments and daily skincare. His 3-Tiered
skincare program targets all levels of skin
concerns from basic prevention to aggressive
correction. ZO® Skin Health is advancing the
standard of skincare to a new level.
Young Pharmaceuticals, Inc. . . . . . . . . 700
1840 Berlin Turnpike
Wethersfield, CT 06109
Phone: 860-529-7919
www.youngpharm.com
Young Pharmaceuticals, Inc. is a developer and
marketer of practice-branded, medically- based
skin care products exclusively for physicians.
Our product development approach is to apply
pharmaceutical standards of quality, stability and
efficacy to cosmeceutical formulations. Our line
includes topical anti-oxidants, retinoids, acne
treatments and melanin-inhibiting agents.
Viscot Medical, LLC . . . . . . . . . . . . . . . . 701
32 West Street
East Hanover, NJ 07936
Phone: 973-887-9273
www.viscot.com
Viscot has offered the broadest line of Surgical
Skin Markers for over 35 years. Our markers are
high quality and very economical. Introducing
the Mini XL and XL fine tip long lasting ink
marker. These prep resistant markers remain
visible on the skin up to 10x longer than
traditional skin markers.
73
TECHNICAL EXHIBITS
WASHINGTON MARRIOTT WARDMAN PARK
HALLS A & B
100 RESIDENT
KNOWLEDGE
BOWL
108 ASDS RESOURCE
CENTER
La RochePosay
74
(as of October 10, 2011)
Michelle Abadir, MD
Abadir Associates
90 S Ridge St Ste LL3
Rye Brook, NY 10573-2836
(914) 937-5500
Naheed R. Abbasi, MD
Summit Medical Group
1 Diamond Hill Rd
Berkley Heights, NJ 07922
(908) 277-8668
Mark Abdelmalek, MD
Drexel Dermatology
219 N Broad St Flr 4
Philadelphia, PA 19107
(215) 762-5550
Sonya Abdulla, MD
Univ of Toronto
2075 Bayview Ave M1-700
Toronto, ON M4N 3M5
CANADA
(416) 480-4767
Naurin Ahmad, MD
1010 Massachusetts Ave NW
Washington, DC 20010-3017
(202) 877-6654
Bishr Al Dabagh, MD
700 Alexan Dr Apt 304
Durham, NC 27707
Murad Alam, MD
Northwestern Univ
Dept of Dermatology
676 N Saint Clair St Ste 1600
Chicago, IL 60611-2997
(312) 695-6647
Zeena Al-Dujaili, MD
620 W 42nd St Apt 9C
New York, NY 10036
(504) 813-0779
Asra Ali, MD
2950 Cullen Parkway #102
Houston, TX 77024-4508
(281) 980-0166
Carter G. Abel, MD
The Concourse at Beaver Brook
1465 Route 31 S
Annandale, NJ 08801
(908) 735-5100
Janet Allenby, MD
Allenby Dermatology
6290 Linton Blvd Ste 204
Delray Beach, FL 33484
(561) 499-0299
Cheryl Aber, MD
12710 Cyprus Rd
North Miami, FL 33181
(305) 981-0120
Tina S. Alster, MD
Washington Institute of
Dermatologic Laser Surgery
1430 K St NW Ste 200
(202) 628-8855
Amanda Abramson, MD
Texas Dermatology Associates
3900 Junius St Ste 145
Dallas, TX 75246
(972) 386-7546
Jennifer Alston-DeSimone, MD
218 West Springfield St
Chevy Chase, MD 20815-5339
Melanie L. Adams, MD
10700 Charter Dr Ste 320
Columbia, MD 21044-3695
(410) 910-2366
Mohammed A. Alsufyani, MD
PO Box 103053
Riyadh 11695,
SAUDI ARABIA
Judith Adler, MD
PO Box 9507
Rancho Santa Fe, CA 92067
Ahmet Altiner, MD
107 West 82nd St #108
New York, NY 10001
Amr Agha, MD
Advanced Dermatology PC
6043 Prestley Mill Rd Ste B
Douglasville, GA 30134
(770) 739-7546
Steven Altmayer, MD
Univ of Maryland Medical System
Dept of Dermatology
419 W Redwood St Ste 240
Baltimore, MD 21201-7007
(410) 328-5766
David S. Aghassi, MD
Newton Wellesley Dermatology
Associates
65 Walnut St Ste 520
Wellesley, MA 02481
(781) 237-3500
Imran Amir, MD
Family Dermatology
9501 Roosevelt Blvd Ste 508
(610) 764-1003
Joan Agnetti, MD
Laser & Skin Surgery Ctr of New
York
317 E 34th St Ste 11N
New York, NY 10016
(212) 686-7306
Syed Amiry, MD
Reston Dermatology &
Cosmetic Ctr
1830 Town Center Dr Ste 410
Reston, VA 20190
(703) 766-2220
Jennifer Ahdout, MD
Univ of California Irvine
C340 Medical Sciences I
Irvine, CA 92697-2400
(949) 824-4405
David M. Amron, MD
120 S Spalding Dr Ste 315
(310) 275-2467
Ryan W. Ahern, MD
Advanced Dermatologic Surgery
PA
1213 Hermann Dr Ste 650
Houston, TX 77004
(713) 528-8882
Renita Ahluwalia, MD
Univ of Toronto
Toronto, ON M4N 3M5
CANADA
(416) 480-4767
Hina Ahmad, MD
417 S Jefferson Apt 313B
Chicago, IL 60607
L. Anderson, MD
1417 Harmony Ln
Annapolis, MD 21409-5720
Sharon Andrews, MD
Derm Resources
2270 La Vista Dr
Pensacola, FL 32504
(877) 692-0171
Robert T. Anolik, MD
Laser & Skin Surgery Ctr of
New York
317 E 34th St Flr 11
New York, NY 10016
(212) 686-7306
PRE-REGISTRANTS
Katharine Arefiev, MD
Stanford Univ School of Medicine
Dept of Dermatology
450 Broadway Pavilion C
Redwood City, CA 94063
(650) 721-7194
David E. Bank, MD
Ctr for Dermatology, Cosmetic &
Laser Surgery
359 E Main St Ste 4G
Mount Kisco, NY 10549-3035
(914) 241-3003
Eric R. Berg, MD
Univ of Wisconsin Madison
Dept of Dermatology
1 S Park St Flr 7
Madison, WI 53715
(608) 287-2464
SkinCare Physicians
1244 Boylston St Ste 302
(617) 731-1600
Susan Bard, MD
Univ of Miami Miller School of
Medicine
Dept of Dermatology &
Cutaneous Surgery
1600 NW 10th Ave Rm 2023A
Miami, FL 33136
(305) 243-6735
Suzanne Berkman, MD
Washington Hospital Ctr
Dept of Dermatology
110 Irving St NW Rm 2B-44
(202) 877-6654
Reynaldo S Arosemeno, MD
Clinica Dermatologica Aroseuna
Panama,
PANAMA
Mayo Clinic
Dept of Dermatology
200 First St SW
Rochester, MN 55905
(507) 284-5475
Robin Ashinoff, MD
Dermatologic Mohs & Laser
Surgery
360 Essex St Ste 201
Hackensack, NJ 07601
(201) 336-8660
Neda Ashourian, MD
Northwestern Skin Cancer
Institute
737 N Michigan Ave Ste 2310
Chicago, IL 60611
(312) 266-6647
Marc R. Avram, MD
905 5th Ave
New York, NY 10021
(212) 734-4007
Mathew M. Avram, MD
193 Marlborough St Apt #2
Boston, MA 02114
(617) 670-1773
David Avram, MD
905 5th Ave
New York, NY 10021
(212) 734-4007
Robert J. Aylesworth, MD
Doctor’s Park
550 E Timber Dr
Rhinelander, WI 54501-0815
(715) 369-4500
Susan Aylesworth, MD
550 E Timber Dr
Rhinelander, WI 54501-0815
(715) 369-4500
Nedhal Ayoub, MD
175 E 95th St
New York, NY 10128
Yoon-Soo Bae, MD
45 E Newton St Unit 717
Boston, MA 02118
Kristin M. Baird, MD
1551 Professional Ln Ste 135
Loveland, CO 80537
(970) 667-3116
Amir A. Bajoghli, MD
8130 Boone Blvd Ste 340
Vienna, VA 22182-2640
(703) 893-1114
David S. Balle, MD
Grosse Pointe Dermatology
Associates PC
18050 Mack Ave
Grosse Pointe, MI 48230
(313) 886-2600
Joseph P. Bark, MD
Dermatology Consultants
1401 Harrodsburg Rd Ste C-415
Lexington, KY 40504
(859) 278-9492
Channing R. Barnett, MD
Barnett Dermatology
163A E 70th St
New York, NY 10021-5109
(212) 734-2800
Jay G. Barnett, MD
Barnett Dermatology
163A E 70th St
New York, NY 10021-5109
(212) 734-2800
Christian Baum, MD
Mayo Clinic
Dept of Dermatology
200 First St SW
Rochester, MN 55905
(507) 284-5975
Karen L. Beasley, MD
107 Charlcote Rd
Baltimore, MD 21218
(410) 666-3960
David S. Becker, MD
205 E 69th St
New York, NY 10021
(212) 772-3600
Ramona Behshad, MD
345 Fairway Lane
Chesterfield, MO 63122
(314) 878-3839
Ira Bell, MD
Saddleback Dermatology &
Laser Ctr
24432 Muirlands Blvd Ste 219
Lake Forest, CA 92630
(949) 770-8115
Teresa Bell, MD
24432 Muirlands Ste 219
Lake Forest, CA 92630
(949) 374-0902
Anthony V. Benedetto, MD
Dermatologic SurgiCenter
1200 Locust St
(215) 546-3666
Ernest A. Benedetto, MD
2221 Garrett Rd
Drexel Hill, PA 19026
(610) 623-5885
10325 Bannockburn Dr
Santa Monica, CA 90404-2053
(310) 315-0171
Carina Rizzo Bercovici, MD
205 E 69th St Apt 1C
New York, NY 10021
(212) 772-3600
Alexander Berlin, MD
US Dermatology Medical Group
723 N Fielder Rd Ste B
Arlington, TX 76012-4695
(817) 860-6647
Eric F. Bernstein, MD
Laser Surgery & Cosmetic
Dermatology Ctrs
32 Parking Plaza Ste 200
Ardmore, PA 19003-2415
(610) 645-5551
Diane S. Berson, MD
211 E 53 St Ste 3
New York, NY 10022
(212) 355-3511
Vince Bertucci, MD
Bertucci MedSpa
8333 Weston Rd Ste 100
Woodbridge, ON L4L 8E2
CANADA
(905) 850-4415
Ashish Bhatia, MD
The Dermatology Institute of
DuPage Medical Group
2155 City Gate Ln Ste 225
Naperville, IL 60563
(630) 547-5040
Kelly M. Bickle, MD
908 S Dakota Ave
Tampa, FL 33606-3004
Donna Bilu Martin, MD
555 Washington Ave Ste 210
Miami Beach, FL 33139
(305) 672-1233
John Q. Binhlam, MD
Advanced Skin & Laser Ctr
10 Cadilac Dr Ste 120
Brentwood, TN 37027-5078
(615) 843-7546
Jeffrey H. Binstock, MD
Aesthetic Dermatology and
Cosmetic Surgery
22 Battery St No 905
San Francisco, CA 94111-5523
(415) 956-8686
Brittony L. Blakey, MD
11750 Old Georgetown Rd Unit
2133
Rockville, MD 20852
Travis W. Blalock, MD
7955 Playmor Ter
San Diego, CA 92122
Veronique Blatiere, MD
Le Parc Dermatologione
1444 Route de Mende
Le Parc Des Graves Bat B
Montpellier, 34 090
FRANCE
33 467 042122
Birgit C. Blessmann-Gurk, MD
Merz Pharmaceuticals GmbH
Eckenheimer Landstrabe 100
Frankfurt Hessen, 60318
GERMANY
00496915031404
75
PRE-REGISTRANTS
Marc E. Boddicker, MD
Advanced Dermatology Ctr PC
705 Columbus St
PO Box 3468
Rapid City, SD 57709
(605) 343-8000
Harold J. Brody, MD
Hailey, Brody, Casey & Wary
MD PC
1218 W Paces Ferry Rd No 200
Atlanta, GA 30327
(404) 525-7409
Benjamin Bogucki, MD
7717 Delmar Blvd Apt A
Saint Louis, MO 63110-1010
(314) 454-8622
Clarence W. Brown, MD
156 W. Superior
Saint Joseph, MI 49085
(269) 428-5199
Andreas Boker, MD
43 E 10thSt
(415) 353-7839
Marc D. Brown, MD
Univ of Rochester Dermatology
Program
601 Elmwood Ave Box 697
Rochester, NY 14642
(585) 275-9208
Diana Bolotin, MD
5519 S Blackstone Ave
Chicago, IL 60637
Jason D Boyd, MD
840 Rockcreek Rd
Charlottesville, VA 22903
Dermatology & Cancer
Associates
4425 Ponce de Leon Blvd Ste 200
Coral Gables, FL 33146
(305) 443-6606
Jeremy Brauer, MD
Laser and Skin Surgery Ctr of
New York
317 E 34th St
New York, NY 10016
(212) 686-7306
Jean B. Braun, MD
Family Dermatology of PA
105 Bierer Ln Lower Level
Uniontown, PA 15401-3117
(724) 439-2574
Marisa A. Braun, MD
2112 F St NW Ste 701
(202) 994-3093
Aesthetic Dermatology and Laser
Surgery
1009 W Fulton St
Chicago, IL 60607
(312) 733-2492
Jerry D. Brewer, MD
Mayo Clinic
Dept of Dermatology
200 First St SW
Rochester, MN 55905
(507) 284-3579
New York
317 E 34th St
New York, NY 10016
(212) 686-7306
Bruce A. Brod, MD
Dermatology Associates of
Lancaster
1650 Crocked Oak Dr Ste 200
Lancaster, PA 17601-4278
(717) 569-3279
David G. Brodland, MD
Zitelli & Brodland PC
South Hills Medical Bldg
575 Coal Valley Rd
Pittsburgh, PA 15025
(412) 466-9400
Amy C. Brodsky, MD
Brodsky Dermatology
2601 Compass Rd Ste 125
Glenview, IL 60026
(847) 843-3376
76
Alia Brown, MD
Gwinnett Dermatology PC
2383 Pate St
Snellville, GA 30078
(770) 972-4845
Mariah R. Brown, MD
4535 Irving St
Denver, CO 80211
L. Daniel Browne, MD
7555 Gateway Blvd
Newark, CA 94560
(510) 742-3417
Suzanne Bruce, MD
Suzanne Bruce & Assoc PA
1900 Saint James Pl Ste 650
Houston, TX 77056
(713) 850-0240
Vivian W. Bucay, MD
Vivian W Bucay MD PLLC
326 W Craig Pl
San Antonio, TX 78212-3307
(210) 692-3000
A. Thomas Bundy, MD
Hilton Head Dermatology
15 Hospital Center Blvd
Hilton Head Island, SC 29926
(843) 689-9200
Ctr for Dermatology &
The Professional Aesthetic
Image Ctr
2311 M St NW Ste 504
(202) 955-5757
Christopher Burnett, MD
39657 Springwater Dr
Northville, MI 48168
Goldman, Butterwick, Fitzpatrick
& Groff
Cosmetic Laser Dermatology
9339 Genesee Ave Ste 300
San Diego, CA 92121
(858) 657-1002
Erik Cabral, MD
Dept of Dermatology
450 Broadway Pavilion C MC
5334
(650) 721-7194
Callender Skin & Laser Ctr
12200 Annapolis Road No 315
Glenn Dale, MD 20769
(301) 249-0970
Ivan Camacho, MD
79 SW 12th St Unit 1107
Miami, FL 33130
Rahel Campbell, MD
819 N Harbor Dr #400
Miguel G. Canales, MD
Restoration Robotic Inc
1383 Shore Bird Way
(650) 965-3612
Marilyn R. Capek, MD
955 Main St Ste 308
Winchester, MA 01890
(781) 729-3150
Elizabeth Gaines Cardone, MD
SUNY Downstate Medical Ctr
Dept of Dermatology
450 Clarkson Ave (Box 46)
Brooklyn, NY 11203
(718) 270-1229
10720 Oregon Ave
Culver City, CA 90232
(630) 638-6380
Pamela M. Carr, MD
Carr Dermatology of Sugar
Land TX
1111 Hwy Six Ste 160
Sugar Land, TX 77478
(281) 494-0034
David R. Carr, MD
199 S 5th St Unit 602
Columbus, OH 43215
Alastair Carruthers, MD
Carruthers Dermatology Centre
Inc
943 W Broadway Ste 820
Vancouver, BC V5Z 4E1
CANADA
(604) 714-0222
Jean Carruthers, MD
Dr Jean Carruthers Cosmetic
Surgery Inc
820 - 943 W Broadway
CANADA
(604) 714-0222
Todd V. Cartee, MD
1093 Derry Woods Dr
Atlanta, GA 30322
(404) 727-3669
John A. Carucci, MD
NYU Dermatologic Surgery
Associates
530 First Ave Ste 7H
New York, NY 10016
(212) 263-7019
Leslie Caudill, MD
ECU Brody School of Medicine
Dept of Dermatology
600 Moye Blvd Brody 3E-117
Greenville, NC 27834-4300
(252) 744-2555
Ashley N. Cauthen, MD
Univ of South Florida College of
Medicine
Cutaneous Surgery
12901 Bruce B Downs Blvd
MDC 79
Tampa, FL 33612-4799
(813) 974-3070
Alex Cazzaniga, MD
(305) 433-6606
Sarah J. Cely, MD
Augusta Dermatology Associates
820 Saint Sebastian Way Ste 6C
Augusta, GA 30901
(706) 722-4280
Joanna Lai-Hwa Chan, MD
122 41st St
Plano, TX 75024-4718
(972) 491-1481
Chung-Yin Stanley Chan, MD
133 Beaconfield Rd Ste 42
Brookline, MA 02445
Byalakere Shivanna
Chandrashekar, MD
#20 3rd Cross Opposite Chandra
Layout Police Station
Next to Chandra Public School
Chandra Layout
Vijaynagar
Bangalore Karnataka, 560040
INDIA
080 23181058
Sabatino Ciatti, MD
Advanced Derm Mohs & Laser
Surgery Ctr
240 E Grove St
Westfield, NJ 07090
(908) 232-7235
David Hermogenes Ciocon, MD
912 Cherokee LN
Franklin Lakes, NJ 07417
(201) 891-8360
C. Drew Claudel, MD
Rivergate Dermatology PLLC
201 Bluebird Dr
Goodlettsville, TN 37072-2301
(615) 859-7546
Agnes Ju Chang, MD
Washington, DC 20037
(202) 293-3990
Lloyd J. Cleaver, MD
Cleaver Dermatology
700 W Jefferson St
PO Box 7545
Kirksville, MO 63501-7545
(660) 626-2191
Jeaneen Chappell, MD
5834 Prince George Court
(314) 256-3433
Donald E. Clemons, MD
720 Harbor Point Drive
Johnson City, TN 37604
(423) 929-7546
Peggy L. Chern, MD
1606 W 14th St
Austin, TX 78746
(512) 328-3376
M. David Cogburn, MD
28 Hilltop Road
Arden, NC 28704-9784
(828) 684-0703
Basil S. Cherpelis, MD
USF College of Medicine
Cutaneous Surgery
MDC 79
Tampa, FL 33612
(813) 974-3856
Joel L. Cohen, MD
AboutSkin Dermatology &
DermSurgery PC
499 E Hampden Ave Ste 450
Englewood, CO 80113
(303) 756-7546
Cameron Chesnut, MD
UCLA Div of Dermatology
52-121 CHS
10833 Le Conte Ave
(310) 825-9182
William P. Coleman, MD
4425 Conlin St
Metairie, LA 70006-2123
(504) 455-3180
Kyle Coleman, MD
8825 Bee Caves Road
Marble Falls, TX 78654
(830) 693-4800
Rodolfo Chirinos, MD
2400 16th St NW Apt 442
Kristina M. Collins, MD
600 Washington St Apt 12K
Boston, MA 02111
Catherine Choi, MD
Drexel Univ College of Medicine
Dept of Dermatology Mail Stop
401 HUH
(215) 762-5550
Samantha Bader Conrad, MD
La Grange
5201 S Willow Springs Rd Ste 430
La Grange, IL 60525
(708) 482-3213
May J. Chow, MD
Well Group Health Partners
333 Dixie Hwy
Chicago Heights, IL 60411
(708) 709-6385
Gary S. Chuang, MD
62 Boylston St Apt 920
Boston, MA 02116-4795
Kee-Yang Chung, MD
Yonsei Univ College of Medicine
Dept of Dermatology
134 Shinchon-dong
Seodaemoontu Ku
Seoul, 120 752
SOUTH KOREA
82 222282080
Joel Cook, MD
Medical Univ of South Carolina
135 Rutledge Ave Box 250578
Flr 11
Charleston, SC 29425
(843) 792-5858
Duke Univ Medical Ctr
Box 3915
Durham, NC 27710-3915
(919) 419-4945
Alicia Cool, MD
360 State St Apt 1809
New Haven, CT 06510
Vinh Chung, MD
Vanguard Skin Specialists
8890 N Union Blvd Ste 171
Colorado Springs, CO 80920
(719) 355-1585
Murray A. Cotter, MD
Dermatology Associatess of
Northern Michigan PC
2240 Mitchell Park Dr
Petoskey, MI 49770
(231) 487-2230
Jennifer L. Chwalek, MD
510 West 52nd St 5M
Hackensack, NJ 07601
(201) 441-9890
L. Courrege, MD
3904 Oleander Dr Ste 102
Wilmington, NC 28403-6717
(910) 452-0400
Seana Patrice Covello, MD
Pine St Dermatology
621 Pine St
(215) 574-9101
John Cowan, MD
Bowling Green Dermatology &
Skin Cancer Specialists
1106 Fairway St
Bowling Green, KY 42103
(270) 783-8003
Sue Ellen Cox, MD
Aesthetic Solutions PA
5821 Farrington Rd Ste 101
Chapel Hill, NC 27517
(919) 403-6200
David L. Cram, MD
2525 Dupont Drive
Piedmont, CA 94611-3827
(510) 547-1824
Katherine L. Craven, MD
840 Rockcreek Rd
Dept of Dermatology
PO Box 800718
Charlottesville, VA 22908-0718
(434) 924-5115
Maryliam Crespi, MD
145 E 32nd St 7th Floor
New York, NY 10016
(212) 684-2626
Terrence A. Cronin, MD
1399 S Harbor City Blvd
Melbourne, FL 32901-3208
(321) 726-1711
Antonio P. Cruz, MD
Brown Univ/Rhode Island
Hospital
Dept of Dermatology APC Flr 10
593 Eddy St
Providence, RI 02903-4923
(401) 444-7024
Kyle Cullingham, MD
8207-415 Hunter Rd
Edmonton, AB T6G 2G3
CANADA
(780) 407-1257
Natalie M. Curcio, MD
1421 Wexford Downs Ln
Nashville, TN 37211
(615) 364-5200
Trenton Custis, MD
52-121 CHS
10833 Le Conte Ave
(310) 825-9182
Erin Dahlke, MD
Univ of Toronto
Toronto, ON M4N 3M5
CANADA
(416) 480-4767
Natalie H. Daniels, MD
Associates in Dermatology
Women’s Pavilion III
4121 Dutchmans Ln Ste 403
Louisville, KY 40207
(502) 897-2599
Lance Davis, MD
Scott and White Clinic
Dept of Dermatology
409 W Adams
Temple, TX 76501-4211
(254) 742-3775
Jeremy Davis, MD
The MetroHealth System
Dermatology
2500 Metro Health Dr
Cleveland, OH 44109
(216) 778-5324
Manju Chacko Dawkins, MD
88 Greenwich St Unit 1404
New York, NY 10006
Aerlyn G. Dawn, MD
Dermatology & Advanced Skin
Care
6021 University Blvd Suite 390
Elliott City, PA 19010
(443) 257-0849
Gail C. de Imus, MD
The Everett Clinic
Mohs Laser & Skin Surgery
3726 Colby Ave
Everett, WA 98201
(425) 257-1450
Arthur J. Dean, MD
Anderson Derm & Skin Surgery
Ctr LLC
1501 N Main St
Anderson, SC 29621-3278
(864) 716-0063
Cynthia DeKlotz, MD
Dept of Dermatology
(202) 877-6654
Amy Delaney, MD
Geisinger Medical Ctr
Dept of Dermatology
115 Woodbine Ln
Danville, PA 17822-5206
(570) 271-8074
Amena DeLuca, MD
John Hopkins Univ School of
Medicine
Dept of Dermatology
601 N Caroline St Flr 6
Baltimore, MD 21287
(410) 955-2400
Amy Derick, MD
Derick Dermatology
1531 S Grove Ave Ste 101
Barrington, IL 60010
(847) 381-8899
Tara Dever, MD
4559 Narragansett Ave
San Diego, CA 92134-2300
(619) 532-9666
Christine DeWitt, MD
2601 Woodley Pl NW #1103
Bethesda, MD 20892
(301) 443-5004
Niteen V. Dhepe, MD
Skin City PG Institute of
Dermatology
Runcoal Regency
Sadhu Waswani Chowk
Pune Maharashtra, 411001
INDIA
91 98 90225599
Stephanie A. Diamantis, MD
3107 Brassfield Rd Ste 300
Greensboro, NC 27410
(402) 659-6244
Melissa Diamantis, MD
Texas Tech Univ Health
Sciences Ctr
Dept of Dermatology MS 9400
3601 4th St
Lubbock, TX 79430
(806) 743-2456
William I. Dillon, MD
Dillon Dermatology Inc
1037 Conneaut St Ste 201
Bowling Green, OH 43402
(419) 373-6046
PRE-REGISTRANTS
Adrian Dobrescu, MD
5333 Prytania St
New Orleans, LA 70115
(504) 909-9584
Jeremy R. Etzkorn, MD
3613 W Tacon St
Tampa, FL 33629
(217) 553-5373
Patrick Dominguez, MD
Harbor-UCLA Medical Ctr
Div of Dermatology Hanley
Hardison Bldg
1124 W Carson St
Torrance, CA 90502
(310) 781-1407
5771 Mission Center Rd Apt 206
Daven Doshi, MD
5243 Riverside Dr Apt 1112
Macon, GA 31210
SkinCare Physicians
(617) 731-1600
Image Dermatology PC
51 Park St
Montclair, NJ 07042
(973) 509-6900
Zoe D. Draelos, MD
2444 N Main St
High Point, NC 27262
(336) 841-2040
Jordan Fabrikant, MD
2901 Cityplace W Blvd Apt 625
Dallas, TX 75204
Tarek Fakhouri, MD
26931 Van Buren
Dearborn, MI 48124
(313) 429-7847
William L. Fangman, MD
Piedmont Plastic Surg &
Dermatology
959 Cox Rd
Gastonia, NC 28504
(704) 866-7576
Patricia Farris, MD
Old Metairie Dermatology
701 Metairie Rd Ste A205
Metairie, LA 70005
(504) 836-2050
Anna Drosou, MD
1420 Brickell Bay dr apt 706
Pembroke Pines, FL 33028
(954) 435-5100
Mark E. Fenster, MD
Dermatologists of Southwest
Ohio Inc
Dover Medical Bldg
5300 Far Hills Ave Ste 215
Dayton, OH 45429-2381
(937) 291-8814
Raymond G. Dufresne, MD
Univ Dermatology Inc
593 Eddy St
Providence, RI 02903-4923
(401) 444-7024
Douglas Fife, MD
Surgical Dermatology & Laser Ctr
9280 W Sunset Rd Ste 310
Las Vegas, NV 89148
(702) 255-6647
Alison Ehrlich, MD
George Washington Univ
Medical Faculty Associates
Dept of Dermatology
2150 Pennsylvania Ave NW Flr 2
(202) 741-2627
Lauren A. Fine, MD
3000 N Halstead Ste 409
Chicago, IL 60657
(773) 271-9200
Michael E. Eidelman, MD
Chelsea Skin & Laser
245 West 19th St
New York, NY 10011-6609
(212) 675-0549
Khaled H. El Hoshy, MD
Somerset Dermatology Institute
14555 Levan Rd Ste 410
Livonia, MI 48154
(734) 462-9499
Nada Elbuluk, MD
951 Fell St Apt 828
Baltimore, MD 21231
Yehia Farouk Elgarem, MD
Alexandria Univ
Dept of Dermatology
Faculty of Medicine
Alexandria,
EGYPT
0020106696232
Lixia Ellis, MD
Univ of Colorado School of
Medicine
1665 Aurora Ct MS F703
Aurora, CO 80045
(720) 848-0510
Jeremy P. Finkle, MD
Northeast Dermatology
Associates
401 Andover St Ste 101
North Andover, MA 01845
(978) 691-5690
Eric Finzi, MD
Chevy Chase Cosmetic Ctr
8401 Connecticut Ave Ste 210
Chevy Chase, MD 20815
(240) 482-2555
Galen H. Fisher, MD
Richmond
7001 Forest Ave Ste 301
Richmond, VA 23230
(804) 855-0372
Emily J. Fisher, MD
Lahey Clinic
Dept of Dermatology
41 Mall Rd
(781) 744-8348
Rebecca Fitzgerald MD Inc
321 N Larchmont Blvd Ste 906
(323) 464-8046
Sorin Eremia, MD
Brockton Cosmetic Surgery Ctr
4440 Brockton Ave Ste 200
Riverside, CA 92501-4026
(951) 275-0988
Timothy Flynn, MD
Cary Skin Ctr
200 Wellesley Trade Ln
Cary, NC 27519
(919) 363-7546
Quenby Erickson, MD
4100 Laclede Ave Ste 102
Saint Louis, MO 63108
(314) 533-4525
S. Ford, MD
68 Thomas Johnson Dr No C
Frederick, MD 21702-4300
(301) 694-5292
Scott W. Fosko, MD
Saint Louis Univ
Dept of Dermatology
1402 S Grand Blvd
(314) 256-3433
Jeanne M. Franck, MD
520 Franklin Ave Ste 207
Garden City, NY 11530
(516) 741-1055
Paul J. Frank, MD
Paul Jarrod Frank MD PC
1049 5th Ave Ste 2B
New York, NY 10028
(212) 327-2919
Yelena Mirensky Frankel, MD
7201 Denberg Rd Ste A
Baltimore, MD 21209
Arden Fredeking, MD
(202) 877-6654
6625 Brompton Rd
Houston, TX 77005
(713) 492-2978
David J. Friedman, MD
Kahanov Six
Jerusalem, 92472
ISRAEL
972 2 5635673
Jennifer Fu, MD
6431 Fairmount Ave Ste 3
El Cerrito, CA 94530
(510) 527-8865
Juian-juian Liu Fu, MD
4834 Socialville-Foster Ste 20
Mason, OH 45040
(513) 459-1988
Charles S. Fulk, MD
Dermatology & Cosmetic Laser
Surgery
400 E Economy Rd Ste 8
Morristown, TN 37814-3736
(423) 587-4600
Francesca J. Fusco, MD
Wexler Dermatology PC
145 E 32nd St
New York, NY 10016
(212) 684-2626
Tanya Futoryan, MD
Westport Dermatology &
Laser Ctr
489 Post Rd E
Westport, CT 06880-4435
(203) 226-3600
Hassan Galadari, MD
Galadari Derma Clinic UAE Univ
PO Box 8716
Dubai, UNITED ARAB EMIRATES
971 4 348 4855
Stephanie Gan, MD
Boston Univ School of Medicine
Dept of Dermatology
609 Albany St
Boston, MA 02118-2515
(617) 638-5534
Kathryn B. Gant, MD
1506 Stack St
Baltimore, MD 21230
Algin B. Garrett, MD
Virginia Commonwealth Univ
Medical Ctr
9000 Stong Point Parkway
Richmond, VA 23235
(804) 560-8919
77
PRE-REGISTRANTS
Michele E. Gasiorowski, MD
Greenwich Dermatology &
Cosmetic Laser Surgery Ctr
40 W Elm St
Greenwich, CT 06830-6463
(203) 661-7546
Henry C. Gasiorowski, MD
Greenwich Dermatology &
Cosmetic Laser Surgery Ctr
40 W Elm St
Greenwich, CT 06830-6463
(203) 661-7546
1035 Fifth Ave
New York, NY 10028
(212) 288-8222
Marguerite A. Germain, MD
Germain Dermatology
Associates PA
612 Seacoast Pkwy
Mount Pleasant, SC 29464
(843) 881-4440
New York
New York, NY 10016
(212) 686-7306
Nima Gharavi, MD
52-121 CHS
10833 Le Conte Ave
(310) 825-3352
Joseph M. Giancola, MD
Southwest Skin Specialists LTD
11130 N Tatum Blvd Ste 100
Phoenix, AZ 85028-1630
(602) 494-1817
Jing F. Gill, MD
757 Huron St
Shreveport, LA 71106
Montgomery O. Gillard, MD
IHA Dermatologic Associates
4990 W Clark Rd Bldg A Ste 200
Ypsilanti, MI 48197
(734) 572-7500
24040 Oak Knoll Cir
Los Altos Hills, CA 94022
Dee Anna Glaser, MD
Saint Louis Univ
Dept of Dermatology
2315 Dougherty Ferry Rd Ste
200C
(314) 977-9666
Stanley F. Glazer, MD
New England Dermatology
Laser Ctr
3455 Main St Ste 5
Springfield, MA 01107
(413) 733-9600
350 Parnassus Ave Ste 400
(415) 564-1261
Hugh M. Gloster, MD
Univ of Cincinnati
4460 Red Bank Rd Ste 130
(513) 821-3376
Ryan Goerig, MD
Thomas Jefferson Univ Hospital
Dept of Dermatology
833 Chestnut St Ste 740
(215) 955-6680
78
Ravinder S. Gogia, MD
Univ of California San Francisco
Dept of Dermatology
1701 Divisadero St Flr 3
Box 0316
(415) 353-9610
David J. Goldberg, MD
Skin Laser & Surgery Specialist
105 Raider Blvd Ste 203
Hillsborough, NJ 08844
(908) 359-8980
Leonard H. Goldberg, MD
DermSurgery Associates
7515 S Main St Ste 240
(713) 791-9966
Goldman, Butterwick, Fitzpatrick
& Groff
Cosmetic Laser Dermatology
9339 Genesee Ave Ste 300
San Diego, CA 92121
(858) 657-1002
Univ of Vermont Medical Group
at Fletcher Allen
Div of Dermatology
111 Colchester Ave WP5
Burlington, VT 05401
(802) 847-5743
Samuel D. Goos, MD
Adult & Pediatric Dermatology PC
242 Baker Ave Ste 302
Concord, MA 01742-2195
(978) 371-7010
Sheldon K. Gottlieb, MD
900 New Hampshire Ave NW
(202) 333-1907
Bombay Hospital
502 Asmita Meeta Kunj CHS
14th Rd
Khar W
Mumbal Maharashtra, 400052
INDIA
91 976 9966696
Emmy M. Graber, MD
Boston Medical Ctr
Dept of Dermatology
609 Albany St J-203
Boston, MA 02118
(617) 848-1613
Donald J. Grande, MD
Mystic Valley Dermatology
Associates PC
92 Montvale Ave Ste 3000
Stoneham, MA 02180-3636
(781) 438-6350
Jeremy B. Green, MD
(305) 443-6606
Lawrence J. Green, MD
15005 Shady Grove Rd Ste 440
Rockville, MD 20850
(301) 610-0663
Roy C. Grekin, MD
UCSF Dermatology
(415) 353-7839
Pearl E. Grimes, MD
Vitiligo and Pigmentation
Institute
5670 Wilshire Blvd Ste 650
(323) 467-4389
Michele Grodberg, MD
Contemporary & Cosmetic
Dermatology
106 Grand Ave Ste 330
Englewood, NJ 07631-3570
(201) 567-8884
Steven L. Harlan, MD
Dermatology & Dermatologic
Surgery Ctr PC
8131 University Blvd
Clive, IA 50325
(515) 225-8180
Howard Hines, MD
Penisula Dermatology
Associates PA
106 Milford St Ste 301
Salisbury, MD 21804-6962
(410) 546-4431
Karyn L. Grossman, MD
Grossman Dermatology
1301 Twentieth St No 350
Santa Monica, CA 90404-2075
(310) 998-0040
Surgical Dermatology Group
2000 Stonegate Trl Ste 112
Birmingham, AL 35242
Julia Ho, MD
Kaiser
836 SW Curry St Ste 1804
Portland, OR 97239
Joanna Harp, MD
Univ of California San Francisco
Dept of Dermatology
Box 0316
(415) 353-9610
Alfred J. Hockley, MD
Dermatology Associates of S
an Antonio
7832 Pat Booker Rd
San Antonio, TX 78233
(210) 657-9338
Tatyana Groysman, MD
2001 Hamilton St Apt 319
Anna D. Guanche, MD
Bella Skin Institute
23622 Calabasas Rd Ste 339
Calabasas, CA 91302-1594
(818) 225-0117
Michael Haeberle, MD
Stuttgarter St 5
D-74653 Kuenzelsau
Kuenzelsau, 74653
GERMANY
49 7940 985100
Elizabeth K. Hale, MD
Laser & Skin Surgery Ctr of New
York
New York, NY 10016
(212) 686-7306
Peter S. Hallarman, MD
Dermatology Partners of the
North Shore
400 Skokie Blvd Ste 475
Northbrook, IL 60062
(847) 272-4433
Shelley J. Halper, MD
La Grange
5201 S Willow Springs Rd Ste 430
La Grange, IL 60525
(708) 482-3213
Anne Han, MD
Medicine
Dept of Dermatology
Baltimore, MD 21287
(410) 955-2400
Sandra Han, MD
132 Duncan St Apt 6
C. William Hanke, MD
Indiana
13400 N Meridian St Ste 290
Carmel, IN 46032-7122
(317) 660-4900
Allison Hanlon, MD
40 Temple St Ste 5A
New Haven, CT 06510
(203) 785-3466
Timothy Hansen, MD
Penn State Milton S Hershey
Medical Ctr
Dept of Dermatology HU14
UPC II
500 University Dr Ste 4300
Hershey, PA 17033-2391
(717) 531-6049
Daniel Hansen, MD
Northern Utah Dermatology
6028 S Ridgeline Dr Ste 102
Ogden, UT 84405
(801) 399-3324
Paul E. Harrison, MD
True Skin Dermatology &
Surgery Inc
10011 S Centennial Pkwy Ste 200
Sandy, UT 84070
(801) 255-7546
Virgil Hatcher, MD
Chelsea Dermatology
420 W 23rd St Ste A GF
New York, NY 10011
(212) 675-4244
Faris Hawit, MD
Calvert Dermatology LLC
PO Box 1540
Prince Frederick, MD 20678
(410) 535-4561
Christine M. Hayes, MD
237 Upland Ave
49 Walnut Pk Bldg 4
Wellesley Hills, MA 02481
(781) 431-0060
Nicole Hayre, MD
Cosmetic Dermatology Ctr
8405 Greensboro Dr Ste 110
McLean, VA 22102
(703) 827-8600
William L. Heimer, MD
Surfside Dermatology
320 Santa Fe Dr Ste 310
Encinitas, CA 92024
(760) 944-7000
C. Lenny Henderson, MD
Univ of Oklahoma Health
Sciences Ctr
Dept of Dermatology
619 NE 13th St
Oklahoma City, OK 73104-5001
(405) 271-4662
Courtney R. Herbert-Joubert, MD
FDL Dermatology PLLC
1715 N George Mason Dr Ste 406
Arlington, VA 22205
(703) 310-7400
Alysa R. Herman, MD
2451 Brickell Ave Apt 6H
Miami, FL 33129
(305) 858-1229
Jordana Herschthal, MD
Medicine
Cutaneous Surgery
Miami, FL 33136
(305) 243-6735
Bryan C. Hicks, MD
Marion Dermatology
5349 SW College Rd Ste 2
Ocala, FL 34474
(352) 368-5858
Carlin B. Hollar, MD
Central Carolina Dermatology
Clinic Inc
404 Westwood Ave Ste 107
High Point, NC 27262-4326
(336) 887-3195
Tyler Hollmig, MD
Dept of Dermatology
(650) 721-7194
Todd E. Holmes, MD
at Fletcher Allen
Div of Dermatology
(802) 847-4570
William D. Holmes, MD
UConn Health Ctr
Dept of Dermatology
263 Farmington Ave MC 6231
Farmington, CT 06030-6231
(860) 679-6759
Shaolin Hong, MD
Beijing Jingcheng Skin Diseases
Hospital
Deshengmen Wai Shuangquanpu
Jia No 4
Chaoyang District
Beijing, 100101
CHINA
86 136 41263110
Michael Horn, MD
Auenbruggerplatz 8
Graz A-8036
AUSTRIA
43-316-38580319
Mikhenan Horvath, MD
Cleveland Clinic Foundation
Dept of Dermatology A61
9500 Euclid Ave
Cleveland, OH 44195-0002
(216) 444-5933
Stephen N. Horwitz, MD
2999 NE 191st St Ste PH1
Aventura, FL 33180
(305) 933-1151
Elizabeth Houshmand, MD
2260 Lehigh Pkwy N
North Allentown, PA 18103
Kenneth L. Howe, MD
145 E 32nd St
New York, NY 10016
(212) 684-2626
George J. Hruza, MD
1001 Chesterfield Pkwy E Ste 101
Chesterfield, MO 63017
(314) 878-3839
Francis Hsiao, MD
Univ of California Davis School of
Medicine
Dept of Dermatology
3301 C St Ste 1400
Sacramento, CA 95816-3367
(916) 734-6371
Jeffrey T.S. Hsu, MD
The Dermatology Institute of
DuPage Medical Group
(630) 547-5040
Jenny Hu, MD
200 Medical Plaza Ste 450
(310) 917-3376
Susan J. Huang, MD
1 Emerson Pl Unit 11-O
Boston, MA 02114
(301) 294-6564
Kristin Hudacek, MD
Drexel Univ College of Medicine
Dept of Dermatology Mail Stop
401 HUH
(215) 762-5550
Shannon Humphrey, MD
Carruthers Dermatology
Centre Inc
820-943 W Broadway
CANADA
(604) 714-0222
Tatyana R. Humphreys, MD
306 Gypsy Ln
Winwood, PA 19107
(215) 955-4118
Dori L. Hunt, MD
Piedmont Plastic Surgery &
Dermatology
315 19th St SE
Hickory, NC 28602-4230
(828) 325-9849
Niquette Hunt, MD
7555 Gateway Blvd
Newark, CA 94560
(650) 641-0224
Christin C. Hurt, MD
7822 Walmsley Ave
(504) 866-4665
Sadaf Hussain, MD
Thomas Jefferson Univ Hospital
Dept of Dermatology
833 Chestnut St Ste 740
(215) 955-6680
Omar Ibrahimi, MD
27 Lexton Dr
Farmington, CT 06032
(917) 301-3781
Adam Ingraffea, MD
634 Sycamore St Apt 4N
(401) 368-8847
Scott Isenhath, MD
Skin Surgery Center PS
3655 NE 73rd St
Seattle, WA 98115-5980
(503) 246-1567
Vivek Iyengar, MD
627 E Sixth St
Tinley Park, IL 60477
(708) 444-8300
Brooke A. Jackson, MD
Skin Wellness Ctr of Chicago SC
111 N Wabash Ave Ste 1116
Chicago, IL 60602
(312) 236-9950
Jeremy Jackson, MD
Univ of Alabama at Birmingham
Dept of Dermatology
1530 3rd Ave S EFH 414
(205) 975-4917
Carolyn I. Jacob, MD
Chicago Cosmetic Surgery and
Dermatology
20 W Kinzie Ste 1130
Chicago, IL 60654
(312) 245-9965
PRE-REGISTRANTS
Alexandre Kaoukhou, MD
2525 Dupont Dr T12N
Irvine, CA 92612
(714) 246-2802
Christine C. Kim, MD
908 20th St Apt A
Santa Monica, CA 90403
3105816514
Shauna K. Kranendonk, MD
1660 S A1A No 322
Jupiter, FL 33477
(561) 694-9493
Baruch Kaplan, MD
Baruch Kaplan MD
165 Derech Hamelech
Givat Shmuel, 54 425
ISRAEL
972 39192020
Chesahna Kindred, MD
Howard Univ Hospital
Dept of Dermatology
2041 Georgia Ave NW
(202) 865-6725
Jessica J. Krant, MD
Art of Dermatology LLC
860 Fifth Ave Ground Flr
New York, NY 10065
(212) 488-5599
Athena G. Kaporis, MD
Westchester Health Associates
Dermatology Division
185 Kisco Ave Ste 3
Mount Kisco, NY 10549
(914) 242-2020
Leon H. Kircik, MD
Physicians Skin Care
1169 Eastern Pkwy Ste 2310
Louisville, KY 40217-1417
(502) 456-2783
David Kasper, MD
3338 Woodland Cir
Huntington Valley, PA 19006
Norma H. Kassardjian, MD
Jeffrey A Klein MD Inc
30280 Rancho Viejo Rd
(949) 248-1632
Andrea Kassim, MD
535 N Michigan Ave Apt 1112
Chicago, IL 60611
Brent Kirkland, MD
250 Durand Way
Palo Alto, CA 94304
(216) 262-2613
Anna I. Kirkorian, MD
UMDNJ-Robert Wood Johnson
Medical School
Dept of Dermatology
1 Worlds Fair Dr Ste 2400
Somerset, NJ 08873-1344
(732) 235-7765
Bruce E. Katz, MD
Juva Skin & Laser Ctr
60 E 56th St Flr 2
New York, NY 10022
(212) 688-5882
Lynn M. Klein, MD
Lankenau Medical Ctr
MOB East Ste 461
100 Lancaster Ave
Wynnewood, PA 19096
(610) 642-2570
Andrew J. Kaufman, MD
The Ctr for Dermatology Care
267 W Hillcrest Dr
Thousand Oaks, CA 91360
(805) 497-1694
Jeffrey A. Klein, MD
Jeffrey A Klein MD Inc
30280 Rancho Viejo Rd
(949) 248-1632
Jesse Jensen, MD
12340 Kenilworth Dr
Sterling Heights, MI 48313
Joely Kaufman, MD
Dermatology & Cancer
Associates
(305) 443-6606
Alan D. Klein, MD
3425 Candlewick Way
Gastonia, NC 28056
(704) 516-2804
A. Johnson, MD
1211 Sarah Drive
Silver Springs, DC 20017
(202) 526-4454
1044 Fifth Ave
New York, NY 10028
(212) 249-9440
Hillary D. Johnson-Jahangir, MD
1305 York Ave F19
New York, NY 10040
(314) 239-6035
Amelia H. Kaymen, MD
3905 Sacramento St Ste 303
(415) 933-8490
Derek H. Jones, MD
Skin Care & Laser Physicians of
Beverly Hills
9201 W Sunset Blvd Ste 602
Los Angeles, CA 90069-1769
(310) 246-0495
Rebecca A. Kazin, MD
Johns Hopkins Cosmetic Ctr
Pavilion One Ste 350
10755 Falls Rd
Lutherville, MD 21093
(410) 847-3767
Nikolaos Kalogeropoulos, MD
Derma Aesthetic Clinic
Vas Georgiou & Kountouriotou 147
Piraeus Attica, 18535
GREECE
30 210 4122095
Sonya Kenkare, MD
Univ of Chicago Medical Ctr
Section of Dermatology
5841 S Maryland Ave MC 5067
(773) 702-6559
Michael S. Kaminer, MD
SkinCare Physicians
(617) 731-1600
Kathryn Kent, MD
2 Draper St Apt 2A
Carlton, MA 02021
Reza Jacob, MD
Dept of Dermatology
609 Albany St
Boston, MA 02118-2515
(617) 638-5534
Ariyanto JahJa, MD
New York, NY
Frances L. Jang, MD
Skinworks
3568 W 41st Ave
Vancouver, BC V6N 3E6
CANADA
(604) 737-7100
Melda A. Isaac, MD
Melda Isaac MD PC
2440 M St NW Ste 703
(202) 393-7546
Edidiong Ntuen Kaminska, MD
Univ of Chicago Medical Ctr
5841 S Maryland Ave MC 5067
(773) 702-6559
Dale H. Isaacson, MD
Drs Isaacson & Berzin LLC
1820 L Street NW Ste 850
(202) 822-9591
Jeremy T. Kampp, MD
921 11th St
(650) 269-8559
Douglas J. Key, MD
Key Laser Institute for Aesthetic
9555 SW Barnes Rd Ste 390
Portland, OR 97225
(503) 291-1953
Laser and Skin Surgery Ctr
3835 J St
Sacramento, CA 95816
(916) 456-0400
Yekaterina Kleydman, MD
2650 Ocean Pkwy Apt 12M
Brooklyn, NY 11235
(646) 388-0537
Mitchell A. Kline, MD
700 Park Ave
New York, NY 10021
(212) 517-6555
Laura McCaskill Kline, MD
3316 Darrah Ave
Morgantown, WV 26508
Nita Kohli, MD
Univ Hospitals/Case Medical Ctr
Dept of Dermatology
11100 Euclid Ave
(216) 844-5794
Alexandria S. Kongsiri, MD
5253 Central Ave
Saint Petersburg, FL 33701
(727) 388-6982
Sandra A. Kopp, MD
Cooper Univ Hospital
Three Cooper Plz Ste 220
Camden, NJ 08103-1438
(856) 342-2014
UBC Dept of Dermatology and
Skin Science
Flr 3 835 W 10th Ave
CANADA
(604) 875-4111
David Kouba, MD
3846 Sulphur Spring Rd
Ottawa Hills, OH 43606
(419) 754-1282
Mark Krasny, MD
305 Elm Ave
Westmount, QC H3Z 1Z4
CANADA
(514) 770-0515
Madeline C. Krauss, MD
Krauss Dermatology
1 Washington St Ste 401
Wellesley Hills, MA 02481-1737
(781) 416-3500
Niels Krejci, MD
BU Ctr for Cosmetic & Laser
Surgery
930 Commonwealth Ave W
Boston, MA 02215
(617) 414-6760
Julia Kwan, MD
Naval Medical Ctr
Dermatology Dept
34520 Bob Wilson Dr Ste 300
(619) 532-9666
Soonyou Kwon, MD
5435 Watertower Ct Apt 293
Oh Sang Kwon, MD
Department of Dermatology
Seoul National University Hospital
Seoul, 110-794
SOUTH KOREA
Barry A. LaBine, MD
CentraCare Dermatology Dept
1900 CentraCare Cir Ste 2575
Saint Cloud, MN 56303-5000
(320) 240-4924
Philippe Lafaille, MD
35 Tsse les Hautvilliers
Outremont, QC H2V 4P1
(438) 887-9464
Marina Landau, MD
56 Joshua Ben Nun St
Herzlia, 46763
ISRAEL
972 9 9505151
Gary Lask, MD
UCLA Medical Ctr
Dept of Dermatology
200 UCLA Medical Plz Ste 465
(310) 825-5420
David A. Laub, MD
Laub Dermatology & Aesthetics
591 Redwood Hwy Ste 2210
Mill Valley, CA 94941-6003
(415) 381-6661
Kerry A. Lavigne, MD
Dept of Dermatology
115 Woodbine Ln
(570) 271-8074
Erica Lee, MD
Memorial Sloan Kettering
Cancer Ctr
160 E 53rd St Flr 2
New York, NY 10022
(212) 610-0724
79
PRE-REGISTRANTS
Patrick K. Lee, MD
Patrick K Lee Inc
13420 Newport Ave Ste G
Tustin, CA 92780
(714) 731-0061
Ken K. Lee, MD
Portland Dermatology Clinic
1414 NW Northrup Ste 600
Portland, OR 97209
(503) 445-2136
Justin Leitenberger, MD
Oregon Health & Science Univ
Dept of Dermatology CH16D
3303 SW Bond Ave
Portland, OR 97239-4501
(503) 494-4713
Bianca Lemos, MD
Emory Univ School of Medicine
Dept of Dermatology WMRB Bldg
101 Woodruff Cir Ste 5001
Atlanta, GA 30322
(404) 778-3354
Beth Lertzman, MD
Genesee Valley Laser Centre
300 White Spruce Blvd
Rochester, NY 14623-1606
(585) 424-6770
Barry Leshin, MD
The Skin Surgery Ctr
125 Sunnynoll Ct Ste 100
Winston Salem, NC 27106
(336) 724-2434
Betsy Leveritt, MD
15075 Michelangelo Blvd Apt 303
Delray Beach, FL 33446
(925) 586-6835
Vicki J. Levine, MD
Corinthian Medical Bldg
345 E 37 St Ste 209
New York, NY 10016-3256
(646) 490-7388
Alan T. Lewis, MD
1500 W Esplanade 11-a
(504) 988-7381
Alexander Lewis, MD
1820 San Miguel Dr
Walnut Creek, CA 94596-4902
(925) 937-8510
Vanessa C. Lichon, MD
Loyola Univ Medical Ctr
Bldg 54 Rm 101
2160 S First Ave
Maywood, IL 60153
(708) 216-8424
Austin Liu, MD
Henry Ford Medical Ctr
Dept of Dermatology
3031 W Grand Blvd Ste 800
Detroit, MI 48202-3141
(313) 916-2171
Laurel Leithauser Livorine, MD
Univ of Cincinnati
Dermatology/Dermatopathology
PO Box 670592
Cincinnati, OH 45267-0592
(513) 558-6302
Ern Loh, MD
Univ of California Davis School
of Medicine
Dept of Dermatology
3301 C St Ste 1400
Sacramento, CA 95816-3367
(916) 734-6371
Sara Lohser, MD
Cleveland Clinic Foundation
Dept of Dermatology A61
9500 Euclid Ave
(216) 444-5933
Maurizio Lombarbo, MD
Via Albiolo A2
Faioppio
ITALY
Vanessa A. London, MD
1401 Walnut St Unit 303
(415) 385-3253
Michael Loosemore, MD
DermSurgery Associates
7515 Main Ste 240
Houston, TX 77030
(713) 791-9966
Gezelle Macon, MD
1932 Ralph Lawrence Rd
Seagrove, NC 27341
Diane C. Madfes, MD
Diane C Madfes MD PC
1 E 69th St
New York, NY 10021
(212) 249-8118
Anna M. Magee, MD
Charlottesville Dermatology
600 Peter Jefferson Pkwy Ste 230
(434) 984-2400
Norma Magee, MD
4600 Seton Center Pkwy Apt 826
Austin, TX 78759-5258
Ian A. Maher, MD
8111 University Dr
Richmond, VA 23229-7425
Matthew J. Mahlberg, MD
1037 Zinser St
Mount Pleasant, SC 29466
Kristen LeBleu Losavio, MD
Dept of Dermatology WMRB Bldg
101 Woodruff Cir Ste 5001
Atlanta, GA 30322
(404) 778-3354
Comron Maleki, MD
Dermatology and Rejuvenation
Medical Ctr
2230 Lynn Rd Ste 105
Thousand Oaks, CA 91360-1901
(805) 496-6611
Ann E. Lott, MD
Cosmetic Dermatology & Laser Ctr
2900 S 70th St Ste 450
Lincoln, NE 68506
(402) 483-1111
Jeremy R. Man, MD
610 W 42nd St Apt 47M
New York, NY 10036
(212) 564-0135
Steven W. Lin, MD
2920 Aldrich Ave S #255
Minneapolis, MN 55455
(612) 624-9964
Janiene Luke, MD
Loma Linda Dept of Dermatology
11370 Anderson St Ste 2400
Loma Linda, CA 92354
(909) 558-2842
80
Jennifer L. MacGregor, MD
Washington Institute of
Dermatologic Laser Surgery
(202) 628-8855
Zaineb H. Makhzoumi, MD
Univ of Virginia Health System
Dept of Dermatology
PO Box 800718
Charlottesville, VA 22908-0718
(434) 924-5115
Ala Lozinski, MD
Aestheticare
15 Mountain Ave S Ste 312
Stoney Creek, ON L8G 2V6
CANADA
(905) 664-5850
Carl H. Ling, MD
Shanti Medical Ctr
26840 Point Lookout Rd
PO Box 2458
Leonardtown, MD 20650-2458
(301) 373-7730
Jillian Macdonald, MD
1005-75 Cleary Ave Unit 1005
Ottawa, ON K2A 1R8
CANADA
Matteo C. LoPiccolo, MD
Dept of Dermatology
(313) 916-2171
Michael K. Lichtman, MD
Brigham and Women’s Hospital
Dept of Dermatology
221 Longwood Ave Rm 149J
Boston, MA 02115
(206) 227-2952
Bertha B. Lin, MD
99 Montecilo Rd
Grosse Pointe Woods, MI 48236
(612) 926-8260
Kirsten M. Lynch, MD
Univ Dermatologists Inc
1611 S Green Rd Ste 146
South Euclid, OH 44121
(216) 382-3806
Mary P. Lupo, MD
Lupo Ctr for Aesthetic & Gen Derm
145 Robert E Lee Blvd Ste 302
New Orleans, LA 70124-2552
(504) 288-2381
William S. Lynch, MD
Univ Dermatologists Inc
1611 S Green Rd Ste 146
South Euclid, OH 44121
(216) 382-3806
Steven N. Mandrea, MD
Illinois Dermatology Institute
1420 N Renaissance Dr Ste 208
Park Ridge, IL 60068
(847) 298-1831
Chikkabagilu Nanjappa
Manjula, MD
#20 3rd Cross Opposite Chandra
Layout Police Station
Next to Chandra Public School
Chandra Layout
Vijaynagar
Bangalore, 560040
INDIA
080 23181058
Ellen S. Marmur, MD
52 East End Ave
New York, NY 10029
(212) 241-6189
Julie Martin, MD
Univ of Texas Medical Branch
Dermatology
McCullough Bldg 4.112
301 University Blvd
Galveston, TX 77555
(409) 772-1911
Jo Martin, MD
Medicine
Dept of Dermatology
Balatimore, MD 21287
(410) 955-2400
Mayo Clinic Jacksonville
Dept of Dermatology
4500 San Pablo Rd
Jacksonville, FL 32224
(904) 953-2303
Seth L. Matarasso, MD
490 Post St Ste 700
(415) 362-2238
Jason McBean, MD
130 Myren St
Fairfield, CT 06824-6966
(203) 259-7709
Skin Care Specialists APMC
1051 Gause Blvd Ste 460
Slidell, LA 70458
(985) 649-5880
Mark A. McCune, MD
Kansas City Dermatology PA
10600 Quivira Rd Ste 430
Overland Park, KS 66215-2311
(913) 541-3230
David H. McDaniel, MD
David H McDaniel MD Laser &
Cosmetic Ctr
125 Market St
Virginia Beach, VA 23462
(757) 417-8300
Allison McDonough, MD
New York
317 E 34th St Ste 11N
New York, NY 10016
(212) 686-7306
Patrick S.J. McElgunn, MD
Piedmont Plastic Surgery and
Dermatology
5815 Blakeney Park Dr Ste 100
Charlotte, NC 28277
(704) 542-2220
S. Teri McGillis, MD
DermaSurgery Ctr PA
230 Harrisburg Ave Ste 4
Lancaster, PA 17601
(717) 399-9800
D. John McKenna, MD
Spire Leicester Hospital
Gartree Rd
Oadby, Leicester, LE2 2FF
UNITED KINGDOM
116 2653625
Anne Marie McNeill, MD
McNeill Dermatology
1441 Avocado Ave Ste 70
Newport Beach, CA 92660-7704
(949) 706-7886
Thomas Mehrel, MD
400 Arthur Godfrey Rd Ste 300
Miami Beach, FL 33140-3523
(305) 674-9009
Sheetal Mehta, MD
1725 W Harrison
Gary Mendese, MD
16 Orne St
Salem, MA 01970
(978) 235-1063
Andrew B. Menkes, MD
2490 Hospital Dr Ste 201
(650) 962-4600
Padman A. Menon, MD
Tidewater Skin Care &
Pathology PC
1157 First Colonial Rd No 300
Virginia Beach, VA 23454
(757) 333-8001
Missy Mesfin, MD
Univ of Michigan Medical Ctr
Dept of Dermatology 1910
Taubman Health Ctr
1500 E Medical Center Dr
Ann Arbor, MI 48109
(734) 936-4193
Andrei Metelitsa, MD
Institute for Skin Advancement
Ste 206 4935 40th Ave NW
Calgary, AB T3A 2N1
CANADA
(403) 284-0748
Aelayna N. Meyer, MD
Dartmouth-Hitchcock Medical Ctr
One Medical Center Dr
Lebanon, NH 03756-1000
(603) 650-9400
Victor R. Michalak, MD
295 NE Gilman Blvd Ste 101
Issaquah, WA 98027-2906
(425) 391-2500
Univ of Texas
MD Anderson Cancer Ctr
1400 Pressler St Unit 1452
Houston, TX 77030
(713) 563-1665
Oswald L. Mikell, MD
29 Dory Ct
Bluffton, SC 29910-3821
(843) 689-5259
Larry E. Millikan, MD
Tulane Derm Associates
2321 13th St
Meridian, MS 39301
(601) 484-3399
Mohsin R. Mir, MD
2728 McKinnon St Apt 621
Dallas, TX 75201-1637
(832) 217-0110
Patricia Missall, MD
Saint Louis Univ
Dept of Dermatology
1755 S Grand Blvd
(314) 256-3433
hautok Dr Marion Moers-Carpi
Residenzstrasse 7
Munich Bavaria, 80333
GERMANY
49 89 222819
Matt Molenda, MD
1516 Grace Ave
Lakewood, OH 44107
Gary D. Monheit, MD
Total Skin and Beauty
2100 16th Ave S Ste 202 Ash Pl
Birmingham, AL 35205-5053
(205) 933-0987
Edward Monk, MD
1200 Locust St
New York, NY 19107
(215) 546-3666
Rachael Moore, MD
1701 Washington Way Apt 6
Venice, CA 90291
(310) 421-8588
Adisbeth Morales-Burgos, MD
7515 Main Ste 240
Houston, TX 77030
(713) 791-9966
Aaron Morgan, MD
UMDNJ - New Jersey Medical
School
Dept of Dermatology
185 S Orange Ave MSB-H576
Newark, NJ 07103
(973) 972-6884
Greg S. Morganroth, MD
525 South Dr Ste 115
Mountain View, CA 94040-4211
(650) 969-5600
Katie Morrison, MD
Univ of Texas Medical School at
Houston
Dept of Dermatology
6655 Travis Ste 980
(713) 500-8334
J. Suzanne Mosher, MD
Harvard Vanguard Medical
Associates
Mohs Micrographic Surgery Unit
485 Arsenal St
Watertown, MA 02472
(617) 972-5111
Trevor T. Muirhead, MD
Dept of Dermatology
(313) 916-2171
Suparna Mullick, MD
The MetroHealth System
Dermatology
2500 Metro Health Dr
Cleveland, OH 44109
(216) 778-5324
Dermatology, Laser & Vein
Specialists of the Carolinas
1918 Randolph Rd Ste 550
Charlotte, NC 28207
(704) 375-6766
Stephen Murray, MD
287 Richardson Rd
Rockhampton Queensland, 4701
AUSTRALIA
61 413 678664
David Myers, MD
The Dermatology Ctr
1385 E 750 N
Orem, UT 84097
(801) 224-5200
Dr. Nam
Dermatology Clinic Severance
Hospital
250 Seongsano Seodaemun-gu
Seoul, 120-752
SOUTH KOREA
Rhoda S. Narins, MD
Dermatology Surgery and Laser
Center
222 Westchester Ave Ste 300
White Plains, NY 10604
(914) 684-1000
Eiman Nasseri, MD
3601 St-Famille Apt 604
Montreal, QC H2X 2L6
CANADA
Elizabeth Naylor, MD
Duke Univ Medical Ctr
Div of Dermatology Rm 3385
Orange Zone Duke South
Box 3643
Durham, NC 27710
(919) 684-6973
Kenneth W. Neal, MD
611 S. Carlin Springs Road
Vienna, VA 22180
(703) 625-2803
Kishwer S. Nehal, MD
Memorial Sloan Kettering
Cancer Ctr
160 E 53rd St Second Floor
New York, NY 10022
(212) 610-0782
Joseph B. Neiman, MD
Neiman Ctr for Dermatology &
Hair Transplantation
1140 Youngs Rd
Buffalo, NY 14221
(716) 688-0020
Karen B. Nern, MD
Vail Dermatology
105 Edwards Village Blvd
D208 PO Box 2736
Edwards, CO 81632
(970) 926-9226
Mark S. Nestor, MD
Skin & Cancer Associates
2925 Aventura Blvd Ste 205
Aventura, FL 33180
(305) 933-6716
Tracey Newlove, MD
New York Univ Medical Ctr
Dept of Dermatology
550 First Ave Rm H100
New York, NY 10016
(212) 263-3722
Gerald W. Newman, MD
2002 Medical Pkwy Ste 650
Annapolis, MD 21401
(410) 224-8001
Rajiv Nijhawan, MD
515 W 59th St Apt 21A
New York, NY 10019
Tanya Nino Richards, MD
Loma Linda Univ
Dept of Dermatology
(909) 558-2842
Dimitra Ntasiou, MD
Derma Clinic
Antonopoulou 114
Valtou 3 Athens Kato Lechonia
Volos, 382 21
GREECE
30 24210 22678
Donna Nunnally, MD
The Dermatology and Aesthetic
Institute
7330 Perkins Rd
Baton Rouge, LA 70808-4325
(225) 769-3376
Kevin W. O’Bryan, MD
161 Ft Washington Ave 12th Flr
New York, NY 10023
Mark I. Oestreicher, MD
162 Kings Highway North
(203) 377-0639
Alicia Ogram, MD
Dept of Dermatology
(202) 877-6654
Byung Ho Oh, MD
Dermatology Clinic Severance
Hospital
250 Seongsano Seodaemun-gu
Seoul, 120-752
SOUTH KOREA
Edit B. Olasz, MD
Medical College of Wisconsin
Dept of Dermatology
9200 W Wisconsin Ave
Milwaukee, WI 53226
(414) 805-5320
Lahey Clinic
Dept of Dermatology
41 Mall Rd
(781) 744-8348
Gale B. Oleson, MD
510 Mock Ave
PO Box 39
Blue Springs, MO 64013-0039
(816) 228-9099
Purvisha Patel, MD
7658 Poplar Pike Bldg 2
Germantown, TN 38138
(901) 759-2322
Michael Payette, MD
UConn Health Ctr
Dept of Dermatology
263 Farmington Ave MC 6231
Farmington, CT 06030-6231
(860) 679-6759
Steven D. Pedro, MD
Steven D Pedro MD PA
7833 Oakmont Blvd
Fort Worth, TX 76132
(817) 336-0661
Jose R. Pena, MD
1517 Mt Isla Harbor Blvd
Huntersville, NC 28078-8405
(704) 316-5070
Oliver Perez, MD
1384 Morrow Road
Pittsburgh, PA 15237-3823
Renata Prado de Fuccio
Oliveira, MD
8795 E 25th Ave
Denver, CO 80238
Ioannis Peros, MD
Marasli 3 Athens
Athens, 10676
GREECE
30 210 729 9448
Olena Oltar, MD
7 Harwood Ave
London, NW1 6IB
UNITED KINGDOM
Jennifer Peterson, MD
4108 Albans
Houston, TX 77005
(806) 778-5361
Oge Onwudiwe, MD
11605 Caplinger Rd
Silver Spring, MD 20904
(202) 359-4343
Mary G. Petrick, MD
Geisinger Health System
Mohs Micrographic Surgery
MC 14 06
100 N Academy Ave
Danville, PA 17822
(570) 271-8050
1241 Beech Valley Rd
Atlanta, GA 30306
(404) 778-3354
Heather Orkwis, MD
44390 Apple Blossom Dr
Sterling Heights, MI 48314-1029
Diane J. Orlinsky, MD
Simmons-O’Brien & Orlinsky
8320 Bellona Ave Ste 20
Towson, MD 21204
(410) 821-7546
Robin G. Oshman, MD
Robin Gail Oshman MD PhD
101 Long Lots Rd
(203) 454-0743
Michael Osleber, MD
7660 SW 84th Drive
Gainesville, FL 32610-0277
(352) 392-4984
Kapila Paghdal, MD
1120 E Kennedy Blvd Apt 922
Tampa, FL 33612-4799
(813) 974-3070
Melanie Palm, MD
2731 MacKinnon Ranch Rd
Encinitas, CA 92024
(760) 944-7000
William T. Parsons, MD
San Antonio
7832 Pat Booker Rd
San Antonio, TX 78233
(210) 657-9338
Vishal Patel, MD
27 James St 1A
New York, NY 10032-3729
(212) 305-5317
Gopal A. Patel, MD
916 Meadow Creek Dr Apt 4104
Irving, TX 75038
PRE-REGISTRANTS
Claudia Piper Shafir, MD
Barros Errazuriz 1954 of 303
Santiago, 7550183
CHILE
56 2 824 8780
James Michael Polo, MD
2115 Neuse Blvd
New Bern, NC 28560
Donald I. Posner, MD
Dermatology & Skin Surgery
9007 Ellerbe Rd
Shreveport, LA 71106
(318) 222-3278
Salma Pothiawala, MD
Univ of South Florida College
of Medicine
Cutaneous Surgery MDC 79
Tampa, FL 33612-4799
(813) 974-3070
Daniel C. Rabb, MD
Northeast GA
974 S Enota Dr NE
Gainesville, GA 30501-2429
(770) 536-7546
Jennifer M. Ragi, MD
UMDNJ-Robert Wood Johnson
Medical School
Dept of Dermatology
1 Worlds Fair Dr Ste 2400
Somerset, NJ 08873-1344
(732) 235-7765
Preethi Ramaswamy, MD
Dept of Dermatology
609 Albany St
Boston, MA 02118-2515
(617) 638-5534
Jeffrey A. Rapaport, MD
333 Sylvan Ave No 207
Englewood Cliffs, NJ 07632
(201) 227-1555
Zaina Rashid, MD
5721 W Windrose Dr
Glendale, AZ 85304
(623) 225-8155
Shadi Rashtak, MD
Mayo Clinic
Dept of Dermatology
200 First St SW
Rochester, MN 55905
(507) 284-5997
Bernard I. Raskin, MD
Advanced Dermatology and
Cosmetic Care
23861 McBean Pkwy Ste E-21
Valencia, CA 91355
(661) 254-3686
Saadia Raza, MD
Skin Surgery Ctr of Missouri
856 Waterbury Falls Dr Ste 100
O’Fallon, MO 63366
(630) 300-9596
Kelley P. Redbord, MD
2425 L Street NW 210
Vienna, VA 22180
7039385700
Kavitha K. Reddy, MD
490 2nd Ave Apt 5D
New York, NY 10016
(617) 638-5534
Kalpana Reddy, MD
442 E 20th St Apt 3F
New York, NY 10009
(614) 395-2897
Thomas D. Regan, MD
634 Olympia Hills Cir
Berwyn, PA 19312
Rachel B. Pritzker, MD
John H Stroger Jr Hospital of
Cook County
Adminstration Bldg Flr 5 Rm 519
1900 W Polk St
(312) 864-4478
Todd K. Remington, MD
Remington Laser Dermatology
Centre
7220 Fisher St SE No 150
Calgary, AB T2H 2H8
CANADA
(403) 253-1422
Melissa Pugliano-Mauro, MD
UPMC Saint Margaret
Dermatolgy
2585 Freeport Rd Ste 204
Pittsburgh, PA 15238
(412) 784-7350
Anetta E. Reszko, MD
1035 Fifth Ave Ste 1C
New York, NY 10028
(212) 794-3548
Morgan E. Rabach, MD
425 Prospect Pl Apt 2i
Brooklyn, NY 11238
Violetta O. Reyes, MD
Skinfirst Inc
Skinfirst Bldg Fourth Floor
8889 Osmena Hwy Bangkal
Makati City, 1233
PHILIPPINES
63 2 8440840
81
PRE-REGISTRANTS
Phoebe Rich, MD
2565 NW Lovejoy St
Portland, OR 97210
(503) 226-3376
Troy K. Richey, MD
3573 Spring Blvd
Eugene, OR 97405
(541) 747-6159
Heather M. Richmond, MD
Advanced Dermatologic
Surgery PA
1213 Hermann Dr Ste 650
Houston, TX 77004
(713) 528-8882
Jennifer M. Ridge, MD
Jennifer M Ridge MD Inc
210 N Breiel Blvd
Middletown, OH 45042
(513) 424-7231
Darrell S. Rigel, MD
35 E 35th St Ste 208
New York, NY 10016-3823
(212) 684-5964
Daniel Rivlin, MD
Skin & Cancer Associates
4308 Alton Rd Ste 510
(305) 674-8865
Wendy E. Roberts, MD
Desert Dermatology Skin Institute
35-280 Bob Hope Dr Ste 105
Rancho Mirage, CA 92270-8007
(760) 346-4262
Randall K. Roenigk, MD
Mayo Clinic
Dept of Dermatology
200 First St SW
Rochester, MN 55905
(507) 284-3668
Ctr for Skin Surgery PLLC
Rotter Bldg
8301 Old Courthouse Rd
Vienna, VA 22182
(703) 442-0300
Adam M. Rotunda, MD
50 Townsend
Irvine, CA 92620
(949) 336-7171
Marie-Christine Roy, MD
Dr. Marie-Christine Roy Centre
De Dermatologie Au Laser
594 Victoria Ste 200
Saint Lambert, QC J4P 2J6
CANADA
(450) 672-2885
Emily Rubenstein, MD
1912 W Cortland
Chicago, IL 60622
Mark G. Rubin, MD
153 S Lasky Dr Ste 1
(310) 556-0119
Paul A. Rusonis, MD
Dermatology & Advanced Skin
Care
6021 Univ Blvd Ste 390
Ellicott City, MD 21043
(410) 203-0607
Caitriona Ryan, MD
Texas Dermatology Associates
3900 Junius St Ste 145
Dallas, TX 75246
(972) 386-7546
Julia B. Sabetta, MD
4 Dearfield Dr Ste 203
Greenwich, CT 06831
(203) 869-6111
Heather Rogers, MD
Madison Skin & Laser Ctr
1101 Madison Ste 1490
Seattle, WA 98104
(206) 215-6600
Neil S. Sadick, MD
Sadick Dermatology
911 Park Ave Ste 1A
New York, NY 10021
(212) 772-7242
Nicole E. Rogers, MD
Old Metairie Dermatology
701 Metairie Rd Ste A205
Metairie, LA 70005
5048362050
Nazanin A. Saedi, MD
1440 Beacon St Apt 810
Brookline, MA 02446
SkinCare Physicians
(617) 731-1600
James A. Rooney, MD
799 Hammond Dr NE Ste 106
Atlanta, GA 30328
(706) 291-0505
Amy Rose, MD
300 East 54th Street
New York, NY 10016
(212) 263-3722
E. Victor Ross, MD
2928 Grape
San Diego, CA 92130
(858) 764-9040
Anthony M. Rossi, MD
Saint Lukes - Roosevelt Hospital Ctr
1090 Amsterdam Ave Ste 11B
New York, NY 10025-1737
(212) 523-3812
Leszek Roter, MD
Warszawska Street 57 1-2
Gdynia, 81-309
POLAND
48 58 6614652
82
Patrick Safo, MD
1115 Deerfield Cir
Wexford, PA 15090
(617) 851-5130
Ritu Saini, MD
225 E 34th St Ste 5G
New York, NY 10016
(917) 915-5106
Eli R. Saleeby, MD
Dermatology Consultants of
South Florida
1460 Univ Dr
Coral Springs, FL 33071
(954) 752-7552
Giovanni Salti, MD
Istituto Medlight
Via delle Panche 97c
Florence, 50141
ITALY
39 055 410180
Sam A. Samimi, MD
Accurate Skin Clinic
10004 Kennedy Rd Ste 210A
(314) 842-3525
Neil Sandhu, MD
UMDNJ - New Jersey Medical
School
Dept of Dermatology
185 S Orange Ave MSB-H576
Newark, NJ 07103
(973) 972-6884
Lori Sanford, MD
2703 Foxbriar Pl
Indianapolis, IN 46203
(317) 460-1775
Sheetal Sapra, MD
Institute of Cosmetic and Laser
Surgery
1344 Cornwall Rd Ste 100
Oakville, ON L6J 7W5
CANADA
(905) 842-2262
Deborah Sarnoff, MD
Cosmetique Derm Laser & Plastic
Surgery
625 Park Ave
New York, NY 10065-6545
(212) 794-4000
Sarah M. Sawyer, MD
201 Office Park Dr Ste 250
(205) 870-3303
Aradhna Saxena, MD
3338 Woodland Cir
Huntingdon Valley, PA 19006
(215) 793-9755
G. Daniel Schachter, MD
27 Rosemary Lane
208 Bloor St W Ste 404
Toronto, ON M5S 3B4
CANADA
(416) 922-9638
Dermatology & Laser Ctr of
Charleston
2093 Henry Tecklenburg Dr
Ste 300
Charleston, SC 29414
(843) 556-8886
Cynthia A. Schlick, MD
Metropolitan Derm & Cutaneous
Surgery
1120 E Wayzata Blvd Ste 100
Wayzata, MN 55391
(952) 476-6733
Dieter K.T. Schmidt, MD
17040 NE 135th Ct
Redmond, WA 98052
(425) 789-0138
1153 Center St Ste 4349
Jamaica Plain, MA 02130-3446
(617) 983-4626
Jeffrey Schuldenfrei, MD
106 Fox Trail Terrace
Gaithersburg, MD 20875
Keith W. Schumann, MD
114 Archers Hope Rd
Williamsburg, VA 23188
(757) 564-1200
Elissa Schwartzfarb, MD
Medicine
Cutaneous Surgery
Miami, FL 33136
(305) 243-6735
Christine M. Sciara, MD
1595 Paoli Pike Ste 105
West Chester, PA 19380
(610) 696-1598
Saundra L. Seaman, MD
8135 Old Georgetown Rd
Bethesda, MD 20814
(202) 415-1413
Theodore S. Sebastien, MD
Reston Hospital Ctr
Dermatology Specialists of
Virginia PC
Reston, VA 20190
(703) 709-1492
Joseph F. Sedrak, MD
7619 Marburg Court
(713) 771-1100
Jennifer Segal, MD
4024 Overbrook Ln
Houston, TX 77027
(713) 589-9537
2521 Calle Galicia
(805) 682-6455
Amie Sessa, MD
Dept of Dermatology
(202) 877-6654
Dwana Shabazz, MD
14 Pidgeon Hill Dr Ste 340
Sterling, VA 20165-6133
(703) 450-5959
Kristina K. Shaffer, MD
Dermatology Consultants
Eagan, MN 55123-1067
(651) 251-3300
Kerry M. Shafran, MD
Univ Dermatology, Cosmetic &
Surgery Ctr
3006 Baucom Rd Ste 100
Charlotte, NC 28269-0720
(704) 596-1787
Ladan Shahabi, MD
240 E 86th St Apt 18C
New York, NY 10028
(917) 232-5186
Ava T. Shamban, MD
Laser Institute for Dermatology &
European Skin Care
2021 Santa Monica Blvd Ste 600E
(310) 828-2282
Shakti Sharma, MD
Group Practice
7117 Bathhurst St Ste 201
Thornhill, ON L4J 2J6
CANADA
(905) 763-2526
Mitchell Shek, MD
Dermatology Associates/Ctr for
Cosmetic Derm
800 S Adams
Birmingham, MI 48009
(248) 646-9597
Mary Sheu, MD
13107 Pendleton Ct
Reisterstown, MD 21136-5682
Norman J. Shiffman, MD
NJ Shiffman Medical Prof Corp
2533 Danforth Ln
Toronto, ON M4C 1L1
CANADA
(416) 698-5521
Ikue Shimizu, MD
The Univ of Texas MD Anderson
Cancer Ctr
1400 Pressler Unit 1452 Rm
FCT11.6099
Houston, TX 77030
Brett C. Shulman, MD
20 Hagen Dr Ste 220
Rochester, NY 14625
(585) 922-9770
Peter R. Shumaker, MD
2022 Hickory St
San Diego, CA 92103
(619) 955-7716
Brooke C. Sikora, MD
SkinCare Physicians
(617) 848-1633
Sirunya Silapunt, MD
1911 Swift Blvd
Houston, TX 77030
Eva F. Simmons-O’Brien, MD
Simmons-O’Brien & Orlinsky
8320 Bellona Ave Ste 20
Towson, MD 21204
(410) 821-7546
Saurabh Singh, MD
730 24th St NW Apt 220
Maral K. Skelsey, MD
The Dermatologic Surgery Ctr of
Washington
5530 Wisconsin Ave Ste 820
(301) 652-8081
Jordan Slutsky, MD
1241 Strassner Dr Unit 1307
Brentwood, MO 63144
(516) 785-6310
Cindy Firkins Smith, MD
Affiliated Community Medical Ctr
101 Willmar Ave SW
Willmar, MN 56201-3556
(320) 231-5000
Kevin C. Smith, MD
Niagra Falls Dermatology & Skin
Care Centre Ltd
2315 Whirlpool St No 175
Niagara Falls, NY 14305
(905) 356-5335
Andrea Smith, MD
25099 Starr St
(909) 558-2842
Clifton Smith, MD
Kentucky Dermatology & Skin
Cancer Clinic
177 Burt Rd
Lexington, KY 40503
(859) 276-1511
Stacy R. Smith, MD
2371 Lagoon View Dr
Cardiff, CA 92007
(619) 787-5723
Jason Sneath, MD
308-77 Walter Hardwick Ave
CANADA
(604) 875-4111
Stephen N. Snow, MD
Univ of Wisconsin West Clinic
Mohs Surgery Clinic
451 Junction Rd
Madison, WI 53717-2656
(608) 263-6226
Joseph Sobanko, MD
Univ of Pennsylvania Hospital
Perelman Ctr for Advanced
Medicine
3400 Civic Center Blvd
Ste 3305 Flr 1
Howard D. Sobel, MD
960 A Park Ave
New York, NY 10028
(212) 288-0060
John M. Soderberg, MD
Aesthetic Solutions PA
5821 Farrington Rd Ste 101
(919) 403-6200
Women’s College Hospital
66 Avenue Rd
Toronto, ON M5R 3N8
CANADA
(416) 964-8888
Brian Somoano, MD
2141 N Harbor Blvd Suite 25000
Fullerton, CA 90740
Shobana Sood, MD
113 Brooke Farm Rd
Wayne, PA 19087
(610) 688-6379
Seaver Soon, MD
1494 Union Street #601
(858) 554-8646
Teresa Soriano, MD
UCLA Medical Ctr
Dept of Dermatology
200 UCLA Medical Plz Ste 465
(310) 825-6911
Miriam Emily Piansay
Soriano, MD
Davao Doctors Hospital
Rm 402 Medical Tower Bldg
E Quirino Ave
Davao City, 8000
PHILIPPINES
6382 227-6120
Luis Soro, MD
1815 Keystone Rd
Allentown, PA 18103
Stephen T. Spates, MD
The Dermatology Group
60 Pompton Ave
Verona, NJ 07044
(973) 571-2121
Divya Srivastava, MD
2728 McKinnon St Apt 610
Dallas, TX 75201-1636
(214) 645-8947
Sharleen St Surin-Lord, MD
PO Box 7224
Largo, MD 20792-7224
(202) 321-2458
Kelly Stankiewicz, MD
The Dermatology Institute
(630) 547-5040
Lala M. Stawowy, MD
711 Lehmann Dr
Kerrville, TX 78028
(830) 257-5733
600 12th Ave S Unit 401
Nashville, TN 37203
Burt Steffes, MD
321 E 9th St
Fond du Lac, WI 54935
J. Barton Sterling, MD
215 Morris Ave
Spring Lake, NJ 07762
(732) 449-3005
Roger H. Stewart, MD
Dermatologic Laser & Surgery Ctr
6550 N Federal Hwy Ste 320
Fort Lauderdale, FL 33308-4609
(954) 491-0510
Stephen Tan, MD
HealthPartners Specialty Ctr Derm
401 Phalen Blvd
Saint Paul, MN 55130
(651) 254-7580
Landon Stigall, MD
Dept of Dermatology
115 Woodbine Ln
(570) 271-8074
Amy F. Taub, MD
275 Parkway Dr Ste 521
Lincolnshire, IL 60069
(847) 459-6400
Susan E. Stinehelfer, MD
Greensboro Dermatology
Associates
2704 Saint Jude St
Greensboro, NC 27405
(336) 954-7546
Jenny L. Stone, MD
Salisbury Dermatologic Clinic PA
203 B Mocksville Ave
Salisbury, NC 28144
(704) 636-0971
Dow B. Stough, MD
The Dermatology Clinic
3633 Central Ave Ste N
Hot Springs, AR 71913
(501) 623-6100
Jamison E. Strahan, MD
421 Cynthia Ln NE
Vienna, VA 22180
(703) 343-6443
Bonnie F. Straka, MD
Albemarle Dermatology
Associates
3350 Berkmar Dr
(434) 923-4651
Mark B. Taylor, MD
Gateway Aesthetic Institute
440 W 200 S Ste 250
Salt Lake City, UT 84101-1462
(801) 595-1600
Craig F. Teller, MD
Bellaire Dermatology Associates
6565 West Loop S Ste 800
Bellaire, TX 77401
(713) 661-4383
Michael J. Terlizzi, MD
138 Haverhill St
Andover, MA 01810-1574
(978) 475-4322
Millard P. Thaler, MD
Papillon Dermatology
2150 S Dobson Ste 1
Mesa, AZ 85202
(480) 820-9774
2520 Robinhood St Unit 805
Houston, TX 77005
(617) 407-5678
Lorna Thomas, MD
3011 W Grand Blvd
Detroit, MI 48202
(313) 874-2500
Hiram M. Sturm, MD
4381 Haris Valley Rd NW
Atlanta, GA 30327
(404) 233-6409
Jacqui Thomas, MD
2780 NE 183rd St Apt 2106
Aventura, FL 33160
(954) 510-7505
Mark F Suchter, MD
51 Sharon Dr
Moosic, PA 18507
Meghan Thomas, MD
Univ of North Carolina
Dept of Dermatology CB7715
410 Market St Ste 400
(919) 966-0785
Hema Sundaram, MD
White Flint Professional Bldg
11119 Rockville Pike Ste 205
Rockville, MD 20852
(301) 412-4943
Lis Surachmiati Suseno, MD
Univ of Indonesia
Dept of Dermatology
JI Diponegoro no 71
Jakarta, 10430
INDONESIA
62 213918301
Atchima Suwanchinda, MD
Medisci Antiaging A Cosmetic Ctr
58/59 M006 Soi Chinnaichet
Tungsonghong Laksi
Bangkok
THAILAND
66813755000
Michael Howard Swann, MD
51978 S. Aleshire Ct
Springfield, MO 65804
(417) 889-3332
Neil A. Swanson, MD
26485 SW Wilken Ln
Portland, OR 97239
(503) 494-6381
James Michael Swinehart, MD
950 E Harvard Ave Ste 630
Denver, CO 80210-7009
(303) 744-1202
Lily Talakoub, MD
PO Box 9143
McLean, VA 22102-0143
Alexandria Thompson, MD
13825 Cordury Ave Apt 6
Hawthorne, CA 90250
(310) 409-5472
Emily P. Tierney, MD
2 Avery St Apt 18F
Boston, MA 02111
Jeffrey B. Tiger, MD
42 Wolf Rd Unit 1024
Lebanon, NH 03766
Samantha Toerge, MD
2814 Bellevue Ter NW
Sanjay Tomar, MD
304 Belrose Dr
Cary, NC 27513
Ella L. Toombs, MD
1612 18th St NW
(202)483-3376
Whitney D. Tope, MD
Academic Dermatology PC
6545 France Ave S Ste 564
Edina, MN 55435
(952) 746-6090
Abel Torres, MD
Loma Linda Univ Faculty Medical
Office
Dept of Dermatology
(909) 558-2890
PRE-REGISTRANTS
Michael A. Trauner, MD
1020 29th St Ste 570B
(916) 453-5955
Lisa Travis, MD
Upper Westside Dermatology PC
211 Central Park W Ste 1F
New York, NY 10024
(212) 769-0069
Erin A. Walker, MD
Westmed Group
210 Westchester Ave
White Plains, NY 10604
(914) 682-6426
William L Waller, MD
1329 St Andrew St Apt 12
(504) 919-4373
Anne Marie Tremaine, MD
Univ of California Irvine
C340 Medical Sciences I
Irvine, CA 92697-2400
(949) 824-4405
Ingrid Warmuth, MD
420 Front St
PO Box 578
Elmer, NJ 08318
(856) 358-1500
Kenneth Y. Tsai, MD
2918 Sunset Blvd
Houston, TX 77030
(713) 500-8260
Molly Warthan, MD
3125 Thomas Ave Apt D
Tallahassee, FL 32308
(850) 877-4134
Yardy Tse, MD
SkinCare Physicians & Surgeons Inc
700 Garden View Ct Ste 100
Encinitas, CA 92024
(760) 633-1000
Melaine Warycha, MD
333 E Ontario St Unit 71213
Chicago, IL 60611
Stacey S. Tull, MD
Skin Surgery Ctr of Missouri
856 Waterbury Falls Dr Ste 100
O’Fallon, MO 63366
(636) 300-9596
Rebecca C. Tung, MD
175 E Delaware Pl Unit 4911
Chicago, IL 60611
(216) 246-0269
Julia E. Tzu, MD
New York Univ Langone
Medical Ctr
Dept of Dermatology
550 First Ave Rm H100 SHCC 7 J
New York, NY 10016
(212) 263-7300
Zeena I. Ubogy, MD
Papillon Dermatology
2150 S Dobson Ste 1
Mesa, AZ 85202
(480) 820-9774
Dept of Dermatology
1365 Clifton Rd Ste A1400
Atlanta, GA 30322
(404)778-3355
Daniel I. Wasserman, MD
Riverchase Dermatology
261 9th St S
Naples, FL 34102
(239) 437-8810
Christine Haughey
Weinberger, MD
at Fletcher Allen
Div of Dermatology
(802) 847-4570
5601-B 21st Ave W
Bradenton, FL 34209
(941) 794-5432
Sanusi H. Umar, MD
Fine Touch Dermatology Inc
819 N Harbor Dr Ste 400
(310) 318-1500
Elliot T. Weiss, MD
317 E. 34th St
11th Floor
Southampton, NY 11968
(631) 287-7307
Sanjay S. Valvani, MD
The Visium Funds
950 Third Ave Flr 29
New York, NY 10022
(646) 840-5815
Maryland Laser, Skin & Vein
Institute
Aspen Mill Professional Bldg
54 Scott Adam Rd Ste 301
Hunt Valley, MD 21030-2845
(410) 666-3960
Marta J. VanBeek, MD
Univ of Iowa Hospitals & Clinics
Dept of Dermatology
200 Hawkins Dr
Iowa City, IA 52242-1090
(319) 356-2856
Karl Vance, MD
Univ of Illinois at Chicago
Dept of Dermatology
808 S Wood St Rm 380 MC 624
(312) 996-1188
George K. Verghese, MD
777 7th St NW 824
(703) 585-5965
Jaime R. Villa Colon, MD
Dr Jaime R Villa Colon CSP
Edificio Parra Ofic 403
2225 Ponce Bypass
Ponce, PR 00717-1320
(787) 259-3391
Christina Wahlgren, MD
1100 9th Ave
Seattle, WA 98101
(206) 223-6781
Robert A. Weiss, MD
Maryland Laser, Skin & Vein
Institute
Aspen Mill Professional Bldg
54 Scott Adam Rd Ste 301
Hunt Valley, MD 21030-2845
(410) 666-3960
Arthur Weissmann, MD
400 Arthur Godfrey Rd Ste 300
(305) 674-9009
Hal M. Weitzbuch, MD
John H Stroger Jr Hospital of
Cook County
Adminstration Bldg Flr 5 Rm 519
1900 W Polk St
(312) 864-4478
Fred Weksberg, MD
1333 Sheppard Ave E Ste 324
Toronto, ON M2J 1V1
CANADA
(416) 499-8242
83
PRE-REGISTRANTS
Ryan Wells, MD
4170 Hughes Lea
Tucker, GA 30084
(770) 696-2411
Kathleen M. Welsh, MD
2299 Post St Ste 312
(415) 292-6350
Spokane Dermatology Clinic
Fifth and Brown Medical Ctr
104 W Fifth Ave Ste 330 W
Spokane, WA 99204
(509) 624-1184
Tina B. West, MD
The West Institute For Skin Laser
and Body Contouring
5530 Wisconsin Ave Ste 925
(301) 986-9378
145 E 32nd St
New York, NY 10016
(212) 684-2626
Christopher Weyer, MD
220 Fox Hollow Dr Apt 107
Mayfield Heights, OH 44124
(520) 977-4747
Faith M. Whalen, MD
Dept of Dermatology
115 Woodbine Ln
(570) 271-8074
Michael B. Whitlow, MD
635 Madison Ave
New York, NY 10022-1009
(212) 753-5382
John K. Wildemore, MD
John K Wildemore MD LLC
744 W Lancaster Ave Bldg 2
Ste 230
Wayne, PA 19087
(610) 688-8750
Andrea Willey, MD
480 Wyndgate Rd
(216) 241-1290
84
Phillip M. Williford, MD
Wake Forest Univ School of
Medicine
Dept of Dermatology
4618 Country Club Rd
Winston Salem, NC 27104
(336) 716-7480
Douglas A. Winstanley, MD
3233 Corporal Dr
San Diego, CA 92124
(619) 840-9762
George B. Winton, MD
Tri-Cities Skin & Cancer
1009 N State of Franklin Access Rd
Johnson City, TN 37604
(423) 929-7546
Allan S. Wirtzer, MD
4836 Van Nuys Blvd
Sherman Oaks, CA 91403-2101
(818) 907-7546
Oliver J. Wisco, MD
20 Gray St
Arlington, MA 02476
Lance D. Wood, MD
Penn State Milton S Hershey
Medical Ctr
Dept of Dermatology HU14
UPC II
500 University Dr Ste 4300
Hershey, PA 17033-2391
(717) 531-6049
Michael J. Yablonsky, MD
300 Court St
Portsmouth, VA 23704-2543
(757) 745-3425
Marjorie F. Yang, MD
Wisconsin
5017 Green Bay Rd Ste 138
Kenosha, WI 53144
(262) 652-6020
Jane Y. Yoo, MD
One Columbus Pl Apt N9J
New York, NY 10019
Avis B. Yount, MD
Augusta Dermatology
Associates PC
820 Saint Sebastian Way Ste 6C
Augusta, GA 30901
(706) 722-4280
Marjan Yousefi, MD
2300 N Pershing Dr Apt 204
Arlington, VA 22201-1428
Siegrid Sisin Yu, MD
UCSF Dermatology
(415) 353-7838
Lisa Zaleski, MD
4133 Florida St Apt 6
San Diego, CA 92104
(619) 532-9660
Sylvia W. Wright, MD
Peachtree Dermatology
Associates PC
3286 Northside Pkwy NW Ste 130
Atlanta, GA 30327-2223
(404) 355-1919
John A. Zitelli, MD
Zitelli & Brodland PC
Shadyside Medical Bldg
5200 Centre Ave Ste 303
Pittsburgh, PA 15232-1306
(412) 681-9400
Ashley Wysong, MD
Dept of Dermatology
(650) 721-7194
Daniel Zivony, MD
Advanced Derm & Skin Surgery
16 Medical Park Dr
Asheville, NC 28803
(828) 274-4880
David M. Zloty, MD
Univ of British Columbia
Dept of Dermatology Flr 3
835 W 10th Ave
CANADA
(604) 875-4888
ABSTRACTS — FRIDAY
RS 213 - Resident Abstract Session
11:00 am
Title:
Sentinel Lymph Node Biopsy in
Cutaneous and Non-cutaneous Cancer
margins for diagnosis. Three academic dermatopathologists could
not agree on her diagnosis and felt the lesion was either a deep
penetrating nevus or a melanoma measuring 4.0 mm in thickness.
The FISH assay was evaluated in this case to assist in the patient’s
further clinical management.
Author(s): C. Lenny Henderson, MD; Tony Nguyen;
Carlos Garcia, MD
Design: The FISH assay is a new technology with limited use in the
clinical arena. We undertook a review of the current literature in
pathology, molecular biology and dermatology to understand the
limits and applications of the FISH assay. The assay was then utilized
to delineate this lesion’s true nature. Summary of the literature
review along with recommendation guidelines for the assay’s use to
practitioners will be presented.
Purpose: The lack of survival advantage for melanoma after Sentinel
Lymph Node Biopsy (SLB) led us to examine the published results
of this test in other malignancies in order to determine if there is
statistical and outcome consistency.
Design: We performed a literature review of The Cochrane, DARE,
EMBASE, and MEDLINE databases for all relevant literature up to
2010. The following search terms were used: “sentinel node biopsy”,
“diagnosis”, “prognosis”, “sensitivity”, “specificity”, “predictive
value”, and “survival”. We linked to specific search terms, including
malignant melanoma, breast cancer, cervical cancer, colorectal
cancer, thyroid cancer, head and neck SCC, penile SCC, anogenital
SCC, non-anogenital SCC, oral SCC as well as word variants of those
terms.
Summary: With MM, there was excellent success at finding the
sentinel lymph node (SNL) and excellent negative predictive value
(NPV) and sensitivity. In all the other cancers, there was also strong
success at finding the SNL. There was also success in most of the
cancers with high NPV with the lowest reported value being 80% in
one colorectal cancer study. The accuracy data was also favorable,
particularly for breast cancer. The most tangible outcome data came
from anogenital SCC which showed the exact same recurrence rate
of 2.44% in patients both after a negative or positive SLNB. With
malignant melanoma, after a negative SNLB, rate of recurrence was
3-7%, with an average of 5.43%. After a positive SNLB in MM, the
rate of recurrence was 11-13% in two studies. With MM, in one
study, 8% of patients died after a negative SLNB, whereas 44% died
after a positive SLNB.
Conclusion: It is well known that the source of one of the great
controversies in SNLB for MM is the dichotomy between its usefulness
in staging versus its usefulness in improving survivability and
outcome measures. We could not find solid evidence of any improved
outcomes for MM in patients that received SLNB. This appears to
be the case in all other cancers studied as we could not find solid
survivability data across the board. This could be a manifestation of
the incredible complexity of cancer and the process of metastasis,
thus limiting the value of any one test to help predict improved
patient outcomes.
Disclosure(s) of Interest:
The author(s) has no relationships to disclose.
11:05 am
Title:
Clinical Application of FISH in the
Management and Diagnosis of
Melanoma
Author(s): Rajiv Nijhawan, MD; Kavita Mariwalla, MD
Purpose: Fluorescence in situ hybridization (“FISH”) has been
examined as an assay to aide in the diagnosis of melanoma. To date,
this technology has been confined mainly to the research arena.
We present a unique case in which FISH technology was utilized as
a diagnostic tool to aide in the management of a pigmented lesion
on the cheek of a 21-year-old girl. The student presented with a two
month history of a non-ulcerated, well-circumscribed, dark black
papule on her left cheek, which was excised with one millimeter
Summary: The FISH analysis revealed chromosomal aberrations
in 60% of cells, consistent with the diagnosis of melanoma. Based
on this analysis, surgeons re-excised the area with one centimeter
margins and performed sentinel lymph node mapping. The margins
were clear and the patient is doing well at 6 months follow-up.
Conclusion: While some pigmented lesions can be challenging
to differentiate histologically as being truly benign or worrisome,
the novel FISH assay can assist in diagnosing and further managing
these difficult to interpret lesions, especially in cosmetically sensitive
areas where misclassification can render severe consequences. These
authors recommend that the FISH assay be used in its current form as
an adjunctive tool in diagnosis though future outcome and prognosis
for the patient cannot be based on the results of this technology
alone. True emphasis should be placed on clinical-molecularpathologic correlation as was done in this case.
The author(s) have no relationship to disclose.
11:10 am
Title:
1064 Nd:YAG Q-switched Laser for the
Treatment of Toenail Onychomycosis
Author(s): Jason D. Boyd, MD; Chad Hivnor, MD; Jason Arnold, MD;
Thomas Regan, MD
Purpose: At present, the medical care of onychomycosis is
based almost exclusively on the use of topical and/or systemic
antifungal therapies, which are often ineffective and may cause
further morbidity. Recent data suggests that laser and light based
technologies may be beneficial in the treatment of this condition.
Given the emergence of this modality, our study aims to specifically
analyze the impact of the 1064 Nd:YAG q-switched laser on toenail
onychomycosis, and determine if toenail thickness and treatment
frequency alter outcomes.
Design: 48 patients with PAS stain proven bilateral big toenail
onychomycosis were split into two treatments groups: 24 patients
with left big toenail thickness <2mm, and 24 patients with left big
toenail thickness >2mm. In each of these two groups of 24 patients,
participants were randomized to receive either one or two treatment
sessions; thus all 48 patients were treated once at baseline, and onehalf of the patients received a second treatment at 3 months. Study
conclusion was performed at 6 months.In all 48 patients, only the
left big toenail was treated, with the right untreated toenail serving
as a control group. At baseline, 3 months, and at the 6 month study
conclusion, various measurements of both large toenails were taken
to assess the effectiveness of the 1064 Nd:YAG q-switched laser, with
the primary end-point being the amount of new clear nail growth.
Summary: There was a statistically significant difference in the
clear nail distance of the treated versus the control nails at the 6
month follow-up.The treated nails that were <2mm thick tended to
85
FRIDAY — ABSTRACTS
do better than the treated nails > 2mm thick. Treatment resulted in
most nails having between 10-40% clearing of the new nail growth
vs 0-5% of the untreated nails. There was no statistical difference
between those who received one versus two treatments.
Conclusion: Laser and light based technologies may offer a simple,
safe, effective alternative to current oral-based treatment options
in onychomycosis.The Nd:YAG 1064nm Q-switched laser may
provide a mild to moderate increase in clear nail distance for toenail
onychomycosis, with greater improvement seen in patients with
thinner toenails.Further research is warranted in this emerging field
to determine the optimal treatment wavelength and other device
specific parameters.
The author(s) have no relationship to disclose.
11:15 am
Title:
Consensus Recommendations and
Current Practices for the Reconstitution
and Storage of Botulinum Toxin Type A
Author(s): Austin Liu, MD; Alastair Carruthers, MD; Joel Cohen, MD;
William Coleman, MD; C. Hanke, MD; Ronald Moy, MD;
David Ozog, MD
Purpose: Current guidelines from the Centers for Disease Control
and Prevention (CDC) regarding the reconstitution and storage
of botulinum toxin type A (BT-A) differ from those of the Centers
for Medicare and Medicaid Services (CMS) and current clinical
practice. CDC guidelines require single-patient use of BT-A vials.
Strict adherence to these guidelines creates waste and a significant
financial impediment, and does not confer increased protection
from infection, assuming standard safe injection practices are
followed.This study examines current clinical practices and provides
expert consensus recommendations regarding the reconstitution
and storage of BT-A. A review of the literature on the sterility and
efficacy of BT-A stored beyond the recommended time period of
four hours is also presented.
11:20 am
Title:
Safety of Storing and Reusing Hyaluronic
Acid Fillers: A Retrospective Chart
Review
Author(s): Patrick Safo, MD; Patrick Safo, MD;
Christina Wahlgren, MD; Suzan Obagi, MD
Purpose: Injectable dermal fillers are an integral component of
cosmetic dermatology for soft tissue augmentation. Many patients
request intermittent, subtle augmentation that does not require
use of the complete syringe of filler material. The ability to safely
store and reuse dermal fillers is of paramount importance to the
cosmetic dermatologist. Previous studies have been limited to
culturing of the stored filler for possible bacterial contaminants. We
investigated potential infectious complications associated with the
reuse of hyaluronic acid (HA) dermal fillers stored in a medical-grade
refrigerator.
Design: We performed a retrospective review of patient records for
infectious complications associated with the use of stored HA fillers
(Restylane and Juvéderm Ultra Plus) from January 1, 2007 to May 31,
2009 at the UPMC Cosmetic Surgery and Skin Health Center
Summary: No infections were observed with the reuse of stored HA
fillers. The number ofsyringes reused during this timeperiod was 116
of Restylane and 199 of Juvéderm Ultra Plus. Patients were retreated
at mean days of 190 (7–456 days) and 195 (5–490 days) with stored
Restylane and Juvéderm Ultra Plus respectively. Majority of calls
from patients occurred within the first week of injection (3.6%
of Restylane patients and 1.5% of Juvéderm Ultra Plus) for local
injection site edema that resolved with ice compress.
Conclusion: There is minimal risk of bacterial infection associated
with use of Hyarulonic acid fillers stored at 4oC for up to a year.
Dr. Obagi is the: President of the Cosmetic Surgery Foundation and
Vice President of the American Board of Cosmetic Surgery.
Design: A total of 1,000 randomly selected physician members of
the American Society for Dermatologic Surgery (ASDS) were invited
to participate in an internet based survey on the use of botulinum
toxin type A. The survey was used to analyze the current practices
of physicians who administer botulinum type A toxins. Consensus
recommendations from leaders in the field are also presented.
11:30 am
Title:
How Accurate is Botulinum Toxin A?
Can we Correct for Eyebrow Height
Asymmetry?
Summary: Of the 1,000 physicians invited to participate in the
survey, 322 responded (32.2%). The majority of physicians surveyed
(46.8%) had been in practice for greater than 15 years. A total
of 77.9% utilize bacteriostatic saline for reconstitution and most
physicians (68.6 %) routinely store BT-A for a period of greater
than one week and safely use each toxin vial for more than one
patient. Not a single case of infection was observed. Lastly, 67% of
respondents felt the reconstituted toxin vials could be safely kept for
treating patients for a duration between one to four weeks.
Author(s): Jason Sneath, MD; Shannon Humphrey FRCPC;
Alastair Carruthers FRCPC; Jean Carruthers, MD
Conclusion: A single vial of BT-A can be safely administered to
multiple patients, assuming standard safe injection techniques are
followed. After reconstitution, BT-A remains safe and effective when
stored beyond the recommended time period of four hours.
The author(s) has no relationship to disclose.
86
Purpose: Botulinum toxin type A (BoNT-A) is commonly used inthe
treatment of dynamic facial rhytides and to achieve a modest brow
lift. Thetheorized mechanism for brow elevation is that it results
from inactivation ofthe brow depressors (procerus, orbicularis oculi,
and corrugator superciliimuscles). Expertconsensus is that increased
injection depth delivers more BoNT-A to thesesdepressors and causes
increased elevation. Conversely, shallow injections have greater
effect on the superficial,brow elevating, frontalis. This techniqueis
applied to the correction of brow height asymmetry but no studies
existdemonstrating the theory.
Design: A prospective, open label, split face analysis wasperformed
on photographs of 23 women in this single centre trial. Subjects
were included upon completionof the upper face rhytides study2
for this addendum study if theyhad investigator identified eyebrow
height asymmetry. The initial upper face study included women of
any racebetween the ages of 18 to 65. Following the completion
of the upper face studyand return to baseline, subjects received
a complimentary allotment of 64 unitsof BoNT-A. The total dose
was divided among the 16 injection sites chosen inthe upper face
study: 5 injections in the glabellar, 5 injections in theforehead,
and 3 injections in each lateral canthal area for crow’s-feet.
Theselected dose for each injection site was symmetrical and chosen
by theinvestigator to achieve the optimal cosmetic result for each
subject,reflecting clinical practice. On the side where increased brow
lift was desired,deep injections into the medial corrugator were
performed, and shallowinjections on the opposite side. Photographs
were taken at baseline and week 4for comparison measurements at
the canthus, midpupillary line, and outer edge.
Summary: All 23 womenenrolled completed baseline injections
and returned for the 4 week follow-up. There was no significant
difference at4 weeks in the change in brow height between the sides
that received deep vs.shallow BoNT-A injection.
Conclusion: It has beenhypothesized that lateral brow lift following
glabellar injection of BoNT-A isactually caused by an inactivation of
the inferomedial frontalis and a compensatoryincrease in the resting
tone of the remainder of the frontalis muscle. This maypartially
explain why a superficial injection can also lead to brow lift.The
lack ofsignificant change in brown height between the sides that
received deep vs.shallow BoNT-A injection is likely due to the
diffusion and migration of BoNT-Abetween the muscle layers.
The author(s) serves on the Advisory Board for Galderma, Graceway
Canada Company, Abbott Laboratories Ltd., Janssen-Ortho Inc.;
received research funding via a grant from Allergan Inc, Irvine,
California.
11:35 am
Title:
Inflammtion and Fibrosis on Mohs
Levels, What Does It Mean?
Author(s): Jason Sneath, MD; Jilian Macdonald, MD;
Bryce Cowan, MD; David Zloty, MD
Purpose: In Mohsmicrographic surgery, many surgeons will take an
additional level based solelyon the presence of scar or inflammation.
We are not aware of any studies examining how frequently tumor
isdetected on subsequent levels. We sought to determine the
frequency with which this occurs and parameterspredicting tumor
discovery on successive levels.
Design: A retrospective study wasperformed on 22,419 lesions
treated with Mohs micrographic surgery at a singleinstitution
between 1996 and 2011. An additional level wastaken based on the
presence of inflammation or fibrosis on 6233 lesions(27.8%). This
resulted indetection of tumor on subsequent levels on 133 lesions
(2.13%) in 132 patients(55 females, 76 males; age range 38-87 yrs).
Slides for these 133 lesions were reviewed by the respective surgeons
to determine the reason for taking the extra level. Patient records
were reviewed to determine tumor type and location.
Summary: Of the 133 lesions found on a level taken based
on the presence of inflammation or fibrosis, 87 lesions were
basal cell carcinoma,31 squamous cell carcinoma, 12 lentigo
maligna, 1 sebaceous carcinoma, 1atypical fibroxanthoma, and
1 dermatofibrosarcoma protuberans. The distribution of the
tumorsincluded: 39% on the nose, 13% eyelids, 12% cheeks, 10%
forehead, 7% ears, 7%scalp, 3% perioral, and 9% were located on
other body sites. Upon review of the slides by therespective surgeons
it was determined that a level was taken for inflammationalone in
63.7%, for fibrosis in 56.0% and for atypia in 16.5%. 14 collision
tumors were identified,mostly superficial multicentric basal cell
carcinoma, and were preceded byinflammation in 71% of cases.
Conclusion: Factors that maypredict the presence of tumor on
subsequent levels include eccentrically placedor shallow first
levels failing to completely encompass previous surgical scar.The
presence of dense inflammation may signal an adjacent collision
tumor ormay mask tumor cells resulting in a false-negative result.
Significant atypia, specifically severeactinic change or extensive
melanocytic hyperplasia, presents a challengingdiagnostic dilemma.
Approximately2.13% of levels prompted by the presence of
inflammation or scar result insubsequent tumor detection. Taking an
addition level may be warranted to ensure complete tumorremoval
and to maintain the low recurrence rates associated with Mohs
surgery.
11:40 am
Title:
Is Cryosurgery or Curettage More
Effective at Treating Seborrheic
Keratoses?
Author(s): Lance D. Wood, MD; Jaimon Stucki;
Christopher Hollenbeak PhD; Jeffrey Miller, MD
Purpose: Comparative determination of efficacy of cryosurgery and
curettage in the treatment of seborrheic keratoses on the trunk and
proximal extremities.
Design: After IRB approval, we conducted a prospective,
randomized right-left, within-patient trial comparing cryosurgery
and curettage for the treatment of seborrheic keratoses. We enrolled
twenty-four patients with multiple seborrheic keratoses on their
trunk and proximal extremities for this study. Seborrheic keratoses
on one side of each patient’s trunk and/or proximal extremities were
treated with cryosurgery and those on the other side with curettage.
Symptom and appearance-related outcomes were evaluated by the
patients via questionnaire and by a blinded physician observer.
Summary: Using a 10-point rating scale (1 no pain, 10 severe
pain), subjects reported a nearly equal amount of discomfort with
cryosurgery and curettage at the time of the procedure (2.6 and
1.8 respectively) and during short-term follow-up (1.2 and 1.8
respectively). No statistically significant difference in the patients’
perspective of the overall cosmesis rating (8.6 for cryosurgery; 8.3
for curettage) [1 lesion unchanged; 10 normal appearing skin]) was
identified. Investigator rating at 6 weeks post- intervention did
reveal a statistically significant texture variation in the cryosurgery
group compared to the curettage group (4.2 and 1.7 respectively [1
flat; 10 lesion elevation unchanged]).
Conclusion: We found no statistically significant difference in
patient preference with regards to curettage versus cryotherapy of
seborrheic keratoses located on the trunk or proximal extremities.
However, there was a trend toward more patients preferring
cryosurgery for the treatment of their seborrheic keratoses. This is
likely due to other factors such as the decreased amount of postprocedure wound care required following cryosurgery in comparison
with curettage. Both treatment interventions resulted in cosmetically
acceptable results as reported by patients.
87
11:45 am
Title:
Sun Screen Use, Behaviors and Attitudes
among NCAA Collegiate Athletes
Author(s): Ashley Wysong, MD; Joyce Copeland, MD;
Jean Tang, MD; Hayes Gladstone, MD
Purpose: Ultraviolet radiation is a known risk factor for melanoma
and non-melanoma skin cancers as well as photoaging and rhytides.
Outdoor sport athletes are at high risk as they experience significant
sun exposure throughout the year and often during the peak
hours of ultraviolet radiation. In addition, sweating due to physical
exertion may facilitate sun damage by increasing photosensitivity
of the skin and increasing the risk of sunburn. Multiple studies have
shown links between early sun exposure during adolescence and skin
cancer. NCAA athletes are arguably at increased risk both in terms of
total early exposure as well as total lifetime exposure. The purpose
of this study was to identify attitudes and behaviors about sunscreen
use among this high risk population as well as to understand specific
characteristics about sunscreen products that may be barriers to use.
Design: An anonymous survey study of a representative sample
of approximately 150 NCAA athletes at a Division I University was
conducted. No protected health information was collected. Data
were obtained on demographics, skin type, sun exposure, sunscreen
use, specific characteristics of sunscreens, and attitudes about
perceived risks and benefits of using sunscreen. We restricted our
participants to athletes over 18 years of age. Statistical analysis was
performed in SAS v10.0.
Summary: A total of 149 NCAA athletes participated in the survey
from 11 different sports teams. Sixty-three percent (95/149) of the
athletes were female. Sixty-eight percent classified themselves as
Fitzpatrick Skin Types II or III with 22% as class IV and 7.5% as class
V or VI. Almost 80% of the respondents spent greater than 2 hours
per day training outdoors with 57% spending 3 or more hours
and 25% spending 5 or more per day. Seventy-two percent of the
athletes spend 8 or more months training and competing outdoors
with 37% spending all 12 months outdoors. The portions of the
body typically exposed include face/head (91%), arms (95%), legs
(80.3%), chest (30%) and back (40%). In addition to outdoor sun
exposure, 29% of athletes had used a tanning bed in the past.Of
the athletes, 82% had experienced greater then one sunburn in the
past year with 22% experiencing four or more sunburns. Thirteen
percent of those with sunburns had developed a blistering sunburn
in the past year. In regards to sun exposure, the athletes were most
concerned about skin cancer (37%), premature wrinkles (21%), and
sunburns (17%). Ninety-seven percent of athletes agree or strongly
agree that sunscreen will help protect them from developing skin
cancer. Almost 30% of athletes have a relative who has had skin
cancer (40% of those known to be melanoma) and 75% know
someone who has ever had skin cancer.Almost 75% of the athletes
use sunscreen less than 3 days per week with over 50% who stated
that they never use sunscreen. Of those who used sunscreen, 18%
used SPF<30, 65% used SPF 30-60, and 18% used SPF>60. The most
common reasons for not using sunscreen included forgetting to put
it on (55%), liking to be tan (40%), inconvenienceof use (38%), and
belief that individual “doesn’t burn” (38%). In regards to specific
characteristics of suncreen that may be barriers to use, athletes noted
most commonly the greasy feel of sunscreen (26%), that applying
sunscreen takes too much time (19%),that sunscreen burns their eyes
(13%), and that sunscreen gives them acne (12%). Additional reasons
for not using sunscreen included that sunscreen smells badly, is too
expensive, often “sweats off”, and causes rashes/irritation.
Conclusion: Elite NCAA athletes have high UV exposure that
arguably puts them at increased risk for skin cancers, photoaging,
and premature rhytides. The average NCAA athlete in our study
88
spent over 3 hours per day, 8-12 months per year training outdoors
which equates to between 480 and 1000 hours of peak sun exposure
per year. Despite 97% agreement that sunscreen willhelp prevent
development of skin cancer and 87% of athletes having experienced
sunburns themselves in the past year, more than 50% never used
sunscreen and almost 75% used sunscreen less than 3 days per week.
Further efforts must be made to reach this high-risk population,
particulary as the behaviors and attitudes of elite athletes often
serve as models for children and young adults. In addition, athletes
could benefit from the continued development and distribution
of photoprotectant sunblocks, sunscreens, and cosmeceuticals that
are easier and faster to apply, more cosmetically elegant (“feel less
greasy”), and do not sweat off or sting the eyes.
Dr. Gladstone: has received equipment lent from Sciton; Dr. Tang
received an NIH K23 award career development award.
11:55 am
Title:
Clinical Efficacy and Safety Evaluation
of the New Monopolar Radiofrequency
(mRF) Device With Comfort Pulsed
Technology for the Treatment of Facial
Skin Laxity: a 10 Month Experience With
64 Patients
Author(s): Arden Fredeking, MD; Ane Massaki, MD;
Sabrina Fabi, MD; Mitchel Goldman, MD
Purpose: To evaluate the efficacy and safety of the new monopolar
radiofrequency (mRF) device with Comfort PulseTechnology (CPT) for
facial skin tightening. Efficacy was determined by photographs and
by a patient answered questionnaire on a 4-point scale.
Design: All patients without cardiac implanted electronic devices
who were treated with the new mRF device with CPT at our clinic
between September 2010 and June 2011 were included. Data was
collected retrospectively. This study is completely nonfunded and
not sponsored by the product’s manufacturer. All patients paid
in full for their procedures. Written consent for photography
release was obtained prior to taking images. Candidates for the
procedure were evaluated based on their degree of skin laxity. All
patients were treated using a similar technique. No topical or oral
anesthetic, regional nerve block or ice application was used before
radiofrequency treatments because providers used patient feedback
to adjust energy settings accordingly. Patients were treated with
two consecutive passes, 2minutes apart, with the 3cm2 tip to the
full treatment area. The remaining treatment passes were used at
the providers’ discretion on vectors needing greater skintightening.
In general, energy levels between 14-24J/cm2 were used with an
average of 900 pulses. Vibration levels of 1, 2, and 3 were used for
the face, on average level 2 was used on patients who could tolerate
the vibration. Weeks to months after the treatment, phone calls
were placed to patients to ask questions with regard to efficacy
and presence of any possible adverse reactionsfrom their treatment.
A 4-point scale (0-no improvement from their own baseline,
1-mild improvement, 2-moderate improvement, and 3-excellent
improvement) was used to quantify their perceived degree of
improvement from the treatment. A similar 4-point scale (0=none,
1=mild, 2=moderate, 3=extreme) was used to quantify the amount
of heat they felt during the procedure, and the degree (if present) of
both edema and erythema after the procedure. Pain was quantified
on a 0-10 scale. Scores of 0-4 are considered mild, 5-7 moderate, and
8-10 is extreme. Photographs were taken at monthly intervals after
the procedure and a sample of patients were able to view their own
before and after photographs and answer the same questions with
regards to efficacy after viewing their photos.
Summary: We describe seventy-eight patients treated with the new
mRF device for mild to moderate facial skin laxity. Fourteen patients
were lost to follow-up and 64 were included in our retrospective
analysis. The majority of our patients 81% (n=52) reported at least
mild correction of their facial skin laxity. A moderate improvement
was reported in 29%(n=19) of patients while only 3% (n=2) of
patients reported excellent correction in skin laxity. The mean level
of skin laxity correction overall was 1.15 (range 0-4) and the mean
skin texture improvement score was 0.9 (range 0-4). The mean
degree of pain was 6.06 (range 0-10) and the meanamount of
heat that patients described was 1.99 (range 0-4). The mean level
of edema experienced by patients after the procedure was 0.34
(between none to mild) which lasted less than 24 hours for 40%
(n=8) patients and for 1-3 days in 40% (n=8) of patients experiencing
edema. One patient experienced edema for greater than one week.
The mean level of erythema experienced was 0.67 (between none
to mild) which lasted for less than 24 hours in the majority (51%) of
patients experiencing erythema. No patient experienced erythema
for more than one week. For patients who were 1-3 months out
from their treatments, skin laxity correction was 0.71(range 0-4) and
skin texture improvement was 0.5 (range 0-4). For patients who were
4-6 months out from their treatments, skin laxity correction was 1.5
and skin texture improvement was 0.90. For patients who were 7-10
months out from their treatments, skin laxity correction was 1.19 and
skin texture improvement was 1.23. Skin laxity correction for patients
4-6 months out from their treatment was significantly greater than
patients who were 1-3 months out from their treatments (p=0.0005).
Skin texture improvement at 7-10 months out from treatment was
significantly greater than skin texture improvement at 1-3 months
(p=0.021). Of the 64 patients who answered the questionnaire, 28
would have the procedure again, 20 would not have the procedure
again and 16 patients were undecided on whether or not they
would consider having the procedure again. Of the patients who
said they would have the procedure repeated, the majority of them
59%(n=16) were 4-6 months out from the procedure. One patient
reported blistering after her treatment andafter investigation,
the company deemed the tip she was treated with as faulty. No
scarring or prolonged pain or fat atrophy was reported in any
patients treated. Follow-up photography was available for 32 of our
78patients.
Conclusion: This study examines the results of skin laxity and
textural correction in seventy-eight patients after treatment with
the new mRF device. Our primary limitation to this study is relying
on patient recall to answer the questionnaire. We also document
our patients’ subjective input regarding skin laxity and textural
correction, since ultimately patient satisfaction with a procedure
and perceived improvement is more important than investigator
grading using constructed parameters. Our study does not describe
efficacy or adverse events after 10 months from treatment. On
average ourpatients experienced mild to moderate results with
moderate pain. Our study however is limited in its retrospective
nature. Although these treatments appear to give mild to moderate
improvement, further studies with longer follow up are needed.
extremely low laser settings are used in combination with deep plane
rhytidectomy. We explored the possibility of combining recently
developed fractional CO2 resurfacing technology with standard
rhytidectomy, and established the extent of skin flap elevation as
well as laser settings for safe resurfacing during this procedure.
Design: Simultaneous supraplatysmal rhytidectomy combined with
full face and neck fractional CO2 resurfacing was performed on
20 patients with an average age of 56 years (range 46-72 years).
Skin flaps were elevated to the level of the nasolabial fold and
midline of the neck. Resurfacing was performed using the Fraxel
Re:pair 10,600 nm Fractional CO2 laser (Solta Medical, Hayward
California). Skin flaps were treated at 20 mJ with a spot density
of 500 microthermal zones of ablation (MTZs) per cm2, with 4
alternating passes creating a uniform final density of 2000 MTZ/cm2.
Non-undermined perioral, nasal and forehead skin was resurfaced
with 4 passes at 40 mJ and 500 MTZ/cm2(Fig. 1B). Excess resurfaced
skin was examined histologically. Flexzan occlusive dressing (Bertek,
Morgan Town WVA) was applied to the face and neck and removed
5 days postoperatively. Patients were seen in follow-up weekly for 2
months.
Summary: We observed no cases of delayed healing or other
complications. Resurfaced skin re-epithelialized within 7 days, and
all patients were able to wear makeup 10 days postoperatively.
Histologic examination of resected skin revealed cylindrical zones
of ablation (MTZs) ~234 µm in width penetrating to a depth of
~445µm. Treated patients were very satisfied with their cosmetic
outcomes and were pleased to avoid undergoing a second procedure
with additional weeks of healing time.
Conclusion: Important differences between traditional CO2methods
and newer techniques of fractional resurfacing made this combined
procedure possible without associated delayed healing or loss in
flap integrity. Although traditional CO2 lasers ablate less than 20
µm per pass, skin surface coverage is 100%. This results in bulk
heating and thermal damage to the cutaneous microvasculature,
potentially causing flap failure after only 1-2 passes. In contrast,
MTZs actually penetrate deeper (400-650 µm) into the dermal
collagen, but spare approximately 80% of tissue, thereby preserving
a functional microvasculature that helps with healing and flap
survival. In vivo experiments demonstrate rapid reepithelialization,
followed by enduring dermal remodeling. Fractional laser technology
also enables the treating physician to overcome limitations in
cosmetic outcome that have prohibited past attempts to combine
rhytidectomy with resurfacing. Traditional CO2 using low energy
settings during rhytidectomy results in inferior resurfacing, and
higher-energy treatments ofisolated areas such as the perioral region
induce lines of demarcation between treated and untreated skin.
Similarly, traditional CO2 is not recommended for the neck, creating
a noticeable difference in quality between the resurfaced face
and untreated neck. In contrast, fractional resurfacing allows the
entire face and neck to be treated during rhytidectomy, imparting
a youthful quality while avoiding lines of demarcation. Patients also
appreciate the convenience of the combined procedure.
12:00 pm
Title:
Establishing the Safety and Efficacy of
Simultaneous Facelift and Intraoperative
Full Face and Neck Fractional CO2
Resurfacing
12:05 pm
Title:
A Novel Approach to the Treatment of
Medial Canthal Webs Using an Ablative
Fractional Laser-based Protocol
Author(s): Tyler Hollmig, MD; Steven Struck, MD; Basil Hantash PhD
Author(s): Tara Dever, MD; Peter Shumaker, MD
Purpose: Current literature provides little support for combining
rhytidectomy with full face CO2 resurfacing, except in cases where
Purpose: Scar contractures in the medial canthal area resulting
in webs are a well-known complication of surgery in this unique
89
region. These webs may interfere with the patient’s central vision
and lead to a poor cosmetic outcome. Conventional management
includes massage, intralesional steroids, and even additional surgical
procedures such as flaps. However, these interventions may be
associated with limited efficacy, a prolonged treatment period,
additional surgical morbidity, and other risks inherent to injections
of a suspension in the region of the ophthalmic circulation.
GD231 - Cutting Edge Research Grant Award and
Dermatologic Surgery Research Abstracts
1:36 pm
Title:
Voriconazole as a Risk Factor for
Squamous Cell Carcinoma in Lung
Transplant Recipients
Design: Ablative fractional laser resurfacing is an emerging
technique with multiple reports demonstrating cosmetic
enhancements in aged and photodamaged skin. However, our
clinical experience using ablative fractional laser resurfacing for
traumatic scars in our wounded warrior population indicates that
this technique frequently results in relaxation of scar contractures
with concomitant cosmetic improvements. We present three cases of
mild to moderate medial canthal webbing following Mohs surgery
that responded to a series of monthly fractional laser treatments
with improvements in scar contracture and overall cosmetic outcome.
Author(s): Andreas Boker, MD; Jonathan Singer, MD, MS2;
Sarah Arron, MD, PhD; Department of Dermatology and
Dermatologic Surgery, University of California, San
Francisco 2 of Pulmonary and Critical Care Medicine,
Department of Medicine University of California,
San Francisco
Summary: Potential advantages include improvements in cosmesis,
decreased use of periocular steroids, and possible elimination of the
need for additional corrective surgery.
Conclusion: A fractional laser-based protocol remains a novel
alternative to the treatment of medial canthal webs.
1:30pm
Title:
Cost comparison of Non-melanoma Skin
Cancer (NMSC) Treatment Options: The
Actual Global Costs Incurred by One
Managed Care Organization
Author(s): Vanessa A. London, MD
Non-melanoma skin cancer (NMSC) is the most common malignancy
in the United States and the incidence has continued to rise steadily.
The costs to Medicare alone are over half a billion dollars annually,
which makes it the 5th most costly cancer. While the morbidity
and mortality are not as high as other cancers, NMSC is a huge
financial burden to society. There are a multitude of treatment
options for NMSC, including: cryotherapy, electrodessication and
curettage (ED/C), topical agents such as imiquimod, traditional
surgical excision, Moh’s micrographic surgery (MMS), and radiation
therapy. Especially in light of the current economic and health care
system changes, it has become even more crucial to understand the
true costs of the many treatment options for NMSC. Many studies
have attempted to compare the costs of different treatments for
NMSC.
However, they fail to compare actual costs and instead use theoretic
models to derive calculated figures. The few studies that do compare
actual costs in a randomized controlled manner do not include many
associated costs. We hope to provide a more
accurate assessment of the true cost of many treatment options
for non-melanoma skin cancer. We plan to combine detailed chart
review with claims data made to a managed care organization to
examine the actual global costs for many treatment options.
90
250-Word Layman’s Statement:
In recent years, several reports have emerged in the dermatology
and transplant literature linking the antifungal voriconazole to
squamous cell carcinoma (SCC) of the skin. Furthermore, it has been
suggested that immunosuppressed patients receiving voriconazole
develop more aggressive tumors and are more likely to die from
their skin cancer. The goal of this project is to investigate the
association between voriconazole use in lung transplant recipients
and the development and behavior of cutaneous SCC in this
population.
To help answer these questions, we have designed a retrospective
cohort study to analyze the relationship of voriconazole and
cutaneous SCC in lung transplant recipients.
We will be using the combined databases of the University of
California San Francisco High Risk Skin Cancer Program and the UCSF
Lung Transplant program. We hypothesize that patients treated with
voriconazole after lung transplant will have a
higher prevalence of SCC, and that this association will be dosedependent. We also postulate that these SCC will be of a more
aggressive histologic subtype.
Identifying specific risk factors leading to more frequent and
aggressive skin cancers in lung transplant recipients receiving
voriconazole will help clinicians tailor antifungal therapy in this
population and identify patients who should avoid this
medication in their post-transplant course.
1:42 pm
Title:
An Investigation of Coagulation Cascade
Activation and Induction of Fibrinolysis
by Foam Scierotherapy of Reticular Veins
Authors:
Sabrina G. Fabi MD, Jennifer D. Peterson MD;
Mitchel P. Goldman MD
Sclerotherapy is a method by which medicine is injected into blood
or lymphatic vessels, to close them off. The medicine injected,
or sclerosant, may come as a liquid or foam, which is made from
mixing a sclerosing solution with room air. In the past few decades
sclerotherapy using foam, was introduced with the advantage of
being more effective at closing off vessels, including leg veins.
The technique used to create foam by mixing sclerosing solution
with air, results in differences in bubble size within the foam. In
blood, these bubbles have been shown to cause the activation
and aggregation of platelets, a cell involved in stopping the
bleeding process and forming a clot. In blood-filled test tubes, high
concentrations of sodium tetradecyl, a type of sclerosing foam,
have been shown to break down factors involved in forming blood
clots and cause platelets to lump together. Disturbances in blood
clotting after foam sclerotherapy of leg veins could potentially have
significant implications.The purpose of this study is to evaluate
the effect foam sclerotherapy of leg veins has on factors involved
in blood clotting. Blood drawn from patients before they have
sclerotherapy will be compared to blood drawn after treatment,
to see if levels of factors involved in blood clotting have changed
significantly.
aim to explore the genetics of non-melanoma skin cancers
(specifically basal cell carcinoma and squamous cell carcinoma) in
patients who develop multiple skin cancers in one year by using
comparative genomic hybridization analysis.
1:48 pm
Title:
Collagenase-Digested Autologous Fat
Transfer
2:00 pm
Title:
Rate of Change in Diagnosis after
Excision of Biopsy-proven Atypical Nevi
and Examination of Risk of Malignant
Potential.
Authors:
Author(s): Kavitha K. Reddy, MD
Naomi Lawrence, MD
Blendzyme digested fat will produce a superior longevity and
increased volume correction of age-related facial rhytides when
compared to nondigested autologous fat. A primary objective of this
study is to provide an enhanced method of soft-tissue augmentation
that can be extended to the correction of volume deficits resulting
from variety of causes including age-related volume loss, traumatic
injuries, and cancer surgery.
Significance of the Research to the Field of Dermatologic Surgery:
The importance of this research is to investigate the most efficacious
and cost-effective method of correcting volumetric deficits. The
results of this study may provide an enhanced method of fat
preparation for autologous fat transfer. The applications for an
autologous, semi-permanent filler are innumerable, and use for
large volume correction of significant defects from traumatic and
post-surgical defects may provide a new standard for reconstructive
surgery.
1:54 pm
Title:
Catastrophic Cutaneous Carcinon,atosis
in the Non-organ Transplant Population
Author(s): Ellen S. Marmur, MD
Catastrophic cutaneous carcinomatosis (CCC) is described as
development of at least ten distinct non-melanoma skin cancers in
organ transplant recipients (OTRs) within one calendar year. Organ
transplant recipients are at increased risk of having both systemic
and cutaneous cancers, with an overall increased risk 3- to 4-fold
greater than that in the general population. In a Norwegian study,
squamous cell carcinoma (SCC) incidence in OTR5 was estimated to
be 65-fold greater, and basal cell carcinoma (BCC) 10-fold greater
than in the general population. In our cutaneous oncology practice
in a tertiary care academic medical center, we have noticed a pattern
of cutaneous carcinomatosis meeting the definition of CCC occurring
in immunocompetent (CCC-lC) patients without a history of organ
transplant or immunosuppression.
These patients appeared to develop many non-melanoma skin
cancers (NMSC5) within a short span of time when compared to
sporadic skin cancer occurring in general population. In a previous
study conducted in the Mount Sinai Department of Dermatology, we
described via a case-control study the epidemiologic characteristics
of the CCC-IC patients. To our knowledge, the genetic variations that
may account for CCC have yet to be established. In this study, we
Excision of clinically atypical nevi is a common practice in
dermatology and represents one of the most common procedures
performed by dermatologists and undergone by patients. Atypical
nevi are initially biopsied to assess the patient’s overall risk for
melanoma and/or to evaluate a particular lesion for melanoma. Once
a biopsy result has been obtained showing incompletely excised
dysplastic nevus, the surgical management remains ill-defined and
largely without evidence-based practice. In particular, a finding of
mild to moderate or moderately atypical nevus is very
common and there is significant variation in management. Surgical
excision is common. It is felt that the risk of the nevus transforming
to melanoma is exceedingly low. Therefore many lesions are excised
for the purpose of complete histologic evaluation to assess for an
area of potentially increased atypia in the residual nevus. Excision
results in a second procedure for the patient with a significantly
larger scar, potential complications, and significant utilization of
health care resources allocated for melanoma prevention. However,
the rate of increased atypia on complete excision has not been
assessed and recommendations for surgical excision of moderately
atypical nevi remain without evidence or reporting of outcomes.
This study aims to determine the rate of clinically significant change
in diagnosis upon complete excision of initially incompletely excised
mild to moderate and moderately atypical nevi, to determine if
recommendations for the patient to undergo complete excision of
the nevus after initial biopsy for the purpose of complete histologic
evaluation are substantiated. The findings would represent the
first report in the literature evaluating this subject and provide
information on outcomes that may aid many thousands of patients
and their dermatologic surgeons who are faced with the
common diagnosis of a moderately atypical nevus, improving the
understanding of the risks and benefits of subsequent surgical
excision.
2:12 pm
Title:
Combining Field Therapies With
Sequential Topical 5-Fluorouracil
Followed By 5-Aminolevulinic Acid
Photodynamic Therapy For Actinic
Keratosis
Author(s): Edidiong Ntuen Kaminska, MD; Maria Tsoukas, MD
Purpose: Established field monotherapies for widespread
actinic keratoses (AKs) include topical 5- fluorouracil (5-FU) and
91
5-aminolevulinic acid photodynamic therapy (ALA PDT). Singly, these
treatments are effective in treating AKs; however both modalities
often require application over several weeks or multiple sessions. Our
goal was to explore combined field therapies with sequential 5-FU
and ALA PDT in two cases involving widespread AKs.
was generally well tolerated, and the 33 patients with advanced
BCC achieved a 58% response rate (LoRusso, Clin Cancer Res
2011;17:2502–2511), leading to a pivotal Phase II study of vismodegib
in patients with laBCC and mBCC. Here we describe the results of this
study, focusing on those patients with laBCC.
Design: Normal 0 false false false EN-US X-NONE X-NONE Lesional
skin was pre-treated for 2 weeks with daily topical 5-FU, followed by
ALA PDT. 20% ALA was applied per manufacture’s protocol (Levulan
Kerastick, Dusa Pharmaceuticals, Inc., 3 hour incubation followed
by16 minute 40 seconds exposure to BLU U, 417 nm). Participants
were followed for up to 15 months.
Design: In this multicenter, nonrandomized study patients received
150 mg daily oral vismodegib until disease progression. Patients
with laBCC had histologically confirmed disease that was inoperable
or for whom surgery would be significantly disfiguring; those with
mBCC had histologically confirmed, radiographically measurable
metastases. The primary endpoint was response rate as assessed by
an independent review facility (IRF). A novel composite endpoint for
laBCC, combining measures of tumor size and ulceration (30% size
reduction by physical exam/radiography and/or complete resolution
of ulceration) was devised. Secondary endpoints included duration of
response, response per investigator (INV), and safety.
Summary: Normal 0 false false false EN-US X-NONE X-NONE One
sequential 5-FU and ALA PDT treatment eradicated up to 99% of
AKs. Our patients had previously required multiple 5-FU or ALA
PDT sessions as single modalities to achieve similar results. Cases
demonstrated minimal recurrence up to 15 months. Excellent
tolerability, compliance and cosmetic results were also observed.
The clinical endpoints after 5-FU pre-treatment were moderate
inflammation and after ALA PDT, redness and crusting. Compared
to 5-FU in sequential therapy, effective 5-FU monotherapy needs
to result in erosions and ulcers, which may cause severe patient
discomfort, poor compliance and undesirable cosmetic outcomes
(i.e. scarring and pigment changes). ALA PDT side effects can be
managed with thorough post-op instructions. The beneficial results
of this mode are supported by the following: a. 5-FU disrupts
the epidermal barrier in AKs, eliminates thick hyperkeratosis and
facilitates ALA penetration. b. Flattening of lesions optimizes
optics during light exposure with decreased scattering and better
light penetration in the skin. c. Erythema post 5-FU treatment
may increase blood flow per unit area, thereby providing higher
amounts of oxygen and facilitating the photodynamic phenomenon
via increased oxygen radicals. d. Photosensitizing activity of 5-FU is
demonstrated with absorption spectra between 250-450nm. This may
contribute to additional photosensitization of targeted AKs.
Conclusion: Normal 0 false false false EN-US X-NONE X-NONE
Sequential 5-FU and ALA PDT optimized AK therapy, decreased
recurrence rates, number of patient visits and procedure
expenses. This combination field therapy may provide an excellent
tool in eradicating AKs in healthy elderly as well as high risk
immunosuppressed patients.
The author(s) has no interest to disclose.
2:18 pm
Title:
Efficacy and Safety of the Hedgehog
Pathway Inhibitor Vismodegib in
Patients with Advanced Basal Cell
Carcinoma: A Pivotal Multicenter Trial
Author(s): Michael R. Migden, MD; Anthony E Oro, MD;
Axel Hauschild, MD; Karl Lewis, MD; Simon Yoo, MD;
Howard Mackey PhD; Ivor Caro, MD;
Aleksandar Sekulic, MD
Purpose: Surgery can effectively treat most cases of basal cell
carcinoma (BCC). In a smaller percentage of patients there is
progression to locally advanced (laBCC) disease that is inoperable
and/or inappropriate for surgery and/or life-threatening and,
rarely, to metastatic (mBCC) disease. There is no standard effective
therapy for these patients. Abnormal signaling in the Hedgehog
(Hh) pathway is implicated in the vast majority of BCC cases.
Vismodegib (GDC-0449) is a first-in-class, oral therapy designed to
selectively inhibit Hh pathway signaling. In a Phase I trial, vismodegib
92
Summary: A total of 104 patients (71 laBCC) were enrolled at 31
sites in the USA, Europe, and Australia. For laBCC, response rates
were 43% (95% CI 31–56%; p<0.0001) and 60% (95% CI 47–72%)
by IRF and INV, respectively. A clinical benefit—a response at any
time or stable disease lasting 24 weeks by IRF—was achieved by
75% of laBCC patients. The median duration of response by IRF
and INV was 7.6 months. Biopsies were required by Week 24 or at
time of INV-assessed response if this was noted before 24 weeks.
Histology of these samples demonstrated no residual BCC in 54%
of laBCC patients. In patients with mBCC, the response rate by IRF
was 30% and median duration of response was 7.6 months by IRF.
Adverse events (AEs) in 30% of patients (laBCC and mBCC) were
muscle spasms, alopecia, taste disturbance, weight loss, and fatigue.
Serious AEs related to vismodegib were reported in 4 patients (4%);
1 patient each with cholestasis, pulmonary embolism, syncope and
dehydration, and cardiac failure and pneumonia. Fatal AEs were
reported in 7 patients (7%), none considered related to vismodegib.
Photographic case studies detailing response to vismodegib in the
presenting author’s own patients with laBCC will be presented.
Conclusion: This pivotal study confirms the substantial clinical
benefit of vismodegib treatment for patients with aBCC, and
demonstrates the potential role of vismodegib for the treatment
of this condition. A novel composite endpoint for response rate
offers dermatologists an additional tool for evaluating therapeutic
response in laBCC.
Dr Migden has participated in advisory boards for Genentech and
Novartis; Dr Oro serves as an advisor for Genentech; has received
research funding from NIH; Dr Hauschild has received speaking
honoraria from Roche, GSK, MSK, BMS, and has received research
funding from MSD, BMS, GSK, Celgene, Eisai, Philochem; Dr Solomon
has no interest to disclose; Dr Mackey is a Roche stockholder; Dr
Sekulic is an advisory board member for Genentech; Dr Hauschild
serves as advisor for Roche, BMS, Celgene, MSD, BioVex, Cubai, GSK,
and Astra Zeneca; Dr Lewis serves as advisor for Genentech and
Prometheus, has received research funding from Genentech; Dr Yoo
has stock options with Wound Care Technology Inc.; Dr Solomon has
received an ADCS Grant
2:24 pm
Title:
Prospective, Double-Blind, Randomized
Pilot Study Comparing Ibuprofen to a
Narcotic for Pain Management During
Micro-Focused Ultrasound Treatment
Author(s): Hema Sundaram, MD; Ashley Lodha, MD
Purpose: Microfocused ultrasound (MFU) has emerged as a new
aesthetic energy technology for skin lifting and tightening, with
FDA clearance in 2009 via the de novo 510(k) process as a Class II
medical device for non-surgical brow-lifting. Prospective, controlled
clinical studies with an evidence level of II using validated, quantified
measurement scales have shown the device to be safe and efficacious
for non-surgical lifting. A challenge reported by some clinicians
is maintaining patient comfort during treatment, which spares
the epidermis and creates micro-zones of thermal coagulation at
specific depths in the dermis and hypodermis. Patients are typically
pre-medicated for pain relief with a single dose of a narcotic such
as hydrocodone/acetominophen. No controlled studies have been
performed previously to substantiate anecdotal reports that this
improves patient comfort during MFU treatment. Furthermore,
an alternative method of pain relief would be advantageous for
patients seeking to resume normal daily activities such as driving
immediately after MFU (which itself produces no post-procedural
recovery time), since this is not possible following pre-medication
with a narcotic. It has been reported anecdotally that ibuprofen may
provide pain relief during MFU treatment.The primary objective of
this study was to compare the level of pain control provided by a
prescription-strength dose of ibuprofen to the level of pain control
provided by a prescription-strength narcotic when used prior to MFU
treatment. Variation in the level of pain during treatment of specific
facial zones, and safety and efficacy of MFU during a 180 day posttreatment period were assessed as secondary outcomes.
Design: 20 healthy subjects were enrolled in the study and randomly
assigned to one of two groups, A and B. Both groups received
MFU treatment to the full face and neck at depths of 3mm and
4.5mm according to a standardized protocol. Group A received
800mg of ibuprofen 60 minutes before treatment, while Group B
received 10mg hydrocodone/500mg acetaminophen 60 minutes
before treatment. The investigator, treating subinvestigator and
study subjects were blinded in regards to the pre-medication that
was given. Subjects reported pain scores on a 10-point Numeric
Rating Scale (NRS) immediately after treatment of each facial zone
(brow/periorbital, cheek, submental and submandibular) and for
each depth to which it was treated (3.0mm or 4.5mm). Treatment
efficacy was assessed by a masked evaluator at 90 and 180 days after
treatment, based on comparison of standardized digital images
before and after treatment. Safety, based on incidence of adverse
effects, was also assessed during and after treatment.
Summary: Pre-medication with either ibuprofen or hydrocodone/
acetominophen resulted in acceptable pain scores (less than 5 out of
10) during MFU treatment of all facial zones except for the brow and
periorbital zone at the 4.5mm treatment depth. Average combined
pain scores were also acceptable (less than 5 out of 10) for all facial
zones at both treatment depths (3mm and 4.5mm). Mean pain
scores for each facial zone and treatment depth were comparable
for Groups A and B. The greatest pain was experienced during
treatment of the brow/periorbital zone. Pain scores were similar
for the 3mm and 4.5mm treatment depths, except in the brow/
periorbital zone where the 4.5mm depth produced more discomfort
in some subjects. Combined average pain scores were below 5 on
the 10-point scale for both groups. Adverse events were minor and
temporary, including temporary tenderness of the treated areas, and
did not differ between groups. In particular, there was no significant
post-treatment ecchymosis in either group. There was no difference
between the groups in treatment efficacy at the evaluation time
points.
Conclusion: The data from this pilot study suggest that a single,
prescription-strength dose of ibuprofen may be comparable
in efficacy for pain relief to a single dose of hydrocodone/
acetominophen, when administered 1 hour prior to MFU. Both
clinicians and patients may prefer the use of ibuprofen instead of
a narcotic as pre-medication for MFU, since it allows patients to
resume normal daily activities, including driving, immediately after
the procedure. Additionally, based on evidence from cold immersion
studies that overall pain perception is diminished if the final
experience during a sequential procedure is less painful, a secondary
recommendation from our study is that the brow and periorbital
zone should not be the last area treated during MFU to the full face
and neck, since this zone was found to be the most painful by some
study subjects. Further clinical data would be helpful in clarifying
whether this is an isolated or consistent finding.Further controlled
studies with larger numbers of subjects are required to substantiate
the findings of this pilot study.
The author(s) serves as a consultant for Biopelle, ColoreScience,
Johnson & Johnson Consumer Products, Medicis, Mentor, Merz
Aesthetics, Merz Pharma, SkinMedica, Suneva, Syneron/Candela,
Ulthera; has received speaking honoraria from Medicis, Mentor,
Merz, SkinMedica, Syneron/Candela, Ulthera, and has received
research funding from Biopelle, Medicis, Merz, Skinmedica, Syneron/
Candela, Ulthera.
CS233 - Cosmetic Abstract Session
3:45 pm
Title:
Topical Botulinum Toxin
Author(s): Gary D. Monheit, MD
Purpose: The development of carrier proteins that will transport
large protein molecules through the epidermis increase our approach
to drug therapy and in some instances, replaces the use of needle
injection. At present, a few studies are ongoing with the use of
trans-epidermal carriers for botulinum type A toxin.
Design: RT001 is presently undergoing multi-centre studies for
treatment of crow’s feet wrinkles with a newly developed 150 kD
botulinum toxin molecule and a linked carrier protein. The carriers
act through both passive and active transport mechanics.The study
involved 532 subjects treated as randomized double-blind study
utilizing two doses of RT001 and a placebo placed on lateral canthi,
measuring lateral canthal lines with a developed scale. The study
evaluated efficacy and safety.
Summary: The efficacy was 90% response with a 1 point
improvement, the same as injectable studies with a duration of 80
days. The treatment was well tolerated with no significant problems
in safety data.
Conclusion: The results will be discussed with photos and a
discussion into the applicability of the treatment in the future.
Dr. Monheit serves as a consultant and/or clinical investigator for
Allergan, Dermik Laboratories, Genzyme Corporation, J&J, Contura,
Ipsen/Medicis, Electro-Optical Sciences, Inc., Kythera, Galderma,
Mentor, Merz;
and has received speaking honoraria Galderma, Ipsen and Merz; and
has received research funding from Allergan Corporation
3:50 pm
Title:
Onset and Durability of Response to
AbobotulinumtoxinA for Glabellar Lines
in Patients With Skin of Color and White
Patients
Author(s): Valerie D. Callender, MD; Valerie Callender, MD;
Xiaoming Lin
Purpose: This pooled post hoc analysis compared the rate of onset
and durability of response to abobotulinumtoxinA for glabellar
93
lines in patients with skin of color (SOC) vs white patients in 3
randomized, double-blind, placebo-controlled clinical trials.
Design: Patients received 50 U abobotulinumtoxinA administered
by 5 equal-volume (0.05- or 0.08-mL) intramuscular injections in a
pattern approximating the location of the procerus and corrugator
muscles. Investigators and patients assessed glabellar line severity
using the Glabellar Line Severity Scale (GLSS; 0 = None, 1 = Mild, 2 =
Moderate, 3 = Severe) at maximum frown on days 0, 14, 30, 60, 90,
120, and 150. Comparisons by group were made of prevalence of 2+
response at day 30, onset of response, and durability of 2+ response.
The definition of 2+ response was improvement of 2 GLSS grades
in the combined investigator and patient assessments. Onset of
response was defined as the first day the patient answered “yes” on
the diary card when asked if he or she had noticed an effect on the
appearance of glabellar lines.
Summary: The intent-to-treat population included 117 patients
with SOC and 216 white patients. Rates (95% CI) of 2+ response at
day 30 with abobotulinumtoxinA and placebo, respectively, were
72% (60%–82%) and 0% (0.0%–8.4%) for SOC patients and 48%
(39%–57%) and 0% (0.0%–4.0%) for white patients. Kaplan-Meier
probability for onset of response was higher in SOC patients vs white
patients, respectively, on day 2 (0.43 vs 0.33), day 3 (0.62 vs 0.51), day
4 (0.69 vs 0.65), day 5 (0.77 vs 0.72), day 6 (0.81 vs 0.78), and days
7–13 (0.86 vs 0.82). The median time to onset of response in both
groups was 3 days. 2+ response was more durable in SOC patients vs
white patients, observed respectively, in 78.6% vs 53.2% on day 14,
71.8% vs 47.2% on day 30, 53.8% vs 18.3% on day 60, 18.4% vs 8.5%
on day 90, and 11.8% vs 1.4% on day 120.
Conclusion: This pooled post hoc analysis showed higher response
rates, faster onset of response, and greater durability in patients
with SOC vs white patients treated with abobotulinumtoxinA for
glabellar lines. Previous reports indicate that abobotulinumtoxinA
was well tolerated in these studies (Brandt et al. Dermatol Surg.
2009; Kane et al. Plast Reconstr Surg. 2009; Rubin et al. J Drugs
Dermatol. 2009).
The author(s) serves as a consultant for Allergan, Galderma, Medicis,
Merz, P&G, SkinMedica, Stiefel, Unilever, and has received research
funding from Allergan, Galderma, Intendis, Johnson & Johnson,
Medicis, Merz, and Stiefel.
3:55 pm
Title:
Multicenter Phase II and Phase III
Studies of Single and Repeat Doses of
IncobotulinumtoxinA in Treatment of
Glabellar Frown Lines for Up to Two
Years
Author(s): Alastair Carruthers, MD, FRCSC;
Jean Carruthers, MD, FRCSC
Purpose: Introduction: The injection of botulinum toxins (BoNT-A)
for aesthetic purposes was the most popular non-surgical cosmetic
procedure performed in the United States in 2009. The series of
studies reported here focused on incobotulinumtoxinA ([IBT-A];
Merz Pharmaceuticals, Frankfurt, Germany), a unique formulation
of botulinum neurotoxin type A free from the complexing proteins
found in other commercially available BoNT-A preparations.
Objective: Using four earlier prospective, randomized, double-blind,
placebo-controlled multi-center single-dose phase II and III clinical
trials as predicate studies, investigators sought to determine safety,
efficacy, and longevity of IBT-A in the first long-term repeat dosing
study for the treatment of glabellar frown lines in patients treated
with multiple sessions over 2 years.
94
Design: Materials and Methods: After informed consent and
following approval by independent ethics committees, patients
were enrolled in one of 2 identically designed trials (Trial A [US/
CA] and Trial B [US only]). Combined study population was 547
subjects. Both trials compared IBT-A to placebo in a single 20U dose
of IBT-A, randomized to a 2:1 IBT-A to placebo ratio. Treatment
consisted of one administration of 20 U IBT-A (0.5 mL) reconstituted
in 0.9% NaCl, distributed in equal aliquots to five injection sites:
procerus muscle; each side in the central part of the corrugator
muscle approximately 1 cm above the bony orbital rim; and each side
in the middle part of the corrugator muscle at least 1.5 cm above
the bony orbital rim. Follow up for evaluation was at 30 days post
injection. Patients who successfully completed either of these trials
were then eligible for enrolment in Trial C, a repeat-dose openlabel, uncontrolled study. Their participation was in a 6-month arm
of Trial C. In addition, 341 patients from 2 other studies were also
eligible for enrolment in a longer arm— lasting 24 months and
including a maximum of 8 treatment sessions—for a total N of 796.
(One study was a Phase III study in Germany; the other was a Phase
II trial in the United States and Canada; neither is reported here.)
In Trial C, each subject received an intramuscular injection of 20
U IBT-A on Visit 1 (Day 0 of Cycle 1), evenly divided to 5 injection
points. Injection sites were those also used in the single-dose studies.
Re-injections could be performed on Day 0 of a subsequent cycle
once again at Day 30 for 6-month subjects, and up to 8 cycles (one
cycle  85 days) for 24-month subjects. Follow up for evaluation
and for additional treatment sessions (up to 8) were at 3-month
intervals, up to 24 months.Efficacy Evaluation: For Trials A and B,
efficacy was measured by a composite endpoint at Day 30 posttreatment consisting of:o 2-point responders on the Facial Wrinkle
Score (FWS) as assessed by the investigator o 2-point responders as
assessed by the patient according to a 4-point scaleA patient was
only assessed as “successful” with a 2-point response in both of the
above groups. Other efficacy endpoints included the percentage of
responders at rest and at maximum frown at Day 30 according to
the investigator’s assessment on the FWS where a responder was
defined as a patient with a rating of “none” or “mild”For Trial C,
efficacy assessment included:o Investigator assessment according
to the FWS with a responder defined as a subject with a score of 0
(none) or 1 (mild) at maximum frown and at resto Patient assessment
according to a 4 point scale in which a responder is a subject with at
least a 1-point improvement compared to Day 0 Patient assessment
according to a 6-point Likert scale. A score of 0 = ‘none at all’ and a
score of 5 = ‘very deep.’ The grades in-between did not have specific
descriptionso The day of onset of effect of IBT-A was assessed by
the subject, memorized, and recorded at the evaluation visitSafety
Evaluation: All treatment emergent adverse events (TEAE) were
tabulated across all study arms in Trials A, B, and C.Results: Efficacy
results in Trials A and B• Composite endpoint rates at maximum
frown on Day 30 post injection for IBT-A were significantly superior
to placebo, with rates of 60.3% and 47.8% compared to 0.0% for
placebo*• Analysis of the composite endpoint at maximum frown on
Day 30 revealed a 2-point response as assessed by the investigator to
IBT-A treatment of 76.6% and 70.9% in Trials A and B, respectively,
compared with 0.0% in the placebo arms* • Patient-assessed 2-point
responder rates to IBT-A were 65.2% (vs 0.0% for placebo) in Trial
A and 55.5% (vs 1.1% for placebo) in Trial B* • Response rates, ie,
a subject with a score of 0 (none) or 1 (mild) on the FWS at Day 30
according to the investigator, were 79.9% and 76.4% compared
to 0.0% placebo* *p<0.0001 for all results Efficacy Results in Trial
C: • The investigator-assessed response rate after each cycle of
IBT-A treatment was high and remained high up to a maximum of
8 cycles (79.1% in Cycle 1, rising to 89.6% in Cycle 8)• The patient
assessment of response also supported this maintained response to
repeat doses over time (86.2% in Cycle 1, rising to 93.8% in Cycle 8)•
At rest the response rate as assessed by the investigator ranged from
77.0% to 81.2% over cycles 1 to 7 and peaked at cycle 8 (87.5%)•
Results were slightly lower for the patient assessment at rest, with
the range of response rates from 67.0% to 77.1%• Patients also
assessed muscle action at the injection visit and then again 30 days
later, using a 6-point Likert scale. There was a decrease in median
score between the two visits and a tendency to lower scores in
later cycles, suggesting an accumulation of efficacy• In all cycles,
approximately 30% of subjects experienced onset of treatment
effect after 2 days (except cycle 8: 22.9%), approximately 50% after
3 days, and 90% after 7 daysSafety: During the study period, 361
(45.4%) subjects experienced at least one TEAE. Overall, 50 (6.3%)
subjects experienced a TEAE related to the study drug, as assessed by
the investigator; most of those were mild (37 [4.6%]) or moderate
(11 [1.4%]) intensity. The most common drug-related TEAE was
headache, observed in 28 (3.5%) subjects. Nine (1.1%) subjects
experienced at least one TEAE of special interest: four (0.5%)
subjects with facial paresis ( “bilateral brow ptosis” [2], “facialis
paresis” [1], and “right brow ptosis” [1]), two (0.3%) subjects with
eyelid ptosis, and one subject (0.1%) each with eyelid function
disorder, muscular weakness (“left arm weakness”) and pneumonia
aspiration. In five (0.6%) subjects, these events were related to the
study drug.Twenty-nine (3.6%) subjects experienced a serious TEAE,
none of which was related to the study drug but 19 of which were
of severe intensity. No fatal AEs were reported. All serious TEAEs
resolved except one which resolved with sequelae (tibia fracture),
and one which was recovering/resolving (arterial stenosis). Overall,
six (0.7%) subjects experienced TEAEs which led to discontinuation
from the study(documented as the “main reason” for premature
termination).
Summary: Discussion: The clinical studies presented here
demonstrate the efficacy of IBT-A for the treatment of glabellar
frown lines after single and repeat doses. Trials A and B show
that at Day 30, a single treatment with 20 U IBT-A is significantly
superior to placebo (p<0.0001).For Trials A and B, the protocols were
amended to include new definitions of responders and a composite
endpoint which were introduced to satisfy FDA requirements.
These include a minimum of a 2-point improvement rather than a
1-point improvement used in the past. In addition, a subject had to
be self-rated as a responder according to a 4-point scale where the
definition was, again, a subject with a 2-point improvement from
Day 0. Only a subject fulfilling these two criteria was counted as
a responder in the composite endpoint results, making these new
assessments the most stringent to date. Trial C was a repeat dose
study in which subjects could receive up to 8 further cycles of IBT-A
treatment. Such a study is important since, having established the
efficacy of IBT-A in the two single-treatment trials, long term data
in trials that more closely resemble the repeated usage of IBT-A in
the clinic are pertinent to clinicians. In this case, regardless of the
treatment received in Trials A and B, repeat dosing of 20 U IBT-A
remains effective, with a slight tendency to increase in response rate,
up to at least 8 cycles of treatment. These results are similar to those
published earlier—also a glabellar frown line study—in which 20
U of onabotulinumtoxin A were administered at 4-month intervals
over a year and efficacy was maintained. In Trial C, IBT-A showed
efficacy with treatment as necessary at 3-5 month intervals over a
period of 2 years. The incidence of AEs remained fairly constant in
each cycle of IBT-A application, indicating that the safety pattern of
IBT-A remained stable after repeated dosing. No new safety concerns
were identified and the AE profile was consistent with previously
published reports of other BoNT-A preparations.
4:00 pm
Title:
Poly-L-Lactic Acid for Chest Rejuvenation:
A Retrospective Study of 28 Cases Using
a 5-point Chest Wrinkle Scale
Author(s): Sabrina Guillen Fabi, MD; Joanna Bolton, MD;
Jennifer Peterson, MD; Mitchel Goldman, MD
Purpose: The primary objective was to evaluate the efficacy and
safety of Poly-L-lactic acid (PLLA) for chest rejuvenation of moderate
to severe rhytides primarily using a 16cc dilution. Improvement of
the rhytides was determined utilizing a novel, validated 5-point
chest wrinkle scale. This scale was designed to assess the extent
of the patient’s rhytides at baseline, compared to those after
treatment. Although multiple wrinkle scales have been described in
the literature, all are based upon facial wrinkles and photodamage;
therefore, we created a scale specifically to address rhytides of the
chest.
Design: All non-immunocompromised patients who were treated
with chest PLLA by physicians at our clinic between March 2008 and
February 2011 were included. Data was collected retrospectively
using electronic medical record entries and coding information.
Written consent for photography release was obtained prior to
images being taken. Phone calls were placed to patients requesting
additional information or photography when appropriate. Eligibility
was determined based on depth and characteristics of chest rhytides
at baseline. A 5-point wrinkle scale was designed to assess the
extent of the patient’s rhytides at baseline, compared to those
after treatment. Patients with baseline scores of 3 or higher were
considered candidates for PLLA injection into the chest. Validation
of the scale was accomplished with an independent verification
process performed by 4 dermatologist colleagues in our clinic. A
16cc (14cc bacteriostatic water: 2cc lidocaine) dilution was primarily
used in our patients (86%, or 55 of 64 treatments). Dilutions of 10
to 13 cc were used in 6 of the 28 patients early in the evaluation
period based on provider preference. All patients were treated
using a similar injection technique into the décolletage starting with
rhytides centrally between the breasts then proceeding laterally and
superiorly. All visible rhytides and areas of shallowing were treated.
Four physicians at our facility performed all of the PLLA injections
(Mitchel P. Goldman, Kimberly Butterwick, Sabrina Fabi and Jennifer
Peterson). No topical anesthetic, regional nerve block, or ice
application was used before PLLA injections. Patients did not have
any treatments to the chest other than PLLA, except for 3 patients
who additionally had IPL treatments between injections.
Conclusion: Repeated dosing of IBT-A is well-tolerated and
efficacious in the treatment of glabellar frown lines over a period
of at least 2 years. Two-point response rates represent a new level
of efficacy for US-approved BTA preparations. Further studies will
elucidate how other BoNT-A preparations compare with IBT-A.
Summary: Herein we describe 28 patients treated with PLLA for
chest rejuvenation of moderate to severe rhytides. All 28 patients
were female and the average age of patients was 52.9 (range 39 to
70). Patients received an average of 2.2 treatments (range 1 to 7). On
average patients had a total of 40.5cc of PLLA solution injected over
the entire treatment course (range 3.75 to 112cc), with the large
majority having received a 16cc dilution at each treatment session
(range 10 to 16cc dilution). The best improvement was noted in
patients who received at least 3 PLLA injections at 16cc dilutions with
16cc injected per treatment. No adverse events were reported during
the study period, and no nodule formation was observed. Followup photography was available for 11 of our 28 patients. Using the
Fabi-Bolton 5-point chest wrinkle scale, on average a 1 to 2 point
improvement was observed.
The author(s) serve as consultant and researcher for Allergan Inc and
Merz Gmbh; serve as a consultant for Allergan Medical and Merz
Gmbh, has received honoraria from Allergan Inc. and Merz Gmbh
and has received research funding from Allergan Inc., Merz Gmbh
and Bioform Medical.
Conclusion: This study examines the results of PLLA injections
for chest rejuvenation in 28 patients demonstrating 1 to 2 point
observable improvement of chest rhytides without significant
complications or formation of nodule. Moreover we introduce a
novel validated scale, the Fabi-Bolton 5-point chest wrinkle scale, to
evaluate chest rhytides. Our primary limitation to this study was a
95
small patient size and lack of long term follow-up beyond 6 months
post treatment; therefore, although PLLA appeared to improve
rhytides, texture, contour, and laxity of chest skin in the patients
examined, studies with longer follow-up are needed. Although
patient satisfaction was not formally included as a measure in this
retrospective study, many patients volunteered their satisfaction with
the treatments and intent to continue treatment with PLLA chest
injections in the future if needed. In the future larger, prospective
trials are needed to further evaluate the potential benefit of
using PLLA alone or in combination with IPL treatments for chest
rejuvenation and to better assess patient satisfaction with these
treatment modalities and duration of effects.
Dr. Goldman: serves on the Advisory Board for Sanofi-Aventis, on the
Advisory Board and Consultant for Johnson & Johnson Medical, Inc.,
Wound Healing Division Medical, Advisory Board, Allergan Skin Care
Chairman, Medical Advisory Board, Bio Med Science; has received
speaking honoraria and has an ownership interest in Lumenis. Dr.
Peterson serves as a consultant for Lumenis. Drs. Bolton and Fabi
have no financial ownership relationships to disclose.
4:05 pm
Title:
Efficacy of a Novel Bi-directional
Sidelight Optical Fiber & 1440 nm
Nd:YAG Laser in the Treatment of
Cellulite as Measured by 3-dimensional
Surface Imaging
Author(s): Bruce E. Katz, MD
Purpose: Cellulite is a cosmetic problem that affects over 80% of
women. To date, there have been no technologies that have had
significant lasting benefits for cellulite.
Design: In this IRB approved study, 15 women had cellulite of the
thighs treated with a novel 1440 nm Nd:YAG laser with a sidelight
3D optical fiber that transmits energy bi-directionally. Follow-up was
at 1 week, 1, 3 and 6 months after a single treatment and results
were monitored by digital photography, patient and physician
questionnaires. A Vectra 3-Dimensional surface imaging system
was used to measure qualitative and quantitative changes in skin
topography at each follow-up visit compared to baseline. The
Sidelight 3D optical fiber was used to thermally subcise subcutaneous
septa, deplane fat cells and heat dermal tissue to promote skin
thickening and tightening.
Summary: 68% of subjects showed significant improvement in
cellulite by photographic evaluation and 65% with Vectra 3D
surface imaging. Patient & physician evaluations revealed goodexcellent results in 76% & 69% of cases, respectively. Except for mild
ecchymoses and edema lasting less than one week, no adverse events
were noted.
Conclusion: A novel sidelight 3-dimensional optical fiber & 1440 nm
Nd:YAG laser appear to have long lasting benefits in the treatment
of cellulite.
The author(s) serves as a consultant for Merz Pharmaceuticals,
Medicis and El-En Engineering and has received research funding
from Cynosure.
96
4:15pm
Title:
Review of a Novel Compound (1%
4-Ethoxybenzaldehyde) in Reducing
Facial Erythema
Author(s): Leon H. Kircik, MD
Purpose: Treatment of facial erythema is one of the greatest unmet
needs in dermatology. Although there are several medical devices
to treat telangectasia, we don’t have much in our armamentarium
to reduce facial erythema. 1% 4-Ethoxybenzaldehydehas shown to
block PGE2, IL-6 and IL-8 production in human keratinocytes in vitro.
Design: We will review a double blind, vehicle controlled, 4
week study for patients with mild to moderate facial rosacea. 1%
4-Ethoxybenzaldehyde was applied twice a day with a cleanser.
Evaluations for erythema were performed at baseline, week 2 and
week 4.
Summary: 28 of 30 subjects completed the study. Subjects treated
with 1% 4-Ethoxybenzaldehyde had 44% reduction in erythema
versus 17% with placebo at week 4. 72% of the subjects had an
average 49% improvement in overall rosacea assessment.
Conclusion: 1% 4-Ethoxybenzaldehyde can be a safe and effective
option in reducing facial eryhthema.
The author(s) serves as a consultant for GSK, Galderma, Skin Medica,
Amgen; has received speaking honoraria from GSK, Galderma,
Biopelle, Amgen, and has received research funding from GSK,
Galderma, Biopelle, Amgen
4:20 pm
Title:
Assessment of Safety and Efficacy of
a Bipolar Fractionated Radiofrequency
Device in the Rejuvenation of Aged and
Photodamaged Skin
Author(s): Jeremy R. Man, MD; Jennifer Chwalek, MD;
Mussarrat Hussain, MD; David Goldberg, MD
Purpose: To evaluate the safety and efficacy of a unique bipolar
fractionated radio frequency (RF) device in subjects of all skin types
in improving wrinkles, dyschromias and texture irregularities.
Design: Thirty subjects, Fitzpatrick skin types (i-IV) between the
ages of 35-70 were enrolled who had aged and/or photodamaged
skin. Each received a total of three treatments to the full face with
the Syneron eMatrix RF device (Syneron Inc.,Irvine, USA) spaced
30 days apart. The device is a fractional bipolar RF device capable
of delivering energy to achieve ablation, coagulation andheating.
Patients were evaluated at each treatment and 30 days after the last
treatment with standardized questionnaires and digital photographs.
Blinded investigators assessed for improvement in wrinkles,texture
and dyschromia.
Summary: A statistically significant improvement in wrinkles,
textureand dyschromia was apparent in most subjects. Further
improvement was observed with repeated treatments.. Adverse
events were generally limited to mild discomfort during treatment,
transient erythema lasting up to two days, and mild swellingon the
day of treatment. Of note, postinflammatory hyperpigmentation was
notseen in any of the Fitzpatrick type IV-VI skin types.
Conclusion: Our study suggests that a unique fractionated radio
frequency device may be effective on all skin types in rejuvenating
aged or photo damaged skin.
The author(s) has received research funding in part provided by
Syneron.
4:25 pm
Title:
Full Face Soft Restoration with
Hyaluronic Acid Gel Fillers and
Microcannulas
Author(s): Giovanni Salti, MD; Giovanni Salti, MD
Purpose: To present a 2 years’ experience with the use of
microcannulas to inject fillers in the face and the use of large
amounts of hyaluronic acid gel for a full face restoration and lift
Design: Full face treatments with hyaluronic acid gels are designed
with the goal of obtaining a soft restoration of the volumes of
the face in its entire boundaries and a consequent lifting effect.
A new technique of injection is described with the use of special
microcannulas that help to reduce the trauma associated with sharp
needles and allow for large volume injections with efficacy and
safety. 66 treatments performed from September 2009 are reviewed
and presented.
Summary: 66 patients were treated for a full face volume
restoration. The average amount of hyaluronic acid gel received per
patient is 8 ml in 2 to 3 sessions spaced about 30 days. 63 patients
had satisfactory results without any serious adverse event. In 2 cases
we had an important swelling long time after the treatment and in
1 case we had an infection. All the adverse events were manageable
and left no consequences.
Conclusion: Full face volume restoration with the use of
microcannulas is a technique addressing volumes and not wrinkles
resembling fat transfer. The goal of the technique is to address the
deflation in volumes, especially in the midface, the periorbital area,
and the jawline in order to get a real lifting effect without surgery.
The author(s) serves as a consultant for QMed, Galderma, Aventis,
Merz; and has received speaking honoraria from QMed.
4:30 pm
Title:
Autologous Fibroblast Therapy for
Treatment of Facial Rhytids
Author(s): Stacy Smith, MD; Girish Munavalli, MD;
Jeanne Novak PhD
Purpose: The use of autologous cultured fibroblasts for
thecorrection of wrinkles and improvement in the skin quality of
patients has beenstudied in several clinical trials. Thispresentation
summarizes the results from several clinical studies demonstratingthe
safety and efficacy of autologous cultured fibroblasts for
aestheticimprovement.
Design: Two separate randomized, double blind and vehiclecontrolled studieswere performed. From a small skinbiopsy, subject’s
fibroblasts were cultured and subjected to serialmultiplication.
Subject’s nasolabialfolds were injected at three different sessions,
five weeks apart with asuspension of their autologous cultured
fibroblasts or with the suspensionmedium alone. Blinded
investigatorsanalyzed efficacy by grading the subjects using a 6-point
scale and subjectsgraded themselves using a 5-point scale. A subset
of subjects from the above studies were selected to participate in
a histological analysis of treated skin. Subjects received additional
injections of their fibroblasts, or of the suspension medium alone in
a blinded fashion in a non-facial area. Serial biopsies of the injected
areas were obtained and analyzed by two dermatopathologists for
inflammation and cellular morphology.
Summary: Three-hundred-seventy-two subjects were enrolled and
received injections (181 active, 191 placebo). Sixty-four percent
of subjects in the activegroups showed at least a one grade
improvement six months after their lastinjection as graded by
the blinded investigators. Improvement was observed as early as
twomonths following the start of treatment, with 53% of patients
treated with autologouscultured fibroblasts showing improvement
as assessed by the blinded investigators. Histological evaluation
ofbiopsies taken three months after the areas were injected showed
a very mildinflammatory response in up to 59% of subjects compared
to up to 10% insubjects injected with the suspension media only.
No changes in cellular morphology wereobserved. Because the
expanded cells areautologous, the safety profile is excellent.
Reactions to the treatment were mild, short-lived, and localized to
theinjection site. Across all clinicalstudies performed with autologous
cultured fibroblasts to date, the most commonadverse reactions were
injection site erythema, edema, bruising and pain. The majority of
these reactions resolvedwithin one week.
Conclusion: Autologous cultured fibroblasts are an effective
product forthe improvement of facial wrinkles and have an excellent
safety profile. Results seen following injection provide anatural and
progressive improvement. Histological evaluations of treated tissue
samples showed no significantadverse changes.
The author(s) serves as a consultant for Medicis, Galderma, Fibrocell
Science, Lithera, Aqua Pharmaceuticals and has received investigators
fees from multiple pharmaceutical and device manufacturers for
commercial research studies. I received fees for some of the work
discussed in this presentation.
4:35 pm
Title:
ATX-101 Treatment Offers Long-term
Durability of Submental Fat Reduction:
Preliminary Follow-up Study Results of
Subjects from Phase 2 Studies
Author(s): Kevin Smith, MD; Greg Goodman, MD;
Sheetal Sapra, MD; Patricia Walker, MD
Purpose: Submental fat (SMF) is an undesirable physical feature,
which can be resistant to weight reduction measures, and is
prevalent even in subjects who are not otherwise overweight.
Currently, there are no approved pharmacologic therapies and the
only treatment options are liposuction and surgical neck lifts. ATX101 is an investigational drug with adipolytic properties. It is based
on an endogenous bile acid and is being evaluated as a minimally
invasive, pharmacologic therapy for the reduction of SMF. We
participated in a long-term follow-up of subjects treated with ATX101 in two Phase 2 studies to evaluate durability of efficacy and
post-treatment safety.
Design: Subjects were originally enrolled into one of two doubleblind, placebo-controlled, Phase 2 studies and randomized to receive
injections directly into the fat of their submental area of one of the
following: ATX-101 (1 mg/cm2, 2 mg/cm2, or 4 mg/cm2) or placebo.
Injections were administered at baseline and at weeks 4, 8, and 12.
At each of these timepoints, and at weeks 16 and 24, subjects were
evaluated for SMF (using the Clinician-Reported Submental Fat
Rating Scale [CR-SMFRS]) and adverse events (AE). Subject satisfaction
97
was evaluated (using the Subject Satisfaction Rating Scale [SSRS]) at
baseline and week 16. All subjects were eligible to participate in an
ongoing, 5-year follow-up study involving additional CR-SMFRS, SSRS
and AE evaluations every 3 months for the first year, every 6 months
for the second year and every 12 months for years 3, 4 and 5.
Summary: A treatment response was defined as a ³ 1-point
improvement based on the CR-SMFRS at week 24 of the original
Phase 2 trial. Preliminary results showed that more than 90% of
ATX-101-treated responders (N=45) sustained their response for 2
years beyond week 24. 80% of ATX-101-treated responders (N=44)
also demonstrated a sustained improvement from baseline in subject
satisfaction score out to 2 years. To date there have been no new
adverse events reported during the follow-up study.
Conclusion: Subjects treated with ATX-101 can experience
reductions in submental fat and improvements in satisfaction that
may be durable for  2 years. ATX-101 demonstrates excellent longterm tolerability and may offer a novel, minimally invasive approach
to reducing submental fat.
Dr. Smith serves as a consultant for Allergan; Dr. Goodman serves
as a consultant for Allergan, Peplin, Galderma, Neutrogena, C3,
Dermatech Sapra, Medicis, Allergan, Merz, Sanofi Aventis, Amgen,
Abbot, has received teaching honoraria from Allergan, Kythera and
Galderma and has received researchf funding from Allergan and
Kythera.
Dr. Sapra has received teaching honoraria from Medicis, Allergan,
Merz, Sanofi Aventis, Amgen, Abbot; Dr. Walker serves as a
consultant for Halscion; owns stock in Kythera and Allergan; has
received speaking honoraria from Smith - Allergan, Cutera and
Kythera.
4:45 pm
Title:
Evaluation of Safety, Efficacy and
Patient Satisfaction After MultiPlane Nonsurgical Lifting of the Face,
Submental Region and Neck with
a Novel Micro-Focused Ultrasound
Device with Simultaneous Ultrasound
Visualization
Author(s): Hema Sundaram, MD, Oge Onwudiwe, MD, Ashley Lodha
Purpose: Skin tightening and lifting are primary concerns for
many patients seeking facial rejuvenation, as is the improvement
of rhytides. A new micro-focused ultrasound device with FDA
510k approval for non-surgical brow lifting was evaluated for
simultaneous lifting and tightening of the face and neck and
improvement of rhytides. The novel feature of this study was the
inclusion of a tissue treatment plane at 1.5mm depth, in combination
with the previously studied 3mm and 4.5mm treatment depths.
The aim of adding this more superficial treatment plane was to
determine whether layered targeting of multiple tissue planes with
micro-focused ultrasound might have a synergistic rejuvenative
effect. The studied device provides bi-modal ultrasound treatment
and visualization,allowing treatment of tissue up to 25mm in length
with simultaneous tissue imaging to 8mm depth. Therapeutic
ultrasound of different frequencies, generated via several
transducers, allows selection of tissue treatment depth and spacing
of the ultrasound pulses. Pulses are focused to produce evenlyspaced points of thermal micro-coagulation within the selected
tissue plane, while sparing intervening and overlying tissue.
Design: Study subjects ranging in age from 30 to 65 years received
a single session of treatment to the face, submental region and
upper neck with the micro-focused ultrasound device. Therapeutic
98
ultrasound frequencies were selected to target the dermis and
hypodermis at 4.5mm depth in areas such as the cheeks and at
a 3mm depth in areas with thinner tissue, such as the forehead.
Ultrasound energy was also delivered more superficially, at a depth
of 1.5mm, to target a tissue plane above that targeted by the 3mm
and 4.5mm treatment depths. Subjects were clinically evaluated
before and immediately after treatment, and subsequently at specific
time points. Standardized digital photography was also performed
before and immediately after treatment and at specific time points
thereafter. Clinical and photographic evaluation continued for 90
days post treatment. Subject self-assessment included quantification
of comfort level during and after treatment, and evaluation of pre
and post-treatment digital images.
Summary: The non-treating investigator and blinded evaluators
noted significant improvement after treatment, as determined by
assessment of contour improvement and skin tightening, by global
assessment of aesthetic improvement, and by assessment of pre and
post-treatment digital images. Improvement in rhytides, including
fine rhytides, was also noted in areas where the micro-focused
ultrasound energy was delivered to the superficial (1.5mm) tissue
plane. Patient satisfaction was high. Treatment was well-tolerated
and adverse events were mild and transient.
Conclusion: Micro-focused ultrasound with simultaneous ultrasound
imaging is a valuable option for nonsurgical lifting and skin
tightening. In appropriately-selected patients, it may serve as a
noninvasive alternative to surgery or to submental liposuction. The
device’s efficient delivery of energy to the dermis and hypodermis
with epidermal sparing is of utility to the increasing number of
patients who seek minimal recovery time. The addition of energy
delivery to a more superficial tissue plane than has previously
been targeted was compatible with energy delivery during the
same treatment session to deeper tissue planes in the dermis and
hypodermis. The effect of this noninvasive, layered treatment with
micro-focused ultrasound was to enhance results by producing
improvement in both contours and rhytides, including fine rhytides,
with little or no recovery time for the study subjects. Targeting
of multiple tissue planes with layered micro-focused ultrasound
represents a promising new paradigm of noninvasive face and neck
rejuvenation that may be both efficacious and cost-effective, since it
combines nonsurgical lifting and improvement of rhytides in a single
treatment session with little or no down time.
The author(s) serves as a consultant for Biopelle, ColoreScience,
Johnson & Johnson Consumer Products, Medicis, Mentor, Merz,
Promius, SkinMedica, Suneva, Syneron/Candela, Ulthera; has received
speaking honoraria from Mentor, Merz, SkinMedica, Syneron/
Candela, and has received research funding from Medicis, Merz,
SkinMedica, Syneron/Candela, Ulthera.
4:50 pm
Title:
The Transplanted Hairline. A Leg Room
for Improvement
Author(s): Sanusi H. Umar, MD
Purpose: Follicular unit techniques in hair transplantation
traditionally use head hair derived from the safe donor area.
However, the large caliber of head hair imparts a coarse hairline
while natural hairlines are typically softer.Objective: To demonstrate
that in hirsute individuals transplantation of leg hair to the hairline
results in a superior aesthetic appearance.
Design: Two case reports are described. One patient received
grafting of 1,025 leg hair follicles to an area covering 0.5-1.0 cm in
front of and 0.5-1.0 cm internal to the original vanguard hair of the
original hairline and temporal recesses; the other patient received
grafting of approximately 1,000 leg hairs and 600 head hairs to
advance and soften his hairline, and to create a custom widow’s
peak with more leg hair in the vanguard area.
Summary: Transplantation resulted in a fully grown and softlooking hairline after 9 months in the first patient. About 75-80%
of transplanted leg hair grew. Mean length of the transplanted leg
hair was longer than the original leg hair with less curliness but
similar hair width. Transplanted leg hair width was significantly
finer compared to existing head hair width. After 4 years, sustained
results were achieved, minimizing concerns hair loss might result
from leg hair cycle variations. In the second patient, similar results
were sustained at 3 years. Limitations: This technique is limited to
individuals with sufficient donor leg hair.
Conclusion: The use of leg hair in transplantation provides more
options in cases with hairlines that need to be refined.
4:55 pm
Title:
Safety of Fractional CO2 Laser of the
Neck and Chest a Review of 122 Cases
Author(s): Susan Van Dyke,MD; Heather Anderson RN
Purpose: CO2 laser has been highly effective for reducing photo
damage and rhytids of the face however side effects and scarring
were common on the neck/chest. With the introduction of the
fractional CO2 laser there is the opportunity to treat the neck/
chest. We routinely treat the face, neck and chest in one sitting.
Information on settings and outcomes is sparse. The purpose of this
review is to add data to the field regarding the safety of resurfacing
of the neck/chest with fractional CO2 laser.
Design: A review of charts of 122 consecutive patients who
were treated with fractional CO2 laser on the neck and chest was
undertaken. Most patients also received treatment of the face at the
same sitting. One hundred and twenty two patients were treated in
our practice from Nov, 2006 to Dec, 2010. All patients were treated
by the same physician utilizing the same laser. Energy level, density,
recovery, outcome, adverse events were analyzed.
Summary: One hundred and twenty two patients had treatment
of the neck/chest with fractional CO2 laser. Although most patients
also had face treated at the same sitting, energy and density
were consistently lower on the neck than settings used on the
face. Treatment parameters were lower on the chest than on the
neck. Recovery typically took 10 to 21 days, lagging behind facial
healing (5 to 7 days).Energy levels of 40mj to 125mj (average:80mj)
neck, 40mj to 70mj (average 59mj) chest were used. One hundred
and four/122 necks and 113/122 chests were treated at density 1
(55% coverage); 17/122 necks and 8/122 chests were treated at
density 2 (68% coverage) and 1/122 necks and 1/122 chests were
treated at density 3 (82% coverage). All patients experienced
erythema, mild irritation and itching in the post operative period.
Events requiring intervention occurred in a total of 47/122 (38.5%).
Twenty/122 (16.4%) were treated with topical steroids (only)
within the first week for intense itching which promptly resolved.
Twenty Seven/122 (22.1%) were treated with antibiotics (antiviral/
antifungal/antibacterial depending on clinical presentation) with
or without topical steroids for prolonged redness, irritation, and
new onset of pain for presumed infection generally around 7 days
with rapid improvement in symptoms. 0ne/122 (0.7%) patient was
hospitalized and treated with multiple IV antibiotics/antivirals/
steroids, cultures were indeterminate and the patient fully recovered
with no sequelae. There were no scars and only a single case of
hypopigmentaion. Hypopigmentaion occurred on the neck of
the single patient treated at density 3 on the neck. Neck/chest
treatment parameters were not predictive of occurrence of adverse
events other than the one density 3 which was 100% predictive of
hypopigmentation on the neck.Average energy for patients treated
with topical steroids only was: neck: 81.6mj (range 60 to 90), chest:
55.0mj (range 40 to70). Average energy for patients treated with
oral antibiotics was: neck: 82.4mj (range 60 to100), chest: 55.0mj
(range 40 to 80). Average energy for those with no need for post
treatment intervention was: neck: 80.1mj (range 40 to 100) chest:
50.0mj (40 to 100).
Conclusion: Fractional CO2 laser resurfacing of the neck and
chest carries with it a prolonged and sometimes difficult recovery
when compared to treatment of face alone. In our experience
patients were accepting of prolonged recovery on neck and chest
because of good pretreatment expectation management. Almost
all patients had neck/chest treatment as an adjunct to the main
concern of facial photodamage and rhytids. The desire for the face/
neck/chest cosmetic unit to blend well motivated patients to seek
neck/chest treatment.Energy levels were similar in all 3 groups: no
post treatment intervention, post treatment topical steroids and
post treatment oral antibiotics.Overall fractional CO2 laser of the
neck and chest is a safe procedure within a broad range of energy
levels when density levels are kept less than 68%. Resurfacing of
the neck and chest is valuable when treating the face to avoid
the contrast of rejuvenated skin adjacent to non rejuvenated skin.
Women are aware that the neck and décolleté can give away one’s
age no matter how youthful the face appears. This area deserves
to be included when contemplating facial rejuvenation. Patients
are happier with their overall results however they must be made
aware of the need for close follow up and more prolonged recovery
compared to facial fractional CO2 laser resurfacing.
The author(s) has a relationship with SVD; has been on advisory
boards and/or speakers bureaus for Kinerase, Solta, Lumenis,
Allergan, RevaleSkin, Medicis.; serves as a consultant for Solta,
Lumenis, RevaleSkin, Kinerase, Allergan, Medicis; and has received
research funding from Solta: treatment tips for 2 studies.
5:00 pm
Title:
Laser Assisted Delivery of Allogeneic
Porcine Mesenchymal Stem Cells
Author(s): Jill S. Waibel, MD; Evangelos Badiavas, MD;
Stephen Davis PhD
Purpose: Mesenchymal stem cells (MSCs) are multipotent cells that
can differentiate into a variety ofcell types. Optimal delivery of
stemcells that enable their viability is a current challenge to MSC
research. Fractional laser technology hasrevolutionized laser therapy.
Thefractional ablative tunnels can be utilized for laser assisted
delivery systemsof a variety of drugs, topicals and other living
tissue. This is the first pilot study to test thehypothesis that ablative
fractional laser could deliver mesenchymal stem cells toskin using a
porcine full thickness wound model.
Design: A porcine model was chosen due to the
morphologicalsimilarities between swine skin and human skin.
Allogeneic cells were obtained by bone marrow aspiration from a
donorpig. Mesenchymal stem cells wereisolated from the donor bone
marrow aspirate and transduced with a lentiviralvector containing a
fluorescent marker gene. One recipient pig was placed under general
anesthesia and sixty fullthickness skin wounds were made using a 10
mm punch biopsy. The wounds were randomly assigned to twolaser
treatment regimens: laser CO2/MSC and laser Er:YAG/MSC. After
99
AFL the stem cells were pipetted intothe vertical channels. Wounds
werecovered with an occlusive polyurethane film dressing. Three
punch and wedge biopsies were takenfrom each group on days 5, 7
and 21.
Summary: Labeled allogeneic bone marrow cells were observed
inpapillary and reticular dermis on days 5 and 7 in both the Er:YAG
and CO2 lasertreated wounds. Some labeled cells werenoted in close
proximity to the ablated vertical channels created by lasertreatment.
Allogeneic cell showedpersistence in the treated wounds despite
intense inflammation associated withthe full thickness wounds
created.
Conclusion: Preliminary study suggests that ablative fractional
lasersmay be useful technology to deliver mesenchymal stem cells
and this has broadimplications for many branches of medicine.
The author(s) serves as a consultant for Sciton, Lumenis, Candela/
Syneron and Deka; has received speaking honoraria from Lumenis,
Candela/Syneron, Sciton, and; has received research funding from
Sciton and Solta.
5:05 pm
Title:
Long-Term Follow-Up For 1927nm
Fractional Resurfacing of Actinic
Keratoses on the Face
Author(s): Elliot T. Weiss, MD; Robert Anolik, MD;
Lori Brightman, MD; Anne Chapas, MD; Julie Karen, MD;
Leonard Bernstein, MD; Roy Geronemus, MD
Purpose: Actinic keratoses (AK) are precancerous epidermal lesions
that arise on skin chronically exposed to ultraviolet radiation.
Available field therapies for facial AK’s include: topical therapies,
photodynamic therapy and chemical/laser resurfacing. A nonablative fractionated 1927nm Thulium laser has recently received
an FDA indication for treating AK. This device utilizes a wavelength
with moderate to high water absorption to create focal, superficial
zones of thermal damage best suited for removal or resurfacing of
epidermal lesions such as AK. In this study, we assess the long-term
safety and efficacy of 1927nm fractional resurfacing of facial AK.
Design: 25 subjects with multiple facial AK received up to 4 full-face
treatments (2-6week intervals) with a 1927nm laser (FraxelDual, Solta
Medical, Inc., Hayward, CA) and were followed for 6 months. Topical
anesthetic and optional intramuscularketorolac were administered 1
hour before treatment. Treatment parameters ranged from 5-20mJ/
pulsewith coverage densities of 30-70%. Transparency mapping of all
AK’s was performed at baseline and at eachfollow-up visit
Summary: IndividualAK counts decreased in all subjects after
treatment. 1 month following the final treatment,average AK
clearance per patient was 88.9% (n=20, range 63-100%). At 3 months
post-treatment, average AKclearance was 85.3% (n=23, range 0-100).
At the final 6 month follow-up visit, average AK clearancewas
85.6% (n=22, range 45-100%). Posttreatment, mild/moderate
erythema and mild exfoliation lasted approximately 1week.
Throughout the study period, noincidents of dyspigmentation,
infection or scarring were observed. At 3 months, average scores
for improvementin photodamage and AK were 3.2/4 for both
subject and investigator ratings. Forimprovement in skin texture
and pigmentation, average scores were 3.0/4 and 3.1/4for subject
and investigator ratings, respectively. At 6 months, average scores
for improvementin photodamage and AK were 3.1/4 and 3.5/4 for
subject and investigatorratings, respectively. For improvementin
skin texture and pigmentation, scores were 3.3/4 for both subject
andinvestigator ratings.
100
Conclusion: In our experience, resurfacing with the fractionated
1927nm laser safelyresults in dramatic clinical clearing of facial AK.
Sustained clearance of treated AK was observedover a 6 month
follow-up period. Significant clinical improvements in skin texture
and pigmentation wereobserved throughout the 6-month follow-up
period. This well-tolerated treatment represents anew field therapy
for facial AK.
Dr. Geronemus serves as an investigator Palomar, Solta, Syneron,
Photomedex, DUSA, and Zeltiq and holds an equity position in
Solta Medical. Dr. Weiss serves as a consultant for Lithera Chapas;
a consultant for Solta, and has received honoraria from Solta.
Dr.Chapas has received honoraria from Solta.
5:10 pm
Title:
Enhancement of the Brow using
Botulinum Toxin A in Combination with
Hyaluronic Acid Filler as Evaluated by
Patient Satisfaction
Author(s): Derek H. Jones, MD
Purpose: Brow elevation has been proven to be accomplished
with 20-40 units of onabotulinum Toxin A into the glabella, or
with treating the lateral obicularis oculi area (immediately under
the lateral portion of the eyebrow) alone in doses of 1-10 units.
Additionally, brow enhancement has been reported using hyaluronic
acid filler to volumize the soft tissue under the brow This study was
designed to evaluate the hypothesis that a combination treatment
of onabotulinum toxin A with hyaluronic acid filler would result in
greater patient satisfaction with the appearance of the brow than
with either treatment alone.
Design: 30 patients (29 F, 1 M; mean age = 47.9 yrs, range 28-62)
were randomly assigned to receive either 20 units onabotulinum
toxin in on-label fashion with 3 units to each tail of the brow (n =
15) first, versus 0.8 ccs total of 24 mg/cc smooth cohesive hyaluronic
acid filler injected subdermally immediately under the hair bearing
eyebrows first (n = 15) in an open-label crossover study. 30 days
after the initial treatment, the opposite treatment was administered.
Satisfaction was measured using the validated 14-question Facial Line
Treatment Satisfaction (FTS) questionnaire at Day 30 and Day 60.
Paired t-tests were used to evaluate differences in FTS satisfaction
for onabotulinum toxin first patients at 30 days and 60 days, and
for hyaluronic acid filler first patients at 30 days and 60 days. Pre
and post treatment 2D and 3D images were taken at each visit, and
patients continue to be followed monthly for 4 months after the
last treatment. Secondary measurements at each visit include Subject
Satisfaction of Appearance Questionnaire (SAS), Self-Perception of
Age (SPA), and Global Assessment in Change in Brow Appearance
(GA)
Summary: Patients who received onabotulinum toxin alone
followed by hyaluronic acid filler were more satisfied at 60 days
than 30 days (average FTS satisfaction 6.4 vs.6.2, p < .01). Patients
expressed greater satisfaction on 11 of 14 FTS questions, two were
lower, and one was unchanged. Three of the 11 FTS questions
that were higher reached statistical significance (p < .05). None
of the other comparisons were significant. Patients who received
hyaluronic acid filler alone followed by onabotulinum toxin were
more satisfied at 60 days than at 30 days (average FTS satisfaction
5.9 vs. 5.2, p < .001). Patients were more satisfied on 12 of 14 FTS
questions, less satisfied on one question, and no change on one. Of
the 12 questions where patients expressed greater satisfaction, 8
were statistically significant (p < .05). None of the other comparisons
were statistically significant. Some secondary measurements of SAS
ABSTRACTS — SATURDAY
and SPA also showed statistical significance in favor of combination
treatment
Conclusion: Combination treatment with onabotulinum toxin and
hyaluronic acid filler resulted in higher patient satisfaction than
either treatment alone, with onabotulinum toxin appearing to
create a higher level of satisfaction when used alone compared to
hyaluronic acid filler used alone
The author(s) serves as a consultant for Allergan, Merz, Kythera,
Lithera, Galderma, Canfield; has received speaking honoraria from
Allergan, Merz, Kythera, Galderma, Canfield, and has received
research funding from Allergan, Merz, Kythera, Galderma, and
Lithera.
RX311 - General Dermatologic Surgery Abstracts
10:45 am
Title:
Cutler-Beard Flap: a Useful Technique
for Repairing Large Full-Thickness Upper
Eyelid Defects
Author(s): Jeremy S. Bordeaux, MD; Jean Hu
Purpose: Illustrate execution of a Cutler-Beard flap under local
anesthesia.
Design: Case report.
Summary: In executing the Cutler-Beard flap, a full-thickness
horizontal incision (through conjunctiva, muscle, and skin) is made
in the lower eyelid 5 mm inferior to the lower eyelid margin. This
serves two purposes. First, this preserves the integrity of the lower
marginal artery, which is crucial to maintaining the viability of the
bridge flap. Second, this preserves the entire lower lid tarsus and
provides more stabilization for the donor lid. The width of the flap
corresponds to the width of the upper eyelid defect. Two vertical
incisions are made at each end of the horizontal transection until
they reached the fornix. A small triangle is excised at the end of each
vertical incision, allowing recruitment of skin from further down. The
flap is mobilized and passed under the lower eyelid margin bridge to
reach the upper eyelid. The deep conjunctival layer of the lower lid
is sutured to that of the upper lid. The flap does not contain tarsus,
a fibrous structure that provides skeletal support. As a result, a
potential complication of the Cutler-Beard flap is shrinkage of upper
lid tissue postoperatively. To prevent this complication, ear cartilage
is harvested in the scaphoid fossa between the helix laterally and
the antihelix medially. The ear cartilage is placed anterior to the
conjunctiva to avoid corneal irritation and sutured to the lateral
and medial border. The muscle layer in the flap is sutured to the
levator aponeurosis to maintain lid function. Finally the skin flap is
sutured to the skin of the defect. Triangular incisions in the lower
lid as well as the defect lateral to the eye are closed with running
sutures. Nine weeks after the surgery, the Cutler-Beard flap has
completely healed and is ready for division. The flap is transected
at xx . The reconstructed upper eyelid has significant edema right
after division. At one-week follow-up after flap division, edema has
subsided and revealed excellent aesthetic and functional results in
the reconstructed upper lid.
Conclusion: The Cutler-Beard flap is a simple, two-stage technique
that is an excellent choice for repairing large upper eyelid defects
and restoring lid form and function.
RX311 – General Dermatologic Surgery Abstracts
10:50 am
Title:
‘Cyanoacrylate Lamination Technique’
in Miniature Punch Grafting in Stable
Vitiligo at Difficult Sites
Author(s): Niteen Dhepe, MD; Javed Shaikh, MD; Ashok Naik, MD;
Shilpa Shah
Purpose: BACKGROUND: Autologous Miniature punch grafting
(MPG) is a one of the common outpatient procedures for the
surgical treatment of chronic stable vitiligo. Graft fixation is difficult
at some sites like joints, lips, eye brows, eyelids, chin, ears, and
ankle due to mobility of these sites or due to relative difficulties
in using conventional dressing technique.Here we are presenting
an innovative technique of graft fixation called “Cynoacrylate
Lamination Technique” with use of cheaper tissue adhesive
Methylcynoacrylate in MPG for stable vitiligo. OBJECTIVE: To study
the safety and efficacy of the application of Methylcynoacrylate by
an innovative technique “Cynoacrylate Lamination Technique” for
the stabilization of miniature punch grafts in the treatment of stable
vitiligo. Evaluationwas done in regards of (A) Graft fixation, (B)
Biological Outcome, (c)Tolerability and safety.
Design: METHODS: In a prospective institution based study
conducted from JUNE 2008 to March 2009 at Dr.Dhepe’s SkinCity, PG
Institute of Dermatology, Solapur, India, total 30 patches (10 patches
on UV sensitive sites and 20 patches on UVA resistance sites) in 30
patients(9-males, 21-females) of stable vitiligo (stability of patches
for a period ofnot less than 1 year) were selected for miniature
punch grafting followed by Lamination with Methylcynoacrylate on
recipient site to fix the grafts instead of regular dressing. All patients
were allowed to do limited movement and therewas no strict
immobilization of recipient sites. After separation of lamination,
phototherapy in form of excimer laser once in a week or NB-UVB
twice in a week for a period of 3 months was started and all patients
were followed after for next 3 months.
Summary: RESULTS: The grafts fixation rate at recipient site was
97% with fixation failure rate of 3%. Patient grafted on ankle
walked on same leg immediately within one hour without dressing.
The graft uptake rate was more than 95%. Only one patient with
secondary infection at recipient sites needed to change antibiotic.
The cynoacrylate lamination was started separating spontaneously
after 5 to 8 days (avg. 6.3 + 1.39 days) and complete separation with
crust was observedafter 12 to 26 days (avg. 17.96+3.05days). Side
effects of methylcyanoacrylate lamination included mild stinging
sensation and slight irritation to eyes while application which were
self limiting requiring no treatment. 20 outof 30 showed excellent
pigmentation (91-100%), 7 showed good (76-90%pigmentation), 2
patients showed Fair (51-75% pigmentation) and 1 patient showed
moderate (31-50 % pigmentation) at the end of 3 months of photo
therapy. Average time required to start pigmentation was 20.66 +
2.06 days, with1 mm peri graft pigment spread at 53.3 + 2.83 days,
2 mm peri graft pigmentation at 84 + 4.73 days. The most common
side effects seen were hyperpigmentation in grafts (9 patients –
30%) and cobble-stoning in 8 patients(26.66%).
Conclusion: Conclusions: Methylcynoacrylate lamination technique
is very useful tool for the fixation of grafts at the recipient area
obviating need of dressing or immobilization at recipient site. It
also eliminates the requirement of frequent change of the dressing
at recipient site. It in fact reduced incidence the post surgical
infection as due to the lamination barrier on the grafted area. The
cynoacrylate lamination does not seem to alter the biological out
come in terms of start of pigmentation and subsequent spread of
pigment, which is comparable to other studies. Methylcynoacrylate
was very well tolerated by patients without any significant adverse
reaction or long term side effects. This is the first study using
101
SATURDAY — ABSTRACTS
methylcyanoacrylate and lamination technique for graft fixation in
vitiligo surgery.
ideal follow-up interval was stated as: 3-4 weeks (33%), 1-2 weeks
(31%), 2-3 months (29%), and 6 months 6%.
Conclusion: The majority of subjects prefer same day consultation
and surgical treatment. Reasons for this preference include previous
experience with dermatologic surgery, the desire to not delay
surgery, the desire to save time, and avoid the inconvenience of
travel. Additionally, nearly all patients prefer some form of followup with their surgeon after removal of their skin cancer. Reasons
of importance to patients include making sure the wound heals
well, checking for tumor recurrence, and checking for more skin
cancers. Statistical analysis regarding associations with perceived
attractiveness, occurrence of complications, satisfaction with
their procedureand the use of mood-altering medications will be
conducted prior to the meeting.
10:55 am
Title:
Dermatologic Surgery Consultation and
Follow-up: A Patient-based Research
Survey
Author(s): Omar Ibrahimi, MD; Victoria Sharon, MD;
Shelbi Jim-On, MD; Summer Youker, MD; Daniel Eisen
Purpose: The value of performing a consultation for Mohs
micrographic surgery or surgical excision of a skin cancer prior to the
day of surgery versus a consultation on the same day of surgery has
not been investigated. Additionally, many dermatologic surgeons
will see their patients fora follow-up visit after cutaneous surgery,
but there is no universally agreed upon time interval during which
this follow-up visit should occur. To the best of our knowledge, no
one has addressed what patient expectations are regarding these
issues from a patient’s perspective. We sought to determine patient
preferences regarding peri-operative aspects of dermatologic
surgery.
Design: One hundred subjects who were seen in an outpatient
university-affiliated dermatology clinic with a history of basal cell or
squamous cell carcinoma treated with Mohs micrographic surgery or
excisional surgery during a 24 month period were recruited to take
a survey regarding their preferences for preoperative consultation
and a postoperative follow-up visit. The survey was administered
via a tablet-computing device using a web-based survey service. The
survey consisted of 17 questions, which included basic demographic
queries regarding age, sex, race, education, income level, and
perceived attractiveness. Subjects were asked their preference for
one versus two visits for consultation and surgical treatment of their
skin cancers, as well as their reasons for their choice. Subjects were
also queried on their desire and reason for post-procedure followup, optimal time interval desired for follow-up, and overall patient
satisfaction with the procedure. Subjects entered data on their
perceived attractiveness, the number of previous skin cancers, type
of skin cancers, and type of dermatologic surgery. Physician entered
data included the use of mood-altering medications by subjects, and
the occurrence of any procedure-related complications.
Summary: One hundred patients were recruited into the study.
Ninety-seven completed all the questions administered. Sixty-six
percent of subjects stated a preference for same day consultation
and surgical treatment versus 34% of subjects preferred a
consultation followed by surgical treatment on a separate day.
Of those subjects that prefer same day consultation and surgical
treatment, 40% of subjects noted a past history of dermatologic
surgery which enabled them to know what to expect, 25% of
subjects did not want to delay surgery, 22% of patients stated
they would like to save time and 12% noted that traveling was
inconvenient. For those patients who preferred a consultation
prior to the dayof surgery, 47% stated they would have liked
the opportunity to talk more tothe surgeon, 28% did not feel
adequately prepared to have the surgery on the same day, and 19%
expressed a desire to think more about other treatment options.
Regarding, postoperative follow-up, sixty percent of subjects stated
follow-ups after surgery were very important, 28% somewhat
important, 7% neutral, 3.1% somewhat unnecessary and 1%
unnecessary. Reasonsthat subjects desired follow-up were stated
as: to make certain wound healed well (50%), to check the cancer
doesn’t come back (28%), to check for more skin cancers (19%), to
answer any questions regarding the surgery (3%). Preference for
102
The author(s) serves as a consultant for Lumenis.
11:00 am
Title:
The Use of Novel Bipolar Wound Sealer
(Radiofrequency with Conductive Saline)
to Achieve Hemostasis in Dermatologic
Surgery
Author(s): Andrew A. Nelson, MD; Ashley Decker, MD;
Carl Schanbacher, MD
Purpose: The purpose of this study was to determine the potential
utility of a novel bipolar wound sealer in dermatologic surgery. The
novel device incorporates radiofrequency with conductive saline to
transform the triple helical structure of collagen, resulting in heatdriven denaturation, shortening, and swelling of the collagen. This
technology can be utilized to gently seal soft tissues, vessels and
bone without the charring, smoke, and collateral tissue destruction
associated with traditional cautery. This technology has been
incorporated into orthopedic and neurosurgical procedures, but has
not previously been studied in dermatologic surgery.
Design: A series of six patients underwent Mohs surgery for biopsy
proven non-melanoma skin cancer. During the Mohs surgery, no
cautery or vessel tie-offs were performed following each layer. At
the time of closure, the novel bipolar device was used to achieve
hemostasis. No vessels were tied during any of the cases. The
patients were then followed for the development of hematomas or
other adverse bleeding in the immediate post-operative period and
for the month following the procedure.
Summary: A total of five patients were treated with this device.
These cases included large scalp rotation flaps, and facial rotation
flaps (>20cm2). In the cases, the novel bipolar wound sealing device
was able to control and seal all actively bleeding vessels. The device
was also able to seal active pulsatile arterial bleeds without the
use of hemostats or any other instruments. No char, burning, or
collateral tissue destruction were observed.
Conclusion: This novel bipolar wound sealer, combining
radiofrequency energy with conductive saline, may offer a safe,
effective, alternative to traditional cautery devices. The device
has the ability to seal actively bleeding vessels, including pulsatile
cutaneous arteries, while providing a clear visual field. Furthermore,
collateral tissue destruction, char and burning are significantly
reduced with this novel hemostasis device.
11:05 am
Title:
Embryonic-like Secreted Proteins
Enhance Follicular Unit Viability and
Improve Donor Site Healing
Author(s): Neil S. Sadick, MD; Michael Zimber, MD;
Craig Ziering, MD; Jonathan Manbridge, MD
Purpose: Although tremendous progress has been made in the field
of hair transplantation over the last few decades post transplant
shock leading to effluvium still remains an issue in seeing immediate
cosmetic improvement. Transplant medicine has progressed greatly
over the past two decades, in large part due to the creation of
transport solutions that maintain the organs and tissues in a more
physiologic state and maximize cell viability New solutions for organ
preservation serve to minimize damage and promote graft survival
and function. It is therefore logical that by creating a more natural
and hospitable environment for follicles during the period they are
outside of the body, the effluvium can not only be lessened, but the
final result of the transplant procedure may be more successful by
improving the quality and health of the newly transplanted follicles
and hairs. The aim of this research was to examine a naturallysecreted, embryonic-like human cell conditioned media (hCCM) as
a holding solution (FHS, or Follicular Holding Solution) for follicles
from extraction to transplant, and determine if this media may aid in
follicle viability and reduced post-transplant shock, as compared to
standard saline solution. This conditioned media is also being studied
as a healing promoter at both the donor and transplant sites.
Design: Neonatal cells are grown in suspension cultures in closed
bioreactors that closely maintain an environment of 3-5% oxygen.
Under these conditions the cells express markers associated with
multipotent cells and produce proteins and growth factors,
particularly Wnt7a, KGF, VEGF, and follistatin, which have long been
associated with hair growth, tissue formation and regeneration.
Over 5000 genes are differentially expressed as compared to
identical growth conditions with normal oxygen, and cell surface
markers are expressed which are normally associated with follicular
stem cells, including Lhx2, SOX 21, Nestin, NFATc1, and Krt 15.
(Figure 1) FHS was evaluated in laboratory and clinical paradigms
to determine its effect on follicular viability, growth and survival.
In vitro evaluation of excess human follicles obtained from routine
transplant procedures was performed by isolating follicular units in
either hCCM or phosphate buffered saline (PBS) at the time of the
procedure. Follicles were then cultured at 37°C in either hCCM or PBS
and followed out over three days to obtain hair length and follicular
cell viability over time. The growth rate of the individual follicles
(10 two-haired units in each evaluation group) were measured at
24 hour intervals using microscopic image analysis, and viability of
the follicular grafts was determined using the MTT cell assay at 24
and 72 hours post-explant. Clinical exploratory studies are being
conducted to evaluate the use of the hCCM as a holding solution, as
compared to a saline control, in a routine hair transplant procedure
as well as to assess the ability of the material to support donor site
and graft site healing.
Summary: Normal 0 false false false MicrosoftInternetExplorer4 /*
Style Definitions */ table.MsoNormalTable{mso-style-name:”Table
Normal”;mso-tstyle-rowband-size:0;mso-tstyle-colband-size:0;msostyle-noshow:yes;mso-style-parent:””;mso-padding-alt:0in 5.4pt 0in
5.4pt;mso-para-margin:0in;mso-para-margin-bottom:.0001pt;msopagination:widow-orphan;font-size:10.0pt;font-family:”Times
New Roman”;mso-fareast-font-family:”Times New Roman”;msoansi-language:#0400;mso-fareast-language:#0400;mso-bidilanguage:#0400;}In vitro evaluation of the hCCM as a follicular
holdingsolution showed significantly greater viability of explanted
human hairfollicular grafts as compared to PBS. In addition, the
data indicates that thehCCM maintains the capacity of the hair to
continue hair growth in vitro, asrevealed through measurements
at 24 hour intervals over 72 hours. (Figure 2) Theresults of this
experiment suggest that FHS would be a significant improvementin
maintaining the viability and growth of human follicular units
during theperiod between explant from donor scalp tissue and
transplantation into therecipient region. In exploratoryclinical trials
to date 50-60% of the transplanted hairs held in PBS are beinglost to
effluvium at the 6 week follow-up whereas 80-90% of follicles held
inhCCM remained intact at this follow-up time point. In addition,
initialclinical experience with a topical formulation of hCCM at donor
sites has shownimproved wound closure and reduced scarring.
Conclusion: Although technique plays a crucial role in the successful
outcome of a hair transplant procedure, issues such as effluvium,
healing and scarring tend to be out of the specialist’s control. In vitro
and case study results with hCCM support the use of this naturallysecreted complex of embryonic-like proteins for hair transplant
applications as a follicular holding solution and as a topical
treatment to promote the healing of post-transplant wounds.
The author(s) serves as a consultant for Merz Aesthetics, Sanofi
Aventis, Radiancy, Dior; and has received research funding from
Merz Aesthetics, DEKA, Allergan, Osyris, Sanofi-Aventis, Cutera,
Palomar, Radiancy, Dior , Histogen, Galderma and Hoya Con Bio.
11:10 am
Title:
The Expanded Utility of the Burow’s
Advancement Flap
Author(s): Oliver J. Wisco, DO; Oliver Wisco DO;
Michael Yablonsky, MD; Krista Reis MS
Purpose: The burow’s advancement flap is a highly effective repair
option for cutaneous surgical defects traditionally used for therepair
of small to medium-sized Mohs surgery defects of the lateral nasal
supratip. We have expanded the use of this flap to defects on
an array of convex surfaces on the head and neck with excellent
cosmetic and functional outcomes. The purpose of this study is
to demonstrate the versatile of this flap beyond the lateral nasal
supratip.
Design: We performed a retrospective study on our experience
using the burow’s advancement flap on the head and neck
fromAugust 2002 to August 2009. The primary focus of the study was
to identify the primary sites to employ this flap and to determine
potential complications or restrictions. Additional analysis was
performed on the sizes of the defects in which the flap was utilized.
Summary: The review of our records between 2008 and 2009
revealed a total of 237 burow’s advancement flaps performed. The
majority was employed on the nose (136 – 57.4%), followed by the
forehead (60 – 25.3%) and temple (10 – 4.2%). The nasal repairs
were subdivided: nasal tip/supratip (43 – 31.6%), nasal sidewall
(48 – 35.3%), lateral nasal dorsum (39 – 28.7%), and nasal ala/alar
crease (6 – 4.4%). Patient post-operative follow-up ranged from 6
months to 18 months. During this period, there were no signicant
complications observed. The defect sizes were consistent with
previously published reports, which employed the flap for small to
medium-sized Mohs surgery defects.
Conclusion: The burows’s advancement flap has become a repair
option used daily in our office. This flap is particularly useful for
small to medium-sized defects on the lateral nasal tip and supratip,
the nasal dorsum and sidewall, as well as the hairline, medial and
lateral suprabrow, lateral forehead, and lip. It should be a readily
considered closure technique for the dermatologic surgeon as it
103
provides an efficient reconstruction with excellent cosmetic results
with minimal potential complications.
11:15 am
Title:
Treatment of Post Burn Hypertrophic
Scars with Fractional CO2 Laser in Indian
Skin
Author(s): Niteen V. Dhepe, MD; Ashok Naik, MD; Sahil Dhavan, MD
Purpose: Introduction: There are no reports from India of treatment
of postburn scars with lasers. We present a report of successful
treatment of postburn scars with a novel fractional CO2 laser
delivery system.
Design: Material and methods: 24patients with post burn scars
of average 6 year duration (6 months to 15 years)were treated
with Ultrapulse Deep FX (Lumenis USA) fractional CO2 laser.
Typical protocol is three treatments at an interval of 2-3 months in
betweenand used 0.12mm spots with density 5%, single stacking
and pulse fluence of20mj to 35mj/pulse as per thickness of scar
with topical tetracaine 7% andlignocaine 7% applied 30 minutes
before treatment. Post operative care includedtopical antibiotic and
white petroleum jelly, frequent wash with diluted aceticacid. The
scars are assessed for thickness, surface wrinkling, colour matchwith
surrounding at the time of each treatment, 1, 2, and 3 months
postoperatively after last sitting by patient, treating physician and
anindependent dermatologist on VAS of 4. Pain during treatment is
scored bypatient on a VAS of 4.
Summary: Results: 3 months after 3 sessions of fractional CO2
treatmentreduced the scar thickness to a mean VAS score of 3.47
out of 4. The scoreincreased from 2.14 before second sitting to
3.47 at 3rd monthfollow up of last sitting. Reduction in scar surface
wrinkling was 3.85 ,and colour match to surrounding was 2.89 on a
VASscale of 4. Pain during procedure scored by patient was 1.12 on
a scale of 4 usingtopical anesthesia. Transient hyperpigmentation
lasted for 4 to 12 weeks.
Conclusion: Conclusion: Fractional Co2 laserwith DeepFx scanner is
a well tolerated and effective treatment of hypertrophicpost burn
scars in Indian patients.
CS312 - Late Breaking Abstracts
11:30 pm
Title:
A Two-Center, Open-Label, Randomized,
Split-Face Study to Assess the Efficacy of
One Versus Three Intradermal Injection
Sites of Abobotulinum toxin A in the
Treatment of Lateral Periocular Rhytides
Author(s): Sabrina Fabi, MD; Hema Sundaram, MD;
Mitchel Goldman, MD; Hazel Marzan, RN
Purpose: Although abobotulinum toxin A has been found to diffuse
in a circumferential manner from points of injection, numerous
clinicians continue to use multiple injection points within the same
treatment area to deliver abobotulinum toxin A. However, no
comparison between the efficacy using one injection versus three
currently exists. This study’s primary objective is to compare the
104
efficacy of using one injection site versus three sites to deliver the
same dosage of abobotulinum toxin A to the lateral periocular areas.
Secondary objectives include determining the safety and incidence
of any adverse effects of using one versus three intradermal
injection points to deliver the same dose (36 units to each side) of
abobotulinum toxin A in the treatment of lateral periocular rhytides.
Design: An open-label, randomized, split-face clinical study was
performed in two outpatient, private physicians’ offices. Subjects
were randomized such that the lateral orbital rhytides on one side
were treated with one injection of 36 Units of abobotulinum toxin
A into the middle of the lateral orbital rhytides, while the lateral
orbital rhytides on the other side were treated with the same total
dose of abobotulinum toxin A via three injection sites, at each of
which 12 Units of abobotulinum toxin A were injected. A separate
clinician remained blinded as to which side of each subject’s face
was treated with one injection site and which was treated with
three injection sites. The injection sessions took place on Day 0 of
the study. Physician and subject self-assessments were performed at
at week 1, week 6, week 12 and week 16, to evaluate lateral orbital
rhytides at maximal contraction and at rest, as well as adverse events
including bruising, ptosis, swelling and diplopia. Standardized digital
photography was completed at each of the three clinic visits.
Summary: Thirty four of 40 subjects (20 at each of the two clinic
sites) with moderate lateral periocular rhytides, including 29 females
and 5 males, aged 22-68 years old (mean 50.2), completed visits
1, 2, and 3 at the time of abstract submission. Prior to treatment,
all subjects had moderate to severe lateral periocular rhytides,
as graded on a validated 4-point scale. After treatment, no
statistically significant differences were found at any of the visits
in the investigator assessments of rhytides at rest and at maximum
contraction (using the 4 point scale) between the 1 injection side
and 3 injection side. Comparison of the changes in improvement
in rhytides at rest and at maximum contraction, from baseline to
day 7, day 42, day 90 and day 120, showed no significant difference
between the two sides. Subjectt self-assessment of rhytides revealed
no significant difference between the 1 injection side and 3 injection
side at any of the visits. There was no statistically significant
difference between the two sides in adverse events, including
swelling, bruising, double vision, ptosis and signs/symptoms of
infection. Only one subject was noted to have ecchymosis at visit 2
(day 7); this was on the side that had received 3 injections, and the
ecchymosis was not apparent at visit 3 (day 42). Six patients were lost
to follow-up.
Conclusion: Injection of abobotulinum toxin A via one injection
site to treat lateral periocular rhytides was found to be as effective
as delivering the same dose of abobotulinum toxin A via 3 injection
sites. No significant difference was noted in adverse events,
including swelling, bruising, double vision, ptosis or signs/symptoms
of infection, between 1 or 3 injection sites. Limitations are that
preliminary data are presented and that this is a two-site study of a
small cohort of patients.
The author(s) has a relationship with Sabrina Fabi - none
Dr. Goldman serves as a consultant with Lumenis, New Star Lasers,
Medicis Pharmaceuticals, Bioniche Pharmaceuticals, Mentor,
Veinacare, Quinova Pharmaceuticals, Ortho Dermatologics, Lithera
Global Alliance Council, is Acting Medical Director, Advisory Board
Sanofi-Aventis – Advisory Board Consultant, Johnson & Johnson
Medical, Inc., Wound Healing Division Medical Advisory Board,
Allergan Skin Care Chairman, Medical Advisory Board, Bio Med
Sciences Medical Advisory Board, Aesthera Medical Advisory Board,
Galderma Medical Advisory Board, Theraplex Acting Medical
Director, Lumenis Ltd. Acting Medical Director, Obagi Medical
Products, Inc., is a stock holder in Lumenis, has received speaking
honoraria from Lumenis, has received research funding from
Intendis, Inc., Bioform/Merz, BTG International, Inc, Eleme Medical,
Inc., LifeWave, Inc, Syneron, Inc., Allergan, Crescendo Therapeutics,
Inc., SkinMedica, Obagi Medical Products, LLC., Photocure ASA,
Mentor Corporation, Sanofi-Aventis, Medicis, Biopelle, Bioform/
Merz, Neocutis, Inc., New Star Lasers, Allergan, Inc., Galderma,
and Obagi. Hema Sundaram serves as consultant for Biopelle,
ColoreScience, Johnson & Johnson Consumer Products, Medicis,
Mentor, Merz Aesthetics, Merz Pharma, SkinMedica, Suneva,
Syneron/Candela, Ulthera; has received speaking honoraria from,
Biopelle, ColoreScience, Johnson & Johnson Consumer Products,
Medicis, Mentor, Merz Aesthetics, Merz Pharma, SkinMedica, Suneva,
Syneron/Candela, Ulthera, and research funding from Biopelle,
Medicis, Merz, Skinmedica, Syneron/Candela, Ulthera. Dr. Fabri has
received research funding from a 2010 ASDS cutting edge research
grant Dr. Marzan has no relationship(s) to disclose.
CS312 - Late Breaking Abstract Session
11:40 am
Title:
A Prospective, Long-Term Observational
Study of the Efficacy & Safety of an
Hyaluronic Acid (HA) Filler in the
Correction of Mild to Severe Mid-Face
Volume Deficits: 18 Month Interim
Analysis
11:35 am
Title:
Repeat Cryotreatment on Motor Nerves
to Reduce Muscle Movement in a Rodent
Model
Purpose: HA fillers are an emergingnon-surgical option for mid-face
volume deficit correction. Few studiesassessing efficacy and durability
have been conducted hence this abstract is designed to address this.
Author(s): Vic A. Narurkar, MD; Michael Hsu PhD; Fang Stevenson,
MD
Purpose: A novel, minimally invasive, percutaneous technology
has been developed to reduce muscle contractility with potential
application in the reduction of dynamic facial wrinkles. The
device applies controlled low temperatures to inhibit motor nerve
conduction via needle-like probes. The thermal algorithm is designed
to temporarily inhibit nerve conduction to the muscle group, without
causing long-term chronic changes in the tissue. The outcomes of
this study compared the consistency of efficacy and safety of a single
versus repeat cryotreatment to motor nerves.
Design: Study of the low temperature (-60±10°C; 27g closed end
probe) device was conducted in 18 Sprague-Dawley rats which
received treatment to the sciatic nerve. Ten rats received a single
treatment, and eight rats received two treatments over a two week
interval. Animals were survived for up to 18 weeks post treatment.
Muscle function was assessed a minimum of 3 times per week using
the toe spread assay, motor function assay, and tissue specimens
were explanted for histological evaluation at 2, 8, 16, and 18 weeks.
Summary: No complications or adverse effects were observed in any
of the treated animals. Toe spread and assay demonstrated an initial
loss of muscle function followed by a gradual recovery to normal
function by 8 weeks post-treatment. Motor function returned to
normal function by 5 weeks. Rats exposed to a repeat at 2 weeks
showed an extended weakening of toe spread and motor function
for 2 weeks followed by normal recovery. Histological examination
demonstrated temporary loss of axons (Wallerian Degeneration)
followed by normal fully functional regeneration; whereas, the
epineurial and perineurial structures of the nerves are left fully
intact.
Conclusion: The preclinical data demonstrate that the device is able
to temporarily reduce muscle contractility by application of a low
temperature. Physiologic weakening correlated with reduction of
nerve function upon histologic examination. The data established
the safety of a repeat treatment does not cause any long term
physiologic dysfunction or histologic aberrations.
The author(s) serves as a consultant for Myoscience clinical trials;
maintains an equity position in Myoscience; and has received
research funding from Myoscience for clinical trials.
Author(s): Gregory J. Goodman, MD; Greg Goodman, MD;
Ian Carlisle, MD; Steven Liew, MD; Terrence Scamps, MD;
Michael Halstead, MD; John Rogers, MD;
Peter Callen, MD
Design: Subjects (n=103; female:81%; mean age:47y) with mild to
severe mid-face volume deficit (based on6-point Mid-Face VolumeDeficit Scale; MVDS) were enrolled in this 104-week,two-phase
study. Subjects were corrected to 0 or 1 (none or mild deficit)
withVOLUMA™ (2 cc per side) at baseline. If required, an additional
treatment(2cc per side) was administered at Week 4. No further
re-treatment waspermissible until Week 78, the first time-point for
interim analysis. Eightytwo subjects entered Phase 2 (post-Week 8).
Summary: At Week 8, 92% of subjectsachieved >1 point
improvement on the physician’s MVDS, while 98% and 100%
ofsubjects, assessed by subjects & physicians, respectively, achieved
>1point improvement on the 5-point global aesthetic improvement
scale (GAIS). AtWeek 78, 84% of subjects maintained >1 point
improvement on the MVDS, while78% and 82% of subjects,
assessed by subjects & physicians, respectively,maintained >1 point
improvement on the GAIS. Based on protocol-definedcriteria, only
38% of subjects required re-treatment at Week 78. 95% ofsubjects
were satisfied or very satisfied with the product and would
recommendto others. Most adverse events were mild to moderate
injection site reactions;resolving over time.
Conclusion: This is the firstprospective study demonstrating long
term efficacy and durability, as well ashigh patient satisfaction of an
HA filler in the correction of mid-face volumedeficit.
The author(s) serves as a consultant for Allergan, Q Med, Kythera,
Galderma, and Elastogen; and has received research funding from
Allergan, and Elastogen.
11:45 am
Title:
A Novel Triple Combination Injection for
Resolution of Keloids and Hypertrophic
Scars
Author(s): Nilesh Goyal, MD
Purpose: Various agents have been injected into keloids and
hypertrophic scars for allieviatingthe symptoms associated with them.
Yet the need for an ideal agent which wouldcompletely resolve the
issues related to scars is sought after. A novel triplecombination
of drugs was injected into the keloids and hypertrophic scars
ofpatients who presented to a private dermatology clinic in
Mumbai. The combinationincluded 5 Fluorouracil, Triamcinolone and
Hyaluronidase. The rationale behindthe combination was that 5 FU
being an antimetabolite drug would arrest the cellcycle and cause
fibroblast apoptosis, Triamcinolone would inhibit fibroblastgrowth
and cause collagen degradation and Hyaluronidase would help
105
in reducingviscosity of the ground substance allowing better
permeability of other injectedagents and eventual softening of the
scar tissue.
Design: All patients (total 9) presenting to the clinic with old
aswell as new keloid and hypertrophic scars were offered the triple
combinationinjection. These scars occurred on different parts of
body and face. They werefound to have been post inflammatory,
post surgical, post burns and even after piercing. Some of the
patientshad previously been injected with triamcinolone on its own
with no long term benefit. At every session, the drugs werecombined
in the ratio of 5 FU (50mg/ml) 0.6 mls, Triamcinolone (40mg/ml)
0.4mlsand Hyaluronidase 1500 i.u. reconstituted to make a total
of 1 ml. Theinjection was given into the body of the scar till the
entire scar was treated.Pain and mild erythema were encountered
immediately afterwards but these wereshort lasting. The injections
were repeated at 1 monthly interval till completeresolution was
achieved. None of the patients reported any untoward effectsafter
the injections.
Summary: The triple combination was found to help both old as
well as new scars. Allpatients reported that pain and itch associated
with keloids were the firstones to resolve followed by softening and
flattening of the scars. The longestfollowup of eighteen months
showed no recurrence of keloid. This combinationhas never been
tried before though each of the ingredients has been found to
beeffective on its own. The patients found the combination to bring
about theresolution faster and lasting longer. It was also found to be
very costeffective.
Conclusion: All patients who had the triple combination were
extremely satisfied by theoutcome. The numbers that I have
treated are very small to comment about theefficacy and benefits
of this triple combination over and above the individualor dual
combination injections. This will have to be studied in a randomized
controlledtrial.
11:50 am
Title:
Fractional Photothermolysis in the
Treatment of Acne Scars: A Comparison
of the CO2, Fraxel and Er:Yag Lasers
Author(s): Timothy Cragun, DO; Ryan Johnson, MD;
Shelly Aldrich, MD; Chad Hivnor, MD
Purpose: The objective of this study was to compare the efficacy
andside-effect profile of three lasers commonly used in the
treatment of acne scaring.
Design: Thirty subjects were enrolled to participate in thestudy.
Inclusion criteria includedFitzpatrick skin types I-III, ages between
18-70 with moderate to severe acnescarring. Those excluded from
thestudy were patients with prior procedures to repair acne scarring,
active acnedisease, history of keloid formation, use of retinoid
within the prior 3 monthsor isotretinoin within the last 9 months.
The patients were randomized to receive two of the threelasers in a
split-face design, witheach side of the face treated with a different
laser. Two treatments were completed on each patient, 6-10
weeksapart. Photos were obtained priorto treatment #1, 6-10 weeks
post-treatment #1, and 6 months post-treatment #2.The settings
selected for each laser were chosen to provide similar footprintin
terms of depth and surface area with a treatment depth of 8001000 microns. Questionnaires were completed by the patients after
eachtreatment and at the end of the study. At the end of the study,
four blinded evaluators evaluated and comparedthe three photos.
106
The baselinephoto was compared with the 6-10 week post-treatment
#1 photo and the baselinephoto was compared with the 6 month
post-treatment #2 photo. Right side was compared with right side(as
this was treated with the same laser each time) and the left side
wascompared with the left side. Improvement was graded as 0%,
1-25%, 26-50%, 51-75% or 76-100%.
Summary: Overall, patientsatisfaction was similar between all three
lasers with patients noting anaverage of 25-50% improvement of
scarring with each laser. The independent reviewers also ratedthe
clinical improvement as equal between all three lasers, however
scored itlower than patients at 1-25% at the 6 month follow-up. The
pain scales for eachtreatment averaged between 3.2 and 5.3 on a
scale of 1-10 with the CO2 laser onthe higher end of the pain scale
at 5.3. Downtime as noted by the patient was less with the Fraxel at
2.9 daysthan with the CO2 at 4.5 days.
Conclusion: The Fraxel, CO2 andProfractional lasers appear to
provide similar clinical improvement forpatients with acne scarring
both by independent reviewers and by the patientsthemselves.
Patients sufferedvery little down and procedural pain with any of
the laser treatments. Theyreported minimal side effects and were
very satisfied with their treatmentsrating all three at 7-8 on a
satisfaction scale of 1-10.
12:00 pm
Title:
A Split-Face Comparison Between
Combined Fractional Ablative with NonAblative Lasers and Fractional Ablative
Lasers
Author(s): Joel Cohen, MD; Vic Ross, MD
Purpose: This study was designed to compare a combined
fractionalablative and non-ablative laser procedure to ablative-only
procedures for facialrejuvenation.
Design: A total of 8 subjects provided signed consent underIRBapproved protocol and received a single, split-face, facial
rejuvenationprocedure. Group A consisted of 6 subjects treated on
one side of the face with fractional 1440nm Er:Glass non-ablativeand
2940nm Er:YAG ablative lasers and an Er:YAG laser using
ProFractional and MicroLaserPeel™ modes on the other. Group
B consisted of 2 subjects treated on one side of the face usingthe
same 1440/2940 treatment as Group A, and a fractional ablative CO2
laser on theother. Follow-up visits were scheduledat a minimum of
1 day, 1 week, 1 month and 3 months. In Group A improvements
in wrinkles and pigmentwere scored at baseline and 3 month using
the 1 to 9 Fitzpatrick Wrinkle Scale(FWS) and a 0 (none) to 5 (severe)
pigment improvement score (PIS),respectively. Group B used the FWS
anda 0 (none) to 10 (severe) Dyschromia Scale (DS).
Summary: Group A subjects immediately after treatment
experienced lesspain, bleeding and erythema on the side treated
with the 1440/2940 combinationcompared to the ablative Er:YAG
alone. At 3 month follow-up improvements in FWS and PIS were
identical for bothsides of the face. Average FWS improvedfrom 5.3
± 2.5 at baseline to 4.0 ± 1.9 at 3 months; and average PIS improved
from 2.3 ± 0.8 to 1.4 ± 0.5. In Group B pain and bleeding after
treatmentwere similar on both sides of the face. Improvements in
wrinkles and pigment at 3 months were the same for bothsides with
overall improvements in FWS from an average of 8.5 at baseline
to7.0, and DS from 6.5 to 5.5 at 3 months. Self-assessments at 3
months from all subjects indicated that 4/8preferred the combined
1440/2940 treated side, 2/8 preferred the Er: YAGtreated side, 0/8
preferred the CO2 treated side, and 2/8 did notrespond.
Conclusion: Facial rejuvenation using a combination treatment
offractional ablative 2940 and non-ablative 1440 lasers provides
improvement inwrinkles and pigmentation equivalent to fractional
ablative Er:YAG or CO2lasers and can result in less post-operative
pain, bleeding and erythema whencompared to ablative Er:YAG
alone.
Drs. Cohen and Ross have participated in clinical research with
Palomar; Dr. Cohen has served as a Consultant for Allergan, Medicis,
Merz, Biopelle, DUSA, SkinMedica, Graceway and Photocure and has
received research funding from Allergan, Photocure, Merz, Biopelle,
Graceway, Medicis.
12:05 pm
Title:
Evaluation of Orbicularis Oculi Muscle
Striping on the Cosmetic Outcome of
Upper Lid Blepharoplasty: A Randomized,
Controlled Study
Author(s): Matteo C. LoPiccolo, MD; Robert Sage, MD;
Austin Liu, MD; David Kouba, MD
Purpose: Many variations in surgicaltechnique of upper eyelid
blepharoplasty have been described, includingorbicularis oculi muscle
stripping. No evidence in the literature exists to support the efficacy
of thistechnique in improving the aesthetic results of the procedure.
We set out toconduct a single blind, randomized, controlled, splitface pilot study toevaluate the effects of orbicularis oculi muscle
stripping on upper lidblepharoplasty.
with the perceived final cosmetic result. In a small percentage of
patients, they regret having had the surgery performed. However,
we hypothesize that cosmetic and cancer anxiety decrease below
baseline levels by 6 months. This finding would provide an evidencebased timeline for Mohs surgeons to accurately counsel patients.
Design: Single-blinded prospective study, with patient volunteers
undergoing MMS of the face derived from those presenting
sequentially to the Skin Care Surgery Centre between November
2010 and July 2011. Questionnaire-based assessment of patient
demographics and evaluation of their anxiety levels using a Visual
Analogue Scale (VAS) pre-operatively and in postoperative follow-up
over the succeeding 6 months.
Summary: To the end July 2011, 150 eligible patients have been
enrolled in the study, and preliminary analysis from 100 patients is
presented. Preoperatively, patients are more anxious about cancer
than cosmesis. Immediately post-operatively, anxiety associated
with cosmesis is significantly greater than cancer anxiety. Cosmetic
anxiety decreases significantly below baseline over 3 months. Factors
that predict increased anxiety include cosmetically significant facial
subunits and the type of closure (graft> flap>linear).Gender, age,
level of education, history of mood disorders, or surgical scar length
are not strong influencers.
Conclusion: Patients undergoing Mohs surgery on the face are more
anxious about the cosmesis of the final reconstruction than having
a cancer. With quantitative knowledge about patient’s anxiety
levels through-out the peri-operative course, it is possible to counsel
patients that over 3-6 months their anxiety diminishes significantly
and their satisfaction with the cosmetic outcome improves.
Design: 10 subjects were randomized to receive upper lid
blepharoplasty withorbicularis oculi muscle stripping on one side,
and skin-only blepharoplasty onthe other. Patients and twoblinded
physicians evaluated the aesthetics of the eyelids at one and threemonths.
Summary: Blinded physician evaluation failedto show a difference
in the overall cosmetic appearance of the eyelids betweenthe control
and treatment groups at both one and three-months. Analysis of
the composite score of all patientscores did show a trend favoring
the control group at three-months, howeverthis difference was not
significant (p = 0.281).
Conclusion: Based on the data from this pilotstudy, orbicularis oculi
muscle stripping appears to have no affect on theaesthetic outcome
of upper lid blepharoplasty.
12:10 pm
Title:
Effect of Anxiety on Patient Satisfaction
With the Post-operative Outcomes in
Author(s): Iren Kossintseva, MD; David Zloty, MD
Purpose: Preoperatively it is assumed that patients undergoing
Mohs Micrographic Surgery (MMS) for facial cancer will exhibit
anxiety regarding both cancer and cosmesis. Postoperatively we
have noted many patients showing even greater anxiety associated
107
POSTERS — ABSTRACTS
Poster # 1
Title:
A Multicenter, Randomised, DoubleBlind Study to Evaluate the Efficacy
of 20 units of OnabotulinumtoxinA
in the Treatment of Glabellar Lines,
When Compared to 30 Units of
IncoboulinumtoxinA
Author(s): Marion Moers-Carpi, MD; Kelvin Tan MD;
Antony Fulford-Smith MD
Purpose: The prescribing information for all type A botulinum
toxins clearly identifies that each has unique potency units that are
specific and not interchangeable. Previously reported biological
activity data demonstrated that units of onabotulinumtoxinA
and incobotulinumtoxinA are not equipotent when tested in the
Allergan LD50 assay. The current study explored the relative efficacy
of different labelled doses of these two botulinum toxins for the
treatment of glabellar lines in a clinical setting.
Design: Patients with moderate/severe glabellar lines were
randomized in an appropriately powered double blind, comparative
study of either 20 units of onabotulinumtoxinA or 30 units of
incobotulinumtoxinA. At days 28, 84, 98 and 112 physicians rated
the severity of glabellar lines at maximum contraction using the
Facial Wrinkle Scale (FWS). The primary endpoint was the proportion
of responders within each treatment group based on the injector’s
rating of FWS at day 28. Treatment response was defined as
achievement of 1 point or greater improvement in FWS. Physicians
also assessed adverse events (AEs) at all follow-up visits.
Summary: A total of 224 subjects were randomized: the groups
were well balanced for age, sex, race and severity of the FWS.
At the primary endpoint, day 28, the number of responders in
the 20 units onabotulinumtoxinA group (108/112, 96%) was
statistically equivalent to the number of responders in the 30 units
incobotulinumtoxinA group (106/112, 95%). The proportion of
subjects rated (by physician) as none or mild on the FWS was also
statistically equivalent at day 28. However at days 84, 98 and 112 the
number of responders in the 20 units onabotulinumtoxinA group
was not statistically equivalent to the number of responders in the
30 units incobotulinumtoxinA group, with a trend demonstrated
in favour of onabotulinumtoxinA. Forty two adverse events (AEs)
were reported, 3 were considered related to study medication
(1 in 20 units onabotulinumtoxinA group and 2 in 30 units
incobotulinumtoxinA group). Most AEs were mild, no patients were
withdrawn due to AEs and no serious AEs were reported.
Conclusion: In this study 20 units of onabotulinumtoxinA was as
effective as 30 units of incobotulinumtoxinA at the 28 day primary
endpoint, despite a 50% difference in unit doses. At later time points
for subjects rated (by physician) as none or mild on the FWS, there
was trend in favour of 20 units onabotulinumtoxinA.
Design: The patient underwent initial treatments withhyaluronic
acid (infused with lidocaine) injections to a linear defect on
herforehead in February 2011. Four monthspostoperatively, the
forehead area was reassessed and photographed. The patient again
received a one-time hyaluronicacid injection along the inferior
border of the lesion in an effortto smooth the forehead contour and
fill one residual area of defect. Thepatient also received a hyaluronic
filler injection to an ipsilateral perioraldepression. Preoperative
clinicalphotographs as well as 6- month follow-up of the forehead
and 1-month follow-upof the perioral area display the observed
results.
Summary: A 38-year-old female presented with a 25-year history
of a slowlyprogressing depressed linear forehead furrow, extending
from the hairline to themedial brow, as well as a depressed
area on her ipsilateral perioral face. Herfacial lesions had been
treated for over 5 years with oral PUVA (psoralens plusUVA light)
with slowed progression but minimal benefit to her disease.
Shesubsequently agreed to treatment of these areas with filler
in hopes of restoringthe contour of the underlying tissue defect
and overall improved symmetry and cosmesis. The patient’s initial
treatment withhyaluronic acid filler provided significant cosmetic
improvement in the contourand symmetry of her forehead but failed
to fully address the caudal portion ofthe forehead furrow. At 4monthfollow-up she again underwent hyaluronic acid implantation
along the inferior aspectof the defect, which completely restored
the natural contour of theforehead . The patient also received
ahyaluronic filler injection to an ipsilateral perioral depression.
Follow-up at 6 - and 1- months for theforehead and perioral lesions
respectively, revealed maintained graft fullnessand excellent overall
cosmesis. The forehead lesion was notable for complete restorationof
the natural contour for this location. Of note, no “Tyndall Effect”
was noted for either area treated.
Conclusion: We report the first case of hyaluronic acid tissue
implantation asa treatment to improve cosmesis in linear
scleroderma. Todate typical treatment of “en coup de sabre” is
typically surgical excision andrepair. There have also been reports
ofautologous fat transfer as well as bone grafting, however, we
offer a lessinvasive treatment negating the trauma of surgery or
autologous grafts. We report excellentcosmetic outcome for the
period of 6 months, offering the technique as a possible treatment
for linear scleroderma “encoup de sabre”. We are optimistic of the
technique’s longevity in the contextof the stability demonstrated
thus far and plan to follow our patient’sprogress over the next 2
years.
Poster # 3
Title:
A Randomized, Evaluator-Blinded,
Controlled Study of the Effectiveness
and Safety of a Small Gel Particle
Hyaluronic Acid for Lip Augmentation
Author(s): Richard Glogau, MD; Xiaoming Lin; Stacy R. Smith MD
Poster # 2
Title:
A Novel Use of Dermal Fillers for Linear
Morphea Associated “En Coup de Sabre”
and Hemifacial Atrophy
Author(s): Antonio Cruz, MD; Antonio Cruz MD;
Raymond Dufresne Jr. MD
Purpose: We report the use of hyaluronic acid tissue matrix
implantation asa novel and successful treatment to improve facial
symmetry and cosmesis in apatient with scleroderma “en coup de
sabre” and morphea-associated hemifacialatrophy.
108
Purpose: To compare the efficacy and safety of small gel particle
hyaluronic acid (SGP-HA) vs. no treatment for lip augmentation.
Design: Adults (n=180; 18–65 y) scoring 1−2 on the validated
Medicis Lip Fullness Scale (MLFS; 1=very thin, 5=very full) for both
lips (Fitzpatrick skin type <IV) or at least 1 lip (Fitzpatrick skin type
IV) were randomized (3:1) to SGP-HA (1.5 mL/lip) or no treatment.
Success was defined as a blind-evaluated MLFS increase of 1 from
baseline to week 8. Secondary efficacy endpoints included MLFS
score increase from baseline, independent photographic review, and
Global Aesthetic Improvement Scale (GAIS) score, assessed at weeks
ABSTRACTS — POSTERS
8, 12, 16, 20, and 24, for both lips and each lip. Safety was assessed
by adverse events (AEs) and standardized assessment of lip function.
Summary: More patients receiving SGP-HA vs. no treatment,
respectively, had treatment success at week 8 (upper lip, 95%
vs 36%; lower lip, 94% vs 39%; both lips, 93% vs 29%; p<0.001)
continuing through week 24 (p<0.001) and improved GAIS score at
week 8 (97% vs 0%; p<0.001) continuing through week 24 (p<0.001).
GAIS and MLFS scores were highly correlated (p<0.001). Anticipated
treatment-related AEs in the SGP-HA group included swelling (58%)
and bruising (44%), and were mostly of mild (88%) or moderate
(11%) severity. No unanticipated device AEs or significant changes in
lip function were noted; 5 serious AEs were reported, all unrelated
to treatment.
Conclusion: Treatment with SGP-HA appears highly effective and
well tolerated for augmentation of lip fullness with improvement
evident to 6 months. Funding Source: Study funded by Medicis
Aesthetics, Inc.
Dr. Glogau has served as an advisor or consultant for Allergan,
Medicis Pharmaceutical, Revance, Liposonix, and Lumenis; has
received grants for clinical research from Allergan, Medicis,
Revance, and Liposonix. Dr. Smith has served as a consultant for
Medicis Pharmaceutical, Galderma, Miramar Labs, Fibrocell Science,
SkinMedica and
Poster # 4
Title:
Acne Keloidalis Nuchae: Surgical
Management with Electrosection and
Second-intention Healing
Author(s): Jordan Carqueville, MD; George Engel MD
Purpose: Acne keloidalis nuchae is a frustrating disorder for both
patient and physician when it is refractory to nonsurgical treatment
options. Excision with adjuvant steroid injections is an accepted
standard treatment for extensive or intractable lesions. However,
surgical excision at this vascular anatomical region can be a tedious
and bloody procedure. Repairs with grafting and flaps usually lead
to less than satisfactory cosmetic results. We describe a surgical
technique for refractory acne keloidalis nuchae that provides a clean
and relatively bloodless surgical field and leaves the patient with
cosmetically pleasing results.
Design: Nine patients with refractory occipital scalp and/or posterior
neck acne keloidalis nuchae were treated with electrosection,
using a blended cut and coagulation current on the Conmed Sabre
2400 electrosurgical unit. Healing was by second-intention, with
no grafting or flaps utilized. The surgical excision was followed by
monthly post-operative intralesional triamcinolone acetonide (40mg)
injections for 3 months.
Summary: All nine patients experienced excellent cosmetic results
with no evidence of recurrence during follow up periods ranging
from 6 to 21 months. Intra-operative bleeding was minimal,
maintaining a clear operating field for the surgeon. Post-operative
pain was controlled with acetaminophen alone or acetaminophen
with codeine.
Conclusion: Electrosection with second-intention healing is a
quick and effective technique for the treatment of refractory acne
keloidalis nuchae with excellent aesthetic results.
Poster # 5
Title:
An Aid in the Selection of Repairs:
Tensile Strength Quantification of Purse
String versus Buried Vertical Mattress
Closures
Author(s): Ern Loh, MD; Kenny Omlin MD
Purpose: To better understand the tension affecting sutures and to
aid in optimum choice of closure technique, we measured the tensile
strength of two common closure stitches, the purse string and buried
vertical mattress.
Design: Studies were performed on the post-mortem skin of Sus
domesticus and utilized 5-0 polyglactin suture on cutaneous defects
ranging from 8 to 16mm in length. Each defect was closed with
either one buried vertical mattress or one purse string tie. The tensile
force for rupturing each closure was measured.
Summary: The purse string closures exhibited greater tensile
strength compared to the buried vertical mattress. The purse string
also deformed to a greater extent.
Conclusion: Purse string sutures may offer greater closure strength
in specific cases. We discuss the potential mechanisms for these
observations and the implications for closure choice in high tension
areas.
Poster # 6
Title:
An Inter- and Intra-Rater Reliability
Study of 3 Photographic Scales for
Classifying Aesthetic Features of the
Perioral Area
Author(s): Joel Cohen, MD; Jane Thomas;
Frederick Beddingfield MD; Adam Rotunda MD
Purpose: Validated rating scales to assess aesthetic features of the
perioral area are limited. Such scales are important because they
can provide objective evaluation standards for clinical trials as well
as benchmarks and guidelines for outcomes in clinical practice. This
study was conducted to validate the reliability of 3 scales that were
designed to evaluate the outcomes of dermal filler and neurotoxin
treatments of the perioral and orofacial areas.
Design: Three, lip-specific photographic scales were developed from
standardized 2-D images of healthy volunteers: Severity Scale for
Perioral Lines at Rest (POL); the Severity Scale for Oral Commissures
(OCS); and the Severity Scale for Perioral Lines at Maximal
Contraction (POLM). Each scale used in the single-day validation
study comprised 4 grades (ranging from none to severe) with 3
exemplary images per grade. The validation panel consisted of 8
specialists in aesthetic dermatology or plastic surgery. Panel members
rated all 55 screened volunteers on each scale in random order
using cards that corresponded to the 4 grades of the 3 scales. This
sequence was completed twice for 2 rounds of evaluations. Subjects
also provided 2 series of self-assessments for comparison with
physician ratings. Physician intra-rater reliability was determined by
comparing round 1 scores with round 2 scores by mean weighted
Kappa coefficient. Physician inter-rater agreement was measured
by intra-class correlation (ICC). Kappa scores in the range of 0.40 to
0.59 indicate moderate agreement; 0.60 to 0.79 indicate substantial
agreement; and 0.80 to 1.00 indicate almost perfect agreement.1
109
Summary: Mean-weighted Kappa coefficients for intra-rater
agreement were 0.725 (substantial) for POL; 0.826 (almost perfect)
for POLM; and 0.789 (substantial) for OCS. Physician inter-rater
agreement was almost perfect for all 3 scales (ICC Shrout-Fleiss single
scores for POL, POLM, OCS were 0.809, 0.853, and 0.817 at round 1
and 0.818, 0.873, and 0.818 at round 2, respectively). Subject intrarater agreement ranged from moderate to substantial. The Pearson
correlation coefficients between subjects’self-ratings and mean
physician ratings were substantial for each scale at rounds 1 and 2,
respectively (POL 0.682, 0.779; POLM 0.761, 0.737; OCS 0.806, 0.768).
Conclusion: Each of the 3 perioral photographic scales exhibited
intra-rater and inter-rater reliability during the validation process
on live subjects. Subject ratings were also reliable and comparable
to physician assessments. These validated photographic scales are
suitable for use in future clinical studies as a standardized assessment
tool for both physicians and subjects.1Landis JR and Koch GG. The
measurement of observer agreement for categorical data. Biometrics.
1977; 33:159-74.
The author(s) serves as a consultant for Allergan, Medicis, Merz, J&J,
Dusa, Graceway, Galderma, Photocure, Leo, BioPelle, SkinMedica,
Obagi, La Roche Posay; has received speaking honoraria from
Allergan (Global Advisory Council), and has received research
funding from Allergan, Medicis, Merz, Graceway, BioPelle,
SkinMedica, Obagi.
Poster # 7
Title:
An Inter-Rater and Intra-Rater Reliability
Study of a Photographic Scale for Lip
Fullness
Author(s): Phillip Werschler, MD; Steven Fagien MD;
Pearl Grimes MD; Jane Thomas; Patricia Walker MD;
Frederick Beddingfield MD
Purpose: Despite the increasing popularity of injectable fillers for
lip augmentation, there has been a paucity of validated rating scales
to evaluate the lip fullness. Validated scales provide a reproducible
means to compare aesthetic outcomes pre- and post-treatment; as
well as comparison of results across studies that utilize the same
scales.
Design: The Lip Fullness Scale (LFS) was developed from
standardized, 2-D photographs of 200 sets of lips. Based on the
comments of a board-certified dermatologist and a technical
review of the photograph quality, 95 photographs deemed to be
representative for the spectrum of lip grades were selected for
additional independent validation of content by 2 board-certified
dermatologists and a board-certified oculoplastic surgeon. The
first dermatologist selected the final photographs for the scale (4
photographs for each grade) based on agreement between the
scores and recommendations from the 3 reviewers. This 4-grade scale
assesses the subject’s lips at rest and assigns a grade corresponding
to the fullness attribute. A grade of “Minimal” describes lips with
minimal red lip showing and a flat or nearly flat contour, “Mild”
describes lips that have some red lip show and no lower lip pout,
“Moderate” describes lips that have a moderate lip show with slight
lower lip pout and may have curves, and “Marked” describes lips
that have significant red lip show and lower lip pout and may be
very curved. The LFS was then validated for inter- and intra-rater
reliability by a panel of 8 physicians; all are specialists in aesthetic
dermatology or plastic surgery. Panel members were seated to
exclude their ability to gain feedback from other panel members.
Each rater assigned a rating to each of 55 prescreened volunteers
in random order, once in a morning session (round 1), and once in
the afternoon (round 2). Subjects were blinded to the physicians’
assessments and also used the LFS to rate their own lips during
rounds 1 and 2. Intra-rater agreement compared round 1 scores
110
with round 2 scores. The mean weighted Kappa coefficient for
the 8 physician raters was 0.799 (95% CI 0.762-0.836) and for 54
subjects was 0.790 (95% CI 0.667-0.912). Inter-rater agreement
was measured by intra-class correlation (ICC), a measure of the
proportion of reliable variance. The ICC (Shrout-Fleiss single) result
among the physician raters was 0.814 for round 1 and 0.787 for
round 2, respectively; and round 1 ICC and round 2 ICC assessing
agreement between subjects self-ratings and mean of physicians
ratings were 0.800 and 0.755, respectively. Kappa scores in the range
of 0.40 to 0.59 indicate moderate agreement, 0.60 to 0.79 indicate
“substantial” agreement, and 0.80 to 1.00 indicate “almost perfect”
agreement.
Summary: Intra-rater agreement among physician raters and
subjects using the LFS was substantial. Inter-rater agreement was
more than substantial among the 8 physician raters and substantial
between physicians and subjects.
Conclusion: Intra- and inter-rater agreement was substantial among
physicians as well as subjects for the newly developed LFS. During
the validation process, the LFS demonstrated both reproducibility
and reliability for physician classification and subject self-evaluation
of lip fullness in live subjects, thus making it a suitable measure for
use in future clinical studies. To our knowledge, this is the first lip
fullness scale validated by direct assessment of live subjects.
The author(s) has serves on the Advisory Board of Allergan, Merz,
Clarisonic, Dermik, J&J, Sanova; as a consultant for Allergan,
Clarisonic, Dermik, SkinMedica, Ulthera; maintains an ownership
interest in Allergan and Medicis; has received speaking honoraria
from Allergan, Merz, Dermik, J&J, Medicis, SkinMedica, and
has received research funding from Allergan, Amgen, Dermik,
Galderma, Genentech and J&J.
Poster # 8
Title:
Assessment of Safety and Efficacy of a
New Bipolar Radiofrequency Vacuum
Assisted Device in the Temporary
Improvement in the Appearance of
Cellulite
Author(s): Jeremy Man, MD; Jennifer Chwalek MD;
Mussarrat Hussain MD; David Goldberg MD
Purpose: The primary objective of the study is to assess the
safetyand efficacy of a new bipolar radio frequency vacuum assisted
device in the temporary improvement in the appearance of cellulite
as assessed by blinded investigator.
Design: Fifteen female patients ranging from the age of 18 to 50
years of age were enrolled with cellulite grade 2-4 on the thighs.
Each patient underwent eight successive weekly treatments on
one leg with the Reaction device(Viora Ltd., Tel Aviv, Israel). The
device combines both vacuum massage with bipolar radio frequency
heating of the skin in order to reduce the appearance of cellulite.
In contrast to current technologies, the Reaction device uses lower
energies than other bipolar vacuumassisted devices and does not
use infrared light. The bipolar nature of the device allows for more
superficial heating of the tissue than the monopolarradio frequency
diathermy devices currently available. Photographs according to
standardized protocol and measurements were taken at each visit
and adverseevents recorded at each visit and 1,2 and 3 months after
the last treatment. Ablinded investigator then assessed the reduction
in the appearance of celluliteon both thighs individually.
Summary: A statistically significant reduction in cellulite was
apparent in most treated subjects. Improvement was seen to persist
months after treatment in some, but not all treated subjects. Adverse
events were limited to mild discomfort in certain areas during
treatment and mild bruising. All subjects were able to complete the
study.
Conclusion: Our study suggests that the use of this novel
bipolarradio frequency vacuum assisted device can temporarily
reduce the appearance of cellulite. It is a safe and effective addition
to the possible treatments used currently for cellulite.
The author(s) has received research funding in part provided by
Viora Ltd.
Poster # 9
Title:
Case Studies Using a Novel Surgical
Stapling Device in Private Practice
Author(s): Todd Schlesinger, MD; Daniel Ward MD
Purpose: Dermatologists treat numerous skin cancers and perform
many skin closures in the United States. In addition to adequate
undermining and hemostasis, basic tenets of good surgical technique
in skin closure include wound edge eversion and low tension closure.
Traditionally, a full-thickness skin wound is closed in a layered
fashion with absorbable subcuticular sutures, which can be arduous
and time consuming to place and cuticular sutures, which cause
numerous percutaneous insults. Track-like scarring can result from
this technique and sutures must be removed in 1-2 weeks. Surgical
stapling using absorbable Poly-Lactic Acid/Poly-Glycolic Acid (PLA/
PGA) co-polymer staples may result in improved cosmesis, shorter
wound closure times and eliminate the need for a suture removal
visit. The purpose of this report is to demonstrate the safety and
effectiveness of a novel surgical stapler as it may be used in a busy
dermatologic surgery practice.
Design: A total of five patients were determined to be candidates
for surgical stapling to close their surgical wounds. The sites were
closed using the INSORB surgical stapler using the manufacturer’s
recommended technique after proper wound preparation and the
insertion of 1-3 deep subcutaneous absorbable sutures to relieve
tension and minimize subcutaneous dead-space. Steri-Strips were
placed over the wound edges in each case. Photographs were
obtained of each site before, immediately following and 2-4 weeks
after surgery. These photographs and case histories are presented.
Summary: Each surgical wound demonstrated good to excellent
cosmetic appearance at 2-4 weeks after closure.
Conclusion: The surgical stapling device described provides a safe
and effective alternative to conventional suturing.
The author(s) serves as a consultant for Innocutis Pharmaceuticals,
Pierre Fabre Laboratories; and has received research funding from
Photocure, Pierre Fabre Laboratories, Amgen, Centocor, Astellas,
Galderma.
Poster # 10
Title:
Controlled Release of Fibrous Septae for
the Treatment of Cellulite
Author(s): Michael Kaminer, MD; Ivan Augusto Rosales Berber MD;
Melanie Kingsley MD; Naheed Abbasi MD;
Elsa Susana Diliz Perez MD
Purpose: Non-invasive treatments for cellulite are partially or
temporarily effective. Manual release of subcutaneous fibrous septae
has been shown to be effective for individual cellulite “lesions”,
but is not a practical treatment for large areas. A novel system has
been developed which provides controlled release of fibrous septae
for lasting, effective treatment of cellulite. Integrated anesthesia
delivery minimizes pain, and multiple depths enable “fractional”
treatment of larger areas.
Design: The system (Cabochon, Inc., Menlo Park, CA) was the subject
of a multicenter non-randomized, open label clinical study in 56
subjects with follow-ups conducted up to 180 days post-treatment.
Efficacy was assessed by independent, blinded physician review of
standardized before and after treatment photographs according to a
validated photonumeric severity scale (0 to 6).
Summary: Effectiveness was verified by blinded physician review.
The average cellulite severity was decreased from 4.6 to 3.1 (p<0.001)
at 90 days and to 2.8 (p<0.001) at 180 days with >90% of subjects
having improved at least one level in cellulite severity. Treatment
was well tolerated with no serious adverse events, minimal pain, and
subject satisfaction >85%.
Conclusion: Controlled release of fibrous septae at precise depths
leads to lasting and visible improvement in cellulite.
The author(s) has a relationship with Advisory Board - Cabochon,
Zeltiq, Miramar; serves as a consultant for Zeltiq, Cabochon,
Miramar; has received speaking honoraria from Solta Medical, and;
has received research funding from Miramar, Cabochon, and Solta
Medical.
Poster # 11
Title:
Evaluating the Efficacy of Cold Air
Cooling in Improving Patient Comfort
During Photodynamic Therapy as Well as
Its Effect on Therapeutic Outcomes
Author(s): Sabrina Fabi, MD; Mitchel Goldman MD
Purpose: Photodynamic therapy (PDT) uses a photosensitizer such
as aminolevulinic acid or methyl aminolevulinate which is converted
to protoporphyrin IX in vivo. These photosensitizers concentrate in
rapidly proliferating cells, sebaceous glands, superficial melanin, and
vasculature. When visible light radiation is applied, reactive oxygen
species are generated. While originally indicated for the treatment
of nonhyperkeratotic actinic keratosis, improvement in the signs of
photoaging and acne has been noticed as advantageous side effects.
Most patients experience stinging or burning during photoactivation
of the photosensitizer, which decreases or resolves by 24 hours after
light exposure. Presently different modalities are utilized to mitigate
the discomfort during photoactivation, including spraying cold
distilled water, or using a fan or cold air cooling. Oxygen is needed
to generate reactive oxygen species during photodynamic therapy.
Applying cold air to the skin during PDT may cause vasoconstriction
of dermal vessels leading to a decrease in cutaneous oxygen delivery,
which may diminish the effects from PDT. The primary objective
of this study was to evaluate the efficacy of cold air cooling in
improving patient comfort during photodynamic therapy (PDT). The
secondary objective was to determine if cooling the skin during PDT
has any effect on expected outcomes.
Design: Patients undergoing PDT for inflammatory acne or
photoaging were randomized to receive cold air cooling to half
of their face during blue and red light exposure. All subjects were
treated with vibrational microdermabrasion for 5 minutes prior to
being degreased with an acetone-soaked gauze pad. Aminolevulinic
acid was then applied to the entire face and incubation occurred
for one hour. All patients receivedtreatment with PDL and IPL.
Patients were then randomized to receive cold air cooling to half of
their face during blue and red light illumination. The investigating
111
physician was blinded to the side that received cold air. Patients
undergoing PDT for acne were assessed prior to treatment using
a 5-point global acne assessment scale, and by counting individual
papules, pustules and nodules, at Day 1 (Visit 1) and Day 30 (Visit
3). Patientsundergoing PDT for photoaging were assessed prior
to treatment using a 5-point global score for photoaging, fine
lines/wrinkles, hyperpigmentation, tactile roughness, sallowness,
telangiectasias and erythema at Day 1 (Visit 1) and Day 30 (Visit 3).
Erythema was assessed on a 5-point scale at visit 2 (day 4 through 7).
Standardized photography was completed at the first and last clinic
visits.
Summary: 7 of 20 patients (3 females, 4 males), aged 34-58 years
old (mean 45.14), completed the study at the time of data analysis.
All patients were Fitzpatrick skin types II-IV with moderate to severe
photodamage or acne. The mean minimum temperature achieved
with cold air cooling was 28.46 degrees Celsius versus 33.56 degrees
Celsius on the side not receiving cold air. A statistical significance
was found in the investigator global acne assessment score (using a
5-point scale) comparing baseline to day 30 in the cold air cooling
exposed side (p = 0.002); compared to the non-exposed side where
no statistical significance was found in the investigator global acne
assessment (using a 5 point scale) comparing baseline to day 30.
There was no significant difference noted in the global assessment
of improvement score (7-point scale), papules, nodules and pustules,
between the cold air exposed side versus the non-exposed side,
when comparing baseline to day 30 in acne patients. Comparing
baseline to day 30, no statistical difference in improvement was
noted in photodamaged patients in investigator global assessment
of improvement score (7-point scale), global photoaging score, fine
lines/wrinkles, hyperpigmentation, tactile roughness, sallowness,
telangiectasias, and erythema. No differences in post-PDT erythema,
4 to 7 days after treatment, were noted between sides. A statistical
significance was noted in patients preferring cold air during
treatment versus no air or having no preference at all; although the
difference in pain reported between both sides was not statistically
significant.
Conclusion: Cold air cooling during photodynamic therapy is
preferred by patients and decreases pain experienced during
treatment, although not significantly, without compromising the
benefits of treatment, for both photoaging and acne. In patients
with acne, the cold air cooling side showed a statistically significant
difference in improvement in the global acne assessment score,
versus the side which was not exposed to cold air. This finding was
unexpected, as the opposite or no difference was expected to be
seen. Presently only preliminary data is available. All twenty patients
are expected to have completed the study by July 1st, 2011. Future
studies using larger study cohorts followed for a longer period of
time are needed to further investigate these findings.
Dr. Goldman: serves on the Advisory Board for Sanofi-Aventis, on
the Advisory Board and Consultant for Johnson & Johnson Medical,
Inc., Wound Healing Division Medical, Advisory Board, Allergan Skin
Care Chairman, Medical Advisory Board, Bio Med Science, Allergan
Skin Care Chairman; has received speaking honoraria and has an
ownership interest in Lumenis. Dr. Fabi has no financial ownership
relationships to disclose.
Poster # 12
Title:
Excimer Laser in the Treatment of
Mycosis Fungoides
Author(s): Ashley Cauthen, MD; Darci Deaver RN;
George Cohen MD; Lubomir Sokol MD
Purpose: To determine the efficacy of excimer laser therapy (both
clinically and histopathologically) in patients with patch stage
mycosis fungoides (MF).
112
Design: A retrospective review of eight patients with stage 1 MF
that received excimer laser therapy between January 2011 and
August 2011.
Summary: Seven patients with stage 1 MF, and one patient with
folliculotropic MF received 308 nm excimer laser therapy after
failure of at least one prior skin directed therapy. All patients had
histological confirmation of the diagnosis prior to initiation of
treatment. Mean age of participants was 52 years, 57% were male,
86% were Caucasian, and 14% were African American. Biopsies
and photos were taken at diagnosis and after the completion of
24 treatments. Treatment was initiated at a dose of 200 millijoules
(mJ) and was increased by 10-15% each subsequent treatment. The
max dose of treatment ranged from 240 mJ to 850 mJ. All patients
achieved clinical improvement in appearance and puritus; majority
reached clinical remission and normalization of skin color.
Conclusion: Narrow band UV light at 311 nanometers is a standard
skin directed treatment for MF. Excimer laser with a wavelength
of 308 nm is similar to nb-UVB but offers the benefit of targeted
application to lesional skin and ability to treat with higher doses,
which theoretically would result in a more rapid response and less
total body radiation exposure. Our study demonstrates the short
term efficacy of excimer laser in the treatment of MF. Further studies
are needed to determine long-term benefits.
Poster # 13
Title:
Full Face Treatment of Argyria Using the
1064nm Q-switched Nd:Yag Laser
Author(s): Whitney Hovenic, MD; Nicholas Golda MD
Purpose: Argyria is a pigmentary condition caused by ingestion
of silver containing medications leading to slate gray discoloration
with accentuation in sun exposed areas. Therapies including
depigmenting creams, hydroquinone, dermabrasion and chelation
have shown minimal efficacy in improving discoloration. Rhee and
colleagues reported the use of the Q-switched Nd:YAG laser in one
patient with argyria and reported dramatic lightening using a 6.5J/
cm2 fluence and a spot size of 2mm. The patient was unfortunately
lost to follow up after treatment of the right half of her forehead
only. Given the poor efficacy of current topical therapies available
to treat argyria and the dramatic results achieved by Rhee and
colleagues, we sought to determine optimal settings for the
clearance and patient tolerance with use of the Q-switched Nd:YAG
Laser for this disfiguring process.
Design: Two patients, age 26 and 64, presented to clinic with
diffuse slate gray pigmentation. Both had a history of colloidal
silver ingestion for one year for “health benefits” and had
developed diffuse slate gray-blue pigmentation particularly of the
face and chest. Hydroquinone had been used previously with no
improvement. Post auricular biopsy of both patients confirmed
the diagnosis of arygria by demonstrating deposition of silver
granules in perieccrine areas in the dermis. Post auricular test sites
were treated with varying settings using the 1064 nm Q-switched
Nd:YAG Laser (Medlite C6, HOYA ConBio, Fremont, CA). Fluences
ranged from 1.5-6J/cm2 and the spot size varied from 3mm to 8mm.
Immediate edema and erythema was achieved with all settings but
no immediate epidermal frosting occurred. There was minimal to no
tissue splatter. Significant discomfort was experienced at all settings
with no setting being preferred over another in terms of patient
comfort. Postoperative care was prescribed and the patients were
discharged with plans to treat the entire face 8 weeks later with
optimal settings to be determined by test site clearance.
Summary: Postoperative photos at one week and three weeks
showed remarkable lightening for both patients in the post
auricular test sites. More significant clearance was achieved in test
areas treated with low-range fluence and larger spot size with the
best results achieved at a setting of 1.5J/cm2 and a 6mm spot size.
Neither patient experienced any post-operative complications. Pain
resolved completely within one hour of treatment without the use
of pain medication and edema resolved after 24 hours. The patients
returned 8 weeks after test site treatment for full face treatment.
Results of the full-face treatment and follow up for 6 months
will be presented. Given the significant discomfort experienced
during treatment, optimal pain management strategies will also be
presented.
Conclusion: With increased popularity of alternative medicines,
treatment of argyria in patients who have ingested colloidal silver
is likely to be a persistent clinical problem. Our treatment of the
full face in two argyria patients will be of use to the dermatologic
surgeon who is presented with this challenge.
satisfaction ratings (7.5 before vs 9.2 after) and a decrease in the
time required to reach resolution of edema (46% before vs 13%
after requiring >8 weeks to reach resolution, P = .06).
Conclusion: Shiatsu is a specialized massage technique used to
treat a variety of ailments. Its stimulatory effect on circulation
and lymphatic drainage make it a safe and effective option to
treat post-operative edema. In this retrospective chart review, we
found that post-operative, office-based manual massage using the
shiatsu technique improved overall patient satisfaction and reduced
postliposuction edema of the abdomen.
The author(s) serves as a consultant for Allergan Skinmedica.
Poster # 15
Title:
Improvement in Skin Appearance with
Blue Light Using Hexyl Aminolevulinate
HCl: A Split Face Study of the
Differential Effect of Microdermabrasion
Author(s): Todd Schlesinger, MD; Rebecca Repaire, PA-C
Poster # 14
Title:
Improvement in Abdominal Edema After
Tumescent Liposuction Using Manual
Lymphatic Drainage Massage
Author(s): Daniel Levy, MD; Daniel Levy MD; Giuseppe Cappalonga;
Mark Dedomenico MD
Purpose: Postliposuction edema (PLE) is a primary concern for
patients undergoing tumescent liposuction. It is a consequence
of leakage of intravascular plasma proteins from traumatized
capillaries, along with liposuction-induced impairment of
subcutaneous lymphatic function. When the entire abdomen is
treated by tumescent liposuction, premature closure of slit incisions
on the abdomen can entrap a considerable volume of blood-tinged
anesthetic solution. The result is prolonged lower abdominal swelling
and tenderness. While this can be minimized by using postoperative
care that includes open drainage and bimodal compression,
the abdomen tends to require more time than other areas for
resolution of PLE. The post-operative use of devices emitting infrared
light, bipolar radiofrequency, ultrasound as well as vacuum and
mechanical massage devices have been described, but only anecdotal
evidence has supported the efficacy of device-based modalities after
liposuction. Even less data exists on the use of manual lymphatic
drainage massage. The purpose of this retrospective review is to
evaluate patient-satisfaction with manual lymphatic drainage
massage in reducing edema of the abdomen following traditional
tumescent liposuction.
Design: A retrospective chart review was performed for 15 patients
who received shiatsu-type lymphatic drainage massage treatments
after tumescent liposuction in a private cosmetic dermatology
practice. Patients were sampled from a 24-month period and all
received at least two shiatsu treatments from a certified shiatsu
massage therapist within 4 weeks of tumescent liposuction of the
abdomen. Patient satisfaction questionnaires were used before
and after implementation of shiatsu massage. Data were gathered
from chart review and patient-satisfaction questionnaires. The
questionnaire responses were compared from before to after
implementation. Tumescent fluid administration and fluid balance
information was found in records and compared with an equal
number of age- and sex-matched control patients who did not
receive postliposuction treatments.
Summary: All (100%) of patients reported improvement in
abdominal swelling. 12 reported complete resolution of edema by
the 8-week follow-up appointment. Patients reported better overall
Purpose: Improvement in the appearance of skin has been shown
using multiple forms of Photodynamic Therapy (PDT). The beneficial
effect of PDT may/has been limited by associated phototoxicity.
Microdermabrasion prior to the application of Hexyl aminolevulinate
HCl may enhance the beneficial effect without an increase in
phototoxicity. The objective is to compare and contrast blue light in
conjunction with application of topical hexyl aminolevulinate HCl
with and without microdermabrasion for effectiveness and safety.
Design: In a randomized prospective split face study, 12 subjects
received 3 treatments (at baseline, 1 month and 2 months) with
application of topical hexyl aminolevulinate HCl to the face,
followed by full face blue light exposure(405-420 nm, 10 J/cm2 BLU-U
Illuminator, DUSA Pharmaceuticals, Wilmington, MA) one hour
later. One side of the face was pre-treated with microdermabrasion
(Vibraderm, Grand Prarie,TX) immediately prior to the application of
hexyl aminolevulinate HCl. Subjects were followed for an additional
3 months after the final treatment. Objective measurements
included skintone/texture, fine lines/wrinkles, skin pigmentation,
porphyrin content measured by UV fluorescence and skin brightness
using natural, polarized and UV light with 3-dimensional spectral
analysis (Image Pro II, Charlotte, NC). Photographs were taken, and
comparative clinical evaluations (crow’s feet, tactile roughness, and
mottled hyperpigmentation) were made at each visit. Safety analysis
of erythema, edema, crusts and erosions, and pain were determined
on a 5-point scale (0=none; 4=severe) at each treatment and followup visit.
Summary: Improvement in the overall appearance of the texture
and tone of the skin was detected as was a reduction of wrinkling
in the peri-ocular area at the conclusion of the study. Adverse
events included minimal to mild erythema (92%), minimal to
mild edema (33%), mild to moderate pain during light treatment
(75%), severe pain during light treatment (8.3%), moderate pain
immediately following light treatment (58%), and rare to moderate
itching (50%). All adverse effects resolved spontaneously. Subjects
demonstrated no difference in adverse effects on the side of the face
pre-treated with microdermabrasion when compared to the opposite
side.
Conclusion: Blue light PDT using topical hexyl aminolevulinate HCl
and microdermabrasion is a safe and effective way to improve the
appearance of skin.
The author(s) serves on the Advisory Board of Suneva Medical; as a
consultant for Innocutis Pharmaceuticals, Pierre Fabre Laboratories
113
and has received research funding from Photocure, Pierre Fabre
Laboratories, Amgen, Centocor, Astellas, Galderma.
Poster # 16
Title:
Infection of the Face and Neck with
the Emerging Pathogen M. Massiliense
Following CO2 Fractional Laser
Resurfacing
Author(s): Bishr Al Dabagh, MD; Al Dabagh Bishr MD;
Claude Burton MD
Purpose: Report of the first case of M. massiliense following
fractional laser resurfacing.Review other worldwide cases, treatment
and implications of the emerging pathogen M. massiliense
Design: First every reported case report regarding this infection with
this emerging pathogen, M. massiliense, following CO2 fractional
laser resurfacing, and associated literature review.
Summary: The patient is a 53 year old Caucasian woman who had
a non-ablative radiofrequency rejuvenation procedure of the face
and neck. This was followed one week later by an C02 fractional
laser resurfacing treatment of the face, neck, and chest. Her neck
and chest did not fully heal after the procedure. Subsequently she
developed erythematous, eroded, very painful, papules on the
chest and neck which subsequently spread to her face. She was
initially treated with trimethoprim-sulfamethoxezole with partial
response but worsening following treatment. She was admitted to
the hospital and valacyclovir and prednisone were initiated. Biopsies
done at the time revealed granulomatous inflammation and copious
acid fast bacilli. Molecular studies identified M. massiliense as the
culprit. She was treated with empiric azithromycin, moxifloxacin,
and tigecycline. After susceptibility testing she was continued
on azithromycin for five months with complete resolution of the
infection but with residual scarring of the neck and chest.
Conclusion: M. Massiliens rapidly growing mycobacterium that is
closely related to Mycobacterium chelonae and M. abscessus. It is
an emerging pathogen in the United States and across the world. A
single clone of M. massiliens has recently been implicated as causing
epidemic infections in Brazil following video assisted surgery. This
clone (BRA100) is resistant to high concentrations of glutaraldehyde.
A case of leg infection in a young woman was recently reported
in South Korea. In Japan, seven cutaneous cases not associated
with any surgical procedure were reported in immunocompetent
individuals who worked at a “hot spa.” We describe the first case
following fractional laser resurfacing.
Poster # 17
Title:
Laser Assisted Bone Marrow
Transplantation
Author(s): Jill Waibel, MD; Stephen Davis PhD; Luis Rodriguez
Menocal MD; Macela Salgado MD
Purpose: Fractional laser technology has greatly advanced theclinical
use of light based ablation therapy. While most often used for
cosmetic purposes, these lasers appear to havethe potential for the
systemic delivery of drugs and cell therapy. In thisfirst pilot study, we
have tested the hypothesis that cells can be deliveredthrough skin
treated with the Er:YAG fractional laser and that the deliveredcells
can enter the systemic circulation and remain functionally intact.
114
Design: A murine bone marrow transplantation model was chosen
forthis study. Immune deficient NOD/SCID mice were recipients
of GFP positive bonemarrow cells derived from a GFP expressing
transgenic mice (C57BL/6-Tg(UBC-GFP)30Scha/J). Recipient mice were
either irradiated tocreate space in the bone marrow compartment
or not irradiated prior tofractional laser treatment and cell delivery.
Cells were delivered in a sealed plastic chamber that was secured to
themouse using an adhesive.
Summary: Three weeks following a single administration of
bone marrowcells to mice, chimerism could be detected by the
presence of circulating GFPpositive blood cells in the recipient
mice. Both irradiated and non-irradiated mice had evidence of
chimerismhowever irradiated mice had significantly higher levels.
Conclusion: These preliminary results demonstrate that using
fractionallaser technology, cells can be delivered systemically through
the skin andremain functional. These findings hold promise for the
use of fractional lasersfor the treatment of a multitude of disorders
using cell and drug basedapproaches.
The author(s) serves as a consultant for Sciton, Lumenis, Candela/
Syneron and Deka; has received speaking honoraria from Lumenis,
Candela/Syneron, Sciton, and; has received research funding from
Sciton and Solta.
Poster # 18
Title:
Nasal Contour Reconstruction with
Full-Thickness Skin Grafting: A Novel
Approach to a Classic Method
Author(s): Jessica Weiser, MD; Jeanne Marie Franck MD
Purpose: To define and illustrate a new perspective on full-thickness
skin grafting which avoids defatting after graft havest thereby using
the attached subcutaneous fat to recreate nasal contour defects after
Mohs micrographic surgery.
Design: Consecutive patients in a single dermatologic surgery
practice from January through August 2010 who underwent Mohs
micrographic surgery to the nose were evaluated. Those with
a specific nasal contour defect involving the nasal tip, supratip,
dorsum, or columella were considered for treatment with a fullthickness skin graft including attached underlying fat from the
graft donor site. All grafts were uniformly harvested, mostly from
preauricular skin. Grafts were not defatted and subcutaneous fat
was maintained after graft placement in order to achieve original
nasal contours. Bolster dressings were placed whenever possible for
1 week following grafting. Photographs were taken prior to Mohs
surgery, after the final defect was achieved, immediately after repair,
and again 6 weeks or more after bolster removal.
Summary: Between January and August 2010 a total of 10 patients
had nasal tip/supratip, nasal dorsum, or nasal columella surgical
defects repaired with full-thickness skin grafts including subcutis with
excellent repair of original nasal contour but without compromising
graft survival. Our results question whether the dermis must be in
direct contact with the wound bed as is classically recommended, or
if an intervening layer of fat can similarly allow for expedient and
complete healing but with improved cosmesis.
Conclusion: Full-thickness skin grafts with attached subcutaneous
fat provide an excellent option for nasal contour reconstruction
following Mohs micrographic surgery on the nasal tip, supratip,
dorsum and columella, demonstrating that an intervening layer of
fat allows for improved cosmetic outcome but does not inhibit graft
survival.
The author(s) has no relationship(s) to disclose.
Poster # 19
Title:
Non-Invasive Ultrasound Treatment
for Circumferential Reduction of the
Abdomen
Author(s): Michael Kaminer, MD
Purpose: Little scientific evidence exists to demonstrate
the effectiveness of non-invasive ultrasound treatment for
circumferential reduction, and several methods need long waiting
periods for measurable results. This pilot study evaluates the
immediate and short term changes after a single treatment with a
new modality.
Design: 10 females between 23 & 59 years with a BMI less than
30 kg/m2 were enrolled at one site and treated once in the braline region with the VASER Shape (Sound Surgical Technologies,
Louisville, CO). They were seen in follow-up at 7 & 130 days.
Circumferential measurements were made before and immediately
after treatment, and at follow-ups.
Summary: The mean circumferential changes were -0.88 cm posttreatment (p=0.01), -1.14 cm at 7 days (p=0.02), and -0.90 cm at
130 days (p=0.23). There were no major complications & all minor
complications resolved without treatment between 1 hour and 3
days.
Conclusion: The VASER Shape non-invasive ultrasound device was
shown to provide an average circumferential reduction of over 1
cm 7 days after one treatment. A nearly 1 cm reduction was also
observed immediately after treatment, and continued through
follow-up. The VASER Shape shows immediate results after one
treatment, allowing both enhanced patient satisfaction and better
tailoring of the treatment regimen for subsequent treatment.
Further studies are needed to determine the optimal treatment
parameters for improved short and long term efficacy.
The author(s) serves on the Advisory Board of Cabochon, Zeltiq,
Miramar; a consultant for Zeltiq, Cabochon, Miramar; has received
speaking honoraria from Solta Medical, and has received research
funding from Miramar, Cabochon, and Solta.
Poster # 20
Title:
Opioid Prescribing Patterns of
Dermatologic Surgeons in the United
States: An email-based Survey
Author(s): Payam Tristani-Firouzi, MD; KaLynne Harris MD;
Michael Hadley MD; Keith Duffy MD;
Payam Tristani-Firouzi MD
Purpose: Prescription opioid use and misuse has increased in
the United States. Little is known regarding opioid use after
dermatologic surgery. The objective of this study is to better
understand opioid prescribing patterns after dermatologic surgery.
Design: An email survey was sent to members of the American
Society for Dermatologic Surgery (ASDS) to document respondent
demographics and opioid prescribing patterns after dermatologic
surgery.
Summary: Twenty percent (583/2858) of ASDS members receiving
the email responded, of which 556 practiced within the United
States and were included in the study. Most respondents (64%)
reported infrequently prescribing opioids (i.e., for  10% of their
surgical cases). Surgeons younger than 55 years old and male
surgeons were more likely to prescribe opioids (p=0.045 andp<0.001,
respectively). Hydrocodone/acetaminophen was the most frequently
prescribed opioid (58%) and 35% of respondents prescribed >15pills.
Surgeons practicing in the Southern and Western United States
were significantly more likely to prescribe opioids than those in
the Northeast orMidwest (p<0.001). These demographic differences
remained significant in multivariate analysis. Reasons cited for
prescribing opioids includedwound/repair size, location, tension, and
patient request.
Conclusion: Most surgeons infrequently prescribe opioids after
dermatologic surgery. There is significant variation in opioid
prescribing based on surgeon characteristics (age, sex, region)
suggesting room for standardization.
Poster # 21
Title:
Persistence of the Reduction of
Abdominal Subcutaneous Fat by LIPO102 (Salmeterol Xinafoate (SX) +
Fluticasone Propionate (FP) for Injection)
Author(s): Mitchel Goldman, MD; Stacy Smith MD;
Steve Cohen MD; MI Peredo MD; Roy Geronemus MD;
Barry DiBernardo MD; Neil Sadick MD; MC Mayton MD
Purpose: LIPO-102 is an injectable aqueous combination of
salmeterol xinafoate (SX) and fluticasone propionate (FP)
for selective, non-ablative fat reduction. This non-treatment,
observational Phase 2 extension study or placebo.
Design: This 3 month non-treatment, observational extension study
followed a randomized, double-masked, placebo-controlled study
that enrolled 164 male and female subjects, aged 18-67 (mean = 37)
with a Body Mass Index (BMI) < 25 kg/m2. In the treatment portion
of the trial, subjects received twenty 1 mL subcutaneous injections
of one of three different doses of LIPO-102 or placebo (0.9% saline).
A template based on the umbilicus was used to ensure reproducible
location the injection points; the injections were spaced 4 cm apart
over abdominal (14 injection sites) and flank (3 injection sites each)
areas of adiposity (total area ~400 cm2 lying between axial planes
of +40 mm to -60 mm, relative to the umbilicus) once per week for 8
consecutive weeks. During the treatment portion of the trial, safety
and efficacy were evaluated weekly for 8 weeks and at 1 week posttreatment; in the extension study, assessments were made 6 and
12 weeks post-treatment. Abdominal volume and circumference
were measured using synchronized digital photographs (Canfield
VectraTM 3D) that allowed 3D reconstruction of the subject.
Measurements of the abdominal circumference were also taken
manually by tape measure. Subjective efficacy endpoints included
a Patient Photonumeric Scale (PPnS), a Patient Global Impression
of Change (PGIC) Scale and the Abdominal Subcutaneous Adiposity
Questionnaire (ASAQ), a patient-reported outcome evaluating the
broader impact of changes in abdominal adiposity.
Summary: Significant mean reductions in abdominal volume were
maintained for 6 and 12 weeks post-treatment with the optimal dose
of LIPO-102 (0.4 µg SX + 20 µg FP) compared to placebo (at 6 weeks:
-251 vs. -59 cc, p=0.01; at 12 weeks: -253 vs. -96 cc, p=0.09). Likewise,
significant mean reductions in circumference at multiple levels
across the abdominal treatment zone (+40 to -60 mm, relative to the
umbilicus) were maintained for 6 and 12 weeks post-treatment with
the optimal dose of LIPO-102 (0.4 µg SX + 20 µg FP) compared to
placebo (at 6 weeks: -1.4 vs. -0.4 cm, p=0.02; at 12 weeks: -1.4 vs. -0.8
cm, p=0.17). In responders defined as those subjects who lost > 100
cc in abdominal volume at 1 week post-treatment, mean volume loss
115
was maintained for 12 weeks post-treatment (-473 cc at 12 weeks)
in responders (63%; 26/41) who had received the optimal dose of
LIPO-102 (0.4 µg SX + 20 µg FP), whereas mean abdominal volume
loss in responders (39%; 15/38) who had received placebo regressed
towards baseline by 12 weeks post-treatment (-177 cc at week 12).
Conclusion: The reductions in abdominal volume and circumference
produced by treatment with LIPO-102 were maintained for at least
12 weeks post-treatment. LIPO-102 may offer a novel, minimallyinvasive, non-ablative approach to localized fat reduction.
This study was supported in part by Lithera, Inc.
Poster # 22
Title:
Post-traumatic and Postoperative
Keratoacanthomas
Author(s): Yekaterina Kleydman, DO; Ellen Marmur MD
Purpose: Our goal is to identify whether a true predilection existsin
developing keratoacanthomas (KAs) at sites of previous trauma. We
will providea review of the literature with similar cases and decipher
the significance ofthis phenomenon by introducing five patient
cases.
Design: After a thorough evaluation ofpatient logs from
January 2008 to January 2011, five cases were included
inthis study. We followed the clinical course of patients who
developedkeratoacanthomas within wound sites after Mohs
micrographic surgery of squamouscell carcinomas (SCCs) or
developed keratoacanthomas after traumatic events. Allsurgical
margins were analyzed and were clear of tumor cells. These five
patientswere seen during a period of two years.
Summary: In our review, the first twopatients developed
keratoacanthomas and SCCs with keratoacanthoma-like
featureswithin surgical scars following excision of SCCs via Mohs
micrographic surgeryand following electrodessication and curettage
of a keratoacanthoma. Our thirdpatient admitted to a prior
history that was significant for a repetitive traumaticinjury to the
affected site on the left shin. Our fourth patient presented witha
history significant for lichen simplex chronicus, and admitted to
unremittingrubbing and scratching of the affected area prior to the
development of a KA. Thefifth patient displayed clinical evidence
of psoriasis and keratoacanthomagrowth. Our patients’ history and
supporting clinical evidence of previousinciting events reinforced
the phenomenon of koebnerization and perhapspathergy as a
contributing cofactor.
Conclusion: Our presented cases support the idea that
keratoacanthomascan be precipitated by injury. Patients identified
in our study had all formederuptive keratoacanthomas, which
followed physical or surgical trauma. Therefore,keratoacanthomas
may be considered as posttraumatic or postsurgicalcomplications,
developing in healing wounds of trauma-prone body surfaces
orsurgical scars in predisposed individuals with a history of skin
cancer. Koebnerizationand the notion of a pathergy reaction may
play a significant role in promotinggrowth of keratoacanthomas.
Furthermore, more research into the treatmentmodalities and the
etiology of these tumors is needed.
116
Poster # 23
Title:
Prevention of Surgical Site Infection
Using 2-Octylcyanoacrylate Following
Mohs Micrographic Surgery on MRSA
Positive Patients
Author(s): Andrew Nelson, MD; Ashley Decker MD;
Kjetil Guldbakke MD; Carl Schanbacher MD
Purpose: The purpose of this study was to determine the potential
utility of 2-octylcyanoacrylate (2-OCA) as a wound closure technique
to reduce the risk and incidence of infection in MRSA positive
patients. 2-OCA has been shown to be an effective barrier against
common bacterial microbes, by creating a physically sealed,
polymerized cyanoacrylate antimicrobial barrier. 2-OCA has been
shown to reduce the rates of infection from 17% to 0% following
shunt insertion for hydrocephalus in children. Furthermore, 2-OCA
has been shown to reduce the rate of infection on cardiovascular
surgery wounds. No current research has studied the use of 2-OCA in
dermatologic surgery to reduce the risk of infection associated with
Mohs surgery.
Design: A series of five patients underwent Mohs surgery for biopsy
proven non-melanoma skin cancer. All patients were diagnosed
with MRSA via nasal swabs for bacterial culture, and had previously
developed surgical site infections with MRSA during previous
procedures. Following the Mohs assisted skin cancer excision, all
patients underwent immediate reconstruction. The wounds were
closed with poliglecaprone buried subcutaneous sutures, and the
epidermis approximated with 5-0 fast absorbing plain gut suture
material. After completing the repair, the entire area was covered
with a thin layer of 2-OCA followed by steri-strips. No oral or topical
antibiotics were administered in either the pre or post-operative
period. The patients were then followed for one month for any
clinical and laboratory indication of wound infection.
Summary: The five patients all had confirmed MRSA carriage
and previous histories of clinical MRSA infections. The patients
underwent surgeries on high risk infection areas in this study. The
repairs included: a V-Y advancement flap on the nose, rhombic
transposition flap with Z-plasty on the temple, bilateral rotation flap
on the chin, cheek advancement flap onto nasal sidewall and lower
eyelid, and a complex linear repair on the lower extremity. None of
the patients developed any sign of infection in the post-operative
period or during the month following surgery.
Conclusion: 2-Octylcyanoacrylate has been previously shown to
reduce the risk of infection in neurosurgical and cardiovascular
surgical procedures. This study is the first to demonstrate the
potential decreased risk of infection associated with 2-OCA in
dermatologic surgery. In this study, 2-OCA appeared to be effective
in reducing the risk of infection in high risk, MRSA positive patients,
without the need to administer either topical or systemic antibiotics.
Additional prospective, randomized trials are now being initiated
to further establish the potential role for 2-OCA in dermatologic
surgery.
Poster # 24
Title:
Reduction of Submental Fat with ATX101: Results from a Phase IIB Study Using
Investigator, Subject, and Magnetic
Resonance Imaging Assessments
Author(s): Jeffrey Dover, MD; Joel Schlessinger MD;
Leroy Young MD; Patricia Walker MD
Purpose: Fat accumulation under the chin—submental fat (SMF)—is
a common occurrence, even in individuals who are not otherwise
overweight. General weight reduction measures may be ineffective
in reducing unwanted SMF and, currently, there are no approved
pharmacologic therapies for localized fat reduction. Liposuction and
surgical neck lifts are therefore the only approaches to treatment.
ATX-101 is an investigational drug based on an endogenous bile acid
that has adipolytic properties. It is being evaluated as a non-surgical,
pharmacologic therapy for the reduction of unwanted SMF. In this
Phase IIB study, we sought to assess the efficacy and tolerability of
ATX-101 treatment at two different doses by both subjective and
objective means—clinician assessments, subject assessments, and
magnetic resonance imaging (MRI).
Design: This was a double-blind, placebo-controlled study conducted
across 10 dermatology and plastic surgery centers in the United
States. Subjects were eligible to enroll if they had: Fitzpatrick skin
type I-VI; prominent or marked SMF considered undesirable; and no
prior intervention for the reduction of SMF. They were randomly
assigned to receive injections of one of two ATX-101 doses (1 mg/
cm2 or 2 mg/cm2) or placebo, administered monthly for up to 5
months into the fat of the submental area. Clinician assessment
was performed using the 5-point Clinician-Reported Submental Fat
Rating Scale (CR-SMFRS) at all treatment visits and at 4 and 12 weeks
after the last treatment visit (week 24 and week 32, respectively).
Subject self-assessments and MRI were performed at baseline,
treatment visit 5 (week 16) and 12 weeks after the last treatment
visit (week 32). Self-assessments were performed using the 5-point
Patient-Reported Submental Fat Rating Scale (PR-SMFRS).
Summary: Overall, 129 subjects were enrolled in the study. The
majority were Caucasian (85%) and female (71%). The mean age
was 46 years and the mean body mass index was 30.6. Clinician
assessments showed that, from week 12 onward, the 2 mg/cm2 dose
of ATX-101 was associated with statistically significantly greater
reductions from baseline in SMF relative to placebo (p<0.01 versus
placebo at weeks 24 and week 32). Subject assessments and MRI
(measuring both SMF volume and thickness) also showed statistically
significantly greater reductions in SMF with 2 mg/cm2 ATX-101 than
with placebo (p<0.05 versus placebo at weeks 16 and 32 with the
PR-SMFRS; p<0.05 at week 16 and p<0.01 at week 32 with MRI).
The 1 mg/cm2dose was associated with a smaller reduction in SMF
than the 2 mg/cm2 dose, suggesting a dose-response relationship.
The most common adverse events (AE) were mild swelling, pain,
numbness, bruising and induration. These AE were limited to the
injection site, and most were temporally associated with treatment
and resolved within the 28-day treatment interval. AE incidence did
not vary significantly between the ATX-101 dosing groups and no
systemic treatment-related AE were reported.
Conclusion: ATX-101 treatment was found to be effective in
reducing SMF. Treatment at a dose of 2 mg/cm2 was associated with
statistically significantly greater reductions from baseline in SMF
relative to placebo according to evaluations by clinicians (CR-SMFRS),
subjects (PR-SMFRS) and MRI. ATX-101 was also well tolerated with
no treatment-related systemic adverse events at the doses evaluated.
ATX-101 may prove to be a valuable non-surgical approach to
reducing SMF.
Dover has no relationship to disclose; Dr. Schlessinger serves as
advisor and researcher for Kythera; Dr. Young serves as advisor for
Renovo, Ltd., Excaliard Pharmaceuticals, Inc., RXI Pharmaceuticals,
Inc. and has received researach funding from Kythera
Biophamraceuticals, Inc., Renovo Pharmaceuticals, Inc., Excaliard
Pharmaceuticals, Inc., AirXpanders, Inc., ASERF, Allergan; Dr. Walker
serves as consultant to Halscion; is a stockholder in Allergan and
Kythera; has received grants for clinical research from Allergan,
Galderma, Medicis, Fibrocell Science, Suneva Medical, SkinMedica,
Miramar Labs and Revan. This research funded by Kythera.
Poster # 25
Title:
Successful Treatment of Acne Scars
with Autologous Cultured Fibroblasts:
A Prospective, Double Blind, Placebocontrolled, Multi-center Clinical Trial
Author(s): Girish Munavalli, MD; Stacy Smith MD;
Jeanne Novak PhD
Purpose: Device treatment of acne scarring has historically involved
ablative laser resurfacing. Fractional resurfacing has been shown
to be effective with reduced downtime, but with side effects such
as post-inflammatory hyperpigmentation. More recently, dermal
fillers have been used to provide temporary contour improvement.
This study was designed to evaluate the safety and efficacy of three
treatments of autologous cultured dermal fibroblasts (ACDF) in
patients with moderate to severe facial acne scarring.
Design: This was a randomized Phase II/III multi-center, doubleblind, intra-patient, placebo-controlled trial in patients with bilateral
moderate to severe facial distensible depressed acne scarring.
Patients were rated by themselves and the Investigator as having
bilateral moderate to severe facial acne scarring based on a five
point Subject Live Acne Scarring Assessment and a validated five
point Evaluator Live Acne Scar Assessment. ACDF were produced
from post auricular skin biopsies. Fibroblasts were isolated in culture
and expanded for each individual patient. These were injected into
acne scar treatment areas of the cheek encompassing at least 9 cm2.
Each patient received a total of three treatments to both cheeks
every 14 ± 3 days. Each patient served as their own control.
Summary: For the co-primary efficacy endpoint, Subjects and
Investigators completed Live Acne Scarring Assessments of each
cheek four months following the third treatment with autologous
cultured fibroblasts. For the Subject assessment, a response was
defined as a 2-point or greater improvement from the Baseline
score. For the Evaluator assessment, a response was defined as a
1-point or greater reduction in the acne severity from the Baseline
score. A total of 122 patients were enrolled, of which, 99 patients
were treated. No patient experienced serious adverse events, or
discontinued treatment or withdrew from the study as a result
of a treatment emergent adverse event. Treatment with ACDF
was associated with a statistically significantly greater number
of responders than was treatment with placebo for the Subject
assessment endpoint (43.1% and 18.3%) as well as the Evaluator
assessment endpoint (58.7% and 42.2%). Subject and Evaluator
assessments at earlier time points showed the proportion of response
for ACDF -treated cheeks was statistically significantly greater than
that of placebo for all but one assessment at one time point. The
response rate continued to increase throughout the follow-up period
for ACDF- treated cheeks, but did not increase after the three month
visit for vehicle control treated cheeks.
Conclusion: ACDF treatment of acne scarring was associated with
statistically significantly greater efficacy than placebo based on both
the Subject and Evaluator responder analyses. Treatment with ACDF
was safe and well tolerated in this study and is a promising novel
treatment for facial acne scars.
117
The author(s) has received research funding from Research Funding
for IRB Trial - Fibrocell Technologies.
The author(s) serves as a consultant for Medicis, Suneva, Lumenis,
and OrthoNeutrogena.
Poster # 26
Title:
Successful Treatment of Exogenous
Ochronosis With Fractionated CO2
Technology
Poster # 27
Title:
The Long Term Utility of Bimatoprost
Ophthalmic Solution (0.03%) for Eyelash
Augmentation in Asian Subjects: A
40-week Comparative Assessment of
the Safety and Efficacy of Ongoing
Bimatoprost Treatment Versus
Treatment Discontinuation After 20
Weeks
Author(s): Gary Mendese, MD; Emmy Graber MD
Purpose: Exogenous ochronosis-like pigmentation has been known
to occur after the topical application of cosmetic bleaching agents,
typically used clinically to lighten melasma and other disorders of
pigmentation. The areas involved correspond directly to where the
therapy was applied and present with a blue-brown hue, typically
after years of overuse. The hyperpigmentation may fade slightly
upon discontinuation of the agent, but the discoloration is usually
permanent. Histopathologic examination shows yellow-brown,
banana-shaped fibers (“banana bodies”) in the papillary and even
reticular dermis. Sarcoidal granulomas with ochronotic particles in
multinucleated giant cells have also rarely been reported. Though
rare, exogenous ochronosis is known to be an extremely difficult
condition to treat, often refractory to more conventional modalities
of Q-switched lasers and retinoic-acid based therapies. For that
reason, we attempted the fractionated CO2 laser for a patient for
whom other treatments had failed.
Design: A 46 year old South American skin type IV woman
presented with ill-defined hyperpigmentation along her oral
commissures. She admitted to using various over-the-counter
bleaching creams over many years. She could not recall any of
the ingredients in these creams, however. A biopsy was consistent
with exogenous ochronosis and revealed typical “banana bodies”
throughout the dermis, extending to a maximum depth of 0.84mm.
She underwent a total of three treatments with the quality-switched
(QS) alexandrite laser (755nm, 3mm spot size) at fluences of 6, 7
and 7.5 J/cm2 over several months without effect. The decision was
then made to attempt treatment with a fractionated CO2 laser
(10,600nm, DeepFx handpiece, UltraPulse, Lumenis, Santa Clara,
CA). Settings were: 25 J/cm2 with 20% density to the affected areas.
Given her darker skin type, the patient experienced expected postinflammatory hyperpigmentation. Over the ensuing months, the
areas progressively lightened by approximately 25% compared to the
pretreated state. The patient was very pleased with her results.
Summary: A number of treatments have been attempted for
exogenous ochronosis with variable efficacy. Retinoic acid and
sunscreen is helpful in some, dermabrasion may be beneficial;
tetracycline may be helpful in sarcoid-like ochronosis. Laser therapy is
reportedly effective in limited case reports. One group reported the
use of a Q-switched 755-nm alexandrite laser to treat hydroquinoneinduced exogenous ochronosis in two patients. Unfortunately,
our patient did not have success with the alexandrite laser.
Fractionated CO2 technology has been used in recent years to treat
dyspigmentation, rhytides, scars and global photoaging, without
the down time conventional CO2 lasers once caused. However,
there are no reports in the literature on the use of this technology
for exogenous ochronosis. Our patient had a mild, albeit clinically
appreciable improvement after just one treatment, with settings
aimed at her greatest pigment depth of 0.84mm. The patient was
very pleased with the outcome. Repeated treatments would most
likely give an added benefit.
Conclusion: Fractionated CO2 technology can be a useful adjunct
when treating exogenous ochronosis. Realistic expectations need to
be set and darker-skinned patients should be warned about postinflammatory hyperpigmentation. However, this simple treatment
should be considered in patients who have found other more
conventional treatments disappointing.
118
Author(s): Oh Sang Kwon, MD; Seung Hwan Paik MD;
Ye-Jin Jung MD; Ji Hye Baek MD; Jun Young Lee MD;
John Rogers, MD; Michael Halstead PhD; Hee Chul Eun, MD
Purpose: 1. To determine whether the therapeutic effects of
bimatoprost in eyelash augmentation can be maintained over 36
weeks in healthy Asian subjects.2. To determine the durability of
these therapeutic effects following discontinuation of bimatoprost
therapy after 20 weeks.
Design: Healthy female subjects were enrolled at 3 investigational
sites in South Korea in this 2-phase, prospective, open label study,
conducted over 40 weeks. All subjects applied bimatoprost each
night to the upper eyelid margin of both eyes for the first 20 weeks
of the study (Phase 1). At the end of Week 20, each subject was
invited to enter Phase 2 to be followed for a further 20 weeks, with
subjects at one site receiving ongoing treatment with bimatoprost
until Week 36, with a 4 week follow-up safety evaluation (Cohort 1).
Subjects at the other 2 sites had the study treatment discontinued at
Week 20 and were followed to Week 36, or to Week 40 for subjects
with ongoing study treatment-related adverse events (Cohort
2). Outcome parameters, assessed at 4 weekly intervals, included
digital image analysis of eyelash length, thickness and intensity
(darkness), and the safety and tolerability of the study treatment.
Two additional assessment scales: the physician’s global assessment
of eyelash prominence (GEA) and subject’s treatment satisfaction
were also evaluated in during the study (Cohort 1 only in Phase 2).
The results for the subjects who completed Phase 2 of the study are
presented.
Summary: Sixty-two Korean subjects were enrolled in the study,
with a mean age of the 37.3 years (range: 23–51). Fifty-nine (95%)
of subjects completed Phase 1, while 47 (76%) subjects consented to
enter Phase 2; of all whom completed the study. Of these subjects,
21 were in Cohort 1, with 26 in Cohort 2. In both groups, timedependant and statistically significant increases from pre-treatment
levels were documented in eyelash length, thickness and intensity
during Phase 1, with peak effects noted between Weeks 20 and
24. In Cohort 1, maintenance of this improvement was observed
in Phase 2 with ongoing bimatoprost treatment. In contrast, the
therapeutic effects of bimatoprost waned over time in Cohort 2
during Phase 2, with the aforementioned parameters at or near pretreatment levels 16 weeks after discontinuation of therapy (Week
36). The investigators also documented a > 1 point improvement
on the GEA scale for all of the subjects in Cohort 1 over the entire
follow-up period in Phase 2, which was consistent with a clinically
relevant improvement in eyelash prominence. In addition, at Week
36, 71% of subject in Cohort 1 were satisfied or very satisfied with
the study treatment (vs. 5% dissatisfied/very dissatisfied), while over
90% indicated that they would recommend bimatoprost to others.
No serious adverse events (AEs) were reported and no subjects
withdrew prematurely due to AEs. The majority of AEs were mild,
presenting primarily in Phase 1 of the study. These included lid
hyperpigmentation and hypertrichosis outside the treatment area.
Conclusion: This 40 week study demonstrated that nightly
application of bimatoprost ophthalmic solution (0.03%) to the upper
lid margin of both eyes safely increased the length, thickness and
intensity of eyelashes in healthy Korean female subjects and is one of
the first reports of the effects of bimatoprost on eyelash growth in
Asian patients. This was associated with a high degree of treatment
satisfaction for these subjects and a clinically relevant improvement
in eyelash prominence, as defined by the physician investigators.
The peak therapeutic effect was documented after approximately
20 weeks of treatment, with this effect maintained thereafter
while treatment was ongoing. It was clear from this study that the
therapeutic effects of bimatoprost decline significantly over several
weeks following cessation, highlighting the requirement for ongoing
treatment to sustain maximum response.
The author(s) serves as a consultant for Allergan Korea and Merck
Korea
Poster # 28
Title:
The Positive Impact of Providing
Information From a Computer-Aided
Multispectral Digital Skin Lesion Analysis
System on Melanoma Biopsy Sensitivity
Author(s): Jane Yoo, MDD; Darrell Rigel MD; Mrinalini Roy;
June Robinson MD; Richard White
Purpose: Diagnosing melanocytic skin lesions has traditionally
relied on a variety of techniques including clinical examination and
dermoscopy. Computer analysis has augmented this process. The
purpose of this study was to determine the impact on diagnostic
performance for melanoma biopsy sensitivity of dermatologists
with varying degrees of experience and training when given the
information from a multispectral digital skin lesion analysis (MSDSLA)
system.
Design: Twenty-four pigmented lesions were chosen for this study
that had been analyzed as part of a prior study by a MSDSLA system
(5 melanomas and 19 other pigmented lesions). The lesions were
grouped into 4 composite patients of 6 lesions each with matching
actual historic and clinical characteristics. One hundred and seventynine clinical dermatologists attending the 2011 Winter Clinical
Dermatology Conference-Hawaii® were presented these patients by
viewing color images that included distant, close-up and dermoscopic
images. For every lesion, information was provided regarding
patient sex, age, and anatomic site and size of lesion as well as
pertinent history. Each participant was asked, “Would you biopsy
this lesion?” They were then given the information provided by the
MSDSLA system and again asked, “Would you biopsy this lesion?”
and responded by keying in their responses through an electronic
keypad. The individual responses before and after their being given
the MSDSLA information was compared to determine the impact the
device had on lesion management.
skin lesions by significantly enhancing sensitivity in selected lesions
requiring biopsy and removal.
The author(s) has no relationships to disclose
Poster # 29
Title:
The Study of Lipoma: Relation Between
Development Site and Location Depth
Author(s): Bark-Lynn Lew, MD; Min-Joong Kim MD;
Woo-Young Sim MD
Purpose: Lipoma is one of the most common benign tumors of
soft tissue. Treatment choice of lipoma is surgery such as, excisional
removal or simple incision with enucleation. Incision with tumor
enucleation is preferred rather than excisional removal because
lipoma is relatively well encapsulated. However, lipoma is not always
easy to be found during surgery. This study was planned to help
prediction of the location depth of lipoma, depending on the site.
Design: We evaluated the medical records and clinical features
of 110 patients(117 lesions), treated and diagnosed as lipoma at
our clinic in the last three years. The location depth of lipoma was
investigated by radiologic examination such as ultra sonography and
computed tomography, and histopathologic evaluation was also
practiced.
Summary: The mean age of patients was 47.4 years. Trunk was
the most frequent sites(44.44%), followed by the arm, face, neck,
leg, scalp, and buttock. Back and forehead was the most common
site among trunk and face area, respectively. The majority of
the lipoma was located in subcutaneous fatty layer(88.03%) and
intermuscular or submuscular area(11.97%). The occurred sites were
forehead, flank and neck or temple in this order, in cases, located
at intermuscular or submuscular area. And 70% of forehead and
83.33% of flank lesions were located at intermuscular or submuscular
area in our cases.
Conclusion: Our results showed that lipomas, occurred at forehead
or flank are often located at intermuscular or submuscular area and
suggested that preoperative radiologic evaluations such as ultra
sonography and computed tomography were helpful for surgery.
Poster # 30
Title:
The Utility of the Purse-string Closure for
the Repair of Facial Defects Following
Author(s): Francis Hsiao, MD; Kenny Omlin MD
Summary: The availability of the MSDSLA information improved
the average biopsy sensitivity of the dermatologists for the 5
melanomas from 69.7% prior to receiving the MSDSLA information
to 94.2% after receiving the information (P<0.001). Biopsy specificity
went from 54% to 39.9% post information receipt (P<0.001).
Multivariate regression analysis of demographic variables revealed
that physician use of dermoscopy impacted both sensitivity (P<0.01)
and specificity (P<0.01) while the number of years in practice only
influenced specificity (P<0.01). The multi-rater kappa statistic for
interobserver agreement improved from 0.32 to 0.45 with the
additional information provided from the MSDSLA system.
Conclusion: Computerized image analysis using a MSDSLA system
has the potential to improve management of potentially dangerous
Purpose: Purse-string closure is rarely used to repair Mohs defects
on the face. It offers a timesaving alternative to more elaborate
closures. As with other repairs, preservation of facial topography and
function are of utmost importance. Great aesthetic outcome is the
ultimate goal. Historically, concerns for concentric redundant skin
folds limit the application of purse-string closure on the face. Herein,
we present a case series study utilizing the purse-string stitch for the
repair of Mohs defects on the face.
Design: This is a prospective case series study. More than 50
patients underwent Mohs micrographic surgery for removal of either
squamous cell carcinoma or basal cell carcinoma involving the face.
Defect size ranged between approximately 0.5cm x 0.5cm and 3.5cm
x 1.5cm, and involved a wide variety of locations including nasal
119
sidewalls, upper cutaneous lips and post-auricular regions. Immediate
repair was performed in all cases utilizing the purse-string stitch.
After meticulously undermining the surgical site, an intradermal,
absorbable pursestring suture was placed. Patients were evaluated at
1week, 1 month, and 2 months.
Summary: After 1 month all patients achieved full excellent
aesthetic outcome without functional deficit or distortion of facial
topography.
Conclusion: The purse-string closure provides and excellent option
for the repair of surgical defects on the face following Mohs
micrographic surgery. Great aesthetic outcome were observed in all
cases. In comparison to more elaborate repairs, purse-string closure
is easier to perform, is timesaving, and offers lower morbidity.
The circumferential nature of the pursestring stitch and resulting
centralized vector forces likely play an integral role in the success of
this repair.
Poster # 31
Title:
Treatment of a Large Intramammary
Defect with Bilateral 180° Rotated Island
Pedicle Flaps
Author(s): Lori Sanford, MD; Ally-Khan Somani MD
Purpose: Topresent a unique reconstructive Mohs case which
utilized 2 symmetrical islandpedicle flaps rotated 180 degrees for a
large challenging post-Mohs truncaldefect in a cosmetically sensitive
location.
Design: This is a case report, which will also review the advantages
of island pedicleflaps, their ability to be rotated, and the
dermatologic literature regardingtheir uses in surgical defects.
Summary: A50 year-old woman with a large infiltrative basal cell
carcinoma of themid-chest underwent Mohs surgery. Completetumor
extirpation resulted in a large 7.5 x 8.2 cm presternal defect
extendingonto the medial aspects both breasts. The large size of the
defect, as well as the cosmeticallysensitive location, required use of
a repair technique that would maintainsymmetry and avoid creation
of symmastia. To repair this large defect, two symmetric triangular
shaped islandpedicle flaps were designed along the inframammary
folds. The flaps were mobilizedon their respective subcutaneous
pedicles in order to achieve a 180°rotation. The inferior edges of
the flaps met centrally and weredeeply sutured to periosteum.
Thepatient retained symmetrical appearance of the breasts. The
island pedicles had good perfusion,although there was minimal
epidermal sloughing of the superior pole of one ofthe flaps. Overall
an excellentcosmetic outcome was achieved.
Conclusion: Islandpedicle flaps are frequently used in dermatologic
surgery due to their healthyvascularity, favorable comesis, and ease
of hemostasis. A large case series of 21 patients withsmall 30-180°
rotated flaps of the head and neck hasbeen published. Our case
illustratesthat this flap type is also useful for very large, truncal
defects. Rotation of such flapsshould be carefully limited to 180° or
less in order to optimize flap vascularity.
120
Poster # 32
Title:
Treatment of Mild to Moderate Acne
Vulgaris Using a Combined Light and
Heat Energy Device: Home-Use Clinical
Study
Author(s): Neil Sadick, MD; Zahava Laver MD; Lior Laver MD
Purpose: Background: This study examined the safety and efficacy
of a handheld device emitting light and heat energy to shorten
time to resolution of acne papules and pustules, as an alternative
treatment for mild-to-moderate inflammatory acne.
Design: A randomized, placebo-controlled, double-blind study
involved sixty-three subjects with at least four inflamed facial acne
lesions. Self-administered, twice daily treatment for four days, lesions
photographed and results assessed (blinded) based on a 4-point VAS
scale and photographic lesion reference scale (PLRS), and by subjects
themselves.
Summary: Twenty nine treatment arm and thirty two placebo
arm subjects (skin types II-VI) completed the study. Based on VAS
scores 92.24% of lesions treated with an active device improved
within a median of 1 day vs. 75.78% in the placebo arm in a median
two days. At 24 hours the improvement rate was 76.72% for the
active vs.15.63% for the placebo arm. Based on PLRS scores, within
a median 2 days, 87.07% of lesions treated with an active device
improved vs 64.8% and 3 days for placebo. 51.7% of active arm
lesions resolved within a median 4 days vs. 36% (no median) for
placebo. No device-related adverse events occurred.
Conclusion: The safety and effectiveness of a handheld, combined
light and heat energy device for at-home treatment of mild to
moderate inflammatory acne lesions was demonstrated, with
statistically significant shorter lesion improvement and resolution
rates.
The author(s) serves as a consultant for Merz Aesthetics, Sanofiaventis, Radiancy, Dior; and has received research funding from Merz
Aesthetics, DEKA, Osyris, Allergan, Sanofi- Aventis, Cutera, Palomar,
Radiancy, Dior, Stiefel , Galderma, Hoya Con Bio, and Storz Medical.
Poster # 33
Title:
Beauty and the Skin Cancer Beast:
Assessment of the Relative Perceived
Newsworthiness of Cosmetic and
Surgical Dermatology Using Content
Analysis of Print Media
Author(s): Kristina Collins, MD; Mollie MacCormack MD;
Emily Fisher MD; Suzanne Olbricht MD
Purpose: Anecdotal evidence and a small body of previous research
suggests that the general public frequently views dermatology as a
primarily cosmetic specialty, and may fail to recognize dermatologists
as surgeons or as physicians managing complex medical issues. It
is clear that the typical pop culture portrayal of a dermatologist
in movie or television characters is a comical figure likened to an
aesthetician. Nevertheless, very little research has focused on the
root of these assumptions by patients and within pop culture. In
other fields of medicine, research has supported a powerful role of
media in both shaping patient assumptions and influencing health
behaviors. To our knowledge no previous research has assessed
whether cosmetic dermatology receives greater media coverage
than other skin health topics. The purpose of this research is to
comparatively analyze news coverage of dermatology issues in
major US print media across various categories, including cosmetic,
oncologic, surgical, and medical.
Design: Using the academic version of Lexis-Nexis, a database
subject search was performed within the top 15 widely circulated
US newspapers for all dermatology-related news published over a
five year period, from 2006-2011. All articles were reviewed and
articles were excluded from the study on the basis of the following
exclusion criteria: at least 50% of the article was not relevant to a
dermatology topic, the search result was an obituary or crime report,
or the story pertained to a local event only (such as the opening
of a dermatology clinic or local skin cancer screening). All other
remaining news stories were included in the study and analyzed
for content, with data recorded for source, general subject, specific
topic, and potential conflicts of interest of information reported.
Summary: We compared the relative coverage of cosmetic and
non-cosmetic dermatology issues in widely circulated US newspapers.
Although national practice data indicates that the average
dermatologist spends a small minority of time per week on cosmetic
dermatology, this study indicates that news coverage of dermatology
focuses a majority of attention on aesthetic concerns. We believe
this is the first quantitative demonstration of the emphasis on
cosmetic news over oncologic, surgical, or medical dermatology
within the media. Insight into which topics within dermatology are
generally considered “newsworthy” is essential in understanding
common public perceptions about our field. Furthermore, identifying
areas poorly covered may help guide future educational outreach
programs.
Conclusion: Cosmetic dermatology is emphasized over other areas
of dermatology, such as skin oncology, within the US print news
media. This focus may influence public perceptions of dermatology
and public health knowledge about skin disease.
Poster # 35
Title:
Eruptive Squamous Cell Carcinomas
Associated with BRAF Inhibitor Therapy
in a Patient with Metastatic Melanoma
Author(s): Navid Ezra, MD; Daniel Behroozan MD
Purpose: Patients with metastatic melanoma have displayed
improved survival outcomes using immunotherapy. Recently,
targeted inhibitors of activated tyrosine kinases (oncogenes) have
shown clinical benefit in several cancers. In 2002, a mutation at the
V600E amino acid of the BRAF serine/threonine kinase was described
as present in over 50% of melanomas, suggesting that it may be a
potential target for therapy.
Design: A 59 year old Caucasian female with an invasive back
melanoma status post resection of her primary disease and
selective nodal dissection (positive in 3/13 nodes), began adjuvant
therapy on an immunologic protocol. Following local recurrence,
lung metastases, and nodal recurrence, she was started on Braf
targeted therapy and showed immediate response in both lymph
node basins, evaluable on physical exam. On day 8 of therapy,
patient experienced an asymptomatic rash and was referred for
dermatologic evaluation revealing diffuse keratotic papules varying
from 3-8mm extensively over the trunk and extremities suspicious of
multiple squamous cell carcinomas. Four diagnostic biopsies showed
varying degrees of keratinocyte atypia ranging from partial to full
thickness consistent with a diagnosis of eruptive squamous cell
carcinomas. Braf inhibitor therapy was immediately withheld and
patient experienced quick regression of all eruptive squamous cell
carcinomas. The patient was then restarted on a lower dose of drug
and experienced significant regression of disease with continued
response. Her resultant SCCs resolved and there was no evidence of
any further lesions.
Poster # 34
Title:
Skin Characteristics After Fractional
Photothermolysis
Summary: We report a case of eruptive squamous cell carcinomas
associated with BRAF inhibitor therapy in a patient with metastatic
melanoma.
Author(s): Byung Ho Oh, MD
Conclusion: With the recent report of BRAF expression levels
exhibiting a decrease from normal skin tissue and actinic keratosis
going to SCC, the decrease of BRAF mRNA levels in SCC suggests a
novel mechanism of target for SCC treatment.
Purpose: To investigate and compare the changes in Asian patients’
skin after two different kinds of fractional photothermolysis system
(FPS) on a split face each.
Design: Half-split face study was performed with 10,600 nm carbon
dioxide FPS on the left and 1,550 nm erbium-doped FPS on the
right. Only one session of laser irradiation was done and several
biophysical measurements were done.
Summary: Although both FPS proved to be effective in treating
acne scar and wrinkle patients, slightly higher satisfaction rating
was seen with 10600nm FPS treatment. Both types of FPS showed
a significant increase in TEWL which decreased gradually after
treatment and returned to pre-treatment level after 1week.
Decreased reviscometer score was sustained for a longer period in
wrinkle area treated with 10,600 nm FPS.
Conclusion: Even though the changes in skin differed according
to different FPS wavelength, adverse outcomes, such as increased
erythema and TEWL were entirely subdued within three months of
treatment.
Poster # 36
Title:
Successful Single Session Treatment
of Facial Acne Scars with Combination
Tumescent Anesthesia, Extensive
Subcision, and Fractional Ablative CO2
Laser Ablation.
Author(s): Mark Taylor, MD
Purpose: This study was initiated to attempt to obtain a greater
percentage improvement in severe acne scars in a single treatment
session using a combination of successful modalities know to
improve acne scars.
Design: Fifty eight patients Fitzpatrick skin types I-V with contoured
and atrophic acne scars were treated using a combination of
tumescent anesthesia, extensive subcision using an innovative custom
surgical tool, and fractional ablative CO2 laser ablation.
Summary: All patients in the study achieved greater than
75% improvement of facial acne scars after a single treatment.
Complications included temporary erythema persistent up to
121
two months postoperatively, temporary post inflammatory
hyperpigmentation and minor temporary acne flares. Patient
acceptance of the procedure is greater than 90%. There were no
permanent adverse effects of the treatment.
Conclusion: A combination treatment using multiple individually
effective modalities is both safe and extremely effective when used
in combination in a single session for the treatment of facial acne
scars.
The author(s) has received research funding from Histogen,
Allergan, Medicis, Cynosure, and Candela.
122
From the lead inventor of Sonicare®, the Clarisonic ® Skin Cleansing System uses
patented sonic technology to remove more dirt, makeup and sebum than manual
cleansing. Proper cleansing each day better prepares your patients’ skin for treatments —
allowing them to work more effectively. Healthier skin begins with cleaner skin.
And cleaner skin begins with Clarisonic. But don’t just take our word, ask a colleague.
Clarisonic.com/professional
Clarisonic is a registered trademark of Pacific Bioscience Laboratories, Inc. Sonicare is a registered trademark of Philips
Oral Healthcare Inc., which is not affi liated with PBL or Clarisonic. © 2011 Pacific Bioscience Laboratories, Inc.
Cleanses 6X better than manual cleansing.

11 Annual Meeting Program - American Society for Dermatologic

Transcription

Similar documents

SETH LERNER, M.D. JASON C. McBEAN, M.D.

LA FONDATION LA ROCHE

BEAUTY THROUGH SCIENCE

Galax Dermatology Joins The Skin Surgery Center

Hickory Dermatology Joins The Skin Surgery Center

course flyer - British Association of Dermatologists

Property taxes due on Nov. 1 - West Side Health Care District

AD West Eye 1

MFI Employee Benefits